,ticker,content
0,BMY,bristol myer squibb company bmy free report announce fda grant approval combination blockbuster immuno oncology drug opdivo nivolumab mg kg low dose yervoy ipilimumab mg kg injection intravenous use treatment adult pediatric patient age year older microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan opdivo yervoy be first immune oncology combination therapy approve type colorectal cancer approval indication have be grant accelerate approval base overall response rate orr duration response dor approval be base positive datum cohort patient msi dmmr mcrc treat combination phase ii checkmate study cohort patient receive prior treatment oxaliplatin irinotecan patient overall response rate orr be responder be complete response crs partial response prs median duration response dor be not reach datum show responder have response greater month have response month share company decline year date compare industry decline note opdivo become first pd immune checkpoint inhibitor gain regulatory approval be currently approve several country include unite state eu japan several cancer indication opdivo yervoy combination be also approve other tumor type opdivo mg kg low dose yervoy mg kg combination be approve previously untreated patient intermediate poor risk advanced renal cell carcinoma opdivo mg kg yervoy mg kg be approve patient unresectable metastatic melanoma accelerate approval base progression free survival however opdivo face stiff competition merck mrk free report pd therapy keytruda be approve first line lung cancer set bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer currently have zack rank hold better rank stock same space be ionis pharmaceutical inc ion free report chemocentryx inc ccxi free report carry zack rank strong buy see complete list today zack rank stock here ionis loss share estimate have narrow cent cent past day earning estimate have moved cent cent past day company deliver positive earning surprise trail quarters average beat chemocentryx loss share estimate have narrow cent past day company deliver positive earning surprise trail quarters average beat stock have rally so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1,BMY,bristol myer squibb company bmy free report announce european commission ec have approve label expansion oncology drug sprycel consequently drug be now approve treatment child adolescent age year year philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp also include powder oral suspension formulation approval be card european medicine agency committee medicinal product human use chmp have give positive opinion same april approval be base positive datum nct study evaluate safety efficacy sprycel pediatric patient newly diagnosed cp cml be resistant intolerant gleevec note sprycel be already approve unite state treatment adult philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp drug also receive fda approval adult ph acute lymphoblastic leukemia be resistant intolerant prior therapy fda also approve sprycel treatment pediatric patient ph cml cp november label expansion exist drug bode well bristol myer bristol myer share have decline year date compare industry decline blockbuster drug opdivo continue perform well label expansion drug further boost top line pricing concern stiff competition immuno oncology space be major cause concern particular merck mrk free report keytruda roche rhhby free report tecentriq stiff competition hence label expansion other drug company maintain top line momentum cancer portfolio also get major boost launch immuno oncology drug empliciti treatment multiple myeloma december bristol myer be co develop empliciti abbvie abbv free report zack rankbristol myer have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2,BMY,roche holding rhhby free report announce phase iii study impower immuno oncology drug tecentriq meet co primary endpoint overall survival os progression free survival pfs first interim analysis indication extensive stage small cell lung cancer es sclc study enrolled person be randomise equally receive tecentriq combination carboplatin etoposide arm placebo combination carboplatin etoposide arm control arm result study show initial first line treatment combination tecentriq chemotherapy carboplatin etoposide enabled patient es sclc live significantly longer compare chemotherapy alone combination also reduce risk disease worsening death pfs compare chemotherapy alone impower meet os pfs co primary endpoint study protocol present roche have ongoing phase iii lung cancer study be evaluate tecentriq alone combination other drug be fourth phase iii study evaluate tecentriq combination study come datum fifth demonstrate positive result note tecentriq be already approve unite state european union patient previously treat metastatic nsclc patient locally advanced metastatic urothelial cancer muc be not eligible cisplatin chemotherapy have have disease progression follow platinum contain therapy roche plan submit datum regulatory body company impower be first phase iii study immunotherapy base combination show improvement os pfs initial treatment extensive stage small cell lung cancer es sclc increase likelihood potential approval label expansion drug boost sale meanwhile fda have accept priority review bristol myer squibb company bmy free report supplemental biologic license application opdivo indication sclc disease have progressed more prior line therapy fda action date be aug hence competition be stiff sclc market roche roche stock have lose so far year industry decline approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3,BMY,bristol myer squibb company bmy free report announce fda accept supplemental biologic license application sbla label expansion blockbuster immuno oncology drug opdivo indication first line advanced small cell lung cancer nsclc patient tumor mutational burden tmb mutation megabase mut mb fda set action date feb filing be base phase iii checkmate study evaluate opdivo base regimen versus platinum doublet chemotherapy patient first line advanced small cell lung cancer squamous squamous tumor histology be co primary endpoint part opdivo low dose yervoy versus chemotherapy overall survival os patient tumor express pd progression free survival pfs patient tmb mut mb pd spectrum primary endpoint part be os study be ongoing share company decline year date compare industry decline note opdivo become first pd immune checkpoint inhibitor gain regulatory approval be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc small cell lung cancer occur patient lung cancer condition lead cause cancer death worldwide notably lung cancer be squamous cell carcinoma squamous nsclc account approximately lung cancer diagnosis moreover significant progress make space disease be associate low survival rate hence label expansion additional indication give product access higher patient population increase commercial potential drug significantly remind investor opdivo face stiff competition merck mrk free report pd therapy keytruda be approve first line lung cancer set also note march roche rhhby free report present datum tecentriq novel combination broad range tumor include lung cancer bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer have zack rank hold better rank stock same space be aeglea biotherapeutic inc agle free report carry zack rank buy see complete list today zack rank stock here aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
4,BMY,aveo pharmaceutical inc aveo free report report first quarter loss cent share wider zack consensus estimate loss cent narrower year loss cent however exclude gain related change fair value warrant liability company report loss cent share aveo first drug fotivda tivozanib receive eu approval august first line treatment advanced renal cell carcinoma rcc company be focuse launch drug european country currently drug be available germany austria unite kingdom company be entitle receive double digit royalty payment eusa pharma net sale drug europe however fotivda be not yet approve unite state rcc company do not record fotivda sale quarter aveo top line comprise collaboration licensing revenue partnership royalty total revenue first quarter be approximately year figure revenue be almost line zack consensus estimate share company crash presumably company say be postpone datum readout key phase iii tivo study aveo share price movement show stock have underperform industry so far year specifically company share have lose compare industry decrease operate development expense be however general administrative expense increase year year cash guidanceaveo expect present cash resource allow company fund plan operation first quarter pipeline earning release company announce be defer anticipate topline datum readout tivo study evaluate fotivda first line rcc third quarter be previously expect second quarter aveo be conduct study address overall survival concern tivo study identify fda datum tivo study tivo study be include regulatory application approval fotivda unite state april aveo announce launch fotivda partner eusa pharma austria february drug be launch unite kingdom trigger milestone payment eusa pharma february aveo announce datum phase ii portion tinivo study evaluate tivozanib combination bristol myer bmy free report pd inhibitor opdivo metastatic rcc datum study show patient achieve orr disease control rate achieve combination therapy be january datum present phase ii study evaluate fotivda advanced hepatocellular carcinoma show fotivda achieve median pfs month week median os achieve be month apart fotivda aveo be also develop ficlatuzumab combination lilly lly free report erbitux phase ii study treat metastatic head neck squamous cell carcinoma phase ib study be evaluate ficlatuzumab combination nab paclitaxel gemcitabine treatment naive pancreatic cancer study be initiate december last year other updatesin february company appoint industry veteran john johnson year experience board director january aveo announce have refinance exist debt facility hercule capital company say term new facility help have additional cash flow compare prior loan aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc quotezack rank stock consideraveo currently carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved remain stable respectively last day company pull positive earning surprise last quarters average beat company stock be so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
5,BMY,exelixis inc exel free report deliver stellar first quarter earning revenue beat estimate strong performance cabometyx follow announcement result share exelixis gain market trading session exelixis share have lose year compare industry decline company report earning cent beating zack consensus estimate cent cent earn year quarter net revenue come year quarter report number surpass zack consensus estimate be report previous quarter exelixis inc price consensus exelixis inc price consensus exelixis inc quote quarter fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy net product revenue come year quarter upside be drive growth second later line advanced rcc business impact additional sale follow fda approval december expand indication cabometyx treatment previously untreated advanced rcc cabometyx generate net product revenue drive growth demand due expand indication demand be drive increase market share refill patient already therapy continue expansion prescriber base sequential increase cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare earn year quarter company record revenue milestone payment due ipsen pharma sas ipsen second quarter potential approval cabozantinib first line treatment advanced rcc european commission report quarter research development expense increase stem higher personnel expense clinical trial cost consult outside service selling general administrative expense be significantly drive increase corporate give personnel expense marketing activity result primarily increase general administrative headcount support company commercial research development organization pipeline updatein march exelixis submit snda fda cabometyx treatment patient previously treat advanced hepatocellular carcinoma hcc base positive result celestial trial fda have previously grant orphan drug designation treatment advanced hcc exelixis european partner ipsen receive positive opinion chmp scientific committee ema cabometyx first line treatment adult intermediate poor risk advanced rcc ipsen also announce application variation cabometyx marketing authorization have be validate ema addition new indication patient previously treat advanced hcc exelixis be entitle receive milestone payment acceptance filing payment term collaboration agreement ipsen exelixis inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent january exelixis announce amendment protocol phase ib trial cabozantinib combination tecentriq patient locally advanced metastatic solid tumor amendment add new expansion cohort trial now include patient small cell lung cancer castration resistant prostate cancer addition previously include patient rcc urothelial carcinoma primary objective expansion stage trial remain determine objective response rate cohort meanwhile imspire trilogy trial evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma have complete enrolment imspire trial evaluate combination cotellic tecentriq versus merck mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma be currently enrolling expect total cost operate expense range takeexelixis first quarter result be impressive earning sale beat estimate wide margin demand cabometyx grow approximately sequentially drive increase new patient start refill patient already therapy expect sale get further boost drug be now approve first line rcc increase eligible patient population caobometyx unite state approximately patient grab market share key drug sutent votrient first line rcc market however competition have further stiffen recent approval opdivo yervoy treatment poor intermediate risk first line rcc expect investor focus remain further label expansion cabozantinib cotellic potential label expansion advanced hcc further boost growth prospect company zack rankexelixis currently carry zack rank hold see complete list today zack strong buy rank stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
6,BMY,incyte corporation incy free report report net loss cent net income cent year quarter incyte have receive milestone payment year quarter boost bottom line zack consensus estimate be earning cent incyte corporation price consensus ep surprise incyte corporation price consensus ep surprise incyte corporation quotequarterly revenue be year year report figure however miss zack consensus estimate year year growth be drive higher sale jakafi incyte stock have lose past year compare industry decline follow disappointing result share be quarter detailjakafi sale grow year year drive strong patient demand net product revenue iclusig amount year quarter product royalty revenue novartis ag nvs free report jakafi ex market grow expense be year quarter sg expense amount year year company continue expect jakafi revenue range iclusig revenue be expect range expense be now expect range sg expense be now expect range earlier expectation pipeline phase ii trial reach trial evaluate jakafi patient steroid refractory acute graft versus host disease gvhd have complete enrolment result be expect first half incyte expect submit snda seek approval jakafi indication second half datum trial evaluate incb patient be expect second half however incyte suffer setback epacadostat external datum monitoring committee edmc review pivotal phase iii study echo evaluate epacadostat combination keytruda patient unresectable metastatic melanoma determine study do not meet primary endpoint improve progression free survival overall population compare pembrolizumab monotherapy phase iii trial echo be evaluate epacadostat merck mrk free report keytruda patient unresectable metastatic melanoma study second primary endpoint overall survival also be not expect reach statistical significance consequently base disappointing datum recommendation edmc incyte stop study enable patient physician consider alternative therapeutic option incyte be also significantly downsize epacadostat development program result incyte collaboration partner have decide pivotal trial epacadostat combination keytruda lung cancer echo echo be converted randomize phase ii trial enrollment be discontinue additional pivotal trial epacadostat combination pembrolizumab pivotal trial epacadostat combination bristol myer squibb bmy free report opdivo be amend enable patient physician consider alternative therapeutic option pivotal trial combination durvalumab stage lung cancer not be initiate however april fda convene arthritis advisory committee discuss resubmission baricitinib nda recommend approval mg dose baricitinib once daily oral medication treatment moderately severely active rheumatoid arthritis adult patient have have inadequate response intolerance methotrexate advisory committee unanimously support efficacy mg dose baricitinib do not recommend approval mg dose baricitinib propose indication base adequacy safety benefit risk profile fda action date baricitinib be june european commission have already approve baricitinib olumiant february treatment moderate severe active rheumatoid arthritis adult patient have respond inadequately be intolerant more disease modify rheumatic drug takeincyte performance first quarter be disappointing company suffer huge setback failure phase iii study echo evaluate epacadostat combination keytruda fail be most promising candidate incyte further approval mg dose baricitinib be also doubtful zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
7,BMY,exelixis inc exel free report be schedule report first quarter result market close exelixis inc price consensus ep surprise exelixis inc price consensus ep surprise exelixis inc company have pretty good earning surprise history have surpass expectation trail quarters average beat however investor weren much impressed company come line earning number last report quarter let see be store quarter exelixis share have lose last month industry fall likely positive surprise proven model show exelixis be likely beat estimate quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be most accurate estimate be cent zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank exelixis carry zack rank combine positive esp increase chance earning beat conversely caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision factor likely impact resultsexelixis stock receive major boost fda approve cabometyx tablet april treatment advanced renal cell carcinoma rcc drug uptake be encourage be expect propel top line forthcoming quarters new patient market share second line set increase end recent fda approval cabometyx treatment previously untreated advanced rcc further boost demand approval come month ahead schedule rcc be most common form kidney cancer adult statistic approximately patient unite state world need first line treatment advanced kidney cancer many patient need same annually unite state drug be now approve first line rcc well company now target entire patient population disease expect sale get further boost company launch drug first line rcc increase eligible patient population caobometyx unite state approximately patient grab market share key drug sutent votrient first line rcc market exelixis be develop cabozantinib broad development program comprise more clinical study multiple indication celestial study advanced hepatocellular carcinoma be also ongoing exelixis have submite snda fda hcc ema accept company application addition hcc indication exelixis inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent collaboration entitle exelixis earn milestone payment royalty boost top line exelixis bristol myer initiate phase iii trial checkmate july be evaluate combination checkpoint inhibition therapy combine cabozantinib compare sutent exelixis have also initiate phase ib study investigator sponsored cabozantinib combination opdivo nivolumab opdivo yervoy patient suffering genitourinary tumor include bladder cancer rcc however expense continue increase raise concern exelixis expect total cost operate expense range stock considerhere be company consider model show also have right combination element deliver beat quarter emergent biosolution inc ebs free report have earning esp zack rank company be schedule release result see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
8,BMY,earning season have start gather steam latest earning preview member accounting index have already release financial figure apr total earning member have report result already be same period last year higher revenue beating ep estimate beating revenue estimate proportion company beating ep revenue estimate be ongoing earning phase seem have also begin encouragingly drug biotech sector major large cap player johnson johnson jnj free report kick season strong note beating zack consensus estimate earning well sale large cap player report earning last week be novartis nvs free report also surpass earning revenue expectation quarter also biogen inc biib free report release result week surpass earning miss sale expectation higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning quarter review pharma biotech giant be schedule report earning result apr let see thing be shape company upcoming release abbvie inc abbv free report be slate releaseresult market open company deliver positive earning surprise last report quarter moreover company performance have be impressive recent past earning surpass expectation trail quarters average positive earning surprise proven model show abbvie be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank hold zack consensus estimate company earning quarter review be peg share company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally other drug namely duopa creon be also likely maintain encourage performance soon be report quarter read more be beat card abbvie earning abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote alexion alxn free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise alexion be likely beat earning be report quarter have positive earning esp zack rank buy zack consensus estimate quarterly earning be peg share see complete list today zack rank strong buy stock here alexion blockbuster drug soliris continue perform well company be work expand soliris label additional indication alexion recently announce acquire sweden base wilson therapeutic transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder alexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quote bristol myer squibb bmy free report be slate report result open bell company deliver positive earning surprise last quarter company deliver positive earning surprise trail quarters average beat model show bristol myer be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quote vertex pharmaceutical incorporate vrtx free report be slate report result market close vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex deliver positive earning surprise model show vertex be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter vertex cystic fibrosis cf drug kalydeco orkambi perform well sale rise almost expect positive trend continue soon be report quarter also boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february expect company provide update symdeko plan initial uptake company be also likely provide full year revenue guidance include symdeko sale call read more be beat store vertex earning season vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quote investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
9,BMY,investor be always look stock be poise beat earning season bristol myer squibb company bmy free report be such company firm have earning come pretty soon event be shape quite nicely report be bristol myer be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface bmy report fact most accurate estimate current quarter be currently cent share bmy compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate bmy give stock zack earning esp head earning season bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give bmy have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead bristol myer beat be card upcoming report investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
10,BMY,expect pfizer inc pfe free report beat expectation report first quarter result market open last quarter company deliver positive earning surprise pharma giant have strong record earning surprise company earning surpass expectation last quarters deliver average positive surprise pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotepfizer share have rise year so far decrease industry factor playin innovative health ih segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner contribute top line meaningfully zack consensus estimate sale ibrance worldwide lyrica ih xeljanz chantix be respectively essential health biosimilar emerge market be expect support sale however loss exclusivity associate generic competition product primarily pristiq unite state continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition zack consensus estimate sale enbrel be prevnar prevenar vaccine franchise continue see lower sale unite state lower demand generic competition continue hurt sale viagra pfizer be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue expect supply shortage continue hurt sale pfizer expect cut sterile injectable shortage new cancer drug bavencio avelumab besponsa inotuzumab ozogamicin mylotarg be likely contribute overall sale time xeljanz sutent bosulif be approve line extension fourth quarter new product line extension be boost sale bottom line be expect be drive cost saving share buyback also expect management provide update initial launch uptake pfizer partner merck mrk free report newly approve oral sglt inhibitor steglatro ertugliflozin tablet apart be approve monotherapy treat type ii diabetes steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent zack consensus estimate cent be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be large health care stock worth consider model have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here celgene corporation celg free report be slate announce financial figure company have earning esp be zack rank stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
11,BMY,merck co inc mrk free report report first quarter result market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be merck co inc price ep surprise merck co inc price ep surprise merck co inc quote merck share have rise year so far decrease industry let see thing be shape announcement factor considermerck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale keytruda sale be be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve set keytruda development program also significantly advanced regulatory approval new indication unite state europe japan approval expand patient population drive sale higher second half momentum be expect be maintain well strong demand most market continue drive sale bridion sugammadex injection however rise competitive pressure have begin hurt sale relatively newer drug zepatier fourth quarter zepatier sale decline sequentially due reduction share volume due increase competition call merck have warn negative trend continue most market outside unite state start come pressure older product continue pricing pressure be hurt sale januvia lower demand due competition be hurt sale isentress vaccine zostavax sale continue be hurt strong competition glaxo gsk free report newly approve shingle vaccine shingrix gardasil gardasil sale be soft fourth quarter due lower sale unite state nonetheless fourth quarter call company have mentioned underlie growth increase coverage rate be still strong unite state remain be see gardasil sale improve soon be report quarter zack consensus estimate total sale vaccine segment be peg animal health franchise sale be likely remain strong zack consensus estimate animal health segment sale be earning whispersour proven model do not conclusively show merck beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be zack consensus estimate most accurate estimate be peg cent share uncover best stock buy sell re report earning esp filter zack rank merck zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be large cap health care stock worth consider model have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be zack rank stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
12,BMY,expect abbvie inc abbv free report beat expectation report first quarter result apr market open last quarter company deliver positive earning surprise share abbvie have marginally outperformed industry so far year stock have decline industry have decrease notably abbvie earning history be quite impressive pharmaceutical company have outpaced estimate last quarters average beat let see thing be shape company quarter factor considerabbvie expect first quarter earning range share revenue be estimate grow mid range operational basis foreign exchange be anticipate gain favorable impact sale period be report company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally zack consensus estimate humira be peg significantly first quarter conference call investor focus also be performance level well label expansion update abbvie cancer drug imbruvica drug have be record strong sale past few quarters trend expect continue even quarter be report zack consensus estimate imbruvica stand other drug namely duopa creon be also likely maintain encourage performance soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue see decline sale affected intense pricing competitive pressure hcv market moreover march abbvie rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line therapy later small cell lung cancer sclc first quarter conference call expect management provide update same notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret secure approval unite state eu canada well japan second half importantly mavyret record global sale last year initial uptake drug have be commendable expect higher sale first quarter well earning whispersour proven model show stock be likely beat earning quarter have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp abbvieha earning esp zack consensus estimate be share positive esp indicate likely earning surprise uncover best stock buy sell re report earning esp filter zack rank abbvieha zack rank increase predictive power esp together positive esp chance stock beating estimate upcoming release be always peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision other stock warrant lookhere be couple other health care stock worth consider right combination element also surpass estimate time pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here bristol myer squibb company bmy free report be schedule report earning apr company have earning esp zack rank celgene corporation celg free report be slate announce financial figure company have earning esp be zack rank player abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
13,BMY,expect allergan plc agn free report beat expectation report first quarter result apr market open last quarter company deliver positive earning surprise allergan share price have decline year so far compare industry decline allergan earning performance have be strong company beating expectation past quarters average positive earning surprise last quarters be allergan plc price ep surprise allergan plc price ep surprise allergan plc quotelet see thing be shape announcement factor consideron fourth quarter conference call company guide first quarter revenue earning share be expect be number indicate lowest revenue earning quarter year fourth quarter favorable timing physician rebate program benefit sale allergan facial aesthetic product benefit be absent first quarter hurt revenue such company expect first quarter revenue growth rate be somewhat lower annual growth rate also generic competition estrace namenda xr hurt sale sharply first quarter generic version namenda xr be launch indian company lupin february estrace cream be launch mylan myl free report january allergan expect generic version restasis second best selling drug be launch april july meanwhile generic version delzicol be expect be launch early second quarter investor focus call be management comment potential impact generic competition key growth driver restasis namenda xr zack consensus estimate restasis be nonetheless allergan establish product botox linzess loestrin juvéderm collection filler new product juvéderm collection filler support sale zack consensus estimate botox be fact recent label expansion botox fda approval forehead line treatment vraylar fda approval maintenance treatment schizophrenia avycaz fda approval habp vabp add sale drug meanwhile addition alloderm lifecell january coolsculpt body contour system zeltiq april acquisition continue support top line quarter however believe sale erosion aczone due generic pressure brand acne category loss exclusivity loe mainly asacol hd minastrin continue hurt top line remind investor call company have say do not expect significant activity allergan expect reevaluate strategy second half year once get loe update be expect upcoming conference call earning whispersour proven model show allergan be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank allergan have zack rank combination allergan zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be large cap health care stock worth consider model also have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be also zack rank stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
14,BMY,healthcare space have be tough journey year popular etf health care select sector spdr fund xlv free report have shed so farwhile vanguard health care etf vht free report fidelity msci health care index etf fhlc free report have gain least meanwhile ishare healthcare etf iyh free report have add mixed trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read healthy earning unitedhealth etfs watch let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate higher chance beating estimate quarter stock have see positive earning estimate revision cent be report quarter deliver average positive earning surprise past quarters have vgm score pfizer be schedule report earning open bell merck be expect report result market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness positive earning estimate revision cent past day be report quarter merck have vgm score amgen carry zack rank have earning esp indicate reasonable chance beating estimate time earning surprise track past quarters be strong average positive surprise addition amgen witness positive earning estimate revision cent past day quarter be report stock have solid vgm score amgen report earning apr market close read small cap biotech etfs be soar abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see solid earning estimate revision cent past month be report quarter stock have solid vgm score company be schedule report apr open bell gilead be expect release earning market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision penny past month be report quarter have vgm score bristol myer likely report earning apr open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have vgm score sum earning surprise well card healthcare sector be expect witness earning growth first quarter suggest upside healthcare etfs particular etfs have zack etf rank see healthcare etfs here want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
15,BMY,astrazeneca azn free report announce have secure fda approval label expansion market drug tagrisso osimertinib first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation notably tagrisso be approve unite state european union japan china second line treatment patient advanced nsclc show progress follow treatment egfr tki due egfr resistance mutation share astrazeneca have outperformed industry year date stock have gain versus industry decline remind investor last december fda accept grant priority review company supplemental new drug application snda tagrisso aforementioned indication fda nod be base positive datum phase iii flaura study compare tagrisso standard care egfr tyrosine kinase inhibitor therapy first line lung cancer set datum trial show chance progression death risk be reduce more half tagrisso arm compare commonly used egfr inhibitor median progression free survival be month patient tagrisso compare month comparator arm tagrisso be well tolerate trial safety profile consistent previous experience importantly similar application tagrisso label expansion be review eu well japan decision expect second half tagrisso register sale reflect growth year period accounting total sale potential approval first line set further boost drug prospect however lung cancer market be crowd several company develop marketing treatment roche hold ag rhhby free report astella tarceva be approve treat nsclc pfizer inc pfe free report be develop drug dacomitinib phase iii study first line treatment indication moreover bristol myer squibb bmy free report be develop opdivo treatment nsclc astrazeneca too have iressa approve treat nsclc be also develop imfinzi same indication astrazeneca plc price astrazeneca plc price astrazeneca plc quote zack rankastrazeneca carry zack rank hold see complete list today zack rank strong buy stock here note be reissue article correct inaccuracy original version publish april longer be rely hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
16,BMY,expect bristol myer squibb company bmy free report beat expectation report first quarter result apr market open bristol myer share have decrease so far year compare industry decline bristol myer track record have be mixed so far company deliver positive earning surprise last quarters miss expectation once average positive earning surprise last quarters be last report quarter bristol myer deliver positive surprise let see thing be shape quarter drive growth bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer opdivo combination yervoy significantly improve progression free survival patient compare chemotherapy potential approval indication be significant boost drug give immense scope lung cancer market zack consensus estimate drug sale first quarter be peg january european commission approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma fda approve drug indication july zack consensus estimate drug sale quarter be november fda approve line extension sprycel pediatric patient ph chronic myeloid leukemia chronic phase drug register growth previous quarter be expect receive boost quarter due expand label zack consensus estimate sprycel sale stand cardiovascular drug eliquis come strong performance sale grow year year sale be expect remain robust first quarter too zack consensus estimate eliquis sale be peg other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter actual figure label expansion bristol myer blockbuster cancer drug opdivo drive company sale last year be expect do so year well moreover cardiovascular drug eliquis also demonstrated strong performance expect trend continue quarter label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact however genericization plavix avapro avalide baraclude unite state due loss exclusivity be significantly hurt company top line company also face stiff competition immuno oncology space hiv business continue face competitive pressure zack consensus estimate sale earning be peg cent respectively likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here abbvie inc abbv free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
17,BMY,week be rule cancer datum presentation drug company annual meeting american association cancer research aacr chicago other jnj free report novartis nvs free report kick pharma earning strong note beating zack consensus estimate earning sale first quarter recap week most important storiesj beat earning raise sale guidance first quarter earning come share sale be number increase year year quite few key product portfolio remicade concerta face generic competition believe new product plaque psoriasis drug tremfya guselkumab cancer drug darzalex imbruvica zytiga currency tailwind contribution acquisition help deliver strong sale profit first quarter year lead raise sale outlook whole year read more top earning estimate raise sale guidance novartis first quarter earning come share beat zack consensus estimate revenue increase year year beat zack consensus estimate strong performance key drug cosentyx entresto lead impressive performance quarter novartis re iterated previously issue guidance read more novartis beat earning revenue estimate merck present successful keytruda datum aacr merck mrk free report present full datum pivotal keynote study evaluate keytruda combination alimta pemetrexed platinum chemotherapy cisplatin carboplatin first line treatment patient metastatic squamous nsclc regardless pd expression datum show keytruda combo significantly improve overall survival reduce risk death half compare chemotherapy alone january merck have announce study meet primary endpoint progression free survival pfs os co primary endpoint notably combination therapy be grant accelerate approval fda aforementioned indication approval be base tumor response rate pfs datum keynote study hence positive readout keynote confirmatory study help company gain continue approval combo therapy support uptake sale read more merck keytruda better survival lung cancer combo study merck also present update datum phase iii eortc keynote study evaluate keytruda monotherapy high risk stage iii melanoma patient adjuvant set datum study demonstrated adjuvant treatment keytruda increase recurrence free survival rfs reduce risk disease recurrence death placebo surgery such patient read more merck keytruda reduce death risk melanoma patient separately merck astrazeneca azn free report announce final overall survival os datum phase iii study evaluate parp inhibitor lynparza metastatic breast cancer aacr median os be month lynparza arm compare chemotherapy bristol myer opdivo focus bristol myer bmy free report present initial result phase iii study checkmate evaluate combination pd inhibitor opdivo yervoy first line treatment advanced nsclc patient high tumor mutational burden initial result show year pfs rate be more triple combination versus chemotherapy vs however result be encourage investor be disappoint merck keytruda seem have fared better opdivo yervoy combination read more bristol myer merck nsclc study fare better opdivo also demonstrated statistically significant overall survival primary endpoint benefit compare chemotherapy late stage study checkmate evaluate predominantly chinese population previously treat small cell lung cancer opdivo reduce risk death versus chemotherapy read more bristol myer report positive datum nsclc trial opdivo development opdivo be approve combination yervoy treatment intermediate poor risk advanced renal cell carcinoma previously untreated patient also bristol myer supplemental biologic license application sbla expand use opdivo monotherapy previously treat patient small cell lung cancer sclc be grant priority review fda fda be expect give decision aug separately bristol myer strike collaboration illumina inc develop commercialize companion diagnostic bristol myer oncology immunotherapy bristol myer also inked deal johnson johnson development bristol myer factor xia fxia inhibitor bms prevention treatment major thrombotic condition company be expect advance bms phase ii trial second half roche hemlibra get btd new indication swiss pharma giant roche rhhby free report haemophilium drug hemlibra be grant breakthrough therapy designation fda treatment haemophilium factor viii inhibitor base positive datum phase iii haven study hemlibra emicizumab be approve routine prophylaxis bleed episode person haemophilium factor viii inhibitor eu february unite state november last year have be successfully launch unite state read more roche hemophilia drug get breakthrough therapy designation shire agree sell oncology unit shire announce definitive agreement sell oncology business french company servier dublin ireland drug giant plan return proceed sale shareholder share buyback japan takeda consider take shire latter oncology business be key area interest takeda read more shire sell oncology unit ahead takeda potential offer shire however thursday reject takeda third offer pound share well say undervalue shire growth prospect pipeline meanwhile allergan agn free report issue press release same day say be early stage consider possible offer shire however later day issue press release say do not intend make offer shire bayer sell stake singapore temasek germany bayer have strike deal sell stake singapore investment company temasek total gross proceed euro latest purchase temasek own approximately bayer stock equity sale raise fund bayer upcoming merger seed maker company astrazeneca tagrisso get fda nod first line set astrazeneca lung cancer drug tagrisso gain fda approval first line treatment adult patient metastatic nsclc tumor have egfr mutation snda be base datum phase iii flaura study similar label expansion application be review eu now tagrisso be approve unite state european union japan china second line treatment option patient egfr mutation positive nsclc read more fda nod astrazeneca tagrisso first line nsclc nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform last trading session merck be biggest gainer last week rise bristol myer decline last month astrazeneca have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup nvs buy avexis pfe abbv drug succeed phase iii next pharma world watch first quarter earning result several drug giant other pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
18,BMY,bristol myer squibb company bmy free report announce fda have accept grant priority review designation supplemental biologic license application sbla label expansion opdivo nivolumab treat patient small cell lung cancer sclc disease have progressed more prior line therapy fda set action date aug submission be base safety efficacy datum sclc cohort phase ii checkmate trial evaluate opdivo monotherapy opdivo yervoy ipilimumab advanced metastatic solid tumor include sclc primary goal be ascertain objective response rate assessed blind independent central review secondary objective include safety overall survival progression free survival duration response share company have decline year underperform industry gain note opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc fda also approve opdivo intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar opdivo have rapidly penetrate second line hcc market label expansion additional indication give product access higher patient population increase commercial potential drug significantly however opdivo face stiff competition merck mrk free report keytruda roche rhhby free report tecentriq bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer carry zack rank hold top rank stock same space worth consider be ligand pharmaceutical lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved respectively last day company deliver positive earning surprise trail quarters average beat company share have rally year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
19,BMY,astrazeneca azn free report announce have secure fda approval label expansion market drug tagrisso osimertinib first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation notably tagrisso be approve unite state european union japan china second line treatment patient advanced nsclc show progress follow treatment egfr tki due egfr resistance mutation share astrazeneca have outperformed industry year date stock have gain versus industry decline remind investor last december fda accept grant priority review company supplemental new drug application snda tagrisso aforementioned indication fda nod be base positive datum phase iii flaura study compare tagrisso standard care egfr tyrosine kinase inhibitor therapy first line lung cancer set datum trial show chance progression death risk be reduce more half tagrisso arm compare commonly used egfr inhibitor median progression free survival be month patient tagrisso compare month comparator arm tagrisso be well tolerate trial safety profile consistent previous experience importantly similar application tagrisso label expansion be review eu well japan decision expect second half tagrisso register sale reflect growth year period accounting total sale potential approval first line set further boost drug prospect however lung cancer market be crowd several company develop marketing treatment roche hold ag rhhby free report astella tarceva be approve treat nsclc pfizer inc pfe free report be develop drug dacomitinib phase iii study first line treatment indication moreover bristol myer squibb bmy free report be develop opdivo treatment nsclc astrazeneca too have iressa approve treat nsclc be also develop imfinzi same indication astrazeneca plc price astrazeneca plc price astrazeneca plc quote zack rankastrazeneca carry zack rank hold see complete list today zack rank strong buy stock here note be reissue article correct inaccuracy original version publish april longer be rely hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
20,BMY,merck mrk free report share increase apr present full datum pivotal phase iii keynote study datum same show keytruda combine eli lilly lly free report alimta pemetrexed platinum chemotherapy cisplatin carboplatin significantly improve overall survival thereby reduce death risk half compare chemotherapy alone study evaluate combination therapy first line treatment patient metastatic squamous small cell lung cancer nsclc regardless pd expression combo treatment show progress overall survival irrespective pd expression include patient tumor testing negative pd meanwhile significant improvement progression free survival pfs be observed decrease death risk keytruda combination arm compare chemotherapy arm median pfs be month keytruda arm compare month chemotherapy pfs improvement be also observed patient tumor test negative pd result be present annual meeting american association cancer research notably january year merck have announce study meet primary endpoint pfs os well importantly keytruda be first pd inhibitor combination show os patient nsclc last combination therapy be grant accelerate approval fda aforementioned indication nod be base tumor response rate pfs datum keynote trial hence positive readout keynote confirmatory study help company gain continue approval combo therapy turn support uptake sale remind investor third quarter merck have mentioned be include overall survival os co primary endpoint keynote program defer readout study be then estimate evaluation be complete february however company release datum keynote study year earlier expect january merck share have gain so far year versus decline industry concurrently bristol myer bmy free report also report datum phase iii study blockbuster drug opdivo nsclc however merck keytruda combination demonstrated better overall survival compare opdivo zack rank key pickmerck carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have soar year breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
21,BMY,share bristol myer squibb company bmy free report fall investor be not much impressed company initial result phase iii study checkmate study be evaluate opdivo mg kg low dose yervoy mg kg combination first line advanced small cell lung cancer nsclc patient high tumor mutational burden tmb mutation megabase mut mb combination demonstrated superior benefit co primary endpoint progression free survival pfs versus chemotherapy initial result show year pfs rate be more triple combination versus chemotherapy vs overall response rate combination be chemotherapy arm responder have ongoing response year chemotherapy grade treatment related adverse event rate opdivo low dose yervoy combination be versus chemotherapy result be encourage investor be disappoint merck mrk free report keytruda seem have fared better opdivo yervoy combination merck announce result phase iii study keynote evaluate pd therapy keytruda combination pemetrexed alimta cisplatin carboplatin first line treatment metastatic nonsquamous nsclc result show keytruda pemetrexed platinum chemotherapy combination significantly improve overall survival os reduce risk death half compare chemotherapy alone consequently share bristol myer decline first line nsclc market competition be stiffening quite few company try capture additional market share share company have gain only past year underperform industry growth concurrently bristol myer announce obtain fda approval opdivo yervoy injection intravenous use first immuno oncology combination therapy previously untreated patient intermediate poor risk advanced renal cell carcinoma phase iii trial checkmate demonstrated significant unprecedented increase os abovemention combination patient population compare current standard care pfizer pfe free report sutent moreover opdivo demonstrated sustain os advantage standard care patient recurrent metastatic squamous cell carcinoma head neck checkmate patient treat opdivo experience reduction risk death year minimum follow note opdivo be currently approve several country include unite state eu japan several cancer indication opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc label expansion additional indication give product access higher patient population increase commercial potential drug significantly bristol myer announce worldwide collaboration johnson johnson jnj free report janssen pharmaceutical inc janssen factor xia fxia inhibitor program include development former factor xia fxia inhibitor bms note bms investigational anticoagulant compound be be evaluate prevention treatment major thrombotic condition company be expect advance bms phase ii trial second half study secondary stroke prevention zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
22,BMY,celldex therapeutic inc cldx free report announce failure lead pipeline candidate glembatumumab vedotin phase iib breast cancer study metric candidate fail meet primary endpoint progression free survival pfs benefit roche rhhby free report chemotherapy xeloda treatment metastatic triple negative breast cancer overexpress gpnmb assessment datum mid stage study show glembatumumab vedotin achieve pfs month versus month xeloda candidate be also not able demonstrate significant advantage key secondary endpoint include overall response rate duration response overall survival follow failure celldex have decide discontinue study evaluate glembatumumab vedotin indication company be currently restructure pipeline focus candidate ongoing clinical study include varlilumab also reduce workforce approve product celldex portfolio discontinuation clinical study follow failure lead candidate come major setback pull stock more apr stock have decline so far year compare industry decline celldex be evaluate varlilumab cd agonist combination bristol myer bmy free report opdivo mid stage study several indication phase ii study be currently enrolling patient evaluate cdx combination eli lilly lly free report erbitux treatment head neck cancer company provide revise estimate first quarter earning release include impact restructure initiative celldex therapeutic inc price celldex therapeutic inc price celldex therapeutic inc quotecelldex carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
23,BMY,gilead science inc gild free report announce encourage datum proof concept study experimental combination therapy patient advanced fibrosis due nonalcoholic steatohepatitis nash datum be present international liver congress paris apoptosis signal regulate kinase ask inhibitor selonsertib be combine acetyl coa carboxylase acc inhibitor gs selective steroidal farnesoid receptor fxr agonist gs therapy patient diagnosed nash liver fibrosis stage base biopsy magnetic resonance elastography mre mri proton density fat fraction mri pdff enrolled study be treat selonsertib mg gs mg selonsertib mg gs mg monotherapy group once daily week post treatment most notable change be observed be decrease liver fat content measure mri pdff occur regimen contain gs result also show improvement liver biochemistry marker fibrosis combination arm study compare baseline moreover patient treat selonsertib gs kinetic labele show reduction fractional synthesis rate lumican marker fibrogenesis hence favorable result suggest combination therapy selonsertib gs gs be evaluate further patient nash fibrosis gilead also announce completion enrolment phase iii trial stellar selonsertib gilead nash pipeline include selonsertib gs gs alone gilead present datum pre clinical study combination treatment approach nash evaluate gs gs together single agent rodent model nash liver fibrosis datum indicate combine agent have greater fibrotic steatotic effect lead improvement liver biochemistry fibrosis marker compare agent alone result gilead have initiate larger phase iib study combination treatment selonsertib gs gs patient advanced fibrosis due nash give persistent decline hcv franchise gilead be look foray market nash car hold great potential estimate nash be expect surpass hepatitis lead reason liver transplant unite state europe gilead stock have lose last month industry decline intercept pharmaceutical icpt free report be also evaluate lead candidate obeticholic acid phase iii study subject compensate cirrhosis due nash bristol myer squibb bmy free report have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo swiss major novartis nvs free report be conduct phase iib involve combination novartis fxr agonist cenicriviroc treatment nash zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
24,BMY,bristol myer squibb company bmy free report announce result phase iii trial checkmate trial blockbuster drug opdivo number person majority be china late stage multinational randomize study compare opdivo docetaxel treatment patient stage iiib iv small cell lung cancer nsclc disease have progressed platinum base doublet chemotherapy result show opdivo demonstrated statistically significant benefit versus docetaxel primary endpoint overall survival os os benefit be observed regardless pd expression tumor histology opdivo reduce risk death versus chemotherapy additionally secondary endpoint objective response rate median duration response demonstrated durability opdivo compare docetaxel objective response rate quadruple opdivo versus docetaxel median duration response not reach opdivo versus month docetaxel result be update immuno oncology trial session american association cancer research aacr annual meeting chicago abstract ct remind investor china food drug administration accept company biologic license application opdivo propose indication previously treat nsclc november tentative approval further boost geographic reach drug efficacy safety opdivo predominantly chinese patient population advanced nsclc be consistent result global checkmate study share company have rally past year outperform industry gain opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc fda also approve opdivo intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar opdivo have rapidly penetrate second line hcc market label expansion additional indication give product access higher patient population increase commercial potential drug significantly earlier company stop phase iii combination study checkmate earlier expect meet co primary endpoint phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma meet co primary endpoint study show superior os compare current standard care sunitinib intermediate poor risk patient fda accept company sbla same take decision apr however opdivo face stiff competition merck mrk free report keytruda roche rhhby free report tecentriq concurrently bristol myer announce collaboration illumina inc ilmn free report use latter next generation sequence technology develop globally commercialize diagnostic assay support bristol myer squibb oncology portfolio zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company re already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
25,BMY,merck mrk free report announce encourage datum phase iii study eortc keynote evaluate pd therapy keytruda high risk stage iii melanoma patient adjuvant set datum study demonstrated adjuvant treatment keytruda significantly increase recurrence free survival rfs surgery compare placebo such patient drug reduce risk disease recurrence death placebo study rfs be achieve patient treat keytruda year compare placebo keytruda also significantly prolong rfs patient pd positive tumor reduce risk recurrence death placebo datum study be present american association cancer research aacr annual meeting be publish new england journal medicine share merck have outperformed industry so far year share have return industry decline say period study be be conduct collaboration european organisation research treatment cancer merck claim keytruda be first pd therapy achieve rfs benefit stage iiia iiib iiic melanoma patient drug have achieve rfs benefit patient irrespective braf mutation merck be evaluate keytruda broad clinical development program melanoma comprise clinical study setting stage disease separate press release merck astrazeneca azn free report announce final overall survival os datum phase iii olympiad study evaluate parp inhibitor lynparza metastatic breast cancer aacr annual meeting median os be month lynparza arm compare chemotherapy please note bristol myer bmy free report pd immune checkpoint inhibitor opdivo have receive approval intravenous administration melanoma patient adjuvant treatment december however keytruda have achieve rfs benefit higher proportion patient compare opdivo clinical study merck co inc price merck co inc price merck co inc quotezack rank stock considermerck carry zack rank hold eli lilly company lly free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here lilly earning estimate slightly increase last day company deliver positive earning surprise trail quarters average beat company be schedule report first quarter earning apr investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
26,BMY,last week have be eventful pharma stock novartis nvs free report announce be acquire gene therapy company avexis merck mrk free report abbvie abbv free report announce successful study result other news pfizer pfe free report kidney cancer drug inlyta miss primary endpoint phase iii study recap week most important storiesnovartis buy avexis big news early week be novartis deal buy avexis lead product candidate avxs be time gene replacement therapy spinal muscular atrophy sma regulatory filing avxs unite state be expect second half year avxs have potential generate million dollar novartis approve company agree pay share avexis represent whooping premium avexis close price friday board company have approve deal buyout be anticipate close second half year read more novartis inks gene therapy deal buy avexis merck keytruda succeed key lung cancer study pivotal lung cancer study keynote merck blockbuster pd inhibitor keytruda meet primary endpoint keynote study evaluate patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent such patient keytruda show significant survival benefit compare platinum base chemotherapy notably keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market read more merck keytruda offer survival benefit lung cancer study abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint phase iii study select program phase iii study select compare evaluate candidate moderate severe rheumatoid arthritis patient be stable background methotrexate elicit inadequate response week treatment acr response first primary endpoint be achieve patient receive mg dose upadacitinib versus placebo second primary endpoint clinical remission be achieve patient upadacitinib arm versus only placebo arm read more abbvie ra candidate meet primary endpoint phase iii meanwhile fda have extend review period abbvie pipeline candidate elagolix month fda decision previously expect second quarter now come third quarter read more fda prolong review date abbvie endometriosis candidate pfizer inlyta miss primary endpoint phase iii study pfizer kidney cancer drug inlyta axitinib fail demonstrate clear improvement primary endpoint extend disease free survival dfs compare placebo phase iii atla study accordingly independent datum monitoring committee recommend study be stop plan interim analysis read more pfizer kidney cancer drug miss endpoint phase iii pfizer also announce initiation dose early stage study evaluate mini gene therapy candidate pf treatment boy duchenne muscular dystrophy dmd most common type muscular dystrophy early datum study be expect first half pacira exparel get fda nod expand label pacira pharmaceutical inc pcrx free report supplemental new drug application snda label expansion exparel nerve block set patient undergo upper extremity surgery get fda nod fda approval come surprise fda committee vote approval expand indication february read more fda okay label expansion pacira exparel stock exparel generate sale represent increase latest label expansion sale be expect go glaxo divest rare disease gene therapy drug private biotech glaxo gsk free report be divest rare disease gene therapy portfolio private biotech orchard therapeutic exchange stake company well seat board divesture be part strategic review glaxo announce july last year divest preclinical clinical program allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation read more glaxo sell rare disease gene therapy private biotech nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report merck astrazeneca be biggest gainer rise respectively bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup lly cyramza shine cancer study pfe azn focus next pharma world watch novartis first quarter earning result other pipeline regulatory update make fortune shift electric carshere stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
27,BMY,nektar therapeutic nktr free report have announce initiation dose phase ii study evaluate combination novel immuno oncology agent nktr nktr patient advanced solid tumor nktr be toll receptor agonist design invite innate immune response fight cancer nktr be immuno stimulatory cd bias agonist share nektar have soar so far year substantially outperform industry decrease phase ii reveal study be open label multicenter dose escalation program design evaluate nktr nktr combination regimen administer initial intratumoral directly tumor injection nktr follow intravenous iv infusion nktr company believe combination therapy enable provide alternative treatment option patient moreover company also plan assess nktr nktr combination bristol myer bmy free report opdivo nivolumab give patient population remind investor september nektar enter clinical collaboration agreement bristol myer nektar nktr be examine combination latter opdivo tumor type include melanoma kidney colorectal bladder small cell lung cancer potential indication phase ii trial meanwhile september company announce initiation phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab be also important note nektar be develop several other candidate important therapeutic area include oncology pain infective immunology other company have make significant progress lead candidate onzeald formerly know nktr currently accelerate assessment eu treat adult advanced breast cancer well brain metastase response be anticipate first half couple other interesting candidate be nktr nktr nktr be be analyze phase iii program treatment chronic pain company initiate phase clinical study nktr treat wide range auto immune disease inflammatory disorder nektar therapeutic price nektar therapeutic price nektar therapeutic quote zack ranknektar carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
28,BMY,ionis pharmaceutical inc ion free report recently inked licensing deal astrazeneca plc azn free report deal ionis have license ionis az lrx azd astrazeneca nonalcoholic steatohepatitis nash fatty liver astrazeneca be responsible further development ionis az lrx ionis receive license fee astrazeneca ionis be entitle additional development regulatory milestone payment well tiered royalty low teen sale drug year share ionis have increase par industry ionis az lrx be third drug enter development strategic cardiovascular renal metabolic collaboration astrazeneca candidate incorporate many advancement ionis have make antisense technology include company ligand conjugate antisense generation chemistry be second drug collaboration incorporate modification astrazeneca have play strategic role advance ionis az lrx provide preclinical development expertise nash have contribute rapid advance drug development ionis believe astrazeneca move program swiftly clinical testing ultimately market astrazeneca ionis have strategic alliance focuse leverage antisense technology collaboration build strong exist relationship company be support ionis expertise cardiovascular disease antisense technology astrazeneca drug development expertise infrastructure note investor have be investing substantial portion source treatment alcoholic steatohepatitis nash company bristol myer squibb company bmy free report be progress pipeline candidate fgf treatment nash ionis pharmaceutical inc price ionis pharmaceutical inc price ionis pharmaceutical inc quotezack rank stock considerionis carry zack rank hold better rank stock same space be ligand pharmaceutical lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved respectively last day company deliver positive earning surprise trail quarters average beat company share have rally year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
29,BMY,last year turn be pretty good pharma biotech stock far fda decision be concern regulatory body approve novel drug easily surpass total tally landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment just quarter go year fda have already grant approval new treatment key approval include jnj free report next generation oral androgen receptor ar inhibitor erleada apalutamide pre metastatic prostate cancer crpc vertex pharmaceutical incorporate vrtx free report third medicine treat underlie cause cf symdeko be combination tezacaftor ivacaftor gilead once daily single tablet hiv regimen biktarvy novartis lutathera certain neuroendocrine tumor drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst let take look few important regulatory event schedule month april note month fda have already approve pacira pharmaceutical exparel new indication nerve block regional analgesia clovis oncology parp inhibitor rubraca maintenance therapy recurrent ovarian cancer second indication novartis kymriah apr fda be expect give decision novartis supplemental biologic license application bla look approval kymriah second indication latest filing novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlblc most common form hodgkin lymphoma have fail more prior therapy kymriah be approve treatment deadly cancer call acute lymphoblastic leukemia last august accord company annual report dlblc patient do not respond initial therapy relapse month treatment indicate significant market potential kymriah dlblc indication fda decision mallinckrodt label expansion amitiza child mallinckrodt plc mnk free report supplemental new drug application snda look get constipation drug amitiza approve paediatric functional constipation year be review fda be expect give decision apr amtiza be add mallinckrodt portfolio february acquisition sucampo pharmaceutical amitiza be already approve chronic idiopathic constipation cic adult irritable bowel syndrome constipation ib adult woman opioid induced constipation oic patient chronic cancer pain accord company press release amitiza approve paediatric functional constipation be first only prescription medication specifically approve such patient have limit treatment option address disease fda panel back gw pharmaceutical epidiolex incyte lilly olumiant fda panel be expect give opinion gw pharmaceutical lead cannabinoid pipeline candidate epidiolex next week gw pharmaceutical be look get epidiolex approve adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy fda grant priority review epidiolex nda response fda be expect jun epidiolex represent blockbuster potential especially be approve possible indication fda panel be also expect give opinion month incyte lilly lly free report olumiant baricitinib treatment adult patient moderately severely active rheumatoid arthritis april company have receive complete response letter crl fda baricitinib fda require additional clinical datum thenda olumiant be re submit january olumiant have already be launch select european country japan fetch sale fda take recommendation panel advisory committe account review application be not bound follow same fda decision rigel tavalisse ultragenyx burosumab april fda be expect give decision rigel pharmaceutical nda tavalisse fostamatinib treatment chronic immune itp apr rigel be prepare launch oral spleen tyrosine kinase syk inhibitor second quarter approve exist therapy treat chronic itp include steroid blood platelet production booster tpos splenectomy however still disease remain inadequately treat many patient mean approve tavalisse enjoy significant market potential fda decision expect apr be ultragenyx pharmaceutical bla burosumab treat pediatric adult patient link xlh burosumab be approve treat xlh trade name crysvita eu february fda decide prometic ryplazim fda decision expect apr be canadian biotech prometic life science biologic license application bla ryplazim treatment congenital plasminogen deficiency ryplazim enjoy orphan drug fast track designation fda say indication bristol myer opdivo yervoy combo get fda approval bristol myer bmy free report have file sbla look get blockbuster drug opdivo approve combination cancer drug yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc fda decision be expect apr clinical study combination have demonstrated superior overall survival os compare current standard care sunitinib intermediate poor risk patient bode well drug give potential target market pd inhibitor be presently approve several country include unite state eu japan several cancer indication label expansion boost opdivo sale further opdivo generate sale almost bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
30,BMY,biggest news week be novartis nvs free report announcement plan spin eye care division alcon new public company committee medicinal product human use chmp european medicine agency ema give positive recommendation grant marketing approval several drug week astrazeneca azn free report relatively new cancer drug lynparza imfinzi be grant marketing approval japan recap week most important storiesnovartis spin alcon novartis announce intention spin eye care division alcon separately trade standalone company novartis have acquire alcon novartis be conduct strategic review business long include retain business separation sale spin initial public offer decision spin alcon look prudent business be not perform management expectation alcon management believe create standalone company capital market exit create additional shareholder value divestiture unit also help novartis focus drug business novartis plan retain ophthalmic pharmaceutical part pharmaceutical portfolio concurrently company announce initiate share buyback program be execute end read more novartis spin alcon separate trading company chmp give positive opinion several drug bristol myer bmy free report pd inhibitor opdivo gain positive chmp opinion recommend expand approval adjuvant treatment adult patient melanoma chmp also give nod astrazeneca new formulation once weekly bydureon pre filled bcise device help improve glycaemic control new formulation be already approve unite state sanofi sny also gain positive chmp opinion cablivi caplacizumab treatment rare blood disorder call acquire thrombotic purpura cablivi be add sanofi portfolio latest acquisition ablynx novartis filing look label expansion car therapy kymriah cell malignancy be also give positive opinion chmp final decision european union product be expect come month astrazeneca gain japan approval new cancer drug astrazeneca parp inhibitor lynparza gain approval second indication japan lynparza olaparib tablet be already approve advanced ovarian cancer be now approve japan treatment patient unresectable recurrent brca mutate metastatic breast cancer patient have receive prior chemotherapy also astrazeneca new pd inhibitor be approve japanese regulatory authority locally advanced unresectable small cell lung cancer nsclc imfinzi be already approve unite state indication application eu be review decision expect second half read more astrazeneca new cancer drug get approval japan merck keytruda sbla get priority review merck mrk free report supplemental biologic license application sbla look expand label keytruda first line treatment metastatic squamous nsclc difficult treat lung cancer patient population be grant priority review fda fda decision be expect oct sbla filing be base datum keynote study remind investor datum present study steal limelight annual meeting american society clinical oncology earlier month datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression read more merck keytruda get priority review difficult lung cancer bristol myer leukemia drug get eu nod expand indication bristol myer announce european commission have give marketing approval leukemia drug sprycel new patient population new formulation sprycel be now approve powder formulation administration pediatric patient philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp adamis get strong partner novartis adamis pharmaceutical admp free report announce exclusive distribution agreement novartis symjepi injection mg market emergency treatment acute allergic reaction include anaphylaxis deal novartis generic arm sandoz gain commercial right symjepi unite state exchange upfront fee potential performance base milestone payment company share profit equally meanwhile approval sandoz also get commercial right symjepi injection mg be presently fda review share adamis surge day partnership swiss pharma giant be announce read more adamis surge follow novartis deal symjepi nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform last trading session stock record increase last week glaxo gsk free report gain most past month too glaxo have be biggest gainer jnj free report decline most see last pharma stock roundup here pharma stock roundup ptct unveil promising datum rhhby acquire rest fmi next pharma world watch earning bigwig pharma world later month begin jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
31,BMY,have be month last earning report bristol myer squibb company bmy free report share have add time frame recent positive trend continue lead next earning release be bmy due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver bristol myer beat earning opdivo myer squibb first quarter earning share exceed zack consensus estimate year quarter earning total revenue be slightly higher zack consensus estimate increase record year period strong sale opdivo eliquis contribute top line report quarter quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase unite state outside country ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year sale drug be label expansion drug pediatric patient unite state last november presumably do not have much impact sale rheumatoid arthritis drug orencia be first quarter melanoma drug yervoy contribute top line report quarter sale drug be opdivo be approve multiple cancer indication generate revenue year period sale cardiovascular drug eliquis be report quarter year year multiple myeloma drug empliciti record sale year year however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively hepatitis franchise lose year quarter sale contribute mere revenue research development expense quarter decrease marketing selling administrative expense decline gross margin be quarter compare year quarter due change product mix regulatory quarter april fda approve opdivo yervoy combination regimen treat intermediate poor risk advanced renal cell carcinoma patient have not receive prior treatment march fda have grant priority review supplemental biologic license application sbla seek approval combination regimen treat microsatellite instability high mismatch repair deficient metastatic colorectal cancer april bristol myer collaborate johnson johnson subsidiary janssen develop commercialize factor xia inhibitor program include bms treat major thrombotic condition same month bristol myer privately hold illumina inc announce collaboration utilize latter next generation sequence technology february bristol myer squibb nektar therapeutic enter strategic development collaboration nektar lead immuno oncology program nktr collaboration company develop commercialize nktr combination opdivo opdivo yervoy more indication tumor type well potential combination other cancer agent respective company third party company plan initiate study renal cell carcinoma melanoma mid pipeline updatein april bristol myer announce datum phase iii study checkmate show superior progression free survival first line small cell lung cancer nsclc treat opdivo yervoy combination compare chemotherapy january bristol myer announce positive datum phase ii checkmate study evaluate combination opdivo yervoy patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer mcrc company also announce datum phase iii study checkmate evaluate opdivo chinese population datum show drug achieve superior overall survival previously treat patient nsclc compare docetaxel datum long term follow phase iii study checkmate show opdivo reduce risk death metastatic squamous cell carcinoma head neck minimum year follow compare standard chemotherapy march bristol myer pfizer announce datum real world datum analysis different direct oral anticoagulant include eliquis xarelto boehringer ingelheim pradaxa datum show eliquis achieve significantly lower rate stroke systemic embolism major bleed compare xarelto pradaxa guidance updatedbristol myer increase adjust earning expectation company now project earning range share previously zack consensus estimate earning be peg company expect worldwide revenue increase mid single digit have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarterbristol myer squibb company price consensus bristol myer squibb company price consensus bristol myer squibb company quotevgm scoresat time bmy have strong growth score grade same score momentum front stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be equally suitable growth momentum investor value investor want look elsewhere outlookestimate have be trend upward stock magnitude revision look promising notably bmy have zack rank hold expect line return stock next few month
32,BMY,share newlink genetic corp nlnk free report plunge announce conduct review study evaluate ido pathway inhibitor indoximod combination pd pd agent several cancer indication include melanoma share company have also decline year compare industry decline newlink decision come response incyte corp incy free report partner merck mrk free report announcement failure key melanoma combination study friday incyte merck say combination incyte epacadostat merck keutruda fail achieve improve progression free survival keytruda alone phase iii study echo keynote study be evaluate combination drug treatment unresectable metastatic melanoma external datum monitoring committee recommend termination study follow review datum pivotal study datum phase iii study demonstrated combination ido inhibitor pd antagonist not hold potential treatment melanoma obviously raise doubt potential success indoximod combination study pd pd agent newlink provide update review be complete newlinkclaims indoximod have differentiate mechanism action moa have demonstrated improve outcome patient cancer combination study result echo study also affected several company bristol myer squibb bmy free report be develop combination immunotherapy treatment cancer newlink genetic corporation price newlink genetic corporation price newlink genetic corporation quotezack rank newlink carry zack rank hold see complete list today zack rank stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
33,BMY,incyte corporation incy free report partner merck mrk free report announce failure combination therapy incyte epacadostat merck keytruda achieve improve progression free survival keytruda alone phase iii study echo keynote study be evaluate combination drug treatment unresectable metastatic melanoma external datum monitoring committee recommend termination study follow review datum pivotal study datum phase iii study demonstrated combination ido inhibitor pd antagonist not hold potential treatment melanoma share company tumble nearly apr follow disappointing news incyte stock have be so far year compare industry loss period epacadostat ido inhibitor immunotherapy be late stage pipeline candidate incyte be be develop combination other immunotherapy include merck pd therapy keytruda bristol myer squibb bmy free report pd inhibitor opdivo ctla inhibitor yervoy incyte be develop combination therapy several other indication include small cell lung cancer renal cell carcinoma squamous cell carcinoma head neck bladder cancer epacadostat combination therapy have achieve improve response rate mid stage study however failure pivotal melanoma study larger patient population increase risk setback other late stage study other indication follow news failure share newlink genetic corporation nlnk free report small ia base biotech company sank nearly friday newlink be also develop ido pathway inhibitor indoximod combination pd pd agent several cancer indication include melanoma incyte corporation price incyte corporation price incyte corporation quotezack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
34,BMY,be happen week pharma stock key development week include new car deal pfizer pfe free report successful study result pfizer lilly lly free report allergan agn free report positive regulatory update astrazeneca azn free report recap week most important storiespfizer car deal tafamidis succeed late stage study pfizer announce alliance private biotech allogene therapeutic expedite development allogeneic car therapy pfizer own stake allogene also get representation latter board meanwhile cnbc report say pfizer be talk consumer giant procter gamble regard sale consumer healthcare segment last month glaxo gsk free report reckitt benckiser group pull discussion pfizer buy same unit read more pfizer inks new car deal talk unit sale pfizer pipeline candidate tafamidis develop treatment transthyretin cardiomyopathy ttr cm meet main goal late stage study attr act top line datum attr act study show treatment tafamidis lead statistically significant reduction combination cause mortality frequency cardiovascular related hospitalization primary endpoint compare placebo month read more pfizer rare disease candidate meet endpoint phase iii pfizer regulatory application pipeline candidate dacomitinib be accept priority review unite state response expect september company be look get drug approve first line treatment patient locally advanced metastatic small cell lung cancer nsclc egfr activate mutation read more pfizer lung cancer candidate get fda priority review lilly cyramza meet os endpoint liver cancer study lilly announce already approve cancer drug cyramza show overall survival benefit thereby meeting primary endpoint late stage study evaluate second line treatment liver cancer study also meet secondary endpoint progression free survival read more lilly cyramza show survival benefit liver cancer study astrazeneca provide regulatory update astrazeneca diabetes treatment bydureon gain fda approval add therapy insulin glargine also biologic license application bla seek approval astrazeneca cd recombinant immunotoxin candidate moxetumomab pasudotox second later line treatment hairy cell leukaemia hcl be grant priority review fda fda grant priority review decision be expect third quarter regulatory development astrazeneca partner merck mrk free report regulatory submission look expand label parp inhibitor lynparza include breast cancer indication be accept eu lynparza be already approve treat ovarian cancer eu latest filing astrazeneca look get lynparza approve brca mutate negative metastatic breast cancer eu unite state lynparza be approve same indication january read more astrazeneca bydureon get fda nod expand use allergan vraylar succeed label expansion study allergan partner gedeon richter say vraylar cariprazine meet primary endpoint late stage study adult major depressive episode associate bipolar disorder bipolar depression be third pivotal study conduct indication datum study be include company label expansion application company plan file second half read more allergan vraylar meet endpoint bipolar phase iii bio path mid stage study leukemia candidate show positive early datum bio path holding announce positive interim datum phase ii study bp lead pipeline candidate prexigebersen be be evaluate combination low dose cytarabine ldac treatment patient acute myeloid leukemia aml elect not be treat more intensive chemotherapy combination therapy demonstrated early leukemic activity nearly evaluable aml patient study total patient achieve form response combo treatment share bio path shot response read more bio path leukemia combo study show positive early datum fda approve sonoma skin gel sonoma pharmaceutical small solution maker skin condition advanced tissue care gain fda approval antimicrobial post treatment gel gel aim treat itch pain associate procedure include laser skin resurface post therapy chemical peel share sonoma shot more response nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report glaxo be biggest gainer rise bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup abbv rova disappoint unit get buyout offer next pharma world watch regulatory pipeline news pharma stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
35,BMY,be week see protagonist stock crash news discontinuation phase iib study amgen reptha get positive chmp opinion verona pharma stock rally positive top line datum copd study fda accept sbla bristol myer opdivo recap past week most important plummet study result share protagonist therapeutic ptgx free report plummet announcement discontinuation phase iib study propel ulcerative colitis uc candidate ptg company decide discontinue study plan interim analysis propel study independent datum monitoring committee determine study not be able achieve primary endpoint clinical remission interim analysis be do datum first patient have complete week treatment ptg total patient population study be company have notified stop further treatment patient currently study protagonist have also postpone decision initiate phase ii iii ptg patient chronic pouchitis await full review interim datum propel study read more protagonist therapeutic stall ulcerative colitis study amgen repatha get positive chmp opinion amgen amgn free report announce committee medicinal product human use chmp european medicine agency ema render positive opinion company regulatory application seek approval include datum cardiovascular outcome study fourier european label pcsk inhibitor repatha application seek new indication repatha label adult establish atherosclerotic cardiovascular disease myocardial infarction stroke peripheral arterial disease reduce cardiovascular risk lower ldl level concurrently chmp give positive opinion marketing authorization amgen allergan agn free report abp biosimilar roche oncology drug herceptin biosimilar have be recommend approval treatment same type cancer positive metastatic breast cancer positive early breast cancer positive metastatic adenocarcinoma stomach junction read more amgen repatha gain chmp nod include outcome datum verona pharma surge study result share verona pharma plc vrna free report surge follow positive top line datum phase iib study evaluate pipeline candidate rpl rpl first class inhaled dual inhibitor be be evaluate maintenance treatment chronic obstructive pulmonary disease copd study meet primary endpoint rpl demonstrated clinically statistically significant improvement lung function dose level additionally secondary endpoint be also meet support potential clinical benefit rpl treatment copd positive result study support progression rpl later stage development inhaled treatment copd patient verona pharma doesn have approve product portfolio successful development drug significantly boost result bristol myer opdivo sbla accept fda fda accept bristol myer squibb company bmy free report supplemental biologic license application sbla blockbuster drug opdivo combination yervoy treatment adult microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan agency have also grant application priority review set action date jul combination be already approve variety oncology indication seattle genetic get breakthrough therapy designation enfortumab seattle genetic inc sgen free report partner astella pharma inc announce fda have grant breakthrough therapy designation antibody drug conjugate adc enfortumab vedotin treatment patient suffering locally advanced metastatic urothelial cancer be previously treat checkpoint inhibitor cpi candidate be be study pivotal clinical trial ev nct monotherapy patient set early phase clinical trial combination cpi therapy ev nct company be also evaluate enfortumab vedotin other solid tumor include ovarian small cell lung carcinoma pharma plunge positive trial pharmaceutical hold company ltd bhvn free report share plunge significantly company announce positive top line result phase iii trial bhv bhv migraine candidate rimegepant formerly know bhv rimegepant be oral cgrp receptor antagonist be be evaluate acute treatment migraine cgrp receptor antagonist represent novel class drug candidate treatment migraine result be statistically significant clinically meaningful multiple outcome measure candidate meet co primary efficacy endpoint superiority placebo hour post dose pain freedom freedom most bothersome symptom company be schedule submit nda rimegepant however investor be not much impressed datum compare rival allergan migraine candidate ubrogepant medical biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock biogen lose last month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup alxn arna study datum prta team celgene next biotech world stay tune more regulatory pipeline update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
36,BMY,bristol myer squibb company bmy free report have announce supplemental biologic license application sbla pd immune checkpoint inhibitor opdivo nivolumab combination yervoy ipilimumab have be accept fda priority review company seek approval label expansion combination therapy address patient previously treat microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc response regulatory body be await jul opdivo yervoy combo regimen have also be grant breakthrough therapy designation fda aforementioned indication notably opdivo acquire nod several country include unite state eu japan several cancer indication share company have rally past year outperform industry gain acceptance application be base positive datum phase ii checkmate study announce january evaluate combination therapy give indication result study show primary endpoint objective response rate investigator assessment be median follow month overall survival rate year be median os be not yet reach outcome show opdivo yervoy provide durable clinical relief patient dmmr msi metastatic colorectal cancer datum demonstrated statistically significant clinically meaningful improvement key patient report include symptom function quality life significantly combination procedure be also assessment phase iii checkmate trial first line treatment small cell lung cancer nsclc last month bristol myer announce positive datum program reflect superior progression free survival first line nsclc patient compare chemotherapy be first study examine combination regime immune oncology drug first line nsclc patient high tumor mutation burden company press release colorectal be most common cancer type third lead cause terminal disease related death unite state approximately new case crc be expect be diagnosed annually country moreover patient msi dmmr metastatic crc have mild possibility benefit conventional chemotherapy treatment hence approval combo treatment provide company access huge patient population base need alternative treatment option apprehend disease however bristol myer face fierce competitive pressure immuno oncology space fact opdivo battle stiff rivalry merck mrk free report pd immunotherapy keytruda roche tecentriq merck keytruda be also be analyze phase iii study crc hence label expansion opdivo yervoy combination lend company wider population base patient opdivo few approve drug treat patient crc be lilly lly free report cyramza roche rhhby free report avastin amgen vectibix bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quote zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
37,BMY,merck kgaa announce japanese ministry health labour welfare mhlw have grant sakigake fast track designation pipeline candidate tepotinib company be develop candidate treatment advanced small cell lung cancer nsclc sakigake designation be grant expedite candidate development review japan focus new unmet area regenerative medicine merck kgaa share have underperform industry so far year stock have lose compare industry decline period designation be grant tepotinib base datum phase ii study evaluate nsclc patient meet exon skip mutation be approve treatment indication datum study be present future medical congress apart tepotinib merck kgaa oncology pipeline include be bifunctional immunotherapy simultaneously block immuno inhibitory pathway be commonly used cancer cell company be evaluate candidate several tumor however most advanced candidate oncology pipeline avelumab be be develop collaboration pfizer pfe free report several indication include lung gastric ovarian kidney cancer press release lung cancer be most common cancer globally nsclc occur lung cancer patient however tepotinib target only nsclc patient have meet exon skip mutation however several big pharma company be already marketing drug treat nsclc include merck mrk free report pd therapy keytruda pfizer xalkori bristol myer bmy free report pd immune checkpoint inhibitor opdivo merck kgaa price merck kgaa price merck kgaa quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
38,BMY,exelixis inc exel free report european partner ipsen receive positive opinion committee medicinal product human use chmp use cabometyx cabozantinib mg mg mg first line treatment adult intermediate poor risk advanced renal cell carcinoma rcc chmp be scientific committee european medicine agency ema decision now be review european commission remind investor exelixis enter collaboration license agreement ipsen february further development cabozantinib ipsen receive exclusive right current potential future cabozantinib indication outside unite state canada japan term exelixis be eligible receive milestone payment approval first line treatment advanced rcc approximately be recognize collaboration revenue first quarter payment be paid ipsen day notification approval decision european commission fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced rcc patient have receive prior angiogenic therapy drug be also approve euorpe september treatment advanced rcc adult follow prior vascular endothelial growth factor vegf target therapy chmp recommendation expand indication be base result cabosun trial meet primary endpoint improve progression free survival compare sunitinib patient previously untreated advanced rcc determine be intermediate poor risk international metastatic rcc database consortium criterium december fda also approve cabometyx treatment previously untreated advanced rcc approximately month ahead assign prescription drug user fee act action date potential approval europe further boost exelixis top line milestone payment exelixis share have rally year outperform industry decline exelixis recently submit supplemental new drug application fda cabometyx tablet treatment patient previously treat advanced hepatocellular carcinoma exelixis have also inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent zack rank stock currently carry zack rank sell better rank stock same space be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
39,BMY,seattle genetic inc sgen free report announce fda have approve supplemental biologic license application seek label expansion adcetris include treatment treatment naive stage iii iv classical hodgkin lymphoma chl combination chemotherapy decision come more month earlier expect fda also approve conversion accelerate approval adcetris regular approval treatment systemic anaplastic large cell lymphoma salcl patient have fail least multus agent chemotherapy regimen therapy approval come basis head head study echelon adcetris chemotherapy compare current standard care seattle genetic share have return so far year industry decline period phase iii echelon study evaluate adcetris combination chemotherapy regimen avd adriamycin vinblastine dacarbazine abvd adriamycin bleomycin vinblastine dacarbazine current standard care chemotherapy regimen treatment newly diagnosed advanced chl datum study show adcetris combination therapy achieve statistically significant improvement progression free survival pfs compare abvd combination therapy reduce risk progression death need additional anticancer therapy patient do not achieve complete remission overall survival os rate be favorable adcetris regimen however do not show significant difference complete remission be achieve patient treat adcetris regimen compare abvd therapy american cancer society approximately half newly diagnosed patient hodgkin lymphoma unite state have stage iii iv disease adcetris be already approve indication include second later line treatment chl drug be only market drug company major revenue generator label expansion certainly boost prospect go forward however drug have several competitor include bristol myer squibb bmy free report opdivo merck mrk free report keytruda be approve relapse refractory chl seattle genetic inc price seattle genetic inc price seattle genetic inc quotezack rank stock considerseattle genetic currently carry zack rank sell horizon pharma public limit company hznp free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here horizon pharma earning estimate increase last day company deliver positive earning surprise trail quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
40,BMY,celldex therapeutic inc cldx free report incur first quarter loss exclude goodwill impairment charge cent share wider zack consensus estimate loss cent narrower year loss cent lower cost higher revenue lead year year improvement total revenue quarter soar year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative frontier biotechnology drive top line share company fall wider expect loss discontinuation development candidate include earlier announce glembatumumab vedotin however stock have not do too well so far year have decline compare industry decrease quarterly detailsresearch development expense be year year quarter general administrative expense be year year mar celldex have cash cash equivalent marketable security compare mar biotech company weaken cash position be due higher operate expense partially offset net proceed raise sale common stock month contract cantor outlookcelldex expect cash position end december net proceed generate sale common stock last month anticipate proceed future sale common stock agreement cantor be adequate fund work capital requirement well plan operation discontinue clinical studiesin april company announce failure antibody drug conjugate adc candidate glembatumumab vedotin phase iib metric study evaluate breast cancer follow failure company have decide discontinue development candidate indication include metastatic melanoma apart glembatumumab vedotin celldex announce earning release discontinuation development early phase adc candidate cdx antibody fusion protein candidate cdx company have take decision better allocation resource pipeline focuscelldex be now focuse development cdx cdx varlilumab cdx be evaluate externally investigator sponsored study however company evaluate varlilumab cdx internally combination study be several preclinical candidate pipeline include cdx january company close enrollment phase ii trial evaluate varlilumab bristol myer bmy free report opdivo include cohort indication namely colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma phase ii study be currently evaluate cdx human monoclonal antibody combination eli lilly lly free report erbitux treatment advanced head neck squamous cell cancer phase study be evaluate cdx several solid tumor celldex be plan add cohort evaluate cdx combination cdx varlilumab investigator initiate study be evaluate cdx advanced small cell lung cancer celldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quotezack rank stock considercelldex currently carry zack rank hold enanta pharmaceutical inc enta free report be better rank stock drug sector carry zack rank buy see complete list today zack rank stock here enanta earning share estimate significantly increase cent last day company come average beat stock have surge so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
41,BMY,week eli lilly lly free report announce cash deal tobuy immuno oncology biotech armo bioscience inc jnj free report multiple myeloma drug darzalex gain fda approval combination use first line set roche rhhby free report announce couple regulatory pipeline update pd inhibitor tecentriq astrazeneca azn free report sell right schizophrenia product parp inhibitor lynparza gain marketing approval eu recap week most important storieslilly expand immunotherapy pipeline armo eli lilly announce definitive agreement buy california base immuno oncology biotech armo bioscience share approximately cash deal acquisition add armo lead product candidate pegilodecakin lilly cancer pipeline pegilodecakin pegylate il be be study late stage study pancreatic cancer well early stage study lung renal cell cancer melanoma other solid tumor type armo bioscience go public january year lilly have well layer oncology strategy involve build key cancer treatment cyramza lartruvo verzenio foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy armo bioscience acquisition add promising next generation immunotherapy pipeline asset lilly portfolio be line strategy transaction be expect close end second quarter darzalex get fda nod first line set multiple myeloma drug darzalexgain fda approval first line set latest approval darzalex now be prescribe combination bortezomib melphalan prednisone vmp treatment ofpatient newly diagnosed multiple myeloma be ineligible autologous stem cell transplantation theapproval first line set expect year be expect darzalex saleswill improve further go forward also announce datum phase iii study evaluate investigational compound esketamine nasal spray combination newly initiate oral antidepressant niod patient treatment resistant depression compare placebo nasal spray niod combination demonstrated statistically significant clinically meaningful rapid reduction depressive symptom treatment flexibly dose esketamine nasal spray niod compare placebo niod study adult however study conduct elderly patient age older esketamine arm witness clinically meaningful effect compare placebo arm study narrowly miss statistical significance primary efficacy endpoint result be present annual meeting american psychiatric association astrazeneca sell seroquel right luye pharma astrazeneca announce agreement sell seroquel seroquel xr treatment schizophrenia bipolar disease right uk china other international market luye pharma group total consideration be include upfront payment well certain future payment astrazeneca transaction expect close second quarter be part company effort focus main therapy area oncology cardiovascular renal metabolism respiratory sale seroquel seroquel xr have be decline drug be face generic competition november seroquel xr record sale represent year year decline astrazeneca merck parp inhibitor lynparza tablet gain euapproval use maintenance therapy platinum sensitive relapse ovarian cancer regardless patient brca mutation status approval thus expand eligible patient population lynparza approval same indication unite state be receive august last year roche tecentriq focus roche supplemental biologic license application sbla label expansion pd inhibitor tecentriq be grant priority review fda latest application roche be look get tecentriq approve combination avastin bevacizumab carboplatin paclitaxel first line treatment advanced squamous small cell lung cancer nsclc fda decision be expect sep tecentriq be presently market treatment second line metastatic nsclc label expansion first line set boost drug sale further tecentriq be also approve treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug record sale chf news tecentriq roche announce late stage study evaluate drug combination cotellic heavily pre treat patient advanced metastatic colorectal cancer crc do not meet primary endpoint overall survival os compare regorafenib nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week bristol myer bmy free report decline lilly rise most past month glaxo gsk free report have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup mixed mrk pfe fda nod kymriah indication next pharma world watch fda decision many pipeline drug line extension market product month medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
42,BMY,total earning total healthcare market capitalization be revenue growth growth rate seem unimpressive compare other sector earning revenue beat ratio respectively be also not great most notable player johnson johnson jnj free report be first major drug company report earning apr follow eli lilly company lly free report bristol myer squibb company bmy free report apr apr respectively other major drug company merck mrk free report pfizer pfe free report report industry bigwig come earning revenue beat earning focusjohnson world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past estimate johnson johnson raise revenue guidance maintain earning share outlook reflect growth read healthcare etfs focus johnson johnson earning drug giant surpass earning estimate lag revenue earning share cent come cent zack consensus estimate revenue fall shy estimate annual basis earning share revenue rise respectively pfizer expect revenue range earning share merckmerck also beat earning estimate miss revenue earning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be estimate merck increase revenue guidance earning share guidance bristol myersbristol myer top estimate front report earning share cent cent zack consensus estimate ahead year earning cent revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lillyeli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue guidance earning guidance etf anglepharma etfs see terrible trading past month mediocre result fail boost confidence space push many fund week lows have highlighted detail fund have zack etf rank hold ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period read be spdr pharmaceutical etf xph free report hot etf right now vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account more share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest least share bmy pfe lly etf have lose month first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly make more ftxh have lower level aum share average daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
43,BMY,celldex therapeutic inc cldx free report be expect report first quarter result last quarter company deliver positive earning surprise company have impressive track record earning beating estimate thrice meeting same once deliver average positive earning surprise however celldex therapeutic share have lose so far year compare decline industry period let see thing be shape announcement factor playcelldex earn revenue entirely product development licensing agreement contract grant company recognize revenue clinical trial collaboration bristol myer squibb company bmy free report varlilumab company continue record revenue source first quarter approve product portfolio investor focus remain pipeline development april celldex have setback lead pipeline candidate glembatumumab vedotin fail phase iib breast cancer study metric candidate be also not able demonstrate significant advantage chemotherapy first quarter celldex add fourth cohort glembatumumab cdx arm phase ii study evaluate glembatumumab vedotin metastatic melanoma combination be evaluate melanoma patient have fail prior fail prior checkpoint therapy company have oncology candidate varlilumab pipeline january company close enrollment phase ii trial evaluate varlilumab bristol myer opdivo several inidcation apart glembatumumab vedotin varlilumab celldex have several promising candidate pipeline include cdx cdx phase ii multiple solid tumor cdx phase advanced renal cell carcinoma other january celldex expand phase study cdx advanced renal cell carcinoma include patient ovarian clear cell carcinoma sg cost decline last report quarter operate expense vary quarterly basis earning whispersour proven model do not conclusively show celldex be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank celldex zack rank increase predictive power esp esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision celldex therapeutic inc price ep surprise celldex therapeutic inc price ep surprise celldex therapeutic inc quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter aptevo therapeutic inc apvo free report have earning esp zack rank company be expect release first quarter result see complete list today zack rank stock here array biopharma inc arry free report have earning esp zack rank company be schedule release first quarter result medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
44,BMY,latest earning preview earning season have already crossed half way mark be gain strength earning revenue growth track reach highest level year total earning member have already report result be same period last year higher revenue beating top line estimate beating revenue estimate proportion company beating earning revenue estimate be ongoing earning season seem have start solid note drug biotech sector major large cap player have report result bristol myer squibb bmy free report abbvie abbv free report beat zack consensus estimate earning well sale amgen inc amgn free report also surpass earning revenue expectation quarter higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor be expect keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue witness rise earning quarter review pharma biotech giant be schedule report earning result let see thing be shape company upcoming release pfizer inc pfe free report be slate releaseresult market open company deliver positive earning surprise last report quarter company performance have be impressive recent past earning surpass expectation trail quarters average beat accord zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp combination company zack rank earning esp make reasonably confident earning beat zack consensus estimate company earning quarter review be peg cent share innovative health segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be expect drive top line essential health biosimilar emerge market be expect support sale bottom line be expect be drive cost saving share buyback read more pfizer earning beat estimate again pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotemerck co inc mrk free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise model do not conclusively show merck beat estimate quarter be stockha earning esp zack rank zack consensus estimate quarterly earning be peg cent share see complete list today zack rank strong buy stock here merck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale read more card merck earning season merck co inc price ep surprise merck co inc price ep surprise merck co inc quotegilead science inc gild free report be slate report result market close company deliver positive earning surprise trail quarters average beat last report quarter gilead deliver positive earning surprise model show gilead be likely beat estimate quarter combination gilead zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share company strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost read more be beat card gilead earning gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteincyte corporation incy free report be slate report result market open incyte track record have be impressive so far company deliver positive earning surprise trail quarters average beat last report quarter incyte deliver positive earning surprise model show incyte be likely beat estimate quarter combination incyte zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter incyte continue gain traction lead drug jakafi performance incyte jakafi performance be strong drive patient demand sale guidance be also impressive october fda approve label update drug include addition new patient report outcome datum comfort study well update warning related progressive multifocal pivotal reach trial evaluate jakafi patient steroid refractory acute graft versus host disease have complete enrollment result be expect first half assume successful result incyte expect submit snda seek approval jakafi indication jakafi sale be expect get boost update label read more jafaki help incyte beat earning estimate incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
45,BMY,biggest news week be pfizer pfe free report announcement plan re organize business new segment effective next year jnj free report be order st loui jury pay approximately nearly dozen woman lawsuit related talc base product merck mrk free report abbvie abbv free report bristol myer bmy free report provide update cancer drug pfizer re organize business unit pfizer be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently pfizer have report segment namely innovative health essential health present innovative health unit be call innovative medicine unit now include biosimilar new hospital business unit infective sterile injectable be presently report essential health essential health unit now be rename establish medicine unit include pfizer legacy brand have lose lose market exclusivity read more pfizer reorganize business new unit pay talc lawsuit be order jury st loui court pay damage woman allege talc base product include baby powder contain asbestos cause develop ovarian cancer damage comprise compensatory damage punitive damage official statement say verdict be unfair appeal also say talc product neither contain asbestos cause cancer face more case talc product trump slam pfizer price hike pfizer defer increase tweet president donald trump slam pfizer raise price several prescription drug effective jul trump say pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas warn administration respond day tweet be publish pfizer issue statement say defer price increase president drug pricing blueprint go effect end year be earlier abbvie imbruvica lymphoma study fail abbvie announce late stage study evaluate cancer drug imbruvica first line treatment diffuse large cell lymphoma dlbcl fail meet primary endpoint study evaluate addition imbruvica chop combination rituximab doxorubicin vincristine prednisone be exist standard care dlbcl aggressive form hodgkin lymphoma nhl versus chop placebo however study datum show add imbruvica chop do not improve event free survival ef target patient population imbruvica be presently fda approve indication include cell blood cancer well chronic graft versus host disease drug abbvie market partnership record sale first quarter include sale international profit sharing abbvie also file supplemental new drug application snda fda label expansion venclexta venetoclax first line treatment acute myeloid leukemia aml abbvie be look get venclexta approve combination hypomethylating agent hma low dose cytarabine ldac aml patient be ineligible intensive chemotherapy read more abbvie imbruvica fail phase iii blood cancer study merck keytruda sbla get priority review merck supplemental biologic license application sbla look expand label keytruda previously treat patient advanced hepatocellular carcinoma hcc most common type liver cancer be grant priority review fda fda decision be expect nov sbla filing be base datum phase ii keynote study read more merck keytruda get fda priority review liver cancer bristol myer opdivo yervoy combo get fda nod colorectal cancer bristol myer announce accelerate approval combination immuno oncology drug opdivo yervoy type colorectal cancer combination be now approve previously treat patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer opdivo yervoy combination be also approve other tumor type first line treatment intermediate poor risk advanced renal cell carcinoma unresectable metastatic melanoma read more bristol myer combo drug get fda nod colorectal cancer cti biopharma slump study failure share cti biopharma ctic free report slump monday pivotal study evaluate combination regimen cancer drug pixuvri hodgkin lymphoma fail improve progression free survival pixuvri have conditional approval europe monotherapy treatment multiply relapse refractory aggressive cell nhl however be yet receive approval unite state read more cti biopharma fall failure pivotal lymphoma study nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record increase last week astrazeneca azn free report gain most past month glaxo have be biggest gainer jnj free report decline most see last pharma stock roundup here pharma stock roundup nvs divest eye care unit chmp give nod several drug next pharma world watch earning bigwig pharma world later month begin jul medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
46,BMY,be not many development pharma sector week swiss pharma giant roche rhhby free report announce be buy remain stake molecular information company foundation medicine inc fmi free report small drugmaker ptc therapeutic inc ptct free report unveil promising early stage datum spinal muscular atrophy sma candidate recap week most important storiesroche buy remain stake foundation medicine swiss pharma giant roche say buy remain stake molecular information company foundation medicine share add total transaction value price mark premium close price foundation medicine jun value cambridge base company deal aim strengthen roche development effort personalize therapy treat cancer leverage foundation medicine high quality comprehensive genomic profile cgp testing innovative datum service deal be expect close second half year roche initially have buy roughly stake foundation medicine read more roche buy rest foundation medicine ptc therapeutic unveil promising early stage datum sma drug ptc therapeutic present encourage preliminary datum early stage study evaluate gene therapy candidate risdiplam baby type spinal muscular atrophy sma early stage datum demonstrated improve muscle performance nearly baby treat risdiplam share ptc therapeutic rise almost response news however share ptc therapeutic decline sharply day follow announcement be rival company sarepta therapeutic announce better expect result early stage study evaluate gene therapy treatment patient duchenne muscular dystrophy dmd ptc therapeutic also market therapy treat dmd fda accept bristol myer sbla opdivo yervoy combo lung cancer bristol myer bmy free report supplemental biologic license application sbla label expansion pd inhibitor opdivo nivolumab combination low dose yervoy first line lung cancer be accept fda bristol myer be look get combination immunotherapy drug approve treatment small cell lung cancer patient tumor mutational burden mutation megabase fda be expect give decision feb next year shire hae drug get fda nod pediatric population shire gain fda approval label expansion hereditary angioedema hae drug cinryze include use pediatric patient year older cinryze be approve unite state october routine prophylaxis attack adolescent adult live hae rare genetic disorder cause painful swell various part body approval pediatric population drive sale drug higher future quarters nordisk sign deal kallyope present positive diabetes study result denmark base pharma giant nordisk nvo free report enter collaboration new york base biotech kallyope inc peptide therapeutic obesity diabetes deal kallyope receive upfront payment potential research development sale milestone depend term deal nordisk also have option agreement license exclusive worldwide right develop commercialize product discover part collaboration case nordisk exercise option kallyope be entitle receive license fee nordisk also present headline result phase iii study oral formulation type ii diabetes medicine semaglutide first study pioneer compare oral semaglutide nordisk other diabetes medicine victoza other study pioneer compare oral semaglutide merck mrk januvia sitagliptin study show oral semaglutide lead statistically significant reduction hba weight compare victoza januvia respectively semaglutide be presently sell ozempic weekly injection several country nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record decline last week pfizer pfe free report bristol myer be flat glaxo decline most past month glaxo gsk free report have be biggest gainer decline most see last pharma stock roundup here pharma stock roundup lly azn alzheimer drug fail mrk keytruda win approval next pharma world watch fda decision several pipeline drug line extension market product month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
47,BMY,bristol myer squibb company bmy free report announce positive result phase ii study eloquent oncology drug empliciti study be evaluate addition empliciti pomalyst low dose dexamethasone epd patient relapse refractory multiple myeloma rrmm international study be evaluate pomalyst base triplet combination patient rrmm receive least prior therapy include revlimid proteasome inhibitor study achieve primary endpoint result show statistically significant clinically meaningful improvement progression free survival pfs patient treat epd compare only pomalyst dexamethasone pd datum be also present rd congress european hematology association datum study show patient randomize epd experience reduction risk disease progression compare patient randomize pd alone median pfs month compare month pd patient additionally pfs benefit experience patient randomize epd be consistent patient have receive prior line therapy more prior line therapy combination therapy approve provide important treatment option patient relapse refractory multiple myeloma disease have progressed treatment lenalidomide proteasome inhibitor bristol myer be co develop empliciti abbvie abbv free report bristol myer share have decline year date compare industry decline earlier company announce china national drug administration have approve blockbuster immuno oncology drug opdivo treatment locally advanced metastatic small cell lung cancer nsclc prior platinum base chemotherapy adult patient egfr alk genomic tumor aberration company be first only pd inhibitor approve china approval be base datum pivotal phase iii study checkmate trial patient enrolled be china note opdivo become first pd immune checkpoint inhibitor gain regulatory approval be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc label expansion additional indication give product access higher patient population increase commercial potential drug significantly however opdivo face stiff competition merck mrk free report keytruda roche rhhby free report tecentriq limit market share gain zack rank stock considerbristol myer carry zack rank hold see complete list today zack strong buy rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
48,BMY,week be rule cancer datum presentation annual meeting american society clinical oncology asco chicago pharma bigwig bristol myer bmy free report merck mrk free report roche rhhby free report other jak inhibitor be news week lilly lly free report finally gain fda approval rheumatoid arthritis ra candidate olumiant baricitinib unite state abbvie abbv free report present positive top line datum fifth late stage study upadacitinib ra recap week most important storiesupdate asco merck steal show asco present datum several cancer study pd inhibitor keytruda key presentation be pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival particularly datum keynote study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be consider practice change investor year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc bristol myer nektar therapeutic nktr present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result drop nektar stock monday read more nektar bristol myer present datum cancer study bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression novartis nvs announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna roche present datum late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone abbvie present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenström rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer pfe free report astrazeneca also make cancer datum presentation meeting lilly get fda nod lower dose olumiant eli lilly partner incyte gain fda approval lower dose mg company jak inhibitor olumiant fda do not approve higher dose mg drug label be approve box warning state risk serious infection malignancy thrombosis olumiant be already market europe japan generate sale first quarter unite state lilly face significant trouble get fda nod olumiant april last year fda have issue complete response letter new drug application seek approval olumiant request additional information determine most appropriate dose year april fda advisory committee have recommend approval lower dose drug not recommend higher dose mg inadequate safety profile support approval relative benefit read more eli lilly olumiant get fda nod rheumatoid arthritis abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint fifth phase iii study select program top line datum study show thata significantly higher proportion patient treat upadacitinib mg dose achieve superior response compare chemotherapy agent methotrexate abbvie plan submit regulatory application upadacitinib rheumatoid arthritis second half year read more abbvie upadacitinib fifth ra study datum positive allergan activist pressure split ceo chairman role allergan agn free report be pressure week hedge fund firm senator investment group appaloosa disclose letter urge company engage management board overhaul firm ask pharmaceutical company split chairman chief executive role presently hold brent saunder other management change appaloosa run david tepper senator investment group run dougla silverman suggest outsider be hire role letter come heel allergan strategic plan announce last week divest woman health infectious disease unit allergan respond say board have be refreshed addition member last month read more allergan request shareholder veto management change glaxo complete buyout novartis stake consumer healthcare jv glaxo announce have complete previously announce deal buy novartis stake consumer healthcare joint venture acquisition novartis stake glaxo now have ownership consumer healthcare unit include product such sensodyne flonase glaxo novartis create jv part part transaction company combine consumer division pfizer invest more venture capital arm pfizer plan invest venture capital arm pfizer venture be invest small biotechs other emerge growth company be earmark company involved promising early stage neuroscience research read more pfizer boost venture capital effort neuroscience focus meanwhile pfizer regulatory application orally available parp inhibitor talazoparib metastatic breast cancer patient inherited brca mutation be accept review fda european medicine agency unite state new drug application nda be grant priority review fda decision accept december year top line result talazoparib registrational study embraca germline brca mutate breast cancer present december demonstrated superiority talazoparib chemotherapy improve progression free survival roche haemophilium candidate get priority review roche sbla look label expansion drug hemlibra person haemophilium factor viii inhibitor be grant priority review fda hemlibra be presently market routine prophylaxis prevent reduce frequency bleed episode haemophilium patient factor viii inhibitor fda grant priority review decision be expect oct separately roche cancer drug rituxan gain fda approval new indication moderate severe pemphigus vulgaris pv potentially life threaten nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week astrazeneca decline merck rise most asco strength past month glaxo gsk have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup zoetis buy abaxis nvs get fda nod migraine drug next pharma world watch fda decision many pipeline drug line extension market product month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
49,BMY,world cancer research be change fast space be see huge development company be take great stride treat variety cancer cancer research be definitely exciting area investor keep close watch come year be disease be lead cause morbidity mortality world precede only heart disease day asco conference chicago be basically most important annual cancer research event conclude yesterday conference featured clinical update several company latest development treat disease merck mrk free report steal limelight asco present datum several cancer study pd inhibitor keytruda datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be difficult treat lung cancer patient population datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression pd be protein present surface cell risk death os be reduce compare chemotherapy alone pfs improvement be nearly half patient keytruda combination group compare chemotherapy alone datum be term practice change cnbc change way doctor look prescribe drug cancer patient further cement merck position lung cancer market be most lucrative oncology sector context mention roche rhhby free report also present datum similar late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone come back merck company also present datum pivotal lung cancer study keynote evaluate keytruda monotherapy first line nsclc patient pd expression least study also show treatment keytruda lead improve survival meanwhile year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd meanwhile keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc merck partner astrazeneca also present positive lynparza combo datum breast cancer share merck have go more friday jun asco strength nektar therapeutic nktr free report be biggest loser asco nektar partner bristol myer bmy free report present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result fall nektar stock jun be probably worst performance index member last year read more nektar bristol myer present datum cancer study merck bristol myer nektar currently have zack rank hold see complete list today zack rank strong buy stock here bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression celgene celg free report partner bluebird bio present early stage datum car cell therapy bb patient late stage relapse refractory multiple myeloma study show median pfs month heavily pre treat patient population datum do not impress investor celgene also present datum car therapy liso ce jcar acquire acquisition juno earlier year datum show month patient relapse refractory aggressive cell hodgkin lymphoma nhl remain remission maintain complete response read more celgene present datum car therapy revlimid pomalyst novartis nvs free report announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna abbvie abbv free report present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenström rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer amgen astrazeneca also make cancer datum presentation meeting today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
50,BMY,nektar therapeutic nktr free report bristol myer squibb bmy free report announce preliminary datum ongoing pivot phase ii study american society clinical oncology asco annual meeting study be evaluate combination nektar lead immuno oncology candidate nktr bristol myer squibb opdivo nivolumab company present datum patient enrolled phase dose escalation stage study first patient consecutively enrolled select dose expansion cohort phase ii pivot study show pre specify efficacy criterium be achieve tumor type first line melanoma first line renal cell carcinoma type kidney cancer first line urothelial cancer company plan commence phase iii registrational study first line advanced melanoma patient third quarter pivotal study be also be design renal cell carcinoma urothelial cancer efficacy criterium recommend phase ii dose be meet first stage patient consecutively enrolled second stage patient consecutively enrolled combination regimen be advanced registrational trial tumor type result treatment naïve patient stage iv metastatic melanoma show objective response rate orr first part study be treat subject response be observed patient stage study further datum show treatment naïve patient stage iv metastatic renal cell carcinoma orr stage study be patient response be see patient second phase study finally result treatment naïve patient stage iv metastatic urothelial carcinoma show orr first part study be patient same response rate pd negative patient pd positive tumour company add enrolment be also continue second stage pivot trial patient melanoma renal cell urothelial small cell lung triple negative breast cancer company add overall study week patient pd negative status baseline be converted pd positive status result show subject achieve stable disease partial response complete response share company be more response rate melanoma kindney cancer study be market expectation company believe nktr combination opdivo potentially expand treatment benefit bring patient cancer company add enrolment be also continue second stage pivot trial patient melanoma renal cell urothelial small cell lung triple negative breast cancer share nektar have decrease year date compare industry gain note opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy also note february nektar inked agreement bristol myer squibb jointly develop commercialize nktr combination bristol myer squibb opdivo opdivo yervoy ipilimumab more indication tumor type nektar be also conduct phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab notably propel study complement company ongoing pivot trial stock warrant looknektar carry zack rank hold see complete list today zack rank stock here nektar therapeutic price nektar therapeutic price nektar therapeutic hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
51,BMY,infinity pharmaceutical inc infi free report report loss cent share fourth quarter narrower zack consensus estimate loss cent company have report loss cent year quarter infinity do not have approve product portfolio company earn revenue form royalty license milestone payment well research development support fee paid partner infinity share have decline year industry gain quarter detailin quarter expense plummet year quarter decline be mainly due company restructure activity licensing duvelisib verastem inc vstm free report general administrative expense be quarter year quarter decrease be mainly due company restructure activity outlook infinity expect net loss be range company anticipate year end cash cash equivalent available sale security balance range moreover infinity expect exist cash cash equivalent available sale security dec be adequate fund company capital need third quarter company report loss cent compare loss cent collaboration revenue come other updatesinfinity be evaluate ipi monotherapy combination bristol myer bmy free report opdivo phase study patient advanced solid tumor phase ib monotherapy combination dose escalation component study have be complete monotherapy expansion component have be fully enrolled further disease specific combination expansion cohort be enrolling recommend phase ii dose mg once daily ipi opdivo mg week patient small cell lung cancer melanoma head neck cancer triple negative breast cancer mesothelioma adrenocortical carcinoma additional combination expansion cohort patient pre select have high baseline blood level myeloid derive suppressor cell be expect open enrollment next few week november infinity announce update datum monotherapy dose escalation component phase ib study ipi sitc annual meeting datum demonstrated ipi dose once daily be well tolerate clinically active company believe ipi have potential increase number patient respond immunotherapy well increase duration response company expect report datum monotherapy expansion combination dose escalation component study combination expansion cohort help define development regulatory strategy ipi restructure initiative take company have lower operate expense expect initiative have significant positive cumulative effect company margin infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc quotezack rank key pickinfinity have zack rank hold better rank stock same space be regeneron pharmaceutical regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat be hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
52,BMY,aveo pharmaceutical inc aveo free report report fourth quarter adjust loss cent share exclude gain due change fair value warrant liability wider zack consensus estimate loss cent well year loss cent however include gain related change fair value warrant liability company report earning cent aveo first drug fotivda tivozanib receive eu approval august first line treatment advanced renal cell carcinoma rcc subsequently november aveo partner eusa pharma launch drug europe start germany company be entitle receive double digit royalty payment eusa pharma net sale drug europe however fotivda be not yet approve unite state rcc aveo top line mainly comprise collaboration revenue milestone other payment total collaboration revenue fourth quarter be approximately compare year figure revenue miss zack consensus estimate share company have decline more mar follow earning release due wider loss lower sale however year date basis aveo share price movement show stock have outperformed industry specifically company share have gain compare industry increase quarterly development expense be however general administrative expense increase year year pipeline updatesin october aveo announce result pre plan futility analysis phase iii tivo study compare fotivda bayer bayry free report nexavar treatment patient refractory advanced rcc base result company continue study unmodified datum study previously complete tivo study support regulatory application approval unite state december company announce completion enrollment phase ii portion phase ib ii tinivo study evaluate fotivda combination bristol myer bmy free report opdivo rcc company expect provide update study second half apart fotivda aveo be also develop ficlatuzumab combination lilly lly free report erbitux phase ii study treat metastatic head neck squamous cell carcinoma phase ib study be evaluate ficlatuzumab combination nab paclitaxel gemcitabine treatment naive pancreatic cancer study be initiate december last year resultsfull year sale stand miss zack consensus estimate however top line drastically increase compare year figure full year earning cent share be narrower zack consensus estimate cent however bottom line be wider year loss cent cash guidanceaveo expect present cash resource allow company fund plan operation first quarter aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc quotezack rankaveo carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
53,BMY,cancer oncology space have always be keenly watch investor interested pharma biotech sector be disease be lead cause morbidity mortality world precede only heart disease major player field include pfizer pfe free report bristol myer bmy free report novartis nvs free report astrazeneca azn free report merck mrk free report roche rhhby free report cancer drug be most important revenue driver bigwig well smaller counterpart clovis oncology tesaro puma biotechnology othersevolution cancer spacea lot progress have be make area last few year company be aim bring newer better treatment immunotherapy gene therapy target therapy other novel therapy fact focus area have increase fda approval car therapy novartis kymriah gilead gild free report yescarta last year path breaking immunocellular therapy be time treatment used patient own cell fight cancer acquisition kite gilead juno celgene have lead renew interest area interest parp inhibitor have also increase considerably well be next major class therapeutic oncology accord imsquintile new cancer drug be approve indication worldwide cost cancer therapeutic supportive care drug shot unite state accounting cost more molecule be late stage development majority be target therapy attack specific feature target cancer cell new cancer drugsnew oncology brand include bristol myer opdivo merck keytruda pfizer ibrance abbvie imbruvica be fast catch give tough competition category stalwart such avastin herceptin rituxan new cancer drug approve last year include pfizer merck kgaa bavencio bladder cancer eli lilly verzenio novartis kisqali puma biotechnology nerlynx breast cancer tesaro zejula ovarian cancer most common indication new drug be small cell lung cancer nsclc hodgkin lymphoma melanoma breast cancer be patient population benefit go say new drug bring million buck company be sell huge amount money however be do enough cure patient help live longer better be relieve pain fatigue consider fact come premium fda have approve number oncology drug recent year also lower bar clinical study goal cancer candidate disease still remain top cause death many population here probably few drug have be successful allow patient limit life expectancy live year however efficacy several other be be question have lead only marginal benefit not much improvement survival quality life many drug be be approve base progression free survival amount time patient live tumor grow larger evidence benefit survival quality life be specially case drug aim treat terminal cancer few treatment option however overall survival os datum once available sometimes show drug do not help person live longer also drug do offer survival benefit gain be often marginal risk long term side effect drug have also be underestimated overall cancer survival have barely change past decade raise concern push get more drug approve instead get effective drug approve large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
54,BMY,astrazeneca plc azn free report have announce final overall survival datum pivotal phase iii mystic study evaluate pd inhibitor imfinzi first line lung cancer be present second half delay first half expect previously mystic study evaluate imfinzi monotherapy combination tremelimumab treatment naïve small cell lung cancer nsclc patient astrazeneca share have inched so far year compare unfavorably industry growth be second negative update astrazeneca relation mystic trial last july pharma company have report study failure meet primary endpoint progression free survival send company share tumble study show imfinzi combination tremelimumab not improve progression free survival pfs compare platinum base chemotherapy patient tumor express pd more cancer cell imfinzi monotherapy also fall short show benefit pfs however mystic study continue thereafter plan assess additional primary endpoint overall survival os monotherapy combination regimen final os datum primary endpoint be initially expect first half imfinzi be key drug london base astrazeneca immuno oncology io pipeline currently be evaluate multiple cancer alone combination other regimen include incyte incy free report epacadostat key phase iii trial combination tremelimumab hepatocellular carcinoma hcc liver cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other be way imfinzi be launch unite state first indication second line advanced bladder cancer be approve second indication unite state early stage lung cancer nsclc february drug generate sale last year talk pd inhibitor merck mrk free report keytruda bristol myer bmy free report opdivo have be notable successful launch keytruda fetch sale almost year year opdivo record revenue period astrazeneca carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
55,BMY,last week senator tina expressed concern big pharma company plan use large corporate tax saving reward shareholder instead bring cost expensive drug benefit consumer senator question letter ceo big pharma company pfizer pfe free report merck mrk free report johnson johnson jnj free report abbvie abbv free report abbott lab free report plan use extra cash please note conference call hold earlier year most big pharma company discuss plan do extra cash save new tax bill company plan invest extra cash capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback not many talk take step lower prescription drug cost apart key announcement week include failure dermira inc derm free report acne candidate pivotal late stage study merck oncology collaboration japan eisai expansion jardiance clinical study eli lilly lly free report fda committee back pfizer xeljanz third indication recap week most important storiesdermira share sink acne candidate fail share dermira plunge announce acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint pivotal phase iii study clareo clareo company say likely stop olumacostat glasaretil development follow failure read more dermira acne candidate fail pivotal trial share sink merck jointly develop eisai cancer drug lenvima similar last year profit sharing deal astrazeneca azn free report merck announce oncology collaboration japan eisai co ltd deal company jointly develop commercialize eisai tyrosine kinase inhibitor lenvima monotherapy combination merck pd therapy keytruda several type cancer deal merck give eisai upfront payment company share global development marketing cost well gross profit lenvima equally read more merck pay upfront co develop eisai cancer drug pfizer xeljanz snda get fda committee back pfizer supplemental new drug application include ulcerative colitis uc indication label receive back fda advisory committee fda drug advisory committee gidac vote unanimously favor jak inhibitor fda decision be expect june xeljanz be already approve treat rheumatoid arthritis active psoriatic arthritis record sale represent growth year year astrazeneca look forxiga eu approval type diabetes astrazeneca application look get sglt inhibitor forxiga approve new indication oral adjunct treatment insulin type diabetes patient be accept european medicine agency forxiga be presently approve monotherapy well combination therapy treat type diabetes approve forxiga become first sglt inhibitor approve europe treatment oral treatment adjunct insulin read more astrazeneca forxiga label expansion filing accept eu glaxo present asthma hiv datum glaxo gsk free report present datum osmo study new respiratory medicine nucala american academy allergy asthma immunology aaaai world allergy organization wao joint congress orlando datum study show patient asthma be uncontrolled xolair witness improve asthma control switch glaxo new respiratory medicine nucala glaxo also present interim datum phase iiib study inspiring investigational hiv candidate dolutegravir medical conference boston read more glaxo encourage asthma hiv datum medical meeting meanwhile glaxo gain approval expand european label once daily laba ics combination treatment relvar ellipta now relvar ellipta be used eu patient asthma be already adequately controlled ics laba label update doctor prescribe asthma patient switch once daily relvar ellipta current twice daily ics laba experience comparable benefit lung function safety profile lilly boehringer expand jardiance clinical study lilly partner boehringer ingelheim announce plan initiate phase iii emperial study evaluate effect lilly sglt inhibitor jardiance exercise ability heart failure symptom person chronic heart failure irrespective have type ii diabetes presently ongoing phase iii emperor outcome study be evaluate effect jardiance long term morbidity mortality outcome person heart failure emperial study investigate treatment jardiance help improve everyday life person live chronic heart failure read more lilly boehringer expand jardiance heart failure program nyse arca pharmaceutical index be last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session major stock rise largest gainer be glaxo lilly last month bristol myer bmy free report gain merck decline see last pharma stock roundup here azn imfinzi get fda nod mrk buy australian firm next pharma world watch regulatory pipeline news pharma stock don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
56,BMY,celldex therapeutic inc cldx free report have incur fourth quarter loss exclude income tax benefit cent share narrower zack consensus estimate loss cent well year loss cent lower cost higher revenue lead upside total revenue quarter soar year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative drive top line share company rise hour trading mar however stock have not do too well past year share company have underperform industry have decline compare industry decrease quarterly detailsresearch development expense decline year period general administrative spend improve dec celldex have cash cash equivalent marketable security compare sep biotech company weaken cash position be due higher operate expense partially offset net proceed raise sale common stock month contract cantor resultstotal revenue year surge higher zack consensus estimate net loss exclude income tax benefit come cent share slightly wider zack consensus estimate cent however company have report loss year outlookcelldex expect cash position december end net proceed generate sale common stock last month anticipate proceed future sale common stock agreement cantor be adequate fund work capital requirement well plan operation pipeline updatecelldex most advanced pipeline candidate be antibody drug conjugate glembatumumab vedotin currently evaluation treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment key metric study be complete august top line datum expect second quarter company also plan file biologic license application second half melanoma study celldex add fourth cohort glembatumumab cdx arm combination be study patient fail prior checkpoint therapy apart glembatumumab vedotin promising candidate company pipeline include varlilumab cdx cdx january company close enrollment phase ii trial evaluate varlilumab bristol myer bmy free report opdivo include cohort indication namely colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex expand phase study january assess cdx advanced renal cell carcinoma include patient ovarian clear cell carcinoma november company initiate phase ii program cdx combination eli lilly lly free report erbitux patient head neck squamous cell carcinoma have develop resistance erbitux company also commence phase study same month evaluate cdx treat locally advanced metastatic solid tumorscelldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quote zack rank stock considercelldex carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive surprise trail quarters average beat share price company have climb year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
57,BMY,bristol myer squibb company bmy free report announce fda approve opdivo label update flexible flat dose option week mg week mg majority approve indication opdivo be now first only fda approve pd inhibitor week dose further opdivo also be approve shorter minute infusion approve indication bristol myer share have return year outperform industry gain new dose schedule be available use patient metastatic melanoma monotherapy monotherapy phase combination treatment yervoy ipilimumab also be available patient previously treat metastatic small cell lung cancer advanced renal cell carcinoma follow prior angiogenic therapy previously treat locally advanced metastatic urothelial carcinoma follow disease progression platinum base chemotherapy be also available treatment patient classical hodgkin lymphoma recurrent metastatic squamous cell carcinoma head neck hepatocellular carcinoma well adjuvant therapy patient completely resect melanoma lymph node involvement metastatic disease remind investor opdivo become first pd immune checkpoint inhibitor gain regulatory approval world july notably drug become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy opdivo continue be launch globally approval label expansion also receive approval several indication include melanoma head neck lung kidney blood cancer fact opdivo yervoy regimen be approve multiple market treatment melanoma opdivo generate revenue fourth quarter year period bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quote zack rank stock considerbristol myer carry zack rank hold few better rank stock same space be regeneron regn free report ligand pharmaceutical lgnd free report enanta pharma enta free report regeneron ligandsport zack rank strong buy enanta pharma carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat ligand earning share estimate have moved respectively last day company deliver positive earning surprise trail quarters average beat company share have rally year enanta pharma deliver positive earning surprise last quarters average beat company share surge year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
58,BMY,aveo pharmaceutical inc aveo free report be expect report fourth quarter result mar last quarter aveo deliver positive surprise company significantly outperformed industry last year stock surge decline industry let see thing be shape quarter factor playin november aveo launch fotivda europe start germany make drug first commercial product company receive double digit royalty payment eusa pharma net sale drug europe however impact top line remain be see august european commission approve fotivda tivozanib treat first line treatment renal cell carcinoma rcc adult drug have demonstrated superiority bayer nexavar treat rcc october aveo announce result pre plan futility analysis phase iii tivo study compare fotivda bayer nexavar treatment patient refractory advanced rcc base result company continue study unmodified datum study previously complete tivo study support regulatory application approval unite state december company announce completion enrollment phase ii portion phase ii tinivo study evaluate fotivda combination bristol myer bmy free report opdivo rcc apart fotivda aveo be also develop ficlatuzumab combination lilly erbitux phase ii study treat metastatic head neck squamous cell carcinoma phase ib study be evaluate candidate combination nab paclitaxel gemcitabine treatment naive pancreatic cancer study be initiate quarter expect research development expense increase quarter due initiation ficlatuzumab study continuation tivo study investor focus likely remain update related fotivda launch progress ficlatuzumab surprise historyaveo performance last quarters have be mixed company surpass expectation thrice miss once average positive surprise earning whispersour proven model do not conclusively show aveo be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank aveo zack rank increase predictive power esp esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision aveo pharmaceutical inc price consensus aveo pharmaceutical inc price consensus aveo pharmaceutical inc quotestock warrant lookhere be couple health care stock want consider model show have right combination element post earning beat quarter celldex therapeutic inc cldx free report be schedule release result mar company have earning esp zack rank see complete list today zack rank stock here gemphire therapeutic gemp free report be expect release result mar company have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
59,BMY,calithera bioscience inc cala free report announce fda have grant fast track designation lead candidate cb candidate be be develop combination exelixis inc exel free report cabometyx cabozantinib treatment metastatic kidney cancer fda grant fast track designation expedite candidate development review treat serious unmet medical condition designation candidate be expect be grant priority review once file new drug application calithera share have underperform industry so far year stock have lose compare industry fall calithera cb selective potent inhibitor glutaminase be be evaluate phase ii study cantata combination cabometyx clear cell renal cell carcinoma rcc patient previously treat least vascular endothelial growth factor tyrosine kinase inhibitor combination bristol myer bmy free report opdivo nivolumab yervoy ipilimumab study be currently enrolling patient primary endpoint be improve progression free survival press release be number therapy approve rcc however still remain significant unmet need advanced stage patient have fail prior systemic therapy kidney cancer be top common cancer type globally american cancer society organization predict estimate new patient be diagnosed disease unite state moreover death be cause due cancer calithera bioscience inc price calithera bioscience inc price calithera bioscience inc quotezack rank stock carry zack rank sell better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved last day company deliver positive surprise trail quarters average beat share price company have rise so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
60,BMY,bristol myer squibb company bmy free report enter research collaboration agreement harvard fibrosis network harvard stem cell institute company have team develop potential new therapy fibrotic disease include fibrosis liver heart term agreement lead academic investigator hepatic cardiac fibrosis harvard fibrosis network collaborate lead scientist bristol myer squibb project year project focus apply fibrosis biology identification noninvasive biomarker novel target potential fibrotic therapy area hepatic cardiac fibrosis bristol myer be build robust pipeline investigational candidate address area high unmet need fibrosis include nonalcoholic steatohepatitis nash idiopathic pulmonary fibrosis ipf bristol myer blockbuster drug opdivo continue perform well several label expansion application opdivo be review unite state europe potential approval boost prospect drug further share company have rally past year outperform industry gain however generic competition loom large company bristol myer pipeline need deliver hence company be look diversify portfolio promising space nash bristol myer extend strategic partnership target pharmasolution inc partnership have be extend target nash multus year deal note company announce new collaboration november treatment nash hcc bristol myer already have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo april company be entitle right research develop commercialize bms ambrx inc other major company promising candidate nash be intercept pharma icpt free report gilead science gild free report novartis nvs free report zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
61,BMY,discourage result phase ii study evaluate abbvie abbv free report promising cancer candidate rovalpituzumab tesirine rova third line later small cell lung cancer sclc grab headline week other news include purchase offer jnj free report diabetes device unit successful study result announce heron therapeutic hrtx free report roche rhhby free report recap week most important storiesabbvie rova fall short key lung cancer study abbvie promising cancer candidate rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line later small cell lung cancer sclc abbvie say not seek accelerate approval rova third line set consult fda rova be add abbvie portfolio follow acquisition stemcentrx june abbvie have significant confidence rova potential failure trinity have raise skepticism rova potential have bring question viability stemcentrx deal read more abbvie stock fall weak lung cancer study outcome get offer lifescan unit say have receive bound offer private equity firm platinum equity lifescan diabetes device unit have time jun offer fail expire have be evaluate potential strategic option diabetes care unit specifically lifescan corporation calibra medical early last year read more get offer lifescan diabetes device unit pfizer get fda priority review expand label xtandi pfizer pfe free report japanese partner astella gain fda priority review regulatory filing be look expand label prostate cancer drug xtandi include early stage patient population regulatory application add metastatic castration resistant prostate cancer crpc indication drug label be base result prosper study xtandi fda grant priority review decision be expect july read more pfizer xtandi label expansion filing get priority review meanwhile british company reckitt benckiser group pull discussion pfizer buy latter consumer health segment last october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain business glaxo also say have withdraw race buy pfizer unit heron htx succeed phase iii heron therapeutic pipeline candidate htx meet primary endpoint pivotal phase iii study evaluate post operative pain control follow bunionectomy hernia repair respectively top line datum study show treatment htx lead statistically significant reduction pain intensity opoid use hour follow surgery candidate be also superior bupivacaine solution be current standard care local anesthetic postoperative pain control read more heron pain candidate meet endpoint pivotal studiesroche tecentriq succeed lung cancer combo study roche tecentriq meet co primary endpoint progression free survival phase iii study evaluate pd inhibitor combination chemotherapy carboplatin abraxane first line treatment advanced squamous small cell lung cancer nsclc tecentriq be already market treatment second line metastatic nsclc label expansion first line set boost drug sale further however roche await overall survival datum study continue read more roche tecentriq phase iii combo study meet primary endpoint novartis tasigna get fda nod label expansion novartis nvs free report leukemia drug tasigna be grant fda approval use pediatric year age older population first second line treatment philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp glaxo begin new combo study benlysta glaxo gsk free report have initiate late stage study bliss believe evaluate systemic lupus erythematosus medicine benlysta combination roche rituxan benlysta previous late stage study have demonstrated consistent efficacy reduce disease activity sle aim new combination study be achieve clinical remission sle patient apart demonstrate low disease activity read more glaxosmithkline initiate phase iii combo study nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform week astrazeneca azn free report be only stock record gain last trading session decline bristol myer bmy free report be last month astrazeneca be biggest gainer merck mrk free report be biggest loser decline see last pharma stock roundup here abbv elagolix meet study goal mrk keytruda focus next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
62,BMY,bristol myer squibb company bmy free report announce encourage datum phase iii checkmate study opdivo checkmate study be ongoing study evaluate immuno oncology combination opdivo nivolumab low dose mg kg yervoy ipilimumab compare pfizer pfe free report sutent sunitinib intermediate poor risk patient advanced renal cell carcinoma rcc year follow period treatment opdivo low dose yervoy lead statistically significant difference patient report outcome baseline versus sunitinib year follow study demonstrated patient show significant benefit disease related symptom improvement cancer related quality life well be benefit occur early opdivo low dose yervoy combination therapy be largely maintain treatment period opdivo maintenance therapy checkmate study patient advanced renal cell carcinoma have earlier show efficacy benefit opdivo low dose yervoy number measure include overall survival objective response rate progression free survival however result present now show patient treat immuno oncology combination also report significant improvement disease related symptom well positive change physical emotional functional well be additional analysis show similar result significant benefit see opdivo low dose yervoy relative sunitinib change baseline pre plan week landmark bristol myer share have decline year date compare industry decline note opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential significantly however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous small cell lung cancer nsclc company be expect suffer further loss market share separate release bristol myer announce fda lift partial clinical hold place checkmate phase iii study evaluate addition opdivo pomalidomide dexamethasone patient relapse refractory multiple myeloma decision follow consultation fda agreement amendment study protocol fda put clinical hold study evaluate opdivo base combination relapse refractory multiple myeloma september fda precaution follow risk identify trial study pd agent keytruda patient multiple myeloma stock warrant lookbristol myer carry zack rank hold better rank stock same space be illumina inc ilmn free report sporting zack rank strong buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year bristol myer squibb company price bristol myer squibb company price bristol myer squibb company hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
63,BMY,nektar therapeutic nktr free report announce submission new drug application nda analgesic opioid candidate nktr treatment chronic low back pain candidate exhibit reduce incidence euphoria associate opioid lead abuse addiction share company be pre market nektar share have outperformed industry so far year stock have soar broader industry decline nda include datum clinical study evaluate safety efficacy nktr patient chronic low back pain be not treat opioid therapy cancer pain study evaluate nktr human abuse potential show significantly less abuse potential compare oxycodone press release low back pain be second most common factor cause disability adult unite state however nektar be expect face intense competition pain market several company develop therapy competitor include collegium pharmaceutical inc coll free report xtampza teva pharmaceutical teva free report naproxen apart nktr nektar pipeline also have several early late stage candidate lead pipeline candidate onzeald be be evaluate phase iii study treat adult advanced breast cancer brain metastase company be develop nktr phase study treat autoimmune disease nktr phase ii study solid tumor nektar have collaborate bristol myer bmy free report develop nktr combination latter immune oncology drug opdivo more indication tumor type nektar therapeutic price nektar therapeutic price nektar therapeutic quotenektar currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
64,BMY,pfizer inc pfe free report announce fda grant breakthrough therapy designation lung cancer drug xalkori crizotinib new indication xalkori be already market treatment alk ro positive locally advanced metastatic small cell lung cancer nsclc fact be only fda approve treatment indicated alk positive ro positive metastatic nsclc fda grant breakthrough therapy designation xalkori treatment patient metastatic nsclc meet exon alteration disease progression platinum base chemotherapy designation indication be support result expansion cohort phase profile study xalkori show antitumor activity indication breakthrough therapy designation be grant xalkori be treatment patient relapse refractory systemic anaplastic large cell lymphoma alcl be alkpositive designation indication be support study study advl nct study nct study show compelling antitumor activity pediatric adult patient treat xalkori designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient share pfizer have decline year date compare industry decline nsclc be difficult treat disease accounting lung cancer case present lung cancer treatment market be highly crowd drug bristol myer squibb bmy free report opdivo merck mrk free report keytruda roche rhhby free report alecensa novartis zykadia taxotere other zack rankpfizer have zack rank hold see complete list today zack rank stock here pfizer inc price pfizer inc price pfizer inc quote today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
65,BMY,roche rhhby free report announce phase iii study impower immunotherapy tecentriq meet co primary endpoint overall survival os progression free survival pfs multicentre open label randomize study evaluate efficacy safety tecentriq combination carboplatin nab paclitaxel versus only chemotherapy chemotherapy naïve patient stage iv squamous small cell lung cancer nsclc study result show combination tecentriq chemotherapy carboplatin abraxane albumin bound paclitaxel nab paclitaxel help patient live significantly longer compare chemotherapy alone first line treatment advanced squamous nsclc moreover tecentriq combination reduce risk disease worsening death progression free survival pfs compare chemotherapy alone note tecentriq be already approve unite state european union previously treat metastatic nsclc patient locally advanced metastatic urothelial cancer muc be not eligible cisplatin chemotherapy have have disease progression follow platinum contain therapy present roche have ongoing phase iii lung cancer study be evaluate tecentriq alone combination other drug be third phase iii study evaluate tecentriq alone combination demonstrate os benefit person nsclc have demonstrated positive result label expansion drug boost sale however competition be stiff nsclc market like merck mrk free report keytruda bristol myer squibb company bmy free report opdivo roche stock have lose year industry gain approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis nvs free report have already launch biosimilar version rituxan mabthera europe fda also approve biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
66,BMY,astrazeneca plc azn free report announce phase iii pacific study evaluate oncology candidate imfinzi durvalumab early stage lung cancer indication meet second primary endpoint overall survival os study be conduct patient locally advanced unresectable stage iii small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt please note imfinzi be approve unite state indication february year base positive progression free survival dataa plan interim analysis show patient receive imfinzi experience statistically significant os benefit clinically meaningful improvement compare placebo os datum be add label imfinzi drive sale drug higher imfinzi be also market unite state second line advanced bladder cancer interim datum study present september last year show imfinzi lead superior progression free survival standard care mentioned patient treatment imfinzi improve pfs more month comparison standard care imfinzi also lead significant reduction risk deterioration health death datum study astrazeneca share have outperformed industry so far year share company have gain industry decline astrazeneca be also develop imfinzi monotherapy well combination therapy treatment nsclc first line adjuvant set drug be also be develop several other cancer indication include head neck gastric pancreatic hepatocellular blood cancer however lung cancer be competitive segment attract several player due huge market opportunity novartis nvs free report roche rhhby free report receive approval respective drug zykadia alecensa treat metastatic nsclc first line set other immunotherapy treat various cancer indication include bristol myer squibb company bmy free report opdivo merck co keytruda zack rankastrazeneca carry zack rank sell see complete list today zack rank strong buy stock here astrazeneca plc price astrazeneca plc price astrazeneca plc quote medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
67,BMY,merck mrk free report announce pivotal study keynote evaluate keytruda chemotherapy combination first line metastatic squamous small cell lung cancer nsclc meet dual primary endpoint overall survival os progression free survival pfs drug combination chemotherapy demonstrated significantly longer os pfs versus chemotherapy alone merck supplemental biologic license application sbla seek continue approval keytruda combine eli lilly lly free report alimta platinum chemotherapy treat metastatic squamous nsclc be review unite state sbla be file base encourage datum phase iii study keynote company plan share datum keynote study fda expand sbla include patient squamous histology company present detailed datum keynote study upcoming annual meeting american society clinical oncology next month share merck be market trading news be announce year so far merck share have outperformed industry share have rise period industry decline notably keytruda be already approve monotherapy first line treatment patient metastatic nsclc tumor express pd protein level greater keytruda also have accelerate approval treat first line patient metastatic nsclc combination alimta chemotherapy merck remain focuse develop keytruda monotherapy combination therapy treatment lung cancer various mutation histology first line set bid further reinforce position segment lung cancer be attractive market be largest cause death cancer patient moreover keytruda be only immune oncology drug be approve treatment lung cancer first line set remind investor bristol myer bmy free report be also develop immune oncology drug opdivo first line lung cancer however keytruda early entry positive datum readout several phase iii study expand first line lung cancer patient bode well company top line note keytruda be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
68,BMY,exelixis inc exel free report european partner ipsen announce european commission ec have grant approval cabometyx cabozantinib expand indication ec approve cabometyx mg mg mg first line treatment adult intermediate poor risk advanced renal cell carcinoma rcc kind kidney cancer european union approval be expect march company receive positive opinion committee medicinal product human use chmp use cabometyx indication eu approval first line set be base result cabosun trial meet primary endpoint improve progression free survival compare pfizer pfe free report sutent sunitinib patient previously untreated advanced rcc cabometyxis already market eu advanced rcc adult follow prior vascular endothelial growth factor vegf target therapy unite state cabometyx be approve first line treatment advanced rcc december last year approximately month ahead assign prescription drug user fee act action date cabometyx generate net product revenue first quarter drive growth demand follow approval first lien set approval europe further boost exelixis top line term collaboration license agreement ipsen exelixis receive milestone payment ec approval be recognize collaboration revenue first quarter payment be make ipsen next day exelixis share have lose year wider industry decline remind investor exelixis enter collaboration license agreement ipsen february further development cabozantinib ipsen receive exclusive right current potential future cabozantinib indication outside unite state canada japan exelixis have also inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent zack rank exelixis have zack rank hold see complete list today zack rank strong buy stock here exelixis inc price exelixis inc price exelixis inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
69,BMY,illumina inc ilmn free report recently announce acquisition edico genome strengthen next generation sequence ngs platform company edico genome dragen bio dragen platform pair well illumina sequence portfolio help deliver rapid streamline output ngs customer edico genome be eminent provider datum analysis acceleration solution ngs dragen be build field programmable gate array fpga technology help proprietary software algorithms help deliver result timely manner decrease datum footprint illumina edico genome have establish strong ngs customer base lead solid adoption dragen standard part sequence believe acquisition help illumina provide enhance datum analysis experience ngs user expand customer base ngs platform focusillumina be consistently work enhance ngs platform illumina recently introduce second fda regulate ce ivd marked ngs system nextseq dx company have also receive product approval nextseq dx instrument ministry food drug safety mfds south korea april company collaborate bristol myer squibb company bmy free report field oncology alliance utilize illumina ngs technology develop globally commercialize diagnostic ivd assay support bristol myer squibb oncology portfolio illumina also announce global strategic partnership wih loxo oncology develop commercialize multus gene panel broad tumor profile result distributable ngs base companion diagnostic cdx pan cancer indication market potentialaccord market market global next generation sequence market be estimate reach worth cagr show acquisition be line company strategy share price performanceover past year illumina have be outperform industry company have gain industry decline zack rank other key picksillumina currently sport zack rank strong buy other top rank stock broader medical sector be intuitive surgical isrg free report cooper company inc coo free report intuitive surgical sport zack rank cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate cooper company have long term expect earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
70,BMY,nektar therapeutic nktr free report report loss cent share first quarter be wider zack consensus estimate loss cent year figure cent due higher cost nektar stock be follow earning release share nektar have outperformed industry so far year stock have rise industry be quarterly revenue soar year period upside mainly be attribute milestone payment collaboration agreement shire plc shpg free report related approval hemophilia drug adynovi europe top line come line zack consensus estimate quarter top line comprise product sale royalty revenue cash royalty revenue license collaboration other revenue first quarter product sale rise year moreover cash royalty revenue increase company report royalty revenue quarter review register improvement year license collaboration other revenue come compare prior year upside research development expense escalate primarily due investment pipeline include key candidate nktr nktr nktr general administrative expense be report quarter primarily due higher stock base compensation pipeline company receive major boost february announce global strategic collaboration agreement bristol myer squibb bmy free report agreement company jointly develop commercialize nektar lead immuno oncology candidate nktr combination bristol myer opdivo nivolumab opdivo yervoy ipilimumab moreover pursuant contract company receive upfront payment proceed share purchase april same month nektar begin dose phase ii study reveal evaluate combination candidate nktr toll receptor agonist nktr immuno stimulatory cd bias agonist advanced metastatic solid tumor cancer moreover company have also collaborate takeda develop nktr combination latter tak dual syk flt inhibitor liquid solid tumor first study collaboration be expect start second half evaluate combination hodgkin lymphoma nektar initiate dose range phase ib study evaluate nktr regulatory cell stimulator patient systemic lupus erythematosus autoimmune disease company have worldwide license agreement eli lilly lly free report related development nktr apart company pipeline include late stage candidate onzeald nktr onzeald be currently evaluation phase iii attain study treatment adult advanced breast cancer have brain metastase company be develop nktr treatment chronic pain new drug application be expect be file fda month nektar therapeutic price ep surprise nektar therapeutic price ep surprise nektar therapeutic quotezack ranknektar carry zack rank sell see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
71,BMY,horizon pharma plc hznp free report report lower expect result first quarter follow news company share go horizon pharma stock have decline year date compare industry fall company report first quarter adjust earning cent share miss zack consensus estimate cent be much lower cent report year quarter sale first quarter be year year miss zack consensus estimate quarter orphan unit record revenue year period growth net sale ravicti generate quarter year year be partially offset lower sale actimmune buphenyl quinsair additionally procysbi contribute performance net sale year year actimmune sale report quarter be year year procysbi lower sale growth quinsair decline sale be due divest marketing right europe middle east africa emea rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive strong continue year year vial demand primary care garner revenue year year decline net sale be due greater anticipate seasonality impact accrual inventory sale channel report quarter net sale pennsaid duexix vimovo be respectively adjust research development expense be adjust selling general administrative expense be year year guidance pharma raise outlook now expect sale range previously mainly drive expect strong growth orphan rheumatology business unit especially krystexxa company expect krystexxa sale increase year year due year delay implementation government health resource service administration final rule drug ceiling price jul other updatesin february company file supplemental new drug application expand age range label raviciti month age older birth older january company announce program develop next generation biologic hzn pasylate uricase technology treatment uncontrolled gout currently horizon pharma be evaluate krystexxa combination commonly used different immunomodulator investigator initiate study recipe triple enhance response rate drug gout patient company be progress well phase iii study evaluation teprotumumab moderate severe active thyroid eye disease company expect complete enrollment study end meanwhile company be work expand actimmune label investigator initiate study moffitt cancer center be underway enrolling patient study be evaluate actimmune combination roche holding rhhby free report herceptin perjeta taxol certain advanced breast cancer patient phase study evaluate actimmune combination bristol myer squibb company bmy free report opdivo kidney bladder cancer actimmune be also be evaluate combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study new operate structurein line horizon pharma long term strategy management announce begin second quarter report result operate segment company separate strategic growth business orphan rheumatology primary care business company expect new structure help better allocation resource develop product unmet treatment need patient rare disease takehorizon pharma first quarter result be not impressive company miss top bottom line estimate however sale guidance be encourage expect krystexxa ravicti actimmune drive further growth company focus develop krystexxa actimmune be beneficial future expect study increase operate expense horizon pharma public limit company price consensus ep surprise horizon pharma public limit company price consensus ep surprise horizon pharma public limit company quotezack rankhorizon pharma currently have zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
72,BMY,infinity pharmaceutical inc infi free report report loss cent share first quarter line zack consensus estimate company have report loss cent year quarter infinity do not have approve product portfolio company earn revenue form royalty license milestone payment well research development support fee paid partner infinity share have return year date industry decline quarter detailin quarter expense increase due higher clinical development charge ipi general administrative expense be quarter year quarter decrease be mainly due reduction bonus stock compensation outlookinfinity reaffirm outlook company expect net loss be range company anticipate year end cash cash equivalent available sale security balance range moreover infinity expect exist cash cash equivalent available sale security dec be adequate fund company capital need third quarter other updatesinfinity be evaluate ipi monotherapy combination bristol myer bmy free report opdivo phase study patient advanced solid tumor phase ib monotherapy combination dose escalation component study have be complete enrollment begin be ongoing disease specific combination expansion cohort seventh combination expansion cohort patient pre select have high baseline blood level myeloid derive suppressor cell mdscs company expect report datum monotherapy expansion component combination dose escalation component study company also expect report initial datum disease specific combination expansion cohort further company expect report more mature clinical translational datum include insight pair tumor biopsy disease specific cohort initial datum cohort patient pre select have high baseline blood level mdsc combination expansion component study second half zack rank other key picksinfinity have zack rank buy few other top rank stock same space worth consider be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report sport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
73,BMY,share exelixis inc exel free report have rally massive year date compare industry gain exelixis lead product cometriq capsule form cabozantinib be approve unite state treatment progressive metastatic medullary thyroid cancer april tablet formulation cabozantinib cabometyx be approve unite state treatment patient advanced renal cell carcinoma rcc have receive prior angiogenic therapy cabometyx post strong sale first month thereby underlie increase demand drug new patient market share second line set increase recent fda approval cabometyx treatment previously untreated advanced rcc further boost demand approval come month ahead schedule note cabometyx cabozantinib tyrosine kinase inhibitor tki be already approve treatment rcc patient have already receive angiogenic therapy cabozantinib inhibit activity tyrosine kinase include meet axl vegf receptor ret approval come back result randomize phase ii trial cabosun result demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus current standard care pfizer inc pfe free report sutent importantly cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death median pfs cabometyx be month versus month sutent corresponding month improvement rcc be most common form kidney cancer adult statistic approximately patient unite state world need first line treatment advanced kidney cancer many patient need same annually unite state sutent be widely used first line treatment rcc hence expect cabometyx challenge sutent market share first line rcc addition drug be also be evaluate advanced hepatocellular carcinoma hcc celestial study october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter hcc be most common form primary liver cancer accounting more case unite state reflect demand therapy hence potential approval drug liver cancer further boost growth potential drug early exelixis inked agreement bristol myer squibb bmy free report roche holding rhhby free report jointly develop cabozantinib combination immunotherapy agent exelixis collaborate bristol myer evaluate cabozantinib combination opdivo alone combination yervoy phase iii trial first line rcc potentially other tumor type include hcc bladder cancer company have initiate phase iii trial checkmate july evaluate opdivo combination cabometyx opdivo yervoy combination cabometyx versus sutent patient previously untreated advanced metastatic rcc exelixis have also collaborate roche evaluate cabometyx combination tecentriq pd antibody patient advanced rcc bladder cancer june exelixis initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma rcc competition stiffen bit fda accept bristol myer supplemental biologic license application priority review opdivo yervoy treat intermediate poor risk patient advanced rcc action date apr expect exelixis ride high performance cabometyx hence be have stock investor biotech portfolio zack rankexelixis carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
74,BMY,merck mrk free report pfizer inc pfe free report announce fda have approve investigational oral sglt inhibitor steglatro ertugliflozin tablet steglujan ertugliflozin sitagliptin adjunct diet exercise improve glycemic control patient type diabetes mellitus steglujan be fix combination steglatro januvia sitagliptin be approve patient be eligible treatment combination apart drug fda also approve segluromet ertugliflozin metformin same indication patient already treat steglatro glucophage metformin inadequately controlled type diabetes mellitus patient be already treat combination ertugliflozin metformin so far year share merck have lose compare industry growth fda approve drug base datum phase iii study evaluate steglatro monotherapy combination januvia bristol myer squibb company bmy free report glucophage study also evaluate steglatro combination insulin sulfonylurea datum study show steglatro single agent combination januvia significantly reduce level measure blood glucose compare placebo steglatro also significantly reduce body weight patient be already receive combination januvia glucophage versus placebo drug also achieve significant reduction systolic blood pressure approval new drug boost merck diabetes portfolio comprise januvia janumet market drug have see volume growth first month have generate sale however merck receive complete response letter fda supplemental new drug application crl seek label expansion januvia janumet janumet xr april company be discussion fda resolve issue crl moreover merck also receive setback earlier month key immune oncology drug keytruda fail phase iii gastric cancer study merck company inc price merck company inc price merck company inc quotezack rank stock considermerck carry zack rank hold therapeutic incorporate cort free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
75,BMY,nektar therapeutic nktr free report report loss cent share fourth quarter substantially narrower zack consensus estimate loss cent year figure cent share nektar have significantly outperformed industry year time stock have sky-rocket industry have decrease quarterly revenue substantially soar year period upside mainly be attribute massive rise license collaboration revenue top line also significantly beat zack consensus estimate quarter top line comprise product sale royalty revenue cash royalty revenue license collaboration other revenue fourth quarter product sale tumble year however cash royalty revenue increase company report royalty revenue quarter review register huge improvement year uptrend be mainly back royalty revenue receive license agreement astrazeneca movantik shire plc adynovate license collaboration other revenue come compare prior year upside be mainly due receipt recur revenue related new sublicense agreement research development expense mount primarily due investment pipeline include key candidate nktr nktr nktr general administrative expense be report quarter resultsfull year sale jump year year sale outpaced consensus mark well previously guide range loss cent share be narrower zack consensus estimate cent year earlier figure cent pipeline most advanced candidate company portfolio be onzeald currently evaluation phase iii attain study treatment adult advanced breast cancer have brain metastase apart onzeald candidate company immuno oncology portfolio be nktr last year september nektar announce initiation phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab datum trial be expect second half phase ii study evaluate nktr potential combination treatment regimen bristol myer squibb bmy free report opdivo be also underway candidate be be examine tumor type include melanoma renal cell carcinoma small cell lung cancer bladder triple negative breast cancer combo therapy also be evaluate more potential indication candidate nktr be be evaluate phase iii program chronic pain management last july company report positive top line result oral human abuse potential study evaluate nktr assess opioid abuse potential compare oxycodone company be plan submit new drug application nda candidate april outlooknektar estimate revenue range exclude payment collaboration bristol myer enter last month agreement company jointly develop commercialize lead immuno oncology candidate nktr former combination latter opdivo opdivo yervoy ipilimumab nektar anticipate cash approximately year end include upfront payment collaboration bristol myer notably cash investment marketable security dec be comparison dec nektar therapeutic price consensus ep surprise nektar therapeutic price consensus ep surprise nektar therapeutic quotezack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
76,BMY,key announcement week include couple acquisition announcement regulatory update novartis nvs free report recap week most important storiesroche buy cancer focuse ignyta roche rhhby free report have strong presence cancer market announce intention acquire ignyta deal value share ignyta be focuse development precisely target therapeutic guide diagnostic test cancer patient acquisition add entrectinib selective cns active tyrosine kinase inhibitor tki roche pipeline entrectinib be be develop tumor harbor ro ntrk fusion be currently pivotal phase ii study support dual nda submission successful entrectinib have breakthrough therapy designation unite state prime designation eu deal be expect close first half read more roche clinch deal acquire ignyta roche be zack rank hold stock see complete list today zack rank strong buy stock here mallinckrodt boost rare disease portfolio sucampo acquisition acquisition deal be announce week specialty pharma company mallinckrodt plc mnk free report say acquire sucampo approximately share deal close first quarter be expect boost mallinckrodt earning least cent share earning least cent share deal add market product amitiza rescula mallinckrodt portfolio couple phase iii asset vts niemann pick type npc cpp sulindac familial adenomatous polyposis fap pipeline peak net sale potential vts be estimate be more cpp sulindac be estimate be more target be file vts potential approval cpp sulindac early follow potential approval later year acquisition addition boost mallinckrodt rare disease portfolio show company effort diversify market product portfolio read more mallinckrodt buy sucampo diversify portfolio regulatory update novartis fda have expand label novartis tasigna so treatment free remission tfr datum be now part label inclusion datum provide additional novel option management philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp novartis also announce tafinlar mekinist combination therapy have be grant priority review fda adjuvant treatment stage iii braf mutation positive melanoma approval make tafinlar mekinist first adjuvant target therapy combination demonstrate significant clinical benefit patient braf mutation fda grant priority review agency be expect respond month date submission application instead usual month novartis have gain year date compare rally industry belong allergan announce combigan ruling allergan agn free report suffer setback unite state court appeal federal circuit ruling certain combigan patent be valid not infringe court say sandoz propose generic version combigan do not infringe patent cover combigan reversed earlier district court decision generic product infringe patent allergan intend file petition day combigan be part allergan eye care portfolio cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be slightly last trading session major stock astrazeneca azn free report be lilly decline last month bristol myer squibb bmy free report be glaxosmithkline gsk free report decline see last pharma stock roundup here aerie rhopressa approve label expansion bmy pfizer drug next pharma world watch regulatory pipeline news pharma stock more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
77,BMY,busy last week filled clinical trial datum presentation annual meeting american society hematology cancer space see regulatory approval label expansion drug week roche hold ag rhhby free report breast cancer drug perjeta receive fda nod label expansion post surgery breast cancer high risk recurrence bristol myer squibb company bmy free report blockbuster pd inhibitor drug opdivo receive approval intravenous administration patient completely resect melanoma lymph node involvement metastatic disease unite state meanwhile pfizer inc pfe free report bosulif have be approve treat philadelphia chromosome positive ph chronic myelogenous leukemia cml first line set exelixis inc exel free report also announce approval cabometyx label expansion previously untreated advanced renal cell carcinoma rcc however celgene corporation celg free report suffer setback key drug revlimid fail phase iii study evaluate maintenance therapy treatment naïve follicular lymphoma patient meanwhile astrazeneca azn free report announce acceptance supplemental new drug application snda fda seek label expansion tagrisso include first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation snda be also grant priority review suggest speedy review decision next month let see major news detail roche perjeta get approval post surgery breast cancer fda approve perjeta combination herceptin chemotherapy adjuvant therapy positive early breast cancer high risk recurrence drug regimen significantly reduce risk disease recurrence death compare herceptin chemotherapy alone read more roche perjeta get fda nod post surgery breast cancer also week roche enter agreement acquire base biotech company ignyta boost oncology portfolio ignyta be focuse develop therapy cancer rare mutation ignyta lead candidate entrectinib be currently phase ii study patient nsclc roche hold ag price roche hold ag price roche hold ag quotepfizer bosulif approve first line therapy leukemia bosulif label expansion first line set patient chronic phase ph cml be approve fda drug be already approve second later setting indication read more pfizer leukemia drug get fda nod first line set fda have also grant breakthrough therapy designation combination therapy bavencio inlyta be be investigate patient advanced rcc first line treatment combination therapy be currently be evaluate phase ib study pfizer inc price pfizer inc price pfizer inc quoteexelixis cabometyx approve first line kidney cancer exelixis rcc drug cabometyx be grant label expansion first line set fda approve label expansion base datum phase ii cabosun study demonstrated cabometyx be superior pfizer sutent treat first line kidney cancer read more exelixis cabometyx get fda nod first line kidney cancer exelixis carry zack rank hold see complete list today zack rank strong buy stock here exelixis inc price exelixis inc price exelixis inc quotecelgene revlimid fail phase iii lymphoma study celgene be follow news failure phase iii revlimid study study evaluate revlimid combination roche rituxan maintenance therapy treatment naïve patient follicular lymphoma combination fail achieve superiority complete response progression free survival standard care rituxan chemotherapy revlimid be primary growth driver celgene label expansion lymphoma have further boost potential celgene corporation price celgene corporation price celgene corporation quotebristol myer opdivo approve intravenous use metastatic melanoma fda approve intravenous administration pd inhibitor opdivo adjuvant treatment post surgery patient melanoma involve lymph node be metatstatic approval be base datum phase iii checkmate study datum study have demonstrated opdivo have significantly improve recurrence free survival compare yervoy opdivo be first drug receive approval adjuvant treatment indication bristol myer have also announce committee medicinal product human use have recommend approval yervoy europe treat pediatric patient year older unresectable metastatic melanoma read more bristol myer yervoy get positive chmp opinion melanoma bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotemeanwhile biolinerx initiate phase iii genesis study evaluate lead pipeline candidate bl study investigate mobilization stem cell patient undergo autologous transplant multiple myeloma juno therapeutic announce partnership thermo fisher scientific use latter cell therapy system activation reagent develop car therapy pipeline look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
78,BMY,exelixis inc exel free report be schedule report fourth quarter result feb market close company have outstanding earning surprise history have surpass expectation trail quarters average exelixis inc price consensus exelixis inc price consensus exelixis inc quote exelixis share have rally last month industry fall likely positive surprise proven model show exelixis be likely beat estimate quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be most accurate estimate be cent zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank exelixis carry zack rank combine positive esp increase chance earning beat conversely caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision factor likely impact resultsexelixis stock receive major boost fda approve cabometyx tablet april treatment advanced renal cell carcinoma rcc drug uptake be encourage be expect propel top line forthcoming quarters new patient start refill patient already therapy continue expansion prescriber base cabometyx be drive drug sale cabometyx deliver strong sale first month underlie increase demand drug new patient market share second line set increase fda approval cabometyx untreated advanced rcc be likely boost demand further drug demonstrated statistically significant clinically meaningful improvement pfs versus current standard care sutent meanwhile exelixis be develop cabozantinib broad development program comprise more clinical study multiple indication celestial study advanced hepatocellular carcinoma be also ongoing exelixis also announce collaboration agreement bristol myer squibb bmy free report roche rhhby free report development cabozantinib combination immunotherapy agent early collaboration entitle exelixis earn milestone payment royalty boost top line june exelixis initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma rcc however expense continue increase raise concern exelixis expect total cost operate expense range stock considerhere be company consider model show also have right combination element deliver beat quarter gemphire therapeutic gemp free report be expect release fourth quarter result mar company have earning esp zack rank see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
79,BMY,astrazeneca azn free report announce fda have approve second indication pd inhibitor imfinzi be now approve unresectable stage iii small cell lung cancer nsclc drug be meant patient disease have not progressed follow concurrent platinum base chemotherapy radiation therapy astrazeneca share have return past year outperform industry gain period approval come back impressive progression free survival datum pfs patient treat imfinzi phase iii pacific study datum show imfinzi improve pfs more month comparison placebo concern patient population median pfs be month patient imfinzi compare month placebo imfinzi be launch unite state first indication second line advanced bladder cancer drug have bring sale press release globally nsclc patient have stage iii disease majority patient diagnosed unresectable tumor currently patient be treat chemotherapy radiation therapy follow active surveillance monitor progression imfinzi first immunotherapy approve indication be better treatment option patient represent better market opportunity astrazeneca astrazeneca be also develop imfinzi monotherapy well combination therapy treatment nsclc first line adjuvant set drug be also be develop several other cancer indication include head neck gastric pancreatic hepatocellular blood cancer however lung cancer be competitive segment attract several player due huge market opportunity novartis nvs free report roche receive approval respective drug zykadia alecensa treat metastatic nsclc first line set other immunotherapy treat various cancer indication include bristol myer squibb company bmy free report opdivo merck co mrk free report keytruda astrazeneca plc price astrazeneca plc price astrazeneca plc quotezack rankastrazeneca carry zack rank sell see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
80,BMY,clovis oncology inc clvs free report incur adjust loss share first quarter be wider year loss share well zack consensus estimate loss clovis only market drug rubraca be grant accelerate approval fda december treatment advanced ovarian cancer patient have receive prior chemotherapy net revenue entirely rubraca be approximately quarter sequentially competition other parp inhibitor be approve patient irrespective brca mutation revenue beat zack consensus estimate company have record total revenue entirely rubraca sale year quarter importantly company register new patient rubraca therapy approval approximately new patient be register first quarter share company decline almost wider expect loss moreover clovis have underperform industry past year stock have lose industry decline quarter detaildure first quarter research development expense increase year year primarily due increase expense clinical study rubraca however selling general administrative sg expense escalate year year reflect increase activity support rubraca cash used operate activity quarter be higher year quarter mainly due higher product supply cost clovis end quarter cash equivalent available sale security support proceed raise share offering make january june last yearupdate quarter april fda approve label expansion rubraca include maintenance treatment recurrent ovarian cancer drug now also be prescribe irrespective brca mutation second line set march committee medicinal product human use chmp european medicine agency ema issue positive opinion recommend approval rubraca treat advanced ovarian cancer indication brca mutation approval be anticipate second quarter additionally clovis have plan submit supplemental application seek approval second line later maintenance treatment indication eu only approve advanced ovarian cancer indication phase ii study atla be initiate quarter evaluate rubraca monotherapy metastatic bladder cancer study be currently enrolling patient july clovis announce collaboration bristol myer squibb company bmy free report evaluate rubraca combination latter pd immune checkpoint inhibitor opdivo multiple tumor type phase iii study be expect start first half evaluate rubraca opdivo treat advanced ovarian cancer first line maintenance set phase iii study be already evaluate combination advanced triple negative breast cancer apart rubraca clovis be also develop lucitanib treat breast lung cancer company partner servier return ex exclude china right candidate follow clovis own global development right lucitanib china takeadoption rubraca be expect increase fda approval use ovarian cancer patient irrespective brca mutation unite state approval bring drug par other approve maintenance therapy include tesaro inc tsro free report zejula astrazeneca plc azn free report lynparza expect operate expense continue increase company incur higher investment support rubraca launch europe expand indication unite state moreover company anticipate product supply cost increase second quarter affect bottom line however cash position be better end second quarter due addition net proceed common stock senior note offer april remind investor clovis have pay milestone payment pfizer related approval rubraca unite state additional be due pfizer approval be receive europe expect further decline bottom line due cost clovis oncology inc price consensus ep surprise clovis oncology inc price consensus ep surprise clovis oncology inc quote zack rank clovis currently have zack rank hold see complete list today zack strong buy rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
81,BMY,aveo pharmaceutical inc aveo free report be expect report first quarter result last report quarter aveo deliver negative surprise company have slightly underperform industry so far year stock fall compare decline industry let see thing be shape quarter factor playfollow launch last year germany fotivda first line treatment patient advanced renal cell carcinoma rcc become first commercial product aveo portfolio company be entitle receive double digit royalty payment partner eusa pharma net sale drug europe expect boost company first quarter revenue zack consensus estimate stand february fotivda be grant positive recommendation approval unite kingdom treatment patient advanced rcc recommendation trigger payment eusa pharma fotivda be currently be evaluate couple study third line treatment rcc advanced rcc december company announce completion enrollment phase ii portion phase ii tinivo study evaluate fotivda combination bristol myer bmy free report opdivo rcc expect company provide update study first quarter earning call apart fotivda aveo be also develop ficlatuzumab combination lilly erbitux phase ii study treat metastatic head neck squamous cell carcinoma phase ib study be evaluate candidate combination nab paclitaxel gemcitabine treatment naive pancreatic cancer study be initiate fourth quarter investor focus likely remain update related fotivda launch progress ficlatuzumab surprise historyaveo performance last quarters have be mixed company surpass expectation thrice miss once average negative surprise earning whispersour proven model do not conclusively show aveo be likely beat estimate soon be report quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank aveo have zack rank strong sell note caution stock zack rank sell go earning announcement especially company be see negative estimate revision aveo pharmaceutical inc price ep surprise aveo pharmaceutical inc price ep surprise aveo pharmaceutical inc quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat upcoming release emergent biosolution inc ebs free report have earning esp zack rank company be schedule release first quarter result see complete list today zack rank stock here vanda pharmaceutical inc vnda free report have earning esp zack rank company be schedule release first quarter result hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
82,BMY,seattle genetic inc sgen free report report loss cent share first quarter wider zack consensus estimate cent year quarter loss cent revenue come year year primarily drive strong sale adcetris revenue also beat zack consensus estimate however seattle genetic share have lose so far year compare industry decline same period quarter detailseattle genetic top line comprise product revenue collaboration license agreement revenue royalty company only market product adcetris generate product sale significant year year collaboration license agreement revenue increase almost mainly drive strong demand adcetris international market collaboration revenue include fee earn company agreement japan base takeda pharmaceutical adcetris other adc collaboration royalty revenue decrease year year due adoption new accounting standard revenue recognition research development expense be year year primarily attributable tucatinib development activity upfront cost related technology licensing pieris pharmamar also selling general administrative sg expense increase mainly due cost related acquisition cascadian therapeutic launch adcetris frontline hodgkin lymphoma outlook launch adcetris new indication company withdraw revenue expectation currently shire expect second quarter sale be range company increase outlook expense range sg expense be expect range previously rise likely be due increase investment development tisotumab vedotin ladiratuzumab vedotin company pipeline program pipeline updatedure quarter label expansion adcetris combination chemotherapy patient previously untreated stage iii iv classical hodgkin lymphoma be approve unite state january drug be approve treatment cutaneous cell lymphoma europe follow approval unite state november last year moreover top line datum echelon study frontline cd express mature cell lymphoma be separate study be also evaluate adcetris combination bristol myer squibb bmy free report opdivo relapse refractory classical hodgkin lymphoma addition company be enrolling patient pivotal study evaluate enfortumab vedotin patient metastatic urothelial cancer patient candidate be grant breakthrough therapy designation quarter moreover seattle genetic astella pharma be evaluate enfortumab vedotin phase ib study combination cpi therapy include merck mrk free report keytruda pembrolizumab patient locally advanced metastatic urothelial cancer first second line set company be plan initiate phase iii study seattle genetic germany base genmab be plan initiate phase ii study evaluate tisotumab vedotin recurrent metastatic cervical cancer metastatic cervical cancer treatment naïve woman range other solid tumor type company be evaluate pipeline candidate polatuzumab vedotin diffuse large cell lymphoma study be be conduct collaboration genentech member roche hold ag rhhby free report other activitiesin bid boost pipeline company enter definitive merger agreement last month acquire cascadian therapeutic acquisition add pivotal stage positive metastatic breast cancer candidate tucatinib pipeline company have initiate pivotal study evaluate candidate metastatic breast cancer seattle genetic inc price consensus ep surprise seattle genetic inc price consensus ep surprise seattle genetic inc quoteseattle genetic carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
83,BMY,horizon pharma plc hznp free report report better expect result fourth quarter follow news company share go however horizon pharma stock have decline year date industry fall company report fourth quarter earning cent share beat zack consensus estimate cent be cent year quarter sale fourth quarter be year year beat zack consensus estimate quarter orphan unit record revenue year period strong performance be backed solid net sale ravicti generate quarter year year drive continue conversion older generation nitrogen scavenger therapy well addition treatment naïve patient due recent label expansion april ravicti label be expand include patient age month year older additionally procysbi contribute performance net sale year year actimmune sale report quarter be year year rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive strong continue year year vial demand primary care garner revenue year year decline net sale be due implementation new contract model order secure broader inclusion company primary care medicine formulary report quarter net sale pennsaid duexix vimovo be respectively research development expense increase selling general administrative expense be year year full year be however company report earning share year year orphan unit record revenue year period drive growth sale procysbi procysbi be acquire october sale rheumatology unit also grow mainly drive sale krystexxa year year however primary care unit sale be full year expense increase selling general administrative expense be higher year year guidancehorizon pharma provide outlook expect sale range mainly drive expect strong growth continue orphan rheumatology business unit company continue invest expansion krystexxa nephrology indication expect sale growth more guidance include assumption lower net average net realize price begin second half primarily result government health resource service administration final rule drug ceiling price implementation schedule july horizon pharma be significantly increase investment key growth driver krystexxa expect net sale grow more company expect higher sg expense first half other updatesin february company file supplemental new drug application expand age range label raviciti month age older birth older december regulatory application seek label expansion procysbi include child year older live nephropathic cystinosis be file fda october company announce first patient be enrolled infuse phase iii confirmatory clinical trial evaluate teprotumumab treatment thyroid eye disease ted remind investor company acquire river vision earlier add biologic candidate teprotumumab pipeline meanwhile company be work expand actimmune label investigator initiate study moffitt cancer center be underway enrolling patient study be evaluate actimmune combination roche holding rhhby free report herceptin perjeta taxol certain advanced breast cancer patient phase study evaluate actimmune combination bristol myer squibb company bmy free report opdivo kidney bladder cancer actimmune be also be evaluate combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study company also have plan develop next generation uncontrolled gout development program maintain market leadership takehorizon pharma fourth quarter result be impressive company beating top bottom line estimate moreover sale guidance be encourage well expect krystexxa ravicti actimmune drive further growth acquisition teprotumumab have diversify company portfolio horizon pharma plc price consensus ep surprise horizon pharma plc price consensus ep surprise horizon pharma plc quotezack rankhorizon pharma currently have zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
84,BMY,expect celldex therapeutic inc cldx free report beat expectation report fourth quarter result next month performance have be encourage beat estimate trail quarters meet same deliver average positive surprise last report quarter company deliver positive earning surprise however celldex therapeutic share have lose past year compare decline industry period let see thing be shape announcement factor playcelldex earn revenue entirely product development licensing agreement contract grant company recognize revenue clinical trial collaboration bristol myer squibb company bmy free report varlilumab company continue record revenue source fourth quarter approve product portfolio investor focus remain pipeline development december company start patient enrollment phase study evaluate new candidate cdx treatment patient advanced solid tumor notably cdx be fully human antibody target cd immune response activator november celldex announce datum phase ii study evaluate combination most advanced pipeline candidate glembatumumab vedotin varlilumab melanoma median progression free survival be month patient have stable disease week more study be also evaluate glembatumumab checkpoint inhibitor include bristol myer opdivo merck keytruda also initiate phase ii study human monoclonal antibody cdx patient advanced head neck squamous cell carcinoma hnscc phase ii study evaluate cdx combination eli lilly erbitux patient advanced hnscc be erbitux resistant previously treat pd checkpoint inhibitor apart glembatumumab vedotin varlilumab celldex have several promising candidate pipeline include cdx cdx phase ii multiple solid tumor cdx phase advanced renal cell carcinoma other sg cost decline third quarter operate expense vary quarterly basis earning whispersour proven model show celldex be likely beat estimate quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be peg loss cent share zack consensus estimate be peg loss cent share uncover best stock buy sell re report earning esp filter zack rank celldex currently carry zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision celldex therapeutic inc price ep surprise celldex therapeutic inc price ep surprise celldex therapeutic inc quoteother stock warrant lookhere be couple health care stock want consider model show have right combination element post earning beat quarter atara biotherapeutic atra free report be expect release result mar company have earning esp zack rank see complete list today zack rank stock here gemphire therapeutic gemp free report be expect release result mar company have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
85,BMY,pfizer inc pfe free report be repute name pharmaceutical sector not just medicine vaccine also consumer healthcare product new york base company be know product prevnar lyrica lipitor celebrex other pfizer share have outperformed large cap pharma industry past month stock have return timeframe compare industry gain pfizer outperformance be backed decent quarterly result positive news flow regulatory update here be reason invest stock year favorable rank earning surprise record pfizer have zack rank buy see complete list today zack rank strong buy stock here itha be consistently beating earning expectation earning surpass expectation last quarters average positive surprise company be expect record earning sale growth respectively meanwhile estimate be respectively past day strategic acquisition collaboration pfizer have be work strengthen product portfolio well pipeline acquisition licensing deal september takeover medivation strengthen pfizer cancer franchise add prostate cancer treatment xtandi portfolio xtandi be also be evaluate various other type cancer hold immense potential june anacor acquisition add eucrisa crisaborole topical ointment treat eczema pfizer pipeline pfizer estimate eucrisa peak sale potential be least hospira acquisition significantly expand sterile injectable biosimilar capability addition acquisition pfizer be look drive growth licensing deal collaborative agreement have strategic deal big name pharma sector merck co mrk free report lung cancer drug xalkori combination newly approve steglatro fix dose combination type ii diabetes bristol myer squibb company bmy free report eliquis glaxo gsk free report breast cancer drug ibrance combination deep pipeline pfizer have commit significant resource development treatment field oncology cardiology metabolic disorder neuroscience pain rare disease immunology inflammation vaccine immuno oncology most signify area company believe take lead position pfizer expect approximately drug approval next year include product have blockbuster potential include line extension xtandi ibrance xeljanz xr half potential blockbuster be expect receive approval pfizer have be work streamline effort have several late stage candidate pipeline include many immuno oncology candidate key candidate immuno oncology pipeline be bavencio avelumab be be evaluate different type cancer collaboration merck kgaa bavencio be already metastatic merkel cell carcinoma mcc advanced bladder cancer bavencio be be consider key long term growth driver pfizer explore world biosimilar pfizer market biosimilar version merck blockbuster medicine remicade unite state inflectra ixifi inflectra be first biosimilar monoclonal antibody available unite state other biosimilar late stage development include biosimilar version roche cancer drug rituxan avastin abbvie humira biosimilar version herceptin be review unite state eu meanwhile pfizer be evaluate biosimilar molecule various stage development aggressive cost cut initiative several product face slate face generic competition pfizer be look cost cut initiative drive bottom line growth company have be undertaking massive restructure cost cut measure past several year management be also look focus effort area have high potential oncology geographic region asia pfizer achieve cost reduction goal be announce end year earlier expect continue generate cost saving company also achieve target bring significant reduction annual spend end face share challenge form genericization key drug supply challenge legacy hospira portfolio pricing pressure rise competition however believe pfizer be able overcome headwind wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
86,BMY,investor be not much impressed exelixis inc exel free report fourth quarter performance company beat revenue earning be line estimate follow announcement result share exelixis fall market trading session exelixis share have rally year outperform industry decline company report earning cent line zack consensus estimate flat year year net revenue come year quarter however company suffer sequential decline generate third quarter increase overall demand be offset reduction approximately week wholesaler inventory build quarter revenue surpass zack consensus estimate exelixis inc price consensus exelixis inc price consensus exelixis inc quote quarter fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy december fda also approve cabometyx treatment previously untreated advanced rcc approximately month ahead assign prescription drug user fee act pdufa action date cabometyx generate net product revenue drive growth demand second line rcc demand be drive increase market share refill patient already therapy continue expansion prescriber base sequential increase cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare earn year quarter fourth quarter research development expense increase stem increase personnel expense clinical trial cost consult outside service selling general administrative expense be significantly drive increase consult outside service support company marketing activity result primarily increase general administrative headcount support company commercial research development organization resultsrevenue come beat zack consensus estimate earning share come cent loss cent line zack consensus estimate cabometyx sale come year year pipeline updatein march fda grant cabozantinib orphan drug designation treatment advanced hepatocellular carcinoma hcc october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter exelixis inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate july be evaluate combination checkpoint inhibition therapy combine cabozantinib compare sutent meanwhile update result ongoing phase trial cabozantinib combination opdivo yervoy patient refractory genitourinary tumor demonstrated acceptable tolerability profile high rate durable response previously treat metastatic uc metastatic rcc cohort january exelixis announce amendment protocol phase ib trial cabozantinib combination tecentriq patient locally advanced metastatic solid tumor amendment add new expansion cohort trial now include patient small cell lung cancer castration resistant prostate cancer addition previously include patient rcc urothelial carcinoma primary objective expansion stage trial remain determine objective response rate cohort imspire trilogy trial evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma be underway imspire trial evaluate combination cotellic tecentriq versus merck mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma have enrolled first patient expect total cost operate expense range takeexelixis fourth quarter result be positive sale beat estimate earning come line expectation exelixis put strong performance drive gain market share cabometyx new patient market share second line set grow approximately end third quarter expect sale get further boost company launch drug first line rcc increase eligible patient population caobometyx unite state approximately patient grab market share key drug sutent votrient first line rcc market expect investor focus remain further label expansion cabozantinib cotellic potential label expansion advanced hcc further boost growth prospect company zack rankexelixis currently carry zack rank buy see complete list today zack strong buy rank stock here note be re issue article correct error original version publish earlier today tuesday february not be rely zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
87,BMY,investor be not much impressed exelixis inc exel free report fourth quarter performance company beat revenue earning be line estimate follow announcement result share exelixis fall market trading session exelixis share have rally year outperform industry decline company report earning cent line zack consensus estimate flat year year net revenue come year quarter however company suffer sequential decline generate third quarter increase overall demand be offset reduction approximately week wholesaler inventory build quarter revenue surpass zack consensus estimate exelixis inc price consensus exelixis inc price consensus exelixis inc quote quarter fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy december fda also approve cabometyx treatment previously untreated advanced rcc approximately month ahead assign prescription drug user fee act pdufa action date cabometyx generate net product revenue drive growth demand second line rcc demand be drive increase market share refill patient already therapy continue expansion prescriber base sequential increase cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare earn year quarter fourth quarter research development expense increase stem increase personnel expense clinical trial cost consult outside service selling general administrative expense be significantly drive increase consult outside service support company marketing activity result primarily increase general administrative headcount support company commercial research development organization resultsrevenue come beat zack consensus estimate earning share come cent loss cent line zack consensus estimate cabometyx sale come year year pipeline updatein march fda grant cabozantinib orphan drug designation treatment advanced hepatocellular carcinoma hcc october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter exelixis inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate july be evaluate combination checkpoint inhibition therapy combine cabozantinib compare sutent meanwhile update result ongoing phase trial cabozantinib combination opdivo yervoy patient refractory genitourinary tumor demonstrated acceptable tolerability profile high rate durable response previously treat metastatic uc metastatic rcc cohort january exelixis announce amendment protocol phase ib trial cabozantinib combination tecentriq patient locally advanced metastatic solid tumor amendment add new expansion cohort trial now include patient small cell lung cancer castration resistant prostate cancer addition previously include patient rcc urothelial carcinoma primary objective expansion stage trial remain determine objective response rate cohort imspire trilogy trial evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma be underway imspire trial evaluate combination cotellic tecentriq versus merck mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma have enrolled first patient expect total cost operate expense range takeexelixis fourth quarter result be positive sale beat estimate earning come line expectation exelixis put strong performance drive gain market share cabometyx new patient market share second line set grow approximately end third quarter expect sale get further boost company launch drug first line rcc increase eligible patient population caobometyx unite state approximately patient grab market share key drug sutent votrient first line rcc market expect investor focus remain further label expansion cabozantinib cotellic potential label expansion advanced hcc further boost growth prospect company zack rankexelixis currently carry zack rank buy see complete list today zack strong buy rank stock here note be re issue article correct error original version publish earlier today tuesday february not be rely zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
88,BMY,bristol myer squibb company bmy free report first quarter earning cent share exceed zack consensus estimate cent year quarter earning cent total revenue be slightly higher zack consensus estimate increase record year period strong sale opdivo eliquis contribute top line report quarter share company be almost pre market trading possibly better expect earning however bristol myer share have decline so far year compare unfavorably industry decrease quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase unite state outside country ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year sale drug be label expansion drug pediatric patient unite state last november presumably do not have much impact sale rheumatoid arthritis drug orencia be first quarter melanoma drug yervoy contribute top line report quarter sale drug be opdivo be approve multiple cancer indication generate revenue year period sale cardiovascular drug eliquis be report quarter year year multiple myeloma drug empliciti record sale year year however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively hepatitis franchise lose year quarter sale contribute mere revenue research development expense quarter decrease marketing selling administrative expense decline gross margin be quarter compare year quarter due change product mix regulatory quarter april fda approve opdivo yervoy combination regimen treat intermediate poor risk advanced renal cell carcinoma patient have not receive prior treatment march fda have grant priority review supplemental biologic license application sbla seek approval combination regimen treat microsatellite instability high mismatch repair deficient metastatic colorectal cancer also april fda grant priority review sbla seek approval opdivo monotherapy patient small cell lung cancer third later line set new dose regimen opdivo mg week be also approve majority indication april bristol myer collaborate johnson johnson jnj free report subsidiary janssen develop commercialize factor xia inhibitor program include bms treat major thrombotic condition same month bristol myer privately hold illumina inc announce collaboration utilize latter next generation sequence technology february bristol myer squibb nektar therapeutic nktr free report enter strategic development collaboration nektar lead immuno oncology program nktr collaboration company develop commercialize nktr combination opdivo opdivo yervoy more indication tumor type well potential combination other cancer agent respective company third party company plan initiate study renal cell carcinoma melanoma mid pipeline updatein april bristol myer announce datum phase iii study checkmate show superior progression free survival first line small cell lung cancer nsclc treat opdivo yervoy combination compare chemotherapy january bristol myer announce positive datum phase ii checkmate study evaluate combination opdivo yervoy patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer mcrc company also announce datum phase iii study checkmate evaluate opdivo chinese population datum show drug achieve superior overall survival previously treat patient nsclc compare docetaxel datum long term follow phase iii study checkmate show opdivo reduce risk death metastatic squamous cell carcinoma head neck minimum year follow compare standard chemotherapy march bristol myer pfizer inc pfe free report announce datum real world datum analysis different direct oral anticoagulant include eliquis xarelto boehringer ingelheim pradaxa datum show eliquis achieve significantly lower rate stroke systemic embolism major bleed compare xarelto pradaxa guidance updatedbristol myer increase adjust earning expectation company now project earning range share previously zack consensus estimate earning be peg company expect worldwide revenue increase mid single digit takebristol myer beat earning expectation primarily robust sale opdivo eliquis quarter increase guidance adjust earning be also encourage be positive bristol myer effort develop pipeline especially opdivo several label expansion application opdivo be review unite state europe potential approval further boost prospect blockbuster drug also superiority eliquis real world datum analysis be expect further boost sale drug bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotebristol myer carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
89,BMY,bristol myer squibb company bmy free report be new york base major producer distributor pharmaceutical other healthcare related product company key oncology product include opdivo sprycel yervoy empliciti other oncology company be focuse immunology cardiovascular drug orencia eliquis also market drug hbv hcv baraclude daklinza company virology portfolio comprise product reyataz sustiva franchise bristol myer be also active partnership front pursue strategic acquisition therapeutic area include immunoscience oncology fibrosis genetically defined disease however many peer bristol myer be face generic competition several key product moreover hiv hcv business be competitive pressure scenario investor focus remain company high profile immuno oncology drug opdivo apart usual top bottom line number bristol myer have mixed record earning surprise recent quarters company earning surpass expectation last quarters average positive surprise currently bristol myer have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning bristol myer beat first quarter earning company report ep cent consensus call ep cent revenue moreover revenue be expectation bristol myer post revenue compare consensus estimate guidance bristol myer increase earning outlook company now expect earning range share previously zack consensus estimate earning stand share pre market trading share be pre market trading key stat fda approve combination regimen opdivo yervoy treatment intermediate poor risk advanced renal cell carcinoma treatment naïve patient moreover new mg dose schedule opdivo week be approve unite state europe check back later full bmy earning report later bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
90,BMY,nektar therapeutic nktr free report share increase more feb company announce global strategic collaboration agreement bristol myer squibb bmy free report agreement company jointly develop commercialize lead immuno oncology candidate nktr former combination latter opdivo nivolumab opdivo yervoy ipilimumab pursuant contract nektar be entitle receive upfront payment include payment cash equity investment nektar also get additional potential payment achievement certain developmental sale base milestone nektar bristol myer share profit respective ratio potential sale nktr worldwide positive note nektar not only retain ownership candidate also continue collaborate other company further development nektar jointly commercialize nktr opdivo combination unite state well major market eu japan bristol myer be entitle solely commercialize combination other global market remind investor nektar be already evaluate nktr opdivo phase ii pivot study tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication latest deal bristol myer have be agree company evaluate nktr opdivo nktr opdivo yervoy combination more cancer indication tumor type november company report positive interim datum dose escalation part study evaluate safety efficacy combo therapy patient melanoma renal cell carcinoma small cell lung cancer nektar share have significantly outperformed industry year time stock have sky-rocket compare industry increase importantly nektar be also conduct phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab notably propel study complement company ongoing pivot trial additionally nektar have enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio nektar therapeutic price nektar therapeutic price nektar therapeutic quotenektar carry zack rank sell see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail be reissue article correct mistake original article issue thursday february longer be rely
91,BMY,roche hold ag rhhby free report announce fda have approve perjeta pertuzumab combination herceptin chemotherapy perjeta base regimen adjuvant surgery treatment positive early breast cancer ebc high risk recurrence patient receive adjuvant perjeta base regimen year cycle perjeta combination herceptin docetaxel be already approve use patient have positive breast cancer have spread different part body metastatic have not receive therapy chemotherapy metastatic breast cancer come back release approval indication be base result phase iii aphinity study study show perjeta herceptin chemotherapy significantly reduce risk invasive breast cancer recurrence death compare herceptin chemotherapy alone combination wasalso grant priority review fda october invasive disease free survival dfs serve primary endpoint secondary endpoint include overall cardiac safety dfs health related quality life addition fda grant full approval use same regimen neoadjuvant treatment positive locally advanced inflammatory early stage breast cancer now neoadjuvant indication have be allow accelerate approval roche stock have rally year date compare industry gain company have strong presence oncology market dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla herceptin growth be drive improve demand unite state europe due longer treatment duration moreover subcutaneous formulation herceptin be be increasingly adopt europe meanwhile sale perjeta have be strong europe largely due uptake neo adjuvant set persistent growth metastatic set kadcyla sale be be drive increase demand europe internationally apart strong breast cancer franchise roche oncology portfolio also boast drug avastin tarceva lung cancer however note roche be face stiff competition like merck co inc mrk free report keytruda bristol myer squibb company bmy free report opdivo immuno oncology space roche hold ag price roche hold ag price roche hold ag quotezack rank stock considerroche carry zack rank sell better rank stock same space be sucampo pharmaceutical carry zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date zack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
92,BMY,share laboratory corporation america holding lh free report scale new week high dec close nominally lower company have gain last month much higher broader industry gain respect share price stock have market cap take stable stock performance consideration expect labcorp scale higher come quarters also company long term expect earning growth rate hold promise further company estimate revision trend current year be favorable past day estimate moved shift consequently estimate be share laboratory corporation america holding price consensus laboratory corporation america holding price consensus laboratory corporation america holding company also have trail quarter average positive earning surprise positive long term growth hold promise well labcorp recently announce agilent dako pathology division development pd ihc pharmdx assay be now available unite state new expand use labcorp test receive approval be used complementary diagnostic bristol myer squibb company bmy free report opdivo nivolumab new indication metastatic urothelial carcinoma bladder cancer squamous cell carcinoma head neck encourage strong third quarter show gradually improve foreign exchange scenario company raise outlook net revenue growth be maintain band year year ahead earlier range free cash flow expectation have be raise new band previous range prior year recent past company successfully close chiltern international group buyout specialty contract research organization chiltern be major partner labcorp serve top biopharma segment help company focus high growth emerge mid market biopharma segment follow takeover company covance drug development report strong growth third quarter several quarters tepid performance zack rank key pickslabcorp carry zack rank hold few better rank medical stock be athenahealth inc athn free report align technology inc algn free report sport zack rank strong buy see complete list today zack rank stock here athenahealth have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
93,BMY,portola pharmaceutical inc ptla free report announce fda have extend review period biologic license application bla reversal agent factor xa inhibitor andexxa andexanet alfa day result regulatory body now announce decision instead previously set deadline feb notably andexxa have be develop patient treat direct indirect factor xa inhibitor reversal anticoagulation be need due life threaten uncontrolled bleed portola share have significantly outperformed industry so far year stock have soar compare broader industry increase review date be extend accommodate resubmission additional datum provide portola august resubmission be request fda complete response letter issue portola last august letter fda have request extra information related product manufacturing importantly regulatory body have also ask more datum support inclusion direct factor xa inhibitor lixiana edoxaban indirect factor xa inhibitor lovenox enoxaparin product label hence view fda have logically ask additional time review application remind investor bla be base positive datum phase iii annexa study have evaluate safety efficacy andexxa reverse anticoagulant activity factor xa inhibitor xarelto rivaroxaban johnson johnson inc jnj free report eliquis apixaban bristol myer squibb company bmy free report older healthy volunteer significantly andexxa enjoy orphan drug status unite state andexxa be also review eu marketing application file third quarter response regulatory body be expect first half company press release more patient treat oral factor xa inhibitor be admit hospital due excessive bleed have also be estimate more patient take injectable factor xa inhibitor lovenox unite state benefit antidote annually currently approve antidote factor xa inhibitor yet be urgent gape unmet need same market go ahead expect investor focus remain further detail andexxa regulatory aspect portola pharmaceutical inc price portola pharmaceutical inc price portola pharmaceutical inc quotezack rank key pickportola carry zack rank hold better rank stock health care sector be therapeutic incorporate cort free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have be revise upward cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
94,BMY,key announcement week include fda approval eye disease drug well diabetes treatment label expansion exist product regulatory pipeline update be also provide company astrazeneca azn free report johnson johnson jnj free report recap week most important storiesaerie rhopressa gain fda approval aerie pharmaceutical aeri free report get boost earlier expect fda approval rhopressa lower elevated intraocular pressure iop patient open angle glaucoma ocular hypertension approval be expect consider favorable advisory panel vote october approval come couple month ahead feb pdufa prescription drug user fee act goal date rhopressa be first product aerie portfolio company expect launch product mid second quarter read more aerie get early fda approval lead drug rhopressa merck pfizer diabetes drug get fda nod sglt inhibitor steglatro ertugliflozin have be develop merck mrk free report pfizer pfe free report gain fda approval treatment type ii diabetes steglatro be enter highly crowd diabetes market already have other sglt inhibitor form invokana farxiga jardiance steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan priority review astrazeneca tagrisso label expansion astrazeneca supplemental new drug application snda use tagrisso osimertinib first line treatment patient metastatic small cell lung cancer nsclc tumor have egfr mutation have be grant priority review fda approval indication expand patient population significantly read more astrazeneca tagrisso label expansion filing accept fda janssen car deal priority review apalutamide janssen biotech have inked worldwide collaboration license agreement legend biotech usa inc legend biotech ireland limit subsidiary genscript biotech corporation development manufacture chimeric antigen receptor car cell drug candidate lcar lcar specifically target cell maturation antigen bcma be currently regulatory review china multiple myeloma mm meanwhile clinical study be be plan unite state term deal global net trade sale exclude greater china area be record janssen company split cost profit equally greater china janssen legend have cost sharing profit split arrangement deal term also include upfront payment janssen additional payment achievement development regulatory sale milestone be latest agreement field car have be attract lot interest recent quarters janssen also announce get priority review status fda new drug application nda apalutamide company investigational next generation oral androgen receptor ar inhibitor treatment man metastatic castration resistant prostate cancer crpc fda grant priority review response be april give be fda approve treatment currently available patient population timely approval be boost company cancer portfolio have gain year date compare rally industry belong allergan provide update vraylar seysara allergan agn free report provide couple update pipeline front company partner gedeon richter say vraylar cariprazine meet primary endpoint late stage adult major depressive episode associate bipolar disorder bipolar depression company plan seek label expansion indication second half read more allergan vraylar positive bipolar disease phase iii allergan also announce nda seysara have be accept review allergan partner paratek pharmaceutical be look get antibiotic approve treatment moderate severe acne vulgaris patient year age older approval come second half fda expand label pfizer bosulif grant btd bavencio fda have give nod label expansion pfizer bosulif use newly diagnosed chronic phase ph chronic myelogenous leukemia ph cml patient bosulif initial approval be use patient chronic accelerate blast phase ph cml resistance intolerance prior therapy expand indication increase addressable patient population significantly accord american cancer society new cml case be diagnosed unite state pfizer also announce fda have grant breakthrough therapy designation btd bavencio avelumab use combination inlyta treatment naïve patient advanced renal cell carcinoma rcc avelumab be partner merck kgaa breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint be second time bavencio have receive btd hard treat cancer first time be treatment patient metastatic merkel cell carcinoma mmcc disease have progressed least previous chemotherapy regimen label expansion clinical trial collaboration bmy opdivo bristol myer squibb bmy free report pd immune checkpoint inhibitor opdivo gain fda approval yet indication regulatory agency grant approval opdivo intravenous use adjuvant treatment patient completely resect melanoma lymph node involvement metastatic disease opdivo be already approve wide range indication alone well combination other agent be currently several study well fact company also announce clinical trial collaboration taris biomedical evaluation safety tolerability preliminary efficacy taris tar gemris combination opdivo phase ib study evaluate combination patient muscle invasive bladder cancer mibc be schedule radical cystectomy opdivo be prioritize brand bristol myer portfolio product bring sale first month bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be slightly last trading session major stock merck be lilly bristol myer decline last month bristol myer be glaxo decline see last pharma stock roundup here teva announce major job cut lilly provide outlook next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
95,BMY,seattle genetic inc sgen free report announce clinical collaboration evaluate sgn liv triple negative breast cancer tnbc sgn liv be antibody drug conjugate adc be develop treatment metastatic breast cancer patient tumor express liv protein seattle genetic share have outperformed industry year date stock have be industry gain company test sgn liv combination merck co mrk free report keytruda phase ib ii study first line treatment locally advanced metastatic tnbc study be expect enroll patient agreement seattle genetic retain global development right sgn liv hold investigational new drug ind study additionally sgn liv be evaluate combination standard chemotherapy neoadjuvant treatment phase ii spy study newly diagnosed stage human epidermal growth factor receptor negative breast cancer study be sponsored quantum leap health care collaborative quantum leap be expect enroll patient sgn liv treatment arm fact study be design way so screen potential treatment specific patient subgroup base molecular characteristic furthermore clinical study be plan sgn liv breast cancer focus tnbc apart sgn liv monotherapy be be evaluate ongoing phase trial patient metastatic breast cancer include patient heavily pre treat tnbc fact breast cancer be most common form cancer woman tnbc also be very aggressive form associate poor patient outcome therefore lot company be develop product space last month infinity pharmaceutical inc infi free report expand exist clinical collaboration bristol myer squibb bmy free report evaluate ipi combination latter checkpoint inhibitor opdivo collaboration include patient tnbc have not be previously expose pd pd therapy notably very few patient triple negative breast cancer respond checkpoint inhibitor alone so be left very limit therapeutic option turn expand collaboration include patient tnbc have not be previously expose pd pd therapy turn enable infinity test ipi combination opdivo increase number patient respond checkpoint inhibition seattle genetic inc price seattle genetic inc price seattle genetic inc quotezack rankseattle genetic carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
96,BMY,hepatitis be infectious disease cause hepatitis virus hcv primarily affect liver gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer bmy free report daklinza johnson johnson jnj free report olysio accord center disease control prevention cdc person unite state be live chronic hepatitis infection many remain unaware be infected be new hepatitis case year unite state many go unreported consider number be not surprise quite few pharma biotech company be work bring new improve shorter duration hcv treatment market market be thus get crowd see increase pricing pressure lot have happened hcv space late september gilead science sovaldi receive approval china component combination antiviral treatment regimen be first gilead hcv drug be approve china meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor gilead share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank hold see complete list today zack rank strong buy stock here meanwhile abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada past couple month mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history abbvie share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank however last week pharmaceutical giant merck mrk free report announce be discontinue further development next generation hepatitis hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company make decision base review available phase ii efficacy datum heavily crowd hcv market merck share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank merck giant johnson johnson also discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir company take decision consider be several highly effective therapy available indication johnson johnson share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank be believe discontinuation merck combination hcv regimen act favor gilead abbvie gilead abbvie benefit lack additional competition enter market least term however company continue face challenge form decline patient volume intense pricing pressure lack additional entrant market also slow rate decline sale do zack investment idea come be welcome download full minute list zack rank strong buy stock free charge be better place start own stock search access full list avoid zack rank strong sell other private research see stock free
97,BMY,abbvie inc abbv free report share have gain impressive past month compare favorably gain record industry share price surge be support series positive news company past few week last week abbvie announce resolution ongoing patent dispute amgen inc amgn free report have delay launch latter biosimilar version abbvie blockbuster arthritis drug humira settlement abbvie grant exclusive license amgen allow latter sell amjevita unite state jan most country eu oct other market different date license amgen pay abbvie pre specify royalty agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market secondly abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada past couple month mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history abbvie announce positive datum phase iii murano study venclexta rituxan relapse refractory cll last month datum show venclexta roche rhhby free report rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll label expansion indication expand patient population venclexta significantly boost commercial potential abbvie also announce collaboration bristol myer squibb bmy free report evaluate combination investigational antibody drug conjugate abbv bristol myer immunotherapy opdivo meet overexpressing small cell lung cancer nsclc lastly abbvie oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra highly statistically significant clinically meaningful result dose mg mg upadacitinib compare placebo upadacitinib also meet primary endpoint phase iib study treatment adult patient atopic dermatitis also know eczema company plan advance candidate phase iii study next year datum upadacitinib study be announce last month fact so far year abbvie share price have increase also compare favorably gain industry abbvie carry zack rank hold see complete list today zack rank strong buy stock here stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
98,BMY,seattle genetic inc sgen free report announce fda have grant breakthrough therapy designation status lymphoma drug adcetris frontline treatment advanced classical hodgkin lymphoma company recently complete phase iii study echelon drug indication remind investor adcetris be currently approve second third line treatment classical hodgkin lymphoma systemic anaplastic large cell lymphoma least fail multus agent chemotherapy regimen unite state well europe breakthrough therapy designation be grant speed development review drug target serious life threaten condition company share close higher monday follow news share seattle genetic have rise so far year underperform industry gain period june company announce positive top line datum echelon study demonstrated adcetris achieve improvement modify progression free survival statistical significance compare standard care chemotherapy echelon study evaluate adcetris addition adriamycin vinblastine dacarbazine patient advanced classical hodgkin lymphoma prior treatment designation be grant base datum company expect submit supplemental biologic license application sbla end seattle genetic be develop drug more clinical study key study include evaluation cell lymphomas hodgkin lymphoma company have complete alcanza phase iii study submit sbla last month expand label include cutaneous cell lymphoma decision be expect december phase iii study be currently evaluate adcetris frontline mature cell lymphomas recently initiate study be evaluate drug combination bristol myer squibb company bmy free report opdivo relapse refractory hodgkin lymphoma adcetris be only market product seattle genetic generate sale first half almost year period further label expansion new indication boost sale number however adcetris face competition other drug include merck co inc mrk free report keytruda be recently approve lymphoma indication seattle genetic inc price consensus seattle genetic inc price consensus seattle genetic inc quotezack rank stock considerseattle genetic carry zack rank hold regeneron pharmaceutical inc regn free report be better rank stock health care sector sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
99,BMY,late last week merck mrk free report announce decision discontinue development couple candidate hepatitis virus hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company decision be base review available phase ii efficacy datum grow competition hcv market merck have market product hcv market form zepatier elbasvir grazoprevir bring sale first month include favorable adjustment rebate accrual due mix business merck continue work expand zepatier utilization world uptake be impact ongoing decline overall patient volume many market increase competition gilead abbvie hcv spotlightmerck announcement have now put spotlight firmly gilead science gild free report abbvie abbv free report key player market gilead be undisputed leader hcv market hcv product bring sale first half company revolutionize treatment paradigm hcv market introduction sovaldi cut duration treatment few week instead prior standard care week moreover need peg interferon injection come several side effect be reduce eliminate completely gilead launch harvoni next first once daily single tablet regimen treatment most prevalent hcv genotype unite state be follow launch epclusa first oral pan genotypic single tablet regimen treatment adult genotype chronic hcv infection year gilead gain approval yet hcv treatment vosevi gilead rule hcv market quite few year sale be decline give intense pricing pressure grow competition pricing scrutiny decline patient population approval newer hcv product have result rapid increase number patient be treat cure follow decline number patient seek care be able access hcv treatment gilead expect hcv net product sale range announce result represent quite drop last year hcv product sale meanwhile abbvie hcv product include mavyret glecaprevir pibrentasivr viekira pak ombitasvir paritaprevir ritonavir tablet co package dasabuvir tablet viekira xr dasabuvir ombitasvir paritaprevir ritonavir mavyret be approve recently viekira sale be first half mavyret company next generation hcv offer be meaningful contributor sale other hcv drug include bristol myer squibb company bmy free report daklinza daclastavir janssen therapeutic olysio simeprevir remind investor merck be not only company have take decision halt development hcv candidate last month johnson johnson jnj free report have announce decision terminate collaboration agreement achillion pharmaceutical achn free report hcv janssen pharmaceutical say be discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir merck drop investigational hcv treatment gilead abbvie benefit lack additional competition enter market least term company continue face challenge decline patient volume intense pricing pressure lack additional entrant market slow rate decline sale gilead have be work expand hcv market encourage baby boomer get test accord company have be increase hcv antibody screening baby boomer start initiative increase testing have lead increase diagnosis person be newly diagnosed hcv represent significant opportunity exist player hcv market gilead abbvie be zack rank hold stock see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
100,BMY,bristol myer squibb company bmy free report announce fda have grant priority review supplemental biologic license application sbla label expansion opdivo company be look get drug approve treat patient melanoma be high risk disease recurrence follow complete surgical resection however drug be already approve treatment patient braf mutation positive unresectable metastatic melanoma generally priority review designation fda be grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease fda also previously grant breakthrough therapy designation application be seventh indication opdivo have receive designation supplemental biologic license application be base datum ongoing phase iii checkmate study bristol myer announce encourage result checkmate study opdivo checkmate be randomize double blind study opdivo versus yervoy patient have undergo complete resection stage iiib stage iv melanoma result study show opdivo mg kg lead significant improvement recurrence free survival rfs compare yervoy mg kg patient stage iiib stage iv melanoma follow complete surgical resection result plan interim analysis show opdivo meet primary endpoint statistically significant improvement rfs compare yervoy july company report positive result same study so far year bristol myer stock have rally compare industry gain fact opdivo become first pd immune checkpoint inhibitor gain regulatory approval anywhere world july notably drug become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy opdivo continue be launch globally approval label expansion also receive approval several indication include melanoma head neck lung kidney blood cancer fact opdivo yervoy regimen be approve multiple market treatment melanoma drug have be perform impressively due demand result rapid commercial acceptance several indication opdivo generate revenue second quarter year period meanwhile fda have put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma also concern astrazeneca azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc bristol myer be expect suffer further loss market share bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer carry zack rank hold better rank stock health care sector include nordisk nvo free report hold zack rank buy see complete list today zack rank strong buy stock here nordisk earning share estimate have moved company pull positive earning surprise trail quarters average beat share price company have increase year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
101,BMY,exelixis inc exel free report announce fda have grant priority review supplemental new drug application snda cabomteyx snda seek approval cabometyx patient previously untreated advanced renal cell carcinoma rcc fda determine snda be sufficiently complete consequently fda assign prescription drug user fee act action date feb snda be base datum phase ii trial cabosun be be conduct alliance clinical trial oncology part exelixis collaboration national cancer institute cancer therapy evaluation program market advanced rcc be huge american cancer society statistic datum clear cell rcc be most common type kidney cancer adult patient unite state globally require treatment estimate patient unite state be need first line treatment advanced kidney cancer year remind investor cabometyx be approve fda april treatment patient advanced rcc receive prior angiogenic therapy new patient start refill patient already therapy continue expansion prescriber base cabometyx be drive drug sale hence potential approval cabometyx be expect boost sale concurrently exelixis partner ipsen announce phase iii trial celestial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement median os compare placebo patient advanced hepatocellular carcinoma hcc consequently independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis company share moved follow news exelixis share price have increase year date higher industry gain exelixis have collaborate bristol myer squibb co bmy free report roche holding rhhby free report development drug combination immunotherapy agentswe note glaxosmithkline plc gsk free report votrient be also approve clear cell rcc zack rankexelixis currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
102,BMY,biotech industry have witness great turnaround year drug pricing issue cripple performance last year decline last year large cap pharma industry have rise so far year outpace gain same time frame nasdaq biotechnology index be almost year date slide nyse arca pharmaceutical index have rise year date ytd decline almost last year pharma biotech sector have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval new drug approve alone continue strong performance legacy product have play pivotal role bring sector track year factor have contribute sector surge be president trump expect action drug price not be onerous previously fear factor be likely drive sector rest year probably next challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug broader macro front propose tax reform approve leave more cash hand company cash be invest merger acquisition have be relatively fewer year compare last meanwhile outlook upcoming third quarter result look bright earning trend article broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning pick likely winnersgiven enormity healthcare space select stock have potential beat estimate appear be quite daunting proprietary methodology make fairly simple way narrow list choice earning season be look stock have combination favorable zack rank zack rank strong buy buy hold positive earning esp more often not positive earning surprise deliver company lead stock price appreciation earning esp be proprietary methodology identify stock have high chance deliver positive surprise upcoming earning announcement show percentage difference most accurate estimate zack consensus estimate research show stock combination chance positive earning surprise be high uncover best stock buy sell re report earning esp filter here be large cap pharma stock be poise beat estimate third quarter accord methodology investing stock large market cap be much more reliable investment fact control large portion give industry also company larger market cap have perform well first pick be eli lilly company lly free report indianapoli base company have earning esp zack rank hold see complete list today zack rank strong buy stock here zack consensus estimate third quarter be share company have mixed earning surprise record fact lilly earning surpass expectation last quarters average negative surprise lilly be schedule report result oct next choice be pfizer inc pfe free report carry zack rank stock have earning esp zack consensus estimate third quarter be peg cent share new york base pfizer have mixed earning surprise track record average negative earning surprise trail quarters be pfizer be schedule announce result oct astrazeneca plc azn free report too have impressive track record company consistently beating earning expectation company earning surpass estimate last quarters average positive surprise look poise beat expectation third quarter well london uk base company carry zack rank have earning esp zack consensus estimate be peg cent share astrazeneca be schedule report result nov bristol myer squibb company bmy free report be solid bet zack rank stock have earning esp new york base company deliver average positive earning surprise trail quarters bristol myer be schedule release result oct zack consensus estimate third quarter peg cent share brentford uk base glaxosmithkline plc gsk free report make list likely outperformer third quarter virtue zack rank earning esp zack consensus estimate be peg cent share glaxo be expect report result oct bottom line challenge form competitive pricing pressure remain however number company healthcare space have fared well pick outperformer space backed solid zack rank positive earning esp lead investor gain earning season stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
103,BMY,clovis oncology inc clvs free report incur adjust loss share fourth quarter be narrower year loss share well zack consensus estimate loss clovis only market drug rubraca be grant accelerate approval fda december treatment advanced ovarian cancer patient have receive prior chemotherapy net product revenue entirely rubraca be approximately quarter mere sequentially however revenue miss zack consensus estimate importantly company register new patient rubraca therapy approval fourth quarter new patient be register presumably adoption rubraca be slower due approval only patient population have brca mutation increase competition recently approve maintenance therapy include tesaro inc tsro free report zejula astrazeneca plc azn free report lynparza year quarter clovis have generate revenue share company decline almost market trading monday lower expect rubraca sale moreover clovis have significantly underperform industry past year stock have lose industry decline quarter detaildure fourth quarter research development expense decrease year year primarily due decrease development activity related rubraca rociletinib program however selling general administrative sg expense escalate year year reflect increase activity support rubraca cash used operate activity quarter be higher year quarter clovis end quarter cash equivalent available sale security support proceed raise share offering make january june sale full year be rubraca have generate sale year period be launch december adjust loss share narrow year year update supplemental new drug application snda rubraca seek label expansion maintenance treatment patient platinum sensitive recurrent ovarian cancer be grant priority review december snda be submit base positive datum ariel confirmatory study decision be expect april ariel confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy be open enrolment rubraca be also review eu advanced ovarian cancer indication brca mutation committee medicinal product human use be expect provide decision march investor expect positive recommendation chmp communicate positive trend vote last week additionally clovis have plan submit supplemental application seek approval second line later maintenance treatment indication eu only approve advanced ovarian cancer indication july clovis announce collaboration bristol myer squibb company bmy free report evaluate rubraca combination latter pd immune checkpoint inhibitor opdivo multiple tumor type company initiate phase ii study december evaluate combination patient metastatic castrate resistant prostate cancer clovis be also evaluate plan develop rubraca several study expand label additional indication prostrate breast pancreatic cancer other monotherapy combination other agent clovis oncology inc price consensus ep surprise clovis oncology inc price consensus ep surprise clovis oncology inc quotezack rankclovis have zack rank hold see complete list today zack strong buy rank stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
104,BMY,key announcement week include fda approval second indication astrazeneca azn free report imfinzi acquisition offer merck mrk free report abbvie abbv free report present new datum pipeline candidate announce alzheimer deal small biotech recap week most important imfinzi gain fda nod second indication astrazeneca pd inhibitor imfinzi gain fda approval early stage lung cancer indication make drug second fda approval latest approval imfinzi now be prescribe treat unresectable stage iii small cell lung cancer nsclc patient disease have not progressed follow chemoradiation therapy imfinzi be launch unite state first indication second line advanced bladder cancer be also be develop several other cancer indication read more astrazeneca imfinzi get fda nod label expansion meanwhile astrazeneca license new antisense drug kidney disease ionis az rx ionis pharmaceutical inc ion free report go forward astrazeneca be responsible develop commercialize ionis az rx read more ionis license second candidate astrazeneca earn merck look buy innovative immuno oncology candidate merck propose buy australian oncolytic immunotherapy maker viralytic limit australian dollar believe deal get strengthen merck presence fast grow immuno oncology market deal merck gain viralytic lead pipeline candidate cavatak oncolytic virus engage innate immune system attack cancer cell transaction be expect be complete second quarter contingent viralytic shareholder approval read more merck buy australian firm boost immunotherapy pipeline abbvie report new mid stage datum upadacitinib abbvie announce new datum phase ii celest study evaluate multiple dose regimen jak inhibitor upadacitinib crohn disease week datum study show patient clinically respond upadacitinib treatment week induction phase maintain response week extension phase study please note result week induction phase celest study be previously announce last year read more abbvie present new datum upadacitinib crohn disease separately abbvie neurocrine bioscience first pivotal phase iii study pipeline candidate elagolix meet primary endpoint elaris uf study be evaluate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid datum study demonstrated elagolix combination low dose add back therapy reduce heavy menstrual bleed compare placebo read more abbvie uterine fibrosis candidate meet goal study elagolix be already review unite state management endometriosis associate pain abbvie also announce global strategic collaboration small biotech voyager therapeutic inc vygr free report develop potential new treatment alzheimer disease other tau related disease nordisk oral ozempic succeed study nordisk nvo free report announce phase iii study pioneer evaluate tablet oral formulation newly approve diabetes treatment ozempic semaglutide achieve primary objective datum study show person type ii diabetes be treat once weekly oral semaglutide glp receptor agonist experience significant superior blood glucose control compare placebo dose mg evaluate meanwhile significant superior weight loss versus placebo be observed patient be give highest dose mg nordisk expect file approval oral formulation ozempic pending datum remain pioneer study ozempic semaglutide be approve last year december once daily pre filled pen improve glycaemic control type ii diabetes patient approval ozempic be base result phase iii sustain study fda accept acorda inbrija nda accorda therapeutic inc acor free report nda parkinson disease candidate inbrija be accept fda marked resubmission nda inbrija fda have issue refusal file letter inbrija august last year declare nda application be incomplete preliminary review fda be expect give decision candidate oct read more fda accept acorda nda parkinson disease candidate large cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session here be major stock perform last trading session major stock decline astrazeneca decline bristol myer squibb bmy free report go last month astrazeneca have gain merck decline see last pharma stock roundup here merck keytruda shine study priority review kymriah label expansion next pharma world watch regulatory pipeline news pharma stock zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
105,BMY,bristol myer squibb company bmy free report be big mover last session company see share rise nearly day move come solid volume too far more share change hand normal session stock picked sharply flat trend past month time frame move come report company have inked multibillion dollar global strategic collaboration agreement nektar therapeutic company have see positive estimate revision past few week zack consensus estimate current quarter have also moved higher past few week suggest more solid trading be ahead bristol myer squibb so make sure keep eye stock go forward see recent jump turn more strength road bristol myer squibb currently have zack rank hold earning esp be bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotea better rank stock large cap pharmaceutical industry be pfizer inc pfe free report hold zack rank buy see complete list today zack rank strong buy stock here be bmy go predict see other think downwall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
106,BMY,incyte corporation incy free report report net loss cent compare net income cent year quarter fourth quarter see significant surge expense exclude time charge stock base compensation expense earning share be zack consensus estimate be loss cent incyte corporation price consensus ep surprise incyte corporation price consensus ep surprise incyte corporation quotequarterly revenue be year year beat zack consensus estimate top line be drive higher sale jakafi unite state iclusig europe well royalty sale jakavi olumiant outside unite state incyte stock lose past year compare industry decline quarter detailjakafi sale grow year year drive strong patient demand indication net product revenue iclusig amount year quarter product royalty revenue novartis ag nvs free report jakafi ex market grow expense be year quarter sg expense amount year year company expect jakafi revenue range iclusig revenue be expect range expense be expect range sg expense be still expect range pipeline phase ii trial reach trial evaluate jakafi patient steroid refractory acute graft versus host disease gvhd have complete enrolment result be expect first half assume success trial incyte expect submit snda seek approval jakafi indication phase iii trial echo evaluate epacadostat keytruda patient unresectable metastatic melanoma be now fully recruit initial datum be expect first half incyte have also open new pivotal trial epacadostat pd antagonist collaboration merck co mrk free report bristol myer squibb bmy free report december new drug application nda baricitinib be resubmit fda be classify class ii resubmission begin new month review cycle pivotal trial baricitinib patient moderate severe atopic dermatitis have also be initiate european commission have already approve baricitinib olumiant february treatment moderate severe active rheumatoid arthritis adult patient have respond inadequately be intolerant more disease modify rheumatic drug takeincyte beat sale fourth quarter strong jakafi performance jakafi sale be drive patient demand sale guidance be also impressive label expansion jakafi gvhd further boost sale meanwhile nda olumiant be resubmit potential approval further boost top line zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
107,BMY,recent fda approval exelixis inc exel free report cabometyx treatment previously untreated advanced renal cell carcinoma have put spotlight space rcc be most common form kidney cancer adult statistic approximately patient unite state world need first line treatment advanced kidney cancer many patient need same annually unite state approval come month ahead schedule note cabometyx cabozantinib tyrosine kinase inhibitor tki be already approve treatment rcc patient have already receive angiogenic therapy cabozantinib inhibit activity tyrosine kinase include meet axl vegf receptor ret approval come back result randomize phase ii trial cabosun result demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus current standard care pfizer inc pfe free report sutent importantly cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death median pfs cabometyx be month versus month sutent corresponding month improvement sutent be widely used first line treatment rcc novartis ag nvs free report votrient however fda approval cabometyx excellent rate pfs weigh sutent go forward pfizer too be strive hard retain drug leadership november fda approve label expansion sutent drug be approve adjuvant treatment adult patient high risk recurrent rcc follow nephrectomy surgical removal cancerous kidney approval be base result trac trial demonstrated significant reduction risk disease free survival event defined interval randomization tumor recurrence secondary primary cancer death cause patient high risk rcc recurrence receive sutent compare placebo adjuvant set meanwhile pfizer drug inlyta tki be also approve rcc bavencio avelumab monoclonal antibody inhibit pd combination inlyta be be develop first line treatment advanced rcc collaboration merck kgaa sector total return sector total return quoteon other hand immunotherapy be gear too place space september bristol myer squibb company bmy free report announce phase iii study be evaluate opdivo yervoy combination patient previously untreated advanced metastatic rcc meet co primary endpoint combination demonstrated superior overall survival os compare sutent intermediate poor risk patient combination also meet secondary endpoint improve os versus sutent randomize patient consequently independent datum monitoring committee have recommend trial be stop early base plan interim analysis last week fda accept bristol myer supplemental biologic license application priority review opdivo yervoy ipilimumab treat intermediate poor risk patient advanced rcc action date april fda have previously grant breakthrough therapy designation application expedite review additionally variety combination therapy be develop rcc include roche rhhby free report avastin tecentriq earlier month roche announce phase iii immotion study meet co primary endpoint investigator assessed pfs demonstrated combination tecentriq avastin provide statistically significant clinically meaningful reduction risk disease worsening death patient disease expressed pd programme death ligand expression protein compare sutent first line treatment person have advanced metastatic renal cell carcinoma mrcc top line result co primary endpoint os be not mature eisai inc merck mrk free report be also evaluate combination former lenvima multiple receptor tyrosine kinase inhibitor include fibroblast growth factor receptor fgfr combination latter pd therapy keytruda treatment naïve previously treat patient metastatic clear cell rcc combination be be evaluate first line use combination ongoing phase iii study clear combination report encourage interim result september hence expect investor keep focus space give stiff competition brewing zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
108,BMY,exelixis inc exel free report recently announce fda approval label expansion lead drug cabometyx treatment previously untreated advanced renal cell carcinoma rcc approval come back positive result randomize phase ii trial cabosun first line kidney cancer result demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus pfizer inc pfe free report sutent remind investor company receive significant boost april fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx treatment rcc patient have already receive angiogenic therapy cabometyx be also approve eu september treatment advanced rcc adult have earlier receive vascular endothelial growth factor vegf target therapy cabometyx rake strong sale first month reflect rise demand drug new patient market share second line set rise hence label expansion drug first line treatment kidney cancer increase target market boost sale exelixis share price have increase year date compare industry gain meanwhile celestial study advanced hepatocellular carcinoma hcc be progress top line result be expect shortly company obtain orphan drug designation same unite state hcc be most common form primary liver cancer accounting more case unite state october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter exelixis have also inked agreement bristol myer squibb company bmy free report roche hold ag rhhby free report develop cabozantinib combination immunotherapy agent zack rankexelixis carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
109,BMY,astrazeneca azn free report announce fda have accept grant priority review supplemental new drug application snda label expansion tagrisso osimertinib astrazeneca snda seek expand tagrisso label include first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation fda grant priority review decision be expect month drug also enjoy breakthrough therapy designation indication be grant october similar application tagrisso label expansion be review eu japan tagrisso be already market second line treatment patient egfr mutation positive nsclc unite state european union japan china astrazeneca share have outperformed industry year date stock have rally compare industry gain period snda be base datum phase iii flaura study compare tagrisso standard care egfr tyrosine kinase inhibitor tki therapy first line lung cancer set datum study show risk progression death be reduce more half tagrisso arm compare commonly used egfr inhibitor median progression free survival pfs be month patient tagrisso compare month comparator arm tagrisso be well tolerate trial safety profile consistent previous experience tagrisso register sale first month reflect growth year period accounting total sale potential approval first line set further boost prospect drug lung cancer market be crowd several company develop marketing treatment roche hold ag rhhby free report astella tarceva be approve treat nsclc pfizer inc pfe free report be develop drug xalkori phase iii study first line treatment nsclc bristol myer squibb bmy free report be also develop opdivo treatment nsclc astrazeneca also have iressa approve treat nsclc be develop imfinzi same indication meanwhile lung cancer be most common cause death cancer indication variation mutation different gene give opportunity different therapy gain market share astrazeneca plc price astrazeneca plc price astrazeneca plc carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
110,BMY,bristol myer squibb company bmy free report announce committee medicinal product human use chmp european medicine agency have recommend approval yervoy pediatric patient year older unresectable metastatic melanoma note european commission take chmp recommendation account consider application be not bound fda have approve drug same indication july remind investor yervoy mg kg monotherapy be approve so far year bristol myer share have rally compare industry gain last week company announce fda have accept supplemental biologic license application priority review opdivo yervoy treatment intermediate poor risk patient advanced renal cell carcinoma rcc application be base datum phase iii study checkmate study be stop ahead schedule base recommendation independent datum monitoring committee follow plan interim analysis overall survival study evaluate combination opdivo yervoy versus sutent previously untreated advanced metastatic rcc fda make decision apr meanwhile company continue evaluate blockbuster immune oncology drug opdivo alone combination therapy yervoy other cancer agent label expansion combination additional indication give product access higher patient population increase commercial potential however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous nsclc company be expect suffer further loss market share virology business be also pressure company be also look counter generic threat key drug deal acquisition company recently enter deal abbvie inc abbv free report halozyme therapeutic inc halo free report zack rank bristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
111,BMY,bristol myer squibb company bmy free report announce fda have accept supplemental biologic license application sbla priority review opdivo yervoy ipilimumab treatment intermediate poor risk patient advanced renal cell carcinoma rcc note fda have grant breakthrough therapy designation application expedite development review same fda make decision apr application be base datum phase iii study checkmate study study be stop ahead schedule base recommendation independent datum monitoring committee follow plan interim analysis overall survival study evaluate combination opdivo yervoy versus sutent previously untreated advanced metastatic rcc study meet co primary endpoint improve overall survival objective response rate compare sutent intermediate poor risk patient combination demonstrated improvement progression free survival relative sutent co primary endpoint do not reach statistical significance so far year bristol myer share have rally compare industry gain note opdivo be already approve number indication include classical hodgkin lymphoma recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy additionally be approve monotherapy treatment squamous cell carcinoma head neck adult progress platinum base therapy opdivo be also approve intravenous use patient hepatocellular carcinoma have be previously treat nexavar drug receive approval liver colorectal cancer meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous nsclc company be expect suffer further loss market share virology business be also pressure company be also look counter generic threat key drug deal acquisition company recently enter deal abbvie inc abbv free report halozyme therapeutic inc halo free report zack rank stock considerbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
112,BMY,bristol myer squibb company bmy free report announce pd immune checkpoint inhibitor opdivo combination yervoy demonstrated superiority improve progression free survival pfs phase iii lung cancer study positive datum again show blockbuster potential opdivo be already approve multiple indication be also be evaluate several other share company have return past year outperform industry gain period phase iii study checkmate be evaluate opdivo monotherapy combination regimen squamous squamous advanced small cell lung cancer nsclc first line set study be be conduct part datum be announce part study evaluate combination regimen overall survival os patient tumor express pd pfs patient high tumor mutation burden tmb regardless pd expression datum show regimen significantly improve pfs patient compare chemotherapy however datum monitoring committee have recommend continue study overall survival endpoint base interim analysis be first study evaluate combination regimen immune oncology drug first line nsclc patient high tmb part study be evaluate opdivo combination chemotherapy broad patient population remind investor combination regimen have achieve durable clinical benefit phase ii study patient dna mismatch repair deficient microsatellite instability high metastatic colorectal cancer please note merck mrk free report pd immunotherapy keytruda be approve first line nsclc datum announce late stage study january show keytruda combination eli lilly company lly free report alimta result significantly improve os pfs metastatic squamous nsclc patient bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer carry zack rank hold exelixis inc exel free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning estimate increase cent cent last day company deliver positive earning surprise trail quarters average beat stock be past year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
113,BMY,bristol myer squibb company bmy free report fourth quarter earning cent share beat zack consensus estimate cent come ahead year quarter earning cent moreover total revenue surpass zack consensus estimate increase record year period strong sale opdivo eliquis contribute top line report quarter share company be almost pre market trading presumably better expect earning bristol myer share have increase past year compare favorably industry increase quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase unite state outside country ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year november fda approve label expansion drug include treatment pediatric patient ph chronic myeloid leukemia chronic phase rheumatoid arthritis drug orencia be fourth quarter melanoma drug yervoy contribute top line report quarter january label expansion drug pediatric patient advanced melanoma be approve europe opdivo be approve multiple cancer indication generate revenue year period drug receive approval intravenous administration melanoma patient adjuvant treatment however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively sale eliquis be report quarter year year multiple myeloma drug empliciti record sale year year research development expense quarter increase mainly due charge related license asset acquisition marketing selling administrative expense decline gross margin be quarter compare year quarter due change product mix december bristol myer privately hold taris biomedical llc announce clinical collaboration evaluate combination bristol myer opdivo taris investigational product tar patient muscle invasive bladder cancer moreover bristol myer also enter agreement japan base ono pharmaceutical same month agreement grant bristol myer right develop commercialize ono selective prostaglandin receptor antagonist ono sale increase primarily drive strong sale opdico follow several line extension opdivo sale rise eliquis sale increase adjust earning share full year come pipeline updatein february bristol myer announce datum phase iii study checkmate show superior progression free survival first line small cell lung cancer nsclc treat opdivo yervoy combination compare chemotherapy moreover january bristol myer announce positive datum phase ii checkmate study evaluate combination opdivo yervoy patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer mcrc december fda lift partial clinical hold phase study phase ii study evaluate opdivo combination regimen relapse refractory multiple myeloma november phase iii study checkmate be stop early opdivo achieve superior overall survival previously treat patient nsclc compare docetaxel earning guidancebristol myer provide adjust earning expectation company project earning range share zack consensus estimate earning be peg company expect revenue increase low mid single digit takebristol myer beat earning expectation primarily robust sale drug opdivo eliquis yervoy quarter guidance be also encourage meanwhile be positive bristol myer effort develop pipeline especially opdivo several label expansion application opdivo be review unite state europe potential approval prospect drug bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotebristol myer carry zack rank hold see complete list today zack rank strong buy stock here better rank company large cap pharma industry be abbvie inc abbv free report pfizer inc pfe free report lundbeck hluyy free report carry zack rank buy share abbvie have gain past year earning estimate have go past day share pfizer have return past year earning estimate have go past day share lundbeck have gain past year earning estimate have go past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
114,BMY,nektar therapeutic nktr free report share increase more feb company announce global strategic collaboration agreement bristol myer squibb bmy free report agreement company jointly develop commercialize lead immuno oncology candidate nktr former combination latter opdivo nivolumab opdivo yervoy ipilimumab pursuant contract nektar be entitle receive upfront payment include payment cash equity investment nektar also get additional potential payment achievement certain developmental sale base milestone nektar bristol myer share profit respective ratio potential sale nktr worldwide positive note nektar not only retain ownership candidate also continue collaborate other company further development nektar jointly commercialize nktr opdivo combination unite state well major market eu japan bristol myer be entitle solely commercialize combination other global market remind investor nektar be already evaluate nktr opdivo phase ii pivot study tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication latest deal bristol myer have be agree company evaluate nktr opdivo nktr opdivo yervoy combination more cancer indication tumor type november company report positive interim datum dose escalation part study evaluate safety efficacy combo therapy patient melanoma renal cell carcinoma small cell lung cancer nektar share have significantly outperformed industry year time stock have sky-rocket compare industry increase importantly nektar be also conduct phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab notably propel study complement company ongoing pivot trial additionally nektar have enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio nektar therapeutic price nektar therapeutic price nektar therapeutic quote zack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
115,BMY,exelixis inc exel free report announce encourage result phase ii investigator sponsored trial cabozantinib first line treatment metastatic radioiodine rai refractory differentiate thyroid carcinoma dtc trial be be conduct center rare cancer personalize therapy abramson cancer center university pennsylvania enrollment trial be complete august patient be enrolled single arm open label trial be administer oral cabozantinib mg once daily trial enrolled metastatic rai refractory dtc patient primary endpoint trial be objective response rate partial response be achieve patient stable disease be report patient recist however evaluate patient experience decrease tumor target lesion secondary endpoint trial include progression free survival pfs time progression ttp duration response clinical benefit rate cbr defined number patient achieve objective response stable disease least month cbr month be median follow study week median pfs have not be reach median ttp patient progressed be week exelixis plan initiate pivotal phase iii study cabozantinib patient advanced dtc later base abovemention result datum other study cabozantinib previously treat dtc exelixis stock have rally year industry decline note exelixis lead product cometriq capsule form cabozantinib be approve unite state treatment progressive metastatic medullary thyroid cancer mtc april tablet formulation cabozantinib cabometyx be approve unite state treatment patient advanced renal cell carcinoma rcc have receive prior angiogenic therapy recent fda approval cabometyx treatment previously untreated advanced rcc further boost demand drug demonstrated statistically significant clinically meaningful improvement pfs versus current standard care pfizer pfe free report sutent meanwhile exelixis be develop cabozantinib broad development program comprise clinical study multiple indication celestial study advanced hepatocellular carcinoma be also ongoing exelixis also announce collaboration agreement bristol myer squibb bmy free report roche rhhby free report development cabozantinib combination immunotherapy agent early zack rankexelixis carry zack rank buy see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
116,BMY,total earning total healthcare market capitalization be revenue growth not only be growth rate impressive earning revenue beat ratio respectively be great too robust number have push healthcare stock higher average gain response earning announcement most notable player johnson johnson jnj free report be first major drug company report earning jan follow pfizer pfe free report eli lilly company lly free report jan jan respectively other major drug company merck mrk free report bristol myer squibb company bmy free report report feb feb respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come couple cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson issue outlook earning share revenue read healthcare etfs focus post jnj result pfizer earning drug giant come earning revenue beat earning share cent come cent zack consensus estimate revenue be also ahead estimate annual basis earning share revenue rise respectively pfizer guide revenue range earning share merck earning focusmerck beat earning estimate miss revenue earning share come cent surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck issue revenue guidance earning share guidance bristol myer earning focusbristol myer top estimate front report earning share cent penny zack consensus estimate year earning cent revenue grow edge past zack consensus estimate company provide earning share guidance see healthcare etfs here eli lilly earning focuseli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly raise earning guidance maintain revenue outlook range etf pharma etfs see terrible trading past month latest global market rout string earning beat bolster confidence space compelling investor cash beaten price have highlighted detail fund have zack etf rank hold suggest room upside day ahead read inverse equity etfs bet historic selloff powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest more share bmy pfe jnj lly etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account least share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month read new pharma etf pill investor need know first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly makeup more ftxh have lower level aum share averaged daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
117,BMY,seattle genetic inc sgen free report report loss cent share fourth quarter narrower zack consensus estimate cent wider year quarter loss cent share revenue come year year primarily back strong sale adcetris revenue also beat zack consensus estimate however seattle genetic share have lose past year compare industry decline same period quarter detailseattle genetic top line comprise product revenue collaboration license agreement revenue royalty company only market product adcetris generate product sale significant year year collaboration license agreement revenue increase almost mainly drive strong demand adcetris international market collaboration revenue include fee earn company agreement japan base takeda pharmaceutical adcetris other adc collaboration royalty revenue increase almost year year attributable higher international sale adcetris takeda pharmaceutical co research development expense be year year also selling general administrative sg expense increase cost be high primarily due investment development adcetris other indication company provide outlook total revenue range expect collaboration license agreement revenue be range royalty be expect range net sale adcetris be expect range company have not include impact potential line extension drug frontline advanced classical hodgkin lymphoma approval be expect company anticipate expense be sg expense be expect range rise sg likely be due inclusion expand commercial activity related potential line extension adcetris pipeline updateseattle genetic continue work expand adcetris label further phase iii study november fda approve expansion adcetris label include cutaneous cell lymphoma january drugwa also approve similar indication europe moreover fda have grant priority review supplemental biologic license application sbla seek approval include frontline advanced classical hodgkin lymphoma label sbla be file base datum phase iii study echelon show adcetris achieve statistically significant improvement modify progression free survival decision be expect moreover top line datum echelon study frontline cd express mature cell lymphoma be separate study be also evaluate adcetris combination bristol myer squibb bmy free report opdivo relapse refractory classical hodgkin lymphoma addition company be evaluate enfortumab vedotin pivotal phase ii study patient metastatic urothelial cancer patient moreover november seattle genetic astella pharma initiate phase ib study evaluate candidate combination cpi therapy include merck mrk free report keytruda pembrolizumab patient locally advanced metastatic urothelial cancer first second line set company be plan initiate phase iii study seattle genetic germany base genmab be plan initiate phase ii study evaluate tisotumab vedotin recurrent metastatic cervical cancer metastatic cervical cancer treatment naïve woman range other solid tumor type company be evaluate pipeline candidate polatuzumab vedotin diffuse large cell lymphoma study be be conduct collaboration genentech member roche hold ag rhhby free report other activitiesin bid boost pipeline company enter definitive merger agreement last month acquire cascadian therapeutic acquisition add pivotal stage positive metastatic breast cancer candidate tucatinib pipeline company fourth quarter loss be narrower estimate sale also beat expectation give positive development adcetris investor focus update label expansion approval hodgkin lymphoma indication year boost sale further datum clinical study other pipeline candidate be also expect year seattle genetic inc price consensus ep surprise seattle genetic inc price consensus ep surprise seattle genetic inc quoteseattle genetic carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
118,BMY,gilead science inc gild free report report fourth quarter result earning revenue surpass expectation however management issue bleak view consequently stock decline market hour trading be expect open red give expectation further decline hepatitis virus hcv franchise nevertheless gilead stock have gain last month industry decline company fourth quarter earning share beat zack consensus estimate however earning be year quarter figure share moreover total revenue top zack consensus estimate however revenue decline year year gilead science inc price consensus gilead science inc price consensus gilead science inc quote harvoni sovaldi plunge furtherproduct sale come year year decline be due lower hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market sale harvoni decline year year quarter further sovaldi sale record steep year year decline epclusa garner sale quarter year figure meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due impact ongoing milestone payment selling general administrative sg expense decrease adjust product gross margin be compare year period resultsrevenue come surpass zack consensus estimate earning share come beat zack consensus estimate guidancegilead now expect net product sale range adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range company acquire kite pharma fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy gilead prospect company recently acquire cell design lab expand further car space dividend share gilead declare cash dividend cent share common stock first quarter increase dividend be payable mar stockholder record close business mar company paid cash dividend repurchase share company top earning revenue estimate fourth quarter magnitude decline hcv sale be larger expect hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report merck mrk free report zepatier pricing market share be expect stabilize mid patient start be expect decline further meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage estimate patient used truvada end approval yescarta also bode well gilead expect decline hcv franchise offset positive momentum hiv franchise gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
119,BMY,big time investor late have be investing substantial portion source treatment alcoholic steatohepatitis nash market nash be poise witness rapid growth other lucrative saturate market cancer chronic liver disease nash be cause excessive fat accumulation liver turn be know steatosis nash be know affect person unite state lead inflammation hepatocellular injury progressive fibrosis cirrhosis be expect be lead cause liver transplantation notably be currently lead cause liver transplant person unite state nash patient be also know be affected obesity type ii diabetes disease be prevalent european country develop country market disease be project treatment currently approve disease market opportunity be significant let take look company candidate be be evaluate present treatment nash intercept pharmaceuticial inc icpt free report be presently evaluate lead drug ocaliva drug be already approve unite state treatment primary biliary cholangitis pbc inadequate response intolerant standard care udca company currently have ongoing phase iii trial regenerate cirrhotic nash patient liver fibrosis top line datum interim analysis be expect first half company also complete phase ii trial control evaluate lipid metabolic effect ocaliva cholesterol management effect concomitant statin administration nash patient company also plan initiate phase iii trial nash patient cirrhosis second half give success phase ii trial expect intercept be first company obtain approval nash biotech bigwig gilead science inc gild free report also have quite few program patient diagnosed nash advanced fibrosis include selonsertib ask inhibitor phase iii gs fxr agonist phase ii gs acc inhibitor phase ii company plan initiate combination study agent give increase competition once lucrative hepatitis market gilead be look diversify portfolio foray emerge field car therapy nash company earlier acquire phenex farnesoid receptor program comprise small molecule fxr agonist treatment liver disease include nash major player biotech space bristol myer squibb company bmy free report have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo april company be entitle right research develop commercialize bms ambrx inc swiss major novartis inc nvs free report enter clinical trial agreement allergan plc agn free report conduct phase iib study april involve combination novartis fxr agonist allergan cenicriviroc treatment nash company have collaboration license agreement conatus pharmaceutical inc cnat free report global development emricasan patient decompensate liver cirrhosis cause nash medical biomedical genetic industry yr return medical biomedical genetic industry yr returnbottom line give potential market be many other big pharma biotech company have pipeline candidate treatment nash expect lot activity space go forward potential approval drug nash attract more player wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
120,BMY,series curious event occur last friday morning continue rube goldberg day be argue even morning pre market trading action friday dow close point nasdaq hived roughly look open triple digit ve see early buy back low start morning first thing have happened be farm payroll report friday morning post very strong month employment gain average hourly earning also gain third percent meaning wage growth be show sign add overall inflation talk fourth interest rate hike next month fed incoming chairman jay powell take add already likelihood rate hike begin next month see year bond yield spike past zack strategist tracey ryniec remark real time friday strong economy inflation mean more free money zack dave bartosiak react perhaps be bond market tell re little concern debt situation ve get now ve cut tax rate senior strategist kevin cook look vix say volume still look tame huge fear spot vix be act move be normal again future be hardly panic cook also point last week be worst week best year rally ve ever see market be so correction be mere pittance comparison especially consider remember back january not long see sell right now even monday future again sell mode re only look not really same ballpark least not yet earning estimate go upif re still concern market swooning start new week good tonic be zack director research sheraz mian latest earning preview point not only be earning season best ve see year future earning guidance be shooting future quarters so do see term pressure valuation outgoing fed chair janet yellen do mention be somewhat concern go forward name game be still earning be only point north earning rounduplast week see host marquee name post quarterly earning report mostly good result fact only bottom line miss see stem tax related down be essentially term nature not result miss expectation apple aapl free report lower anticipate iphone sale notwithstanding week see just many report hit tape even be not quite same household name last week foodservice giant sysco syy free report beat estimate top bottom line morning cent share surpass cent share revenue expect earning result zack rank buy company rise year year more syy earning click here british pharma major bristol myer bmy free report also top expectation beating bottom line penny cent share quarterly sale outpaced zack consensus estimate guidance be ratchete bit still zack consensus more bmy earning click here arconic arnc free report engineer product segment formerly belong aluminum giant alcoa aa easily outperformed sale earning estimate company see cent share revenue ahead cent share have be expect guidance top line rise past zack consensus full year earning remain range more arnc earning click here
121,BMY,cancer capable striking fear even strongest heart be malignancy characterize uncontrolled growth abnormal cell not treat lead death accord american cancer society be more type cancer deadliest be breast cancer skin cancer lung cancer colon cancer prostate cancer blood cancer presentation european society medical oncology esmo congress hold sep madrid spain dominate headline cancer space week major presentation include bristol myer squibb company bmy free report astrazeneca plc azn free report positive result ongoing phase iii study melanoma lung cancer patient respectively pfizer inc pfe free report disappointing datum lung cancer candidate recap week most important imfinzi positive phase iii lung cancer study astrazeneca announce promising lung cancer datum late stage study new cancer drug imfinzi interim datum phase iii study pacific demonstrated imfinzi achieve improvement month progression free survival standard care patient locally advanced unresectable small cell lung cancer nsclc have not progressed follow chemoradiation datum separate phase iii flaura study lung cancer drug tagrisso show drug reduce risk progression death more half compare other commonly used egfr inhibitor read more astrazeneca lung cancer study datum promising bristol myer opdivo superior yervoy melanoma patient bristol myer announce datum phase iii study checkmate compare opdivo yervoy treat patient stage iiib stage iv melanoma have undergo complete resection interim datum study show opdivo be superior yervoy opdivo achieve statistically significant improvement recurrence free survival compare yervoy read more bristol myer report positive result melanoma study pfizer xalkori fail lung cancer study xtandi positive prostate cancer study pfizer ongoing phase iii study profile evaluate xalkori first line treatment alk positive nsclc do not meet secondary endpoint significant improvement overall survival os rate median follow month median os patient treat xalkori be month be month patient randomize chemotherapy however pfizer prostate cancer candidate xtandi achieve statistically significant improvement metastasis free survival drug be be evaluate combination androgen deprivation therapy phase iii study prosper potential label expansion include early stage prostate cancer patient read more pfizer lung cancer drug overall survival datum unfavorable disappointing week roche fda accept sandoz generic arm novartis biologic license application biosimilar version roche rhhby free report leukemia treatment rituxan rituximab novartis have receive approval rituxan biosimilar europe june rituxan have record sale almost first half setback fda approve amgen allergan biosimilar version key drug avastin treat multiple cancer indication include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi read more novartis bla biosimilar rituxan accept fda other updatesapart abovemention news be few other update cancer space fda accept new drug application ndas array biopharma seek approval combination binimetinib encorafenib treat patient braf mutant advanced unresectable metastatic melanoma regulatory body also accept supplemental nda teva pharmaceutical industry ltd teva free report trisenox seek label expansion drug include treatment naïve acute promyelocytic leukemia patient nektar therapeutic announce initiation dose phase ii study evaluate efficacy safety lead immuno oncology candidate nktr combination roche tecentriq merck mrk free report keytruda look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
122,BMY,key announcement week be teva pharmaceutical industry ltd teva free report restructure plan eli lilly company lly free report outlook focus also remain datum presentation annual conference american society hematology ash company roche rhhby free report bristol myer squibb bmy free report merck mrk free report be present recap week most important storiesash highlight several company be ash datum approve pipeline drug roche present phase ii datum show polatuzumab vedotin bendamustine mabthera rituxan br increase complete response rate compare br alone previously treat aggressive lymphoma complete response rate increase addition polatuzumab vedotin br patient treat combination live longer compare patient br alone month versus month roche also present datum tecentriq avastin combination certain person advanced kidney cancer read more roche report positive datum tecentriq combination study venclexta venclyxto mabthera rituxan combination previously treat chronic lymphocytic leukemia read more roche abbvie report positive phase iii result venclexta bristol myer be also present ash datum sprycel dasatinib add standard chemotherapy show year survival benefit pediatric patient newly diagnosed ph acute lymphoblastic leukemia read more bristol myer report positive datum leukemia drug company partner seattle genetic also present interim result phase ii study combination adcetris opdivo relapse refractory hodgkin lymphoma combination datum show objective response rate complete response rate lilly provide outlook lilly provide outlook say expect recently launch product trulicity taltz basaglar jardiance verzenio cyramza olumiant lartruvo drive low single digit revenue growth company expect earning share revenue however challenge remain company form loss patent exclusivity product ciali impact generic competition strattera effient axiron pricing access pressure also remain headwind meanwhile company continue expect earning share revenue lilly raise quarterly dividend well company also reaffirm guidance average annual revenue growth least say expect operate margin least pipeline front lilly expect regulatory action unite state baricitinib treatment rheumatoid arthritis galcanezumab migraine treatment new indication verzenio breast cancer launch new indication taltz psoriatic arthritis read more lilly issue guidance new drug drive top line stock have gain year date compare rally industry belong teva share restructure plan week speculation teva be cut workforce company announce restructure plan see job cut more company global workforce next year majority expect new ceo goal be reduce cost base simplify organization improve business performance profitability cash flow generation productivity company expect cut cost base estimate end plan also call optimization global generic portfolio especially unite state price adjustment product discontinuation several manufacturing plant unite state europe israel growth market well facility headquarters other office location geography be shut divest far pipeline be concern program be review so core project be identify other project be terminate immediately company also suspend dividend payment annual bonus say continue look opportunity divest core asset step come time teva be face several challenge company have significant financial obligation come year environment remain challenge company largest generic market unite state teva also expect fewer generic product launch unite state teva share be restructure announcement investor cheer step take company execution remain key priority review bristol myer opdivo yervoy combination fda have grant priority review bristol myer supplemental biologic license application sbla label expansion opdivo use combination yervoy treatment intermediate poor risk patient advanced renal cell carcinoma rcc regulatory agency grant priority review response be apr update sanofi sanofi sny free report provide update pipeline project include new molecular entity novel vaccine analyst meeting week company say expect start least late stage study least pivotal phase iii study be expect start next month period sanofi expect file regulatory approval investigational cancer drug cemiplimab isatuximab type diabetes treatment sotagliflozin potential treatment uncontrolled persistent asthma dupilumab fact sanofi partner regeneron announce positive topline result pivotal mid stage study cemiplimab patient advanced cutaneous squamous cell carcinoma cscc second deadliest skin cancer melanoma overall response rate orr be observed study company have start submit roll biologic license application bla pd antibody submission expect complete first quarter read more regeneron sanofi report positive top line skin cancer datum meanwhile sanofi gain fda approval admelog insulin lispro injection rapid act insulin similar lilly humalog management blood sugar level mealtime admelog be approve eu earlier year july read more sanofi win fda approval biosimilar lilly humalog update merck keytruda merck provide couple update related pd therapy keytruda week company say sbla seek label expansion use keytruda treatment relapse refractory primary mediastinal large cell lymphoma pmbcl have be grant priority review fda company also present datum ash show use keytruda result overall response rate difficult treat patient population fda grant priority review response agency be apr approval make second blood cancer indication keytruda earlier indication be use certain patient classical hodgkin lymphoma read more merck keytruda get fda priority review rare lymphoma however keytruda fail meet primary endpoint overall survival pivotal study second line treatment patient advanced gastric junction gej adenocarcinoma progression free survival pd positive population also fail show statistical significance merck be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock astrazeneca be merck gain last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here fda nod nvo ozempic second indication lilly taltz next pharma world watch regulatory pipeline news pharma stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
123,BMY,bristol myer squibb company bmy free report announce positive datum phase ii study sprycel patient receive sprycel mg tablet powder oral suspension once daily addition chemotherapy regimen modelled berlin frankfurt munster high risk backbone year occurrence unacceptable toxicity ongoing nct study study evaluate sprycel pediatric patient newly diagnosed philadelphia chromosome positive ph acute lymphoblastic leukemia add chemotherapy regimen combination demonstrated event free survival rate study primary endpoint overall survival rate year meanwhile patient have minimal residual disease mrd end first block treatment mrd remain mrd positive detectable level additional high risk chemotherapy block be eligible hematopoietic stem cell transplantation hsct first remission remind investor sprycel be approve unite state treatment adult ph chronic myeloid leukemia cml chronic phase cp be resistant intolerant prior therapy include imatinib sprycel be also approve adult ph be resistant intolerant prior therapy drug be also approve treatment adult newly diagnosed cp ph cml sprycel receive fda approval expand indication treatment pediatric patient cp ph cml november label expansion improve sale further so far year bristol myer share have rally compare industry gain bristol myer immuno oncology opdivo continue perform well eliquis orencia company be look expand opdivo label further recently obtain fda approval liver colorectal cancer however opdivo be currently face competitive challenge unite state virology business be also pressure company be also look counter generic threat key drug deal acquisition company recently enter deal abbvie inc abbv free report halozyme therapeutic inc halo free report zack rank stock considerbristol myer currently carry zack rank hold better rank health care stock be sucampo pharmaceutical zack rank strong buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
124,BMY,pfizer inc pfe free report announce superiority breast cancer candidate talazoparib chemotherapy improve progression free survival pfs phase iii study embraca talazoparib be investigation dual mechanism poly adp ribose polymerase parp inhibitor company present datum study san antonio breast cancer symposium share pfizer have gain past month outperform industry rise period embraca study evaluate talazoparib single agent patient germline brca positive breast cancer have receive prior chemotherapy treatment candidate achieve significant reduction risk disease progression median pfs be month talazoparib arm versus month chemotherapy arm moreover patient talazoparib arm achieve complete partial response patient receive chemotherapy parp inhibition be new target therapy inhibit repair dna cell thus destroy cell label expansion application astrazeneca azn free report parp inhibitor lynparza be review unite state meanwhile clovis oncology inc clvs free report have collaborate bristol myer squibb company bmy free report develop parp inhibitor combination latter pd immune checkpoint inhibitor opdivo breast cancer apart talazoparib pfizer be also develop key drug ibrance treat advanced high risk early breast cancer ibrance be currently approve negative advanced metastatic breast cancer pfizer inc price pfizer inc price pfizer inc quotepfizer carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
125,BMY,bristol myer squibb company bmy free report announce late stage study evaluate opdivo versus docetaxel be stop earlier expect meet primary endpoint checkmate study be be conduct mainly chinese patient be previously treat advanced metastatic small cell lung cancer nsclc study show patient receive opdivo nivolumab demonstrated superior overall survival benefit os compare receive standard care treatment docetaxel base top line result bristol myer submit biologic license application bla chinese regulatory authority seek approval opdivo previously treat lung cancer patient approve opdivo become first immuno oncology treatment approve previously treat lung cancer patient china so far year bristol myer share have rally compare industry gain note opdivo be already approve number indication include classical hodgkin lymphoma recurrent metastatic squamous cell carcinoma head neck scchn disease progression platinum base therapy additionally be approve monotherapy treatment squamous cell carcinoma head neck scchn adult progress platinum base therapy opdivo be also approve intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar drug receive approval liver colorectal cancer well meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential significantly however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous nsclc company be expect suffer further loss market share zack rank stock considerbristol myer carry zack rank hold better rank health care stock same space be sucampo pharmaceutical therapeutic inc cort free report sucampo sport zack rank strong buy hold zack rank buy see complete list today zack rank stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
126,BMY,monday february series curious event occur last friday morning continue rube goldberg day be argue even morning pre market trading action friday dow close point nasdaq hived roughly dow look open triple digit ve see early buy back low start morning first thing have happened be farm payroll report friday morning post very strong month employment gain average hourly earning also gain third percent meaning wage growth be show sign add overall inflation talk fourth interest rate hike next month fed incoming chairman jay powell take add already likelihood rate hike begin next month see year bond yield spike past zack strategist tracey ryniec remark real time friday strong economy inflation mean more free money zack dave bartosiak react perhaps be bond market tell re little concern debt situation ve get now ve cut tax rate senior strategist kevin cook look vix say volume still look tame huge fear spot vix be act move be normal again future be hardly panic cook also point last week be worst week best year rally ve ever see market be so correction be mere pittance comparison especially consider remember back january not long see sell right now even monday future again sell mode re only look not really same ballpark least not yet earning estimate go upif re still concern market swooning start new week good tonic be zack director research sheraz mian latest earning preview point not only be earning season best ve see year future earning guidance be shooting future quarters so do see term pressure valuation outgoing fed chair janet yellen do mention be somewhat concern go forward name game be still earning be only point north earning rounduplast week see host marquee name post quarterly earning report mostly good result fact only bottom line miss see stem tax related down be essentially term nature not result miss expectation apple aapl free report lower anticipate iphone sale notwithstanding week see just many report hit tape even be not quite same household name last week foodservice giant sysco syy free report beat estimate top bottom line morning cent share surpass cent share revenue expect earning result zack rank buy company rise year year more syy earning click here british pharma major bristol myer bmy free report also top expectation beating bottom line penny cent share quarterly sale outpaced zack consensus estimate guidance be ratchete bit still zack consensus more bmy earning click here arconic arnc free report engineer product segment formerly belong aluminum giant alcoa aa free report easily outperformed sale earning estimate company see cent share revenue ahead cent share have be expect guidance top line rise past zack consensus full year earning remain range more arnc earning click here mark vickerysenior editorquestion comment article author click here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
127,BMY,fourth quarter earning result be pour focus be back healthcare sector high president trump agenda be attempt repeal replace affordable care act less year trump administration achieve primary objective tax cut new healthcare legislation tax cut job act new law effectively repeal individual mandate be essential proper function obamacare read more however upbeat quarterly result rise demand new product sale successful innovation fda approval product line expansion strong clinical study result well continue strong performance legacy product propel large cap drug sector new high tailwind be expect drive sector growth even read more healthcare sector jump past year better rally sign sector success become more evident last month nyse arca pharmaceutical index nasdaq biotechnology index gain respectively broader industry grow same time period merck co inc mrk free report sanofi sny free report schedule report feb feb respectively be good time figure be better stock stock carry zack rank hold see complete list today zack rank strong buy stock here other major pharma earning schedule period include bristol myer squibb company bmy free report astrazeneca plc azn free report price have see gain past month sanofi have decline so merck be clear winner respect better return rival sanofi broader industry rise same period most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major merck sanofi be undervalue relative broader industry have ev ebitda value however sanofi hold edge here lower ev ebitda value compare merck value dividend yieldover last year merck sanofi offer dividend yield respectively industry return dividend yield so merck have take lead here too respect sanofi broader industry net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention allegedly exorbitant drug pricing help sector maintain steep margin net margin value sanofi underperform rival merck have net margin value comparison broader industry have net margin value return equityreturn equity roe be key financial ratio pharma company entity employ huge amount capital bring product market respect used roe help evaluate company ability generate ample profit equity capital pharma company merck sanofi have comparatively lower roe respectively broader industry value however compare individual performance merck hold edge sanofi earning history espconsider more comprehensive earning history merck have deliver positive surprise prior quarters average earning surprise comparison sanofi deliver average positive earning surprise trail quarters merck manage post earning beat trail quarters meanwhile sanofi register earning beat only first quarter result be line estimate next consider earning esp merck be once again clear winner esp sanofi be disadvantage merck esp be conclusionour comparative analysis show sanofi hold edge merck consider only ev ebitda ratio however consider price performance roe net margin merck be advantage sanofi additionally merck also sport better dividend yield sanofi more comprehensive look previous earning performance merck be clearly better stock clinch case favorof merck point time be have positive esp be lead indicator likely positive surprise be be better bet merck sanofi prepare report earning next few day wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
128,BMY,several important development be report week key highlight include termination hepatitis virus deal approval first cancer biosimilar unite state presentation datum company pfizer pfe free report bristol myer squibb bmy free report other recap week most important hcv deal termination achillion pharmaceutical achn free report share fall termination company partnership agreement johnson johnson janssen pharmaceutical hepatitis virus hcv janssen say not continue development jnj combination direct act antiviral al odalasvir simeprevir decision discontinue development do not come big surprise give intense competition pricing dynamic hcv market achillion intend focus development advanced multiple small molecule factor inhibitor complement alternative pathway read more achillion hcv partnership terminate stock fall first cancer biosimilar get fda nod fda approve allergan agn free report amgen mvasi biosimilar version roche blockbuster cancer drug avastin bevacizumab mvasi be used eligible indication reference product approval be line expectation consider favorable vote biosimilar get fda advisory panel recently approval be quite boost company well effort lower drug price so far biosimilar be yet make significant dent reference product sale unite state mvasi be review eu pfizer xtandi prosper late stage study pfizer partner astella pharma well be path boost sale prostate cancer drug xtandi company announce positive top line datum late stage study prosper patient metastatic castration resistant prostate cancer crpc company plan discuss datum regulatory authority expansion drug label xtandi sale have be pressure receive boost approval patient population bristol myer sign deal present cancer datum bristol myer squibb present datum european society medical oncology esmo congress show treatment opdivo lead superior recurrence free survival compare yervoy patient resect high risk melanoma read more bristol myer report positive result melanoma study meanwhile company have sign deal halozyme latter enhanze technology global collaboration license agreement be focuse use halozyme technology subcutaneous administration bristol myer immuno oncology drug thereby provide patient more flexible convenient treatment delivery option bristol myer shell upfront make future milestone royalty payment dilutive transaction be expect hit bristol myer earning penny earning cent lilly baricitinib fare well mid stage eczema study eli lilly company lly free report incyte present new safety efficacy datum mid stage study baricitinib eczema annual meeting european academy dermatology venereology eadv baricitinib combine mid potency topical corticosteroid tcs significantly improve sign symptom eczema compare tcs alone company intend commence phase iii program eczema indication later year baricitinib be currently approve eu trade name olumiant moderate severe active rheumatoid arthritis however approval be yet come unite state regulatory filing be resubmit jan lilly stock have gain year date compare rally industry belong teva appoint new ceo teva teva free report have finally end search chief executive officer ceo company announce appointment kare schultz company president ceo seasoned veteran healthcare industry schulz bring almost year experience segment schulz be recently serve president ceo lundbeck be responsible implement significant restructure initiative launch robust turnaround strategy schulz have daunting task ahead consider challenge be face teva include generic pricing erosion company need work pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track read more teva hire kare schultz ceo be recovery card positive fda panel vote glaxo shingle vaccine glaxosmithkline gsk free report get positive vote fda vaccine related biological product advisory committee vrbpac shingrix prevention herpes zoster shingle adult age give positive vote chance gain approval look pretty high note merck zostavax live attenuate virus vaccine be currently available prevention shingle same patient population read more glaxo shingle candidate get positive fda committee vote glaxo be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session almost major stock record gain pfizer gain bristol myer slip last month bristol myer be glaxo decline see last pharma stock roundup here lilly cut job streamline operation nvs ceo step next pharma world watch usual pipeline regulatory update fda advisory panel be meeting sep discuss supplemental new drug application snda submit pfizer cancer drug sutent adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney moreover fda decision regard label expansion merck pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma be sep look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
129,BMY,nektar therapeutic nktr free report announce initiation phase ii propel study evaluate efficacy safety lead immuno oncology candidate nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab notably checkpoint inhibitor tecentriq be approve treatment metastatic urothelial carcinoma unite state keytruda be recently approve refractory classical hodgkin lymphoma chl unite state eu nektar share have significantly outperformed industry so far year stock have surge much broader industry increase propel study complement nektar ongoing pivot trial nktr be be evaluate combination bristol myer bmy free report opdivo nivolumab tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication phase ii study propel study be aim establish synergy nktr combine tecentriqor keytruda study be conduct separate arm patient first arm evaluate combination nktr tecentriq dose regimen week patient adhere approve treatment setting tecentriq include patient small cell lung cancer bladder cancer other hand second arm assess dose regimen nktr combination keytruda week approve treatment setting keytruda include patient melanoma small cell lung cancer bladder cancer company combination therapy provide cancer patient suffering multiple tumor type new treatment option combine approve checkpoint inhibitor therapy apart nktr interesting candidate company portfolio be onzeald currently accelerate assessment eu treat adult advanced breast cancer have brain metastase however july nektar file request re examination negative opinion adopt chmp same meanwhile nektar initiate randomize phase iii confirmatory study attain onzeald compare single agent chemotherapy physician choice patient advanced breast cancer have brain metastase shortly positive result study support regulatory filing unite state other pipeline candidate company portfolio include nktr mu opioid analgesic candidate chronic pain condition phase iii nktr autoimmune disease phase successful development candidate boost company top line consider lucrative market be target nektar therapeutic price nektar therapeutic price nektar therapeutic quotezack ranknektar currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
130,BMY,bristol myer squibb company bmy free report be new york base major producer distributor pharmaceutical other healthcare related product company key oncology product include opdivo sprycel yervoy empliciti other oncology company be focuse immunology cardiovascular drug orencia eliquis also market drug hbv hcv baraclude daklinza company virology portfolio comprise product reyataz sustiva franchise bristol myer be also active partnership front pursue strategic acquisition therapeutic area include immunoscience oncology fibrosis genetically defined disease however many peer bristol myer be face generic competition several key product moreover hiv hcv business be competitive pressure scenario investor focus remain company high profile immuno oncology drug opdivo apart usual top bottom line number bristol myer have mixed record earning surprise recent quarters company earning surpass expectation last quarters average positive surprise currently bristol myer have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning bristol myer beat fourth quarter earning company report ep cent consensus call ep cent revenue moreover revenue be expectation bristol myer post revenue compare consensus estimate guidance bristol myer provide earning outlook company expect earning range share zack consensus estimate earning stand share pre market trading share be pre market trading check back later full bmy earning report later bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
131,BMY,pipeline regulatory update be focus week fda approve first drug hiv treatment unite state european commission ec grant approval johnson johnson jnj free report tremfya expand label novartis nvs free report tasigna recap week most important storiesj glaxo hiv drug get fda nod glaxosmithkline gsk free report gain fda approval first drug hiv treatment unite state juluca combine approve hiv drug tivicay mg edurant mg single once daily pill maintenance treatment virologically suppress hiv infection company expect make drug available pharmacy december juluca mark begin new era hiv treatment other company gilead also work bring better treatment market read more glaxo get fda approval first drug hiv regimen eu nod psoriasis drug janssen cilag international nv company gain eu approval psoriasis drug tremfya use adult moderate severe plaque psoriasis be candidate systemic therapy approval be expect consider committee medicinal product human use chmp have adopt positive opinion september drug be approve unite state earlier year july psoriasis market be pretty crowd person world be estimate suffer psoriasis include european case be consider moderate severe tremfya be currently late stage development treatment psoriatic arthritis johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here roche present datum hemophilia cancer drug roche rhhby free report present positive datum recently approve hemophilia drug hemlibra late stage study haven adult adolescent age year older hemophilia inhibitor factor viii study meet primary endpoint well key secondary endpoint hemlibra significantly reduce bleed roche also present positive datum combination cancer drug tecentriq avastin patient type advanced lung cancer drug chemotherapy be find significantly cut risk disease worsening death first line treatment patient roche intend submit datum fda well other regulatory agency datum be not fully mature roche say initial observation show encourage overall survival os datum next os analysis be schedule first half read more roche report positive datum tecentriq combination study label expansion novartis cancer drug ec have expand label novartis tyrosine kinase inhibitor tki tasigna nilotinib so be used treatment pediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp pediatric patient ph cml cp resistance intolerance prior therapy include gleevec imatinib approval indication be expect give positive chmp opinion issue september treatment option be limit child cml be significant unmet need patient population read more novartis receive ec nod tasigna label expansion seek label expansion darzalex janssen cilag international nv be look expand label immunotherapy darzalex so be used combination velcade bortezomib melphalan prednisone treatment adult patient newly diagnosed multiple myeloma be ineligible autologous stem cell transplant approval expand patient population significantly regulatory application have be submit unite state well eu fda approval make fifth indication darzalex unite state first frontline set read more seek darzalex label expansion first line set have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock astrazeneca azn free report be merck mrk free report decline last month bristol myer bmy free report be glaxo decline see last pharma stock roundup here fda nod astrazeneca severe asthma drug bayer sign deal loxo next pharma world watch regulatory pipeline news pharma stock more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
132,BMY,investor be always look stock be poise beat earning season bristol myer squibb company bmy free report be such company firm have earning come pretty soon event be shape quite nicely report be bristol myer squibb be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface bmy report analyst have very recently bump estimate bmy give stock zack earning esp head earning season bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give bmy have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead bristol myer squibb beat be card upcoming report wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
133,BMY,be quite few important development week eli lilly company lly free report announce be streamline operation cut workforce focus develop new medicine improve cost structure meanwhile novartis nvs free report announce ceo be step recap week most important storieslilly streamline operation cut job lilly announce restructure plan see company streamline operation so focus develop new medicine improve cost structure company be cut job most reduction expect voluntary early retirement program lilly also be close certain site move production larchwood ia animal health manufacturing facility exist plant fort dodge ia research development office bridgewater nj lilly china research development center shanghai china also shut lilly expect generate annualize saving be used improve cost structure new product launch label expansion study streamline program result company incur pre tax charge post tax charge cent share be recognize third fourth quarters cut report earning guidance adjust earning outlook remain unchanged lilly also say streamline effort now expect achieve opex revenue ratio less indicate improvement previous forecast merck buy rigontec immuno oncology focuse deal immune oncology space continue attract interest big pharma player merck mrk free report announce intention acquire rigontec deal worth include upfront payment rigontec expertise lie access retinoic acid inducible gene rig pathway be part innate immune system goal induce immediate long term tumor immunity acquisition add rigontec lead candidate rgt merck pipeline rgt be currently early stage development patient various tumor also read merck opt buy german immuno oncology biotech merck also announce european commission have expand label pd therapy keytruda treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer also read merck keytruda get eu approval bladder cancer bmy opdivo impress rcc study bristol myer squibb company bmy free report have mixed news pd immune checkpoint inhibitor opdivo company say late stage study checkmate evaluate opdivo yervoy be stop early show overall survival os benefit patient previously untreated advanced metastatic renal cell carcinoma rcc follow plan interim analysis independent datum monitoring committee dmc recommend study be stop early combination provide rcc patient new first line treatment option approval indication boost sale significantly be significant unmet need area rcc be most common type kidney cancer adult year survival rate advanced metastatic stage be second set opdivo related news be not so encourage company say partial clinical hold have be place fda opdivo base combination study multiple myeloma fda decide place study partial hold follow identification risk identify combination study evaluate merck keytruda multiple myeloma mylan face month delay herceptin biosimilar decision mylan nv myl free report partner biocon have bit longer get response fda biosimilar version roche blockbuster drug herceptin trastuzumab fda inform mylan be extend target action date month so review clarificatory information submit part application review process result regulatory body now issue response regard approval status biosimilar dec biosimilar version have receive favorable vote july fda oncologic drug advisory committee odac herceptin be approve wide range indication include breast cancer metastatic adjuvant setting novartis ceo retire replacement announce novartis ceo joseph jimenez be step position board director have appoint vasant vas global head drug development chief medical officer successor effective feb also read replace jimenez novartis ceo novartis stock have gain year date outperform rally industry belong novartis be zack rank hold stock see complete list today zack rank strong buy stock here fda issue warning letter pfizer pfizer get warning letter fda regard manufacturing facility meridian medical technology inc brentwood mo letter mention significant violation current good manufacturing practice cgmp requirement combination product company have be accuse fail thoroughly investigate several serious component product failure epipen product manufacture behalf mylan include failure associate patient death severe illness earlier year march meridian medical technology have announce voluntary recall epipen product follow receipt previously disclose report outside unite state failure activate device due potential defect supplier component cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session most major stock record gain astrazeneca azn free report rise bristol myer be last month bristol myer be merck decline see last pharma stock roundup here novartis car drug get fda nod lilly give baricitinib update next pharma world watch usual pipeline regulatory update safety effectiveness glaxosmithkline plc gsk free report shingle vaccine shingrix be review fda vaccine related biological product committee vrbpac sep more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
134,BMY,bristol myer squibb company bmy free report announce fda put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma fda put study hold due risk identify merck co mrk free report keytruda pd agent patient multiple myeloma fda maintain datum obtain opdivo study indicate risk pd pd treatment pomalyst revlimid possibly pd pd treatment alone other combination outweigh potential benefit patient multiple myeloma consequently new patient be enroled study patient be currently enroled checkmate checkmate experience clinical benefit continue treatment company be work tandem fda address issue note july fda place clinical hold keynote keynote keynote combination study keytruda multiple myeloma decision be take follow review datum datum monitoring committee higher death be report keytruda arm keynote keynote lead halt enrolment news come disappointment investor earlier company suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum bristol myer stock have gain year date industry gain note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy label expansion additional indication give product access higher patient population increase commercial potential drug moreover opdivo be face competitive challenge unite state addition concern astrazeneca azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo zack rank key pickbristol myer currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company have top estimate trail quarters average more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
135,BMY,cancer be second most common cause death precede only heart disease traditional cancer treatment include surgery radiation chemotherapy however immunotherapy gene therapy other new novel therapy be be develop improve supplement replace traditional cancer treatment target reduce remove cancerous growth accord report american cancer society almost new cancer case be expect be diagnosed create significant need effective cancer medication go say big pharma company be gear develop bring innovative cancer treatment market well expand label market oncology drug pharma biotech giant have significant financial resource disposal have even collaborate pool resource technology here discuss pharma giant possess industry strongest oncology pipeline portfolio astrazeneca azn free report astrazeneca be work strengthen oncology product portfolio have several candidate pipeline company target be launch least new oncology medicine include lynparza tagrisso imfinzi be already approve market interesting candidate company immuno oncology pipeline be imfinzi durvalumab be evaluate multiple cancer alone combination other regimen include phase iii trial combination tremelimumab first line urothelial cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other imfinzi be launch first indication second line advanced bladder cancer other phase iii oncology candidate astrazeneca pipeline include acalabrutinib blood cancer moxetumomab pasudotox leukaemia selumetinib thyroid cancer savolitinib kidney cancer lynparza presently market advanced ovarian cancer be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer tagrisso be also be evaluate earlier line setting lung cancer astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here so far year astrazeneca share have moved compare unfavorably increase large cap pharma industry pfizer pfe free report pfizer newly approve immunotherapy bavencio be be consider significant top line driver new york base pharma giant bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be review eu mcc decision expect third quarter pfizer be focuse continuously grow expand bavencio new indication market globally pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development pfizer other oncology candidate have also be approve fda recently besponsa relapse refractory acute lymphoblastic leukemia august mylotarg new relapse cd positive acute myeloid leukemia september other cancer candidate pfizer pipeline include talazoparib advanced breast cancer dacomitinib advanced nsclc egfr activate mutation pfizer be also aggressively work expand label approve cancer drug ibrance xalkori pfizer also carry zack rank hold so far year pfizer share have moved abbvie abbv free report abbvie be work expand accelerate presence oncology build grow position hematological oncologyabbvie imbruvica currently approve several cancer indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease abbvie be position imbruvica pipeline molecule treatment be several company sponsored study acquisition cancer drugmaker stemcentrx abbvie gain late stage candidate rovalpituzumab tesirine rova additional early stage compound solid tumor indication significant portfolio pre clinical asset rova be currently registrational study small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing accord abbvie candidate have blockbuster potential be launch abbvie intend study candidate additional indication estimate peak sale close abbvie be also study market cancer drug venclyxto venclexta expand label address broader relapse refractory cll patient population expand earlier line therapy broaden other hematologic malignancy abbvie also carry zack rank so far year abbvie share have moved bristol myer bmy free report bristol myer pd inhibitor opdivo have be perform impressively bristol myer be work expand label opdivo further alone combination therapy yervoy other cancer agent further bristol myer cancer portfolio include multiple myeloma drug empliciti leukemia drug sprycel contribute top line addition bristol myer be evaluate other immune system pathway treatment cancer pathway help company bring market potentially immunotherapy combination monotherapy help fight different type cancer bristol myer also carry zack rank so far year bristol myer share have moved other not far behindmerck mrk free report be also conduct numerous study evaluate highly successful pd therapy keytruda more type cancer more study include more combination study roche rhhby free report dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla apart strong breast cancer franchise roche oncology portfolio also boast lung cancer drug avastin tarceva immuno oncology drug tecentriq newly approve multiple sclerosis drug ocrevus label expansion effort be ongoing cancer drug swiss drugmaker novartis nvs free report also boast many experimental cancer drug pipeline include couple biosimilar version popular cancer drug novartis cancer pipeline be bolster deal buy most glaxo gsk free report oncology portfolio lilly lly free report also layer oncology strategy call hold july involve build key treatment cyramza lartruvo abemaciclib foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy cancer market be fierce not pipeline candidate be successful however pharma biggy have enough late stage cancer program portfolio be chance quite few rollout come year surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
136,BMY,fda approve novel drug last year have give approval drug so far include august key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential recent landmark approval be novartis kymriah make first gene therapy unite state mark begin new era treatment cancer other serious life threaten disease drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month september fda follow advisory panel vote mylan herceptin biosimilar mylan nv myl free report hear fda soon approval status biosimilar version roche blockbuster drug herceptin trastuzumab company partner biocon ltd get favorable vote fda oncologic drug advisory committee odac july biosimilar herceptin be approve wide range indication include breast cancer metastatic adjuvant setting earlier year mylan have enter global settlement agreement roche genentech hoffmann la roche ltd herceptin trastuzumab mylan get global license exclude japan brazil mexico trastuzumab product mylan well be first launch biosimilar version herceptin unite state approval boost investor sentiment company have lose year date versus decline industry fda advisory panel discuss glaxo pfizer ptc therapeutic few fda advisory panel meeting be schedule month fda vaccine related biological product committee vrbpac be meeting sep discuss safety effectiveness glaxosmithkline plc gsk free report shingrix glaxo be look get live recombinant vaccine approve prevention herpes zoster shingle person be year old shingle common potentially serious condition cause last pain other complication such scarring visual impairment then sep fda odac be meeting discuss supplemental new drug application snda submit pfizer pfe free report cancer drug sutent pfizer be look expand sutent label adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney fda be expect render final decision regard label expansion jan sutent bring sale first half later month sep fda peripheral central nervous system drug advisory committee discuss ptc therapeutic ptct free report new drug application nda translarna ataluren treatment patient due nonsense mutation gene translarna be already approve outside unite state fda be expect give response regard approval status drug oct fda grant approval amgen allergan avastin biosimilar amgen amgn free report allergan be also expect decision fda biosimilar version roche cancer drug avastin bevacizumab company get favorable vote fda advisory panel odac recently chance gain approval fda action date sep look good share amgen have gain year date significantly outperform industry rally merck bristol myer seek label expansionmerck mrk free report be look expand label pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma keytruda be priority review indication response expect sep keytruda bring sale first half be key product merck portfolio be be evaluate wide range indication merck have gain year date versus growth industry bristol myer squibb company bmy free report be also look expand label pd inhibitor opdivo opdivo be priority review use patient hepatocellular carcinoma hcc prior treatment nexavar sorafenib fda be expect give response sep opdivo prioritize brand bristol myer portfolio bring sale first half bristol myer have gain year date versus growth industry fda approve plivensia johnson johnson investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor be fda review response expect sep however early august plivensia fail get support fda arthritis advisory committee safety concern be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person unite state fda be not require do so usually follow advice advisory panel consider safety concern raise panel quite likely agency ask additional information grant approval share have gain year date outperform industry rally neos therapeutic be also await decision month nt amphetamine xr liquid suspension product candidate attention deficit hyperactive disorder adhd approval sep allow company go ahead plan launch product jan zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
137,BMY,incyte corporation incy free report announce european society medical oncology esmo publish abstract contain new update datum ongoing phase ii echo trial epacadostat echo study nct be evaluate safety efficacy incyte selective ido enzyme inhibitor epacadostat combination merck co mrk free report keytruda patient advanced melanoma datum study reveal robust durable response patient advanced melanoma treat combination epacadostat keytruda efficacy evaluable advanced melanoma patient median progression free survival pfs be month pfs rate month month month respectively median pfs be not reach patient be treatment naïve advanced disease landmark pfs rate month month month respectively echo clinical trial program be be conduct investigate efficacy safety epacadostat core component combination therapy oncology incyte be evaluate epacadostat combination pd pd inhibitor broad range solid tumor type well hematological malignancy echo nct phase iii randomize double blind placebo controlled study be investigate keytruda combination epacadostat placebo treatment unresectable metastatic melanoma be also ongoing fully recruit meawnhile incyte have extend collaboration bristol myer squibb company bmy free report evaluate epacadostat combination opdivo pivotal study tumor type plan initiation end incyte sign clinical trial collaboration agreement merck bristol myer roche hold ag rhhby free report other evaluate epacadostat respective pd pd agent phase ii study incyte stock gain year so far compare industry gain believe agreement not only validate company research approach also enhance company financial position incyte stand earn revenue form milestone payment royalty successful development however june incyte roche decide end echo trial epacadostat tecentriq further enrolment slow study recruitment zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
138,BMY,pfizer inc pfe free report partner avillion announce supplemental new drug application snda bosulif have be accept grant priority review fda remind investor bosulif be currently approve treatment chronic accelerate blast phase philadelphia chromosome positive ph chronic myelogenous leukemia cml adult be resistant intolerant prior therapy company be look get drug approve first line treatment patient suffering chronic phase ph cml decision fda be expect december additionally european medicine agency ema have also accept similar regulatory application review pfizer share have gain so far year underperform industry gain same period application also include patient be not eligible treatment novartis ag nvs free report gleevec tasigna bristol myer squibb company bmy free report sprycel regulatory application eu base datum phase iii bfore study evaluate mg dose bosulif newly diagnosed ph cml patient result show bosulif achieve major molecular response month significantly higher number patient compare gleevec press release be patient cml new case be expect be diagnosed represent opportunity bosulif approve first line treatment ph cml pfizer be expect decision fda label expansion leukemia drug mylotarg first line set treat acute myeloid leukemia september july fda advisory panel have vote favor approval snda mylotarg pfizer inc price consensus pfizer inc price consensus pfizer inc quotezack rank stock considerpfizer have zack rank hold better rank stock pharma sector be therapeutic incorporate cort free report carry zack rank buy see complete list today zack rank strong buy stock here earning estimate increase cent cent cent cent last day company deliver average earning beat trail quarters stock be so far year surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
139,BMY,johnson johnson jnj free report announce submission regulatory application fda european medicine agency ema seek label expansion multiple myeloma mm drug darzalex first line set potential approval allow darzalex be used combination proteasome inhibitor mm drug velcade bortezomib melphalan prednisone treat mm treatment naïve patient have autologous stem cell transplantation bone marrow approve be fifth indication drug be encourage effort expand darzalex label further drug generate sixth company total oncology sale first month note darzalex be first approve november monotherapy mm patient treat least prior line therapy follow approval past year combination therapy second third line setting share have outperformed industry so far year company share have gain compare industry gain have submit top line datum phase iii alcyone study support regulatory application geography datum study show darzalex combination therapy reduce risk disease progression death compare treatment bortezomib melphalan prednisone standard care alone present datum annual meeting american society hematology schedule be hold dec dec note license darzalex genmab subsidiary janssen hold worldwide right develop manufacture commercialize drug have pay milestone payment genmab national cancer institute new patient be likely be diagnosed mm cause death unite state alone darzalex compete other approve market treatment mm include celgene corporation celg free report revlimid amgen inc amgn free report kyproli bristol myer bmy free report emplicti johnson johnson price johnson johnson price johnson johnson quotej carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
140,BMY,celldex therapeutic inc cldx free report announce initiation phase ii study human monoclonal antibody cdx patient advanced head neck squamous cell carcinoma hnscc approve product portfolio investor focus remain progress celldex pipeline candidate share company be more friday follow news however celldex share be so far year underperform industry gain period phase ii study evaluate cdx combination eli lilly lly free report erbitux patient advanced hnscc be erbitux resistant previously treat pd checkpoint company believe patient population be evaluate study have limit availability treatment option particularly poor prognosis study continue treatment progression disease start patient become intolerant combination therapy primary objective study be achieve objective response rate stage study enroll patient first stage initiate second stage achieve partial complete response least patient remind investor complete phase ib study combination therapy have show promising tumor activity hsncc patient include durable complete response single patient disease have progressed erbitux monotherapy celldex be also progress well lead pipeline candidate glembatumumab vedotin be be evaluate phase iib study patient triple negative breast cancer phase ii study melanoma patient company be also evaluate candidate combination bristol myer bmy free report opdivo merck mrk free report keytruda separate cohort melanoma study celldex therapeutic inc price celldex therapeutic inc price celldex therapeutic inc quotecelldex currently hold zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
141,BMY,infinity pharmaceutical inc infi free report provide update lead pipeline candidate ipi also issue financial guidance infinity be currently focuse development lead immuno oncology candidate ipi be orally administer treatment selectively inhibit kinase pi gamma infinity have clinical trial collaboration bristol myer bmy free report evaluate ipi combination latter pd inhibitor opdivo nivolumab patient advanced solid tumor january company have announce achievement development milestone ipi company also plan report datum monotherapy expansion combination dose escalation component company expect announce initial datum combination expansion component phase ib study ipi opdivo second quarter second half infinity expect report more mature clinical datum combination expansion component study include translational insight pair tumor biopsy multiple disease company also announce expansion phase ib study ipi include combination cohort ipi opdivo enroll patient high baseline level myeloid derive suppressor cell ipi represent potentially complementary approach restore tumor immunity combination other immunotherapy such checkpoint inhibitor successfully develop approval ipi provide massive boost infinity portfolio company also provide financial guidance expect end year end cash investment balance range base current operational plan infinity expect exist cash cash equivalent available sale security december be adequate satisfy company capital need first quarter october infinity enter license agreement verastem inc grant exclusive worldwide right develop commercialize oncology candidate duvelisib latter october infinity receive cash payment verastem verastem plan submit new drug application duvelisib first quarter infinity progress candidate have be impressive moreover clinical trial collaboration bristol myer have provide infinity strong partner expertise field immuno oncology further allow infinity expedite development ipi however infinity face stiff competition field immuno oncology company bristol myer astrazeneca azn free report celgene celg free report merck novartis pfizer roche eli lilly other wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
142,BMY,horizon pharma plc hznp free report top earning sale estimate second quarter company also raise sale guidance company share moved better expect second quarter result increase guidance however horizon pharma stock be year date industry gain company report second quarter earning cent share beat zack consensus estimate cent include stock base compensation expense exclude time item be cent year quarter exclude stock base compensation expense company report ep cent sale second quarter be year year fuel solid growth orphan rheumatology business unit report sale also beat zack consensus estimate horizon pharma plc price consensus ep surprise horizon pharma plc price consensus ep surprise horizon pharma plc quotequarter orphan unit record revenue year period strong performance be backed solid net sale ravicti generate sale quarter year year drive continue conversion older generation nitrogen scavenger therapy well addition treatment naïve patient due recent label expansion apr fda approve supplemental new drug application ravicti expand age range chronic management urea cycle disorder patient month older year older additionally procysbi contribute performance net sale actimmune sale report quarter be year year rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive continue strong year year vial demand primary care garner revenue year year decline net sale be due implementation new contract model order secure broader inclusion company primary care medicine formulary net sale pennsaid duexix vimovo be respectively report quarter company raise outlook now expect sale range compare earlier estimate horizon pharma be significantly increase investment key growth driver krystexxa expect net sale krystexxa drive higher demand guidance include assumption lower net average net realize price begin second half primarily result government health resource service administration final rule drug ceiling price implementation schedule oct company expect continue double digit net sale growth ravicti room additional uptake due recent label expansion drug be also expect be launch europe second half sale procysbi decline divestiture european right sale actimmune be project grow low single digit drive year year growth second half other updatesdure quarter company acquire river vision thereby add biologic candidate teprotumumab late stage development thyroid eye disease confirmatory phase iii trial be slate be year end company expect annual net sale teprotumumab exceed jun horizon pharma sell marketing right procysbi quinsair europe middle east africa region chiesi farmaceutici company focus higher return business meanwhile company be work expand actimmune label company have collaborate fox chase cancer center evaluate actimmune combination bristol myer squibb company bmy free report opdivo phase dose study treatment kidney bladder cancer national cancer institute have plan evaluate actimmune combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study remain track begin later year takehorizon pharma second quarter result be impressive company beating top bottom line estimate moreover increase sale guidance be encourage well net sale rare disease drug increase expect krystexxa ravicti actimmune drive growth second half acquisition teprotumumab have further diversify company portfolio however key drug duexis vimovo face competition pfizer inc pfe free report celebrex generic other brand steroidal inflammatory drug nsaid cheaper generic version nsaid zack rankhorizon pharma currently have zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
143,BMY,seattle genetic inc sgen free report partner takeda pharmaceutical company limit announce european commission have extend current conditional marketing authorization expand indication lymphoma drug adcetris brentuximab vedotin marketing authorization be extend treatment adult patient cd positive cutaneous cell lymphoma least prior systemic therapy decision be base positive opinion issue committee medicinal product human use nov note adcetris be only market product seattle genetic drug be approve relapse hodgkin lymphoma relapse systemic anaplastic large cell lymphoma patient suffering classical hodgkin lymphoma be high risk relapse progression post autologous hematopoietic stem cell transplantation auto hsct consolidation year share seattle genetic have decline industry gain marketing aurthorization be mainly base positive datum phase iii trial alcanza study patient cutaneous cell lymphoma ctcl interestingly alcanza study achieve primary secondary endpoint study show ctcl patient treat adcetris have superior outcome primary secondary endpoint compare patient control arm be treat methotrexate bexarotene standard care agent marketing authorization adcetris be valid country european union november fda have approve adcetris treatment primary cutaneous anaplastic large cell lymphoma cd express mycosis fungoide have receive prior systemic therapy approval be be base positive datum phase iii trial alcanza phase ii investigator sponsored trial patient ctcl label expansion be expect boost sale drug further evidently sale drug third quarter grow year year furthermore seattle genetic be develop drug more clinical study key study include evaluation cell lymphomas hodgkin lymphoma phase iii study be also evaluate adcetris frontline mature cell lymphomas again drug be be study combination bristol myer squibb company bmy free report opdivo relapse refractory hodgkin lymphoma however adcetris face competition other drug include merck co inc mrk free report keytruda be also approve lymphoma indication seattle genetic inc price seattle genetic inc price seattle genetic inc quote zack rank stock considerseattle genetic carry zack rank hold better rank stock health care space be exelixis inc exel free report carriy zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average share price company surge past year wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
144,BMY,biocryst pharmaceutical inc bcrx free report idera pharmaceutical inc idra free report announce have enter definitive merger agreement merged entity focus development drug treat rare disease new company be lead idera chief executive officer ceo vincent milano biocryst chairman robert ingram chair board combine entity deal have be approve board company stock decline idera be almost jan raise concern prospect merger still await shareholder approval biocryst share have decline past year zack drug industry increase idera share have increase compare zack biomedical genetic industry gain period term stock deal biocryst shareholder receive stock combine entity share own idera shareholder receive stock follow completion deal biocryst shareholder hold stake new company idera stockholder own transaction be expect be complete second quarter company expect merger bring cost synergy be expect boost bottom line new company moreover combine company have robust pipeline include phase iii phase ii pipeline candidate phase iii candidate be biocryst bcx hereditary angioedema capsule formulation idera imo combination bristol myer bmy free report yervoy pd refractory melanoma candidate enjoy orphan drug designation phase ii candidate be idera imo dermatomyositis biocryst liquid formulation bcx several datum readout be expect study act catalyst new company moreover combine entity have cash balance be enough support ongoing study activity potential approval continue business development activity zack rank stock idera carry zack rank hold exelixis inc exel free report be better rank stock pharma sector sporting zack rank strong buy see complete list today zack rank stock here exelixis earning estimate have remain stable cent increase cent cent last day company deliver positive earning surprise trail quarters average beat stock have return past year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
145,BMY,pfizer inc pfe free report partner bristol myer squibb company bmy free report present finding phase iv study eliquis demonstrated oral anticoagulation potential achieve maintain normal heart rhythm cardioversion study emanate compare eliquis standard care heparin reduce occurrence acute stroke systemic embolism major bleed clinically relevant major bleed cause death valvular atrial fibrillation nvaf patient undergo cardioversion remind investor eliquis be already approve reduction risk stroke systemic embolism patient nvaf treatment deep vein thrombosis dvt pulmonary embolism pe reduction risk recurrent dvt pe follow initial therapy prophylaxis dvt lead pe patient have undergo hip knee replacement surgery however drug be not approve reduction stroke nvaf patient undergo cardioversion pfizer have underperform industry so far year stock have gain period industry gain come back latest news cardioversion procedure be associate concern clot blood heart travel brain stroke other body part systemic embolism emanate study show be stroke eliquis group compare stroke heparin arm however systemic embolism be observed drug group eliquis also reduce number major bleed event clinically relevant major bleed event compare heparin current standard care heparin coumadin require monitoring potential dose adjustment administer reduce risk stroke however eliquis be administer fix dose mg twice daily note eliquis be anticoagulant increase risk bleed become serious potentially fatal company also announce datum real world analysis eliquis nvaf patient separate press release analysis eliquis show lower risk stroke lower rate major bleed compare coumadin nvaf patient well select high risk patient sub population eliquis face competition anticoagulant segment johnson johnson jnj free report xarelto boehringer ingelheim pradaxa approval portola pharmaceutical inc ptla free report bevyxxa june competition be expect intensify stroke event be major concern nvaf patient finding show eliquis become prefer treatment same boost potential drug pfizer bristol myer try get label eliquis expand include finding give drug edge other market blood thinner pfizer inc price consensus pfizer inc price consensus pfizer inc quotecurrently pfizer carry zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
146,BMY,key news week include priority review roche rhhby free report experimental hemophilia drug eu approval novartis nvs free report advanced breast cancer drug meanwhile deal involve company astrazeneca plc azn free report eli lilly company lly free report be also announce week recap week most important storiespriority review roche hemophilia drug roche investigational hemophilia treatment emicizumab get priority review fda agency expect give decision feb roche be look get emicizumab prophylaxis preventative approve once weekly subcutaneous treatment adult adolescent child hemophilia factor viii inhibitor accord information provide company person hemophilia develop inhibitor standard factor viii replacement therapy result treatment option be limit be increase risk life threaten well repeat bleed also read roche hemophilia drug grant priority review lilly inks multus year deal topas lilly have enter multus year research option agreement focuse immune tolerance germany base biotechnology company topas therapeutic initial focus be external antigen thought induce inflammation autoimmune disease pre clinical proof principle study be conduct topas receive funding lilly lilly have option license develop candidate produce collaboration deal signify lilly focus immunology immune tolerance have be attract interest quite few large player celgene signing exclusive global research collaboration anokion privately hold company develop novel tolerance induce therapeutic autoimmune disease earlier year astrazeneca mrna focuse deal ethris astrazeneca enter strategic deal germany base ethris development mrna therapy respiratory disease year strategic research deal be focuse use ethris proprietary snim rna technology new stabilize immunogenic mrna therapy respiratory disease astrazeneca make upfront payment upfront provide research funding well other payment include research development milestone payment sale related royalty astrazeneca have option take exclusive worldwide license target collaboration be not first time astrazeneca have sign mrna focuse deal company be collaborate moderna therapeutic mrna therapeutic candidate treatment range cancer cardiovascular metabolic renal disease well meanwhile astrazeneca also announce result new sub analysis datum phase iii pegasus timi study show risk reduction cardiovascular cv death treatment brilinta compare placebo patient take low dose aspirin still high risk event major cause acute coronary syndrome cv death astrazeneca be zack rank hold stock see complete list today zack rank strong buy stock here cardiome brinavess regulatory update cardiome pharma share be news fda have inform company datum package resubmission regulatory application antiarrhythmic drug brinavess not be sufficient company be look resubmit new drug application nda brinavess base original file year accumulate safety datum brinavess sale country well interim result more patient enrolled spectrum study prospective post authorization eu safety study pre clinical datum subsequent study complete company fda request eu nod novartis advanced breast cancer drug novartis cdk inhibitor kisqali gain approval eu use combination inhibitor first line treatment postmenopausal woman hr locally advanced metastatic breast cancer approval be largely expect consider positive committee medicinal product human use chmp opinion earlier year june accord information provide company woman be diagnosed advanced breast cancer year world third patient early stage breast cancer eventually develop advanced disease kisqali be approve mar novartis be work launch full commercial campaign gain formulary coverage share novartis have gain year date outperform industry cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock bristol myer squibb bmy free report be lose last month be merck co mrk free report decline see last pharma stock roundup here multiple sclerosis drug price focus mixed datum bmy opdivo next pharma world watch usual pipeline regulatory update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
147,BMY,celldex therapeutic inc cldx free report announce completion enrollment phase iib study metric evaluate lead pipeline candidate glembatumumab vedotin treat patient metastatic triple negative breast cancer share celldex have underperform industry year date stock have massively plunge versus industry gain period metric be randomize phase iib study enrolled total patient give indication patient trial be randomize glembatumumab vedotin roche hold ag rhhby free report breast cancer drug xeloda capecitabine primary endpoint study be progression free survival pfs top line datum study be expect second quarter remind investor phase ii study glembatumumab vedotin be currently underway patient metastatic melanoma single agent datum study be present june annual meeting american society clinical oncology asco glembatumumab vedotin perform well single agent set response rate disease control rate median duration response month patient have fail prior line therapy study also include new cohort glembatumumab varlilumab arm glembatumumab checkpoint inhibitor arm include bristol myer squibb company bmy free report opdivo merck co inc mrk free report keytruda glembatumumab vedotin celldex pipeline comprise important candidate varlilumab be be evaluate several phase ii combination study multiple type cancer celldex therapeutic inc pricecelldex therapeutic inc price celldex therapeutic inc quotezack rankcelldex currently carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
148,BMY,celldex therapeutic inc cldx free report announce have start patient enrollment phase study evaluate new candidate cdx treatment patient advanced solid tumor notably cdx be fully human antibody target cd immune response activator share celldex have increase more follow news release however stock have underperform industry so far year share have lose compare unfavorably industry increase period study be expect enroll total patient recurrent locally advanced metastatic solid tumor be design evaluate safety tolerability cdx different dose level range mg kg mg kg once week disease progression intolerance significantly company be also plan evaluate combination cdx other tumor agent remind investor last november celldex present positive pre clinical datum cdx society immunotherapy cancer annual meeting trial outcome demonstrated cdx bound cd high affinity do not block cd ligand bound also show direct tumor activity immune deficient mouse human lymphomas apart cdx celldex have interesting candidate oncology pipeline call varlilumab candidate be be evaluate combination bristol myer bmy free report opdivo phase ii study include cohort indication namely colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex plan complete enrolment cohort phase ii portion study first quarter other promising candidate be cdx cdx phase ii multiple solid tumor collaboration citn cdx phase advanced renal cell carcinoma other importantly celldex expect cdx add stimulus company grow immunotherapy pipeline celldex therapeutic inc price celldex therapeutic inc price celldex therapeutic inc quotezack rank other key pickscelldex carry zack rank buy other top rank stock health care sector be therapeutic inc cort free report achillion pharmaceutical inc achn free report carry zack rank see complete list today zack rank strong buy stock here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
149,BMY,be major news cancer space week failure pfizer inc pfe free report bavencio gastric cancer study setback eisai co ltd esaly free report national institute health care excellence nice do not recommend approval breast cancer drug halaven use second line set uk meanwhile astrazeneca azn free report filing label expansion tagrisso first line set treat lung cancer be accept european medicine agency ema apart bristol myer bmy free report blockbuster drug opdivo again prove worth achieve superior overall survival os phase iii lung cancer study moreover celldex therapeutic inc cldx free report also announce initiation phase study new oncology candidate cdx solid tumor recap week most important storiespfizer bavencio fail gastric cancer study pfizer germany base partner merck kgaa announce failure phase iii study evaluate key pipeline candidate bavencio avelumab treatment gastric cancer third line set study javelin gastric evaluate bavencio monotherapy patient unresectable recurrent metastatic gastric junction adenocarcinoma disease have progressed follow prior therapeutic regimen however study javelin gastric continue evaluate drug first line switch maintenance set read more pfizer merck kgaa bavencio fail gastric cancer study pfizer inc price pfizer inc price pfizer inc quoteeisai halaven suffer setback uk eisai announce nice do not recommend approval halaven uk second line set treat locally advanced metastatic breast cancer have receive chemotherapy approval have give competitive advantage drug drug be already approve uk third later line set same indication eisai co price eisai co price eisai co quotebristol myer opdivo superior lung cancer study bristol myer pd immune checkpoint inhibitor opdivo achieve superior os compare docetaxel phase iii study study checkmate evaluate drug previously treat advanced metastatic small cell lung cancer study be conduct mainly chinese patient achieve primary endpoint os earlier expect company biologic license application file basis positive result study have be accept china food drug administration bristol myer squibb company price bristol myer squibb company price bristol myer squibb company week ema accept mylan myl free report marketing authorization application biosimilar roche rhhby free report breast gastric cancer drug herceptin amgen neutropenia drug neulasta medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
150,BMY,report tech giant amazon meeting generic drugmaker make round company pfizer pfe free report teva pharmaceutical industry ltd teva free report be news former report late stage datum latter announce leadership organizational change recap week most important storiesis amazon talk generic drugmaker accord cnbc report tech giant amazon be preliminary discussion generic drugmaker include mylan myl free report novartis generic arm sandoz enter pharmacy market not much information be available be lot speculation discussion industry watcher way tech giant be plan enter market drug wholesaler retailer pfizer merck kgaa bavencio fail late stage study pfizer merck kgaa suffer setback effort expand label checkpoint inhibitor bavencio avelumab therapy fail meet primary endpoint superior overall survival os compare physician choice chemotherapy late stage study be be conduct evaluate bavencio third line treatment unresectable recurrent metastatic gastric junction gej adenocarcinoma patient disease progressed follow prior therapeutic regimen regardless pd expression company continue evaluate bavencio first line switch maintenance set gastric cancer accord information provide company gastric cancer be fifth most common cancer world third most common cause cancer death survival advanced disease be poor usually less year third line set be difficult treat population read more pfizer merck kgaa bavencio fail gastric cancer study leadership organizational change teva teva new ceo have announce change organization well leadership structure company key change be generic specialty medicine segment now operate single segment region north america europe growth market generic specialty organization also be merged global group newly form marketing portfolio function be set change dr michael hayden dr rob koreman dipankar bhattacharjee be exit teva effective dec several new appointment be also announce detailed restructure plan be unveil mid december teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track generic competition copaxone mg be major setback stock teva have lose value year date versus decline record industry mylan biosimilar eu review mylan partner biocon say european medicine agency ema have accept marketing application biosimilar version roche herceptin trastuzumab amgen neulasta pegfilgrastim herceptin be used treatment certain positive breast gastric cancer neulasta be used reduction duration neutropenia low count neutrophil type white blood cell incidence fever associate neutropenia adult patient treat chemotherapy certain type cancer marketing application have be withdraw earlier follow audit be conduct european inspect authority biocon drug product facility biocon say have complete corrective preventive action capas base audit be verify inspection part regulatory review process meanwhile company get response fda regulatory application biosimilar version herceptin december earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar fda be not require do so usually follow recommendation advisory panel partner commence hiv vaccine efficacy study focus world aids day today johnson johnson jnj free report bill melinda gate foundation national institutes health have initiate first efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine efficacy safety reduce incidence hiv infection woman sub saharan africa be significant unmet need vaccine hiv lot progress have be make treat manage disease almost person become infected year develop vaccine hiv have prove be challenge due unique property virus include ability mutate rapidly moreover genetic diversity multiple strain subtype prevalent different part world be additional hurdle note efficacy study evaluate different vaccine candidate be be conduct south africa be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong viiv start late stage study hiv prevention viiv healthcare global specialist hiv company majority own glaxosmithkline gsk free report pfizer shionogi limit shareholder have commence late stage study long act cabotegravir prevention hiv infection sexually active woman study compare cabotegravir injection give month daily oral pre exposure prophylaxis prep emtricitabine tenofovir disoproxil fumarate cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock bristol myer bmy free report be astrazeneca decline last month bristol myer be glaxo decline see last pharma stock roundup here fda approve glaxo hiv drug roche present datum next pharma world watch regulatory pipeline news pharma stock response fda regard approval status mylan biocon biosimilar version roche blockbuster cancer drug herceptin trastuzumab be december nordisk nvo free report key player diabetes market also get know approval status latest type ii diabetes product offer semaglutide month medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
151,BMY,very few option be available treat ovarian cancer primarily include chemotherapy radiation surgery effective treatment have many side effect chemotherapy destroy patient immune system radiation kill normal cell cancerous cell surgical process be ineffective cancer spread approval astrazeneca azn free report merck mrk free report lynparza december new target therapy treat ovarian cancer come market drug inhibit enzyme cell parp help repair dna cell thus destroy cell other parp inhibitor be approve fda tesaro inc tsro free report zejula clovis oncology inc clvs free report rubraca parp inhibitor have show more tolerability effectiveness clinical study however none market parp inhibitor rubraca zejula lynparza have be approve first line set date be many other company develop parp inhibitor include pfizer inc pfe free report abbvie inc abbv free report other let see market drug be perform have better prospect lynparza recent label expansion august be indicated maintenance treatment patient suffering platinum sensitive recurrent psr ovarian cancer regardless brca mutation status be also approve brca mutate ovarian cancer third line set drug be available capsule tablet formulation drug record sale first month grow annually drug be also be develop first line maintenance treatment brca mutate ovarian cancer astrazeneca merck expect file label expansion mid however lynparza sale have fall lately unite state launch zejula april year label expansion august include ovarian cancer patient regardless brca mutation have bring par zejula moreover potential approval first line set next year give edge other drug also astrazeneca have collaborate merck co develop lynparza combination immunotherapy successful development be boon patient rubraca receive accelerate approval fda late last year monotherapy advanced ovarian cancer patient deleterious brca mutation treat more chemotherapy clovis be conduct confirmatory study convert approval full approval meanwhile company file supplemental new drug application last month seek label expansion maintenance treatment patient psr ovarian cancer rubraca be review eu drug report sale first month however drug lag other drug be approve treat ovarian cancer irrespective brca mutation meanwhile clovis be evaluate drug phase iii study combination bristol myer bmy free report opdivo first line maintenance therapy stage iii iv high grade ovarian cancer patient be treat platinum base chemotherapy zejula be first parp inhibitor be approve maintenance treatment recurrent ovarian cancer regardless brca mutation be launch april drug be used patient do not have brca mutation be prescribe broader patient population moreover also remove requirement diagnosis brca mutation thereby reduce treatment cost time due competitive advantage zejula have register impressive growth launch have also encroach lynparza rubraca market share drug have generate sale launch company have also claim be most frequently prescribe parp inhibitor ovarian cancer further boost prospect drug european commission grant marketing authorization earlier week tesaro be also develop zejula combination merck pd drug keytruda patient platinum resistant ovarian cancer discussion be evident zejula have edge due requirement brca mutation status have fared better thus far however expand label lynparza be set get back lose share believe rubraca be relatively weaker position drug be uncertainty perform europe lynparza zejula be already approve however have end see actual performance drug few label expansion be expect next year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
152,BMY,healthcare be perform well start new year thank encourage industry trend favorable policy environment notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain nearly so far bullish trend be likely continue head earning season big name johnson johnson jnj free report pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read tax bill etf investor need know let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stocksjnj have zack rank earning esp indicate lower chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive momentum style score value growth style score johnson johnson be slate release earning jan open bell see healthcare etfs here pfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see positive earning estimate revision penny be report quarter deliver average negative earning surprise past quarters have impressive growth value momentum style score respectively pfizer be schedule report earning jan open bell merck be expect report result feb market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision couple cent past day be report quarter merck have value growth momentum style score respectively amgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day quarter be report stock have solid value style score growth momentum style score look dull amgen report earning feb market close read wave push biotech etfs higher abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter stock have solid value growth style score momentum style score be unimpressive company be schedule report jan open bell gilead be expect release earning feb market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision cent past month be report quarter have solid value style score growth momentum style score look ugly bristol myer likely report earning feb open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have solid momentum growth style score respectively unfavorable value style score sum earning surprise well card healthcare sector be expect witness earning growth fourth quarter suggest upside healthcare etfs particular etfs have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
153,BMY,bristol myer squibb company bmy free report announce new datum cohort phase ii checkmate study opdivo checkmate study be ongoing study evaluate opdivo nivolumab yervoy ipilimumab previously treat patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer result study show primary endpoint objective response rate investigator assessment be median follow month overall survival rate year be median os be not yet reach result show opdivo yervoy provide durable clinical benefit patient dmmr msi metastatic colorectal cancer datum show statistically significant clinically meaningful improvement key patient report outcome include symptom function quality life bristol myer share have rally past year compare industry gain note opdivo be already approve number indication include classical hodgkin lymphoma recurrent metastatic squamous cell carcinoma head neck scchn disease progression platinum base therapy additionally be approve monotherapy treatment scchn adult progress platinum base therapy opdivo be also approve intravenous use patient hepatocellular carcinoma have be previously treat nexavar drug receive approval liver colorectal cancer well meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential significantly however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous small cell lung cancer nsclc company be expect suffer further loss market share bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quote zack rank stock considerbristol myer carry zack rank hold few better rank stock health care space be exelixis inc exel free report xoma corporation xoma free report xoma sport zack rank strong buy exelixis carry zack rank buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average share price company surge xoma loss share estimate have narrow cent cent last day company post positive earning surprise last quarters average beat share price company sky-rocket hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
154,BMY,week company novartis nvs free report merck mrk free report johnson johnson jnj free report be news merck provide datum keytruda novartis be news gain priority review status label expansion car therapy kymriah recap week most important storiesmerck keytruda shine st line lung cancer study merck score week pd therapy keytruda combination alimta pemetrexed cisplatin carboplatin meeting primary endpoint overall survival os progression free survival pfs late stage study first line treatment patient metastatic squamous small cell lung cancer nsclc interim analysis conduct independent datum monitoring committee show keytruda combination result significantly longer os pfs compare alimta platinum chemotherapy alone read more merck strong confirmatory phase iii lung cancer study priority review label expansion novartis kymriah novartis first company gain fda approval car therapy kymriah say agency have grant priority review company regulatory application seek expand label product novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible relapse autologous stem cell transplant asct kymriah also get accelerate assessment status european medicine agency ema treatment child young adult cell acute lymphoblastic leukemia adult patient dlbcl be ineligible asct read more novartis sbla car therapy kymriah accept fda unfavorable ipr decision suffer setback week patent trademark office pto issue final written decision parte review ipr related sole unexpired patent list cover company prostate cancer therapy zytiga abiraterone acetate fda orange book generic drug company argentum pharmaceutical have challenged claim patent be due expire aug issue statement regard pto decision say be evaluate option rehearing appeal court appeal federal circuit zytiga bring sale first month novartis sandoz global partnership biocon biosimilar sandoz novartis division be enter global partnership biocon development manufacture multiple biosimilar immunology oncology company share responsibility end end development manufacturing global regulatory approval number product have cost profit share arrangement responsibility be divide partnership allow company address next wave biosimilar opportunity globally sandoz biocon have have success biosimilar space sandoz portfolio include biosimilar market various country world company be currently seek fda approval biosimilar version abbvie blockbuster immunology drug humira regulatory application biosimilar be recently accept review fda pfizer gilead clinical trial collaboration pfizer pfe free report have enter clinical trial collaboration kite gilead gild free report company safety efficacy kite car cell therapy yescarta axicabtagene ciloleucel be evaluate combination pfizer utomilumab fully humanize bb agonist monoclonal antibody patient refractory large cell lymphoma phase ii study be expect commence year pfizer be zack rank buy stock see complete list today zack rank strong buy stock here company stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock merck be bristol myer squibb bmy free report decline last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here nordisk reveal bid acquire ablynx pfizer other healthcare conference next pharma world watch usual pipeline regulatory update well fourth quarter earning announcement january make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
155,BMY,pfizer inc pfe free report announce fda have approve label expansion cancer drug sutent sunitinib malate latest approval sutent label have be expand adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow surgery approval make first only adjuvant therapy recurrent rcc most common type kidney cancer sutent be market first line treatment advanced renal cell carcinoma rcc remind investor supplemental new drug application snda drug be accept fda earlier subsequently september drug label expand indication get mixed response fda oncologic drug advisory committee odac committee vote favor benefit risk profile sutent expand indication however drug label expansion be approve earlier target action date january pfizer share have underperform industry so far year stock have gain compare unfavorably industry rally period notably fda approval be base positive datum phase iii study trac evaluate sutent adjuvant treatment patient high risk recurrent rcc follow nephrectomy surgical removal cancer contain kidney full datum present october last year show trial meet primary endpoint improve disease free survival dfs determine blind independent central review such patient datum demonstrated sutent extend dfs year compare year placebo arm result overall risk reduction application use same patient population be also review eu significantly kidney cancer market be already pretty crowd drug face stiff competition bristol myer squibb bmy free report opdivo novartis nvs free report afinitor votrient bayer amgen nexavar roche rhhby free report avastin tecentriq other sutent generate sale year date year year due competitive pressure however approval expand patient population sale drug improve information provide company rcc account kidney cancer also high risk recurrence represent approximately patient be estimate high risk patient have rcc recurrence year hence potential market opportunity drug be huge additional indication pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
156,BMY,laboratory corporation america holding lh free report labcorp recently announce agilent dako pathology division development pd ihc pharmdx assay be now available unite state new expand use labcorp test have get approval be used complementary diagnostic bristol myer squibb company bmy free report opdivo nivolumab new indication metastatic urothelial carcinoma bladder cancer squamous cell carcinoma head neck respectively be encourage note test clinical study support approval new indication assay be perform company center molecular biology pathology laboratory labcorp opdivo be already approve aforementioned indication use test however pd ihc pharmdx test provide vital information patient be most likely respond positively opdivo earlier pd ihc pharmdx assay be approve use complementary diagnostic opdivo treat certain patient squamous small cell lung cancer nsclc melanoma time too labcorp central clinical trial laboratory be only provider testing support clinical trial approval squamous nsclc treatment indication company successfully demonstrate combine capability labcorp clinical laboratory infrastructure covance central clinical trial laboratory be pave new way clinical trial labcorp consistent effort expand grow field complementary companion diagnostic be gradually fetch unmatched result notably company have adopt strategy work closely health system have expressed interest become prefer partner labcorp covance clinical trial regard company have sign agreement several major health system recently earlier year company enter agreement thermo fisher scientific join ngs companion diagnostic center excellence program have also inked exclusive deal distribute omniseq immune profile tumor profile test diagnostic labcorp have make strong progress consumer patient face initiative company labcorp walgreen collaboration be terrific start respect patient volume net promoter score patient feedback ride year experience site drug development business company be focuse drive future profitable growth expand solution enhance operational capability acquisition chiltern close sep be significantly strengthen labcorp strategic position clinical development well accelerate revenue profit growth covance labcorp be trading broader industry last month stock have gain compare industry gain zack rank key pickslabcorp carry zack rank hold better rank medical stock be petm express inc pet free report align technology inc algn free report sporting zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar roughly year align technology have long term expect earning growth rate stock have sky-rocket year time zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
157,BMY,third quarter earning season draw close focus be back deal regulatory approval pipeline update week company astrazeneca azn free report bayer bayry free report be news former announce fda approval severe asthma drug bayer sign cancer focuse deal loxo oncology recap week most important storiesfda approval astrazeneca severe asthma drug astrazeneca continue deliver pipeline company score couple fda nod week regulatory body grant approval company respiratory biologic fasenra benralizumab add maintenance treatment severe asthma patient age year disease be drive eosinophilic inflammation read more astrazeneca asthma drug benralizumab approve fda moreover astrazeneca get positive opinion committee medicinal product human use chmp european medicine agency ema fasenra read more astrazeneca get positive chmp opinion asthma candidate astrazeneca also gain fda approval use cancer drug faslodex expand patient population faslodex now be used combination eli lilly lly free report cdk inhibitor verzenio abemaciclib woman hr advanced metastatic breast cancer mbc disease have progressed endocrine therapy study result have show month progression free survival pfs combination treatment mark second fda approval faslodex cdk inhibitor treatment be already approve use combination pfizer cdk inhibitor ibrance palbociclib fda advisory panel meeting pacira exparel snda specialty pharma company pacira pharmaceutical inc pcrx free report announce supplemental new drug application snda exparel use nerve block regional analgesia be discuss fda anesthetic analgesic drug product advisory committee aadpac meeting be schedule be hold feb final response fda regard approval snda be expect apr read more pacira exparel snda be review fda advisory committee bayer oncology deal loxo bayer enter collaboration agreement loxo company focuse development highly selective medicine patient genetically defined cancer deal see bayer shell see company collaborate global development loxo highly selective trk inhibitor larotrectinib loxo patient trk fusion cancer agreement term include upfront payment loxo receive achievement certain regulatory commercial milestone additional milestone related loxo development cost be split equally company company co promote unite state loxo receive tiered double digit royalty net sale sale milestone totale ex territory larotrectinib be schedule be file fda approval late early janssen biotech licensing deal zymework janssen biotech johnson johnson jnj free report company have enter licensing agreement zymework development next generation bispecific antibody therapeutic deal janssen get worldwide royalty bearing license research develop commercialize bispecific antibody used zymework azymetric efect platform zymework be entitle upfront payment development milestone commercial milestone payment well tiered royalty potential sale janssen also have option add more bispecific program deal mean additional money zymework johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here chmp positive merck drug merck mrk free report get positive opinion chmp prevymis recently gain approval unite state merck be seek eu approval prevymis prevention cytomegalovirus cmv reactivation disease adult cmv seropositive recipient allogeneic hematopoietic stem cell transplant hsct chmp give positive opinion chance gain approval look high decision regard eu approval be expect month read more merck get chmp nod infection candidate prevymis update datum bristol myer immuno oncology combination bristol myer squibb bmy free report announce update result combination opdivo bms selective once daily oral ido inhibitor ongoing phase iia dose escalation expansion study study show maximum tolerate dose combination be mg mg dose be determine be recommend dose base safety pharmacodynamic datum moreover company say encourage response be observed heavily pre treat patient advanced cancer objective response rate orr disease control rate dcr be respectively bladder cancer cohort orr dcr be respectively cervical cancer cohort bristol myer also announce expansion label blockbuster drug sprycel now be used treatment child ph chronic phase cp chronic myeloid leukemia cml bristol myer have gain year date compare rally industry belong cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock astrazeneca be merck decline last month bristol myer be glaxo decline see last pharma stock roundup here astrazeneca earning roche merck drug get fda nod next pharma world watch regulatory pipeline news pharma stock zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
158,BMY,nektar therapeutic nktr free report partner bristol myer squibb bmy free report announce positive interim datum dose escalation part phase ii study evaluate safety efficacy combination lead candidate nktr bristol myer opdivo nivolumab combination therapy be be evaluate treatment patient melanoma renal cell carcinoma small cell lung cancer nsclc datum study be present annual meeting society immunotherapy cancer sitc notably september last year nektar have enter clinical collaboration agreement bristol myer evaluate opdivo nktr combination therapy tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication phase ii study company share cost combination study equally nektar retain global commercial right nktr nektar share have significantly outperformed industry so far year stock have sky-rocket industry have increase pivot phase ii study be conduct total patient number dose cohort datum trial demonstrated positive response rate tumor type pd positive pd negative patient company report treatment discontinuation due adverse event importantly nktr be cd bias agonist opdivo be pd immune checkpoint inhibitor different complementary mechanism comprise combination regimen provide new treatment option cancer patient remind investor nektar be also conduct phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab propel study complement nektar ongoing pivot trial earlier nektar have enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio nektar therapeutic price nektar therapeutic price nektar therapeutic quotezack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
159,BMY,seattle genetic inc sgen free report announce fda approve expand indication lymphoma drug adcetris brentuximab vedotin company announce fda have approve adcetris treatment primary cutaneous anaplastic large cell lymphoma pcalcl cd express mycosis fungoide mf have receive prior systemic therapy notably approval be receive month action date set fda dec august fda grant priority review supplemental biologic license application bla file get adcetris approve primary cutaneous alcl mf be most common subtype cutaneous cell lymphoma ctcl be blood cancer skinadcetris be only market product seattle genetic drug be approve relapse hodgkin lymphoma relapse systemic anaplastic large cell lymphoma salcl patient suffering classical hodgkin lymphoma be high risk relapse progression post autologous hematopoietic stem cell transplantation auto hsct consolidation so far year share seattle genetic have increase compare industry gain latest approval be mainly base positive datum phase iii trial alcanza phase ii investigator sponsored trial patient cutaneous cell lymphoma ctcl interestingly alcanza study achieve primary secondary endpoint study show ctcl patient treat adcetris have superior outcome primary secondary endpoint compare patient control arm be treat methotrexate bexarotene standard care agent go forward expand label further boost sale drug evidently sale drug third quarter grow year year furthermore seattle genetic be develop drug more clinical study key study include evaluation cell lymphomas hodgkin lymphoma phase iii study be also evaluate adcetris frontline mature cell lymphomas again drug be be study combination bristol myer squibb company bmy free report opdivo relapse refractory hodgkin lymphoma however adcetris face competition other drug include merck co inc mrk free report keytruda be recently approve lymphoma indication zack rank stock considerseattle genetic carry zack rank hold better rank health care stock same space be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
160,BMY,merck kgaa report third quarter earning american depositary share lower year figure net sale report quarter come mere organic sale growth be drive healthcare life science segment however unfavorable foreign exchange impact sale portfolio change have slight negative impact share company have perform almost line industry so far year company rise industry increase same period segment sale company report result segment healthcare life science performance material healthcare division record sale year year due negative impact foreign exchange rate negative impact portfolio change however organically sale segment be part strategy focus discovery development innovative pharmaceutical company divest biosimilar business fresenius company be also look divest consumer health business have register higher sale compare year period erbitux sale be year period due increase competition negative currency movement rebif sale come due organic decline negative currency impact gonal sale be due continue competitive pressure north america europe unfavorable currency impact sale life science segment amount primarily due growth business segment partially offset unfavorable foreign exchange effect moreover witness positive portfolio effect organic basis too segment witness sale growth process solution apply solution business record organic sale growth research solution business register organic growth performance material sale be however organically segment witness decline sale other updatein august company receive approval mavenclad europe treatment relapse multiple sclerosis ms meanwhile nice recommend approval erbitux squamous cell carcinoma head neck be follow recommendation approval mavenclad unite kingdom ms november merck kgaa be evaluate lead immuno oncology candidate avelumab number phase iii study several cancer indication partnership pfizer inc pfe free report september candidate receive approval treatment metastatic merkel cell carcinoma mmcc europe japan tradename bavencio first half bavencio receive approval mmcc advanced bladder cancer unite state however bristol myer squibb company bmy free report opdivo roche hold ag rhhby free report tecentriq be available market treatment bladder cancer outlook maintainedmerck kgaa have maintain guidance company expect net sale lower end range due appreciation euro dollar merck kgaa price consensus ep surprise merck kgaa price consensus ep surprise merck kgaa quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
161,BMY,exelixis inc exel free report ipsen announce positive detailed result pivotal phase iii celestial study cabometyx cabozantinib demonstrate significant overall survival benefit patient previously treat advanced hepatocellular carcinoma hcc celestial study meet primary endpoint cabozantinib provide statistically significant clinically meaningful improvement versus placebo overall survival os median os be month cabometyx compare month placebo median progression free survival pfs more double month cabometyx compare month placebo trial show disease control partial response stable disease be achieve cabometyx group compare placebo group company plan present result symposium san francisco later week remind investor cabometyx be already approve unite state treatment patient advanced renal cell carcinoma rcc have receive prior angiogenic therapy december fda approve label expansion cabometyx treatment previously untreated rcc approval come back positive result randomize phase ii trial cabosun first line kidney cancer result demonstrated statistically significant clinically meaningful improvement pfs versus pfizer inc pfe free report sutent exelixis share price have increase year compare industry gain hcc be most common form liver cancer accounting more case unite state hence be dire need bring new treatment option exelixis plan submit supplemental new drug application fda first quarter cabometyx rake strong sale first month courtesy increase demand drug potential approval further boost sale drug exelixis have also initiate phase ib study investigator sponsored cabometyx combination bristol myer squibb company bmy free report opdivo nivolumab opdivo yervoy patient suffering genitourinary tumor include bladder cancer rcc exelixis have also inked agreement bristol myer squibb roche hold ag rhhby free report develop cabozantinib combination immunotherapy agent exelixis inc price exelixis inc price exelixis inc quote zack rankexelixis sport zack rank strong buy see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
162,BMY,focus week be annual jpmorgan healthcare conference several biotech pharma company provide preliminary look result also provide pipeline update well outlook recap week most important storieskey takeaway jpmorgan healthcare conference several pharma company be present annual jpmorgan healthcare conference largest most informative healthcare investment symposium industry key update pfizer pfe free report say expect be rich datum delivery year bristol myer squibb company bmy free report also provide look pipeline include opportunity opdivo company also say business development remain important priority focus be deal make sense financial perspective asset technology be strategically align priority be potentially merck mrk free report be also lookout business development deal exercise financial discipline company say be look opportunity licensing deal bolt acquisition add drug technology address unmet medical need read more key takeaway pfizer other drug stock healthcare conference allergan be also present conference preliminary financial outlook read more allergan sale guidance lower expect glaxosmithkline gsk free report meanwhile be look strengthen pharma pipeline prioritize development capital focus core respiratory hiv infectious disease potential therapy immuno inflammation oncology area glaxo be zack rank buy stock see complete list today zack rank strong buy stock here nordisk go public ablynx proposal nordisk nvo free report confirm be look acquire belgium base biopharma company ablynx nordisk have initially propose acquire ablynx share cash however company come back revise offer ablynx reject first proposal nordisk latest offer include upfront cash payment share contingent value right cvr worth share total equity valuation approximately offer too have be reject ablynx company board announce proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity currently be rumor additional bidder eu approval caplacizumab well change scenario far nordisk be concern acquisition make sense caplacizumab be good fit company hematology portfolio deal also give boost nordisk pipeline especially give continue pricing pressure diabetes care particularly unite state read more nordisk confirm bid ablynx face rejection sanofi regeneron boost investment dupixent cemiplimab sanofi sny free report partner regeneron have decide boost investment development cemiplimab pd antibody oncology dupixent il il pathway block antibody type allergic disease base decision investment cemiplimab shoot least increase approximately initial agreement company contribute equally cemiplimab be be study monotherapy well combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas regulatory application cemiplimab advanced cutaneous squamous cell carcinoma be schedule be submit european union unite state first quarter meanwhile dupixent currently approve eczema have potential be evaluate additional indication include chronic obstructive pulmonary disease peanut allergy grass allergy patient have multiple allergic condition be addition ongoing development pediatric atopic dermatitis pediatric asthma eosinophilic esophagitis nasal polyposis regeneron sanofi be currently seek fda approval dupixent uncontrolled persistent asthma patient least year old candidate benefit additional investment be regn il antibody potential atopic dermatitis asthma chronic obstructive pulmonary disease development update merck merck provide late stage datum pd therapy keytruda monotherapy surgically resect high risk melanoma keytruda meet primary endpoint recurrence free survival rfs merck also announce fda have accept regulatory application doravirine investigational nucleoside reverse transcriptase inhibitor nnrti treatment hiv infection adult response agency be expect oct fda also grant breakthrough therapy designation eisai lenvima lenvatinib combination keytruda treatment patient advanced metastatic renal cell carcinoma rcc breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint read more merck keytruda combo get breakthrough therapy status merck stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock johnson johnson jnj free report be pfizer decline last month bristol myer be glaxo decline see last pharma stock roundup here allergan announce job cut pfizer inks deal next pharma world watch usual pipeline regulatory update zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
163,BMY,expect bristol myer squibb company bmy free report beat expectation report fourth quarter result feb market open bristol myer share have increase past year industry record increase bristol myer track record have be mixed so far company deliver positive earning surprise last quarters miss expectation twice average positive earning surprise last quarters be last report quarter bristol myer deliver negative surprise let see thing be shape quarter factor playbristol myer blockbuster immuno oncology drug opdivo be expect continue primary sale driver fourth quarter drug be already approve multiple cancer indication past quarters drug receive approval line extension be expect boost sale moreover december opdivo label be expand adjuvant therapy completely resect melanoma fda approval merck mrk free report keytruda first line treatment metastatic squamous nsclc have lower expect impact third quarter sale zack consensus estimate fourth quarter keytruda sale be peg flat year actual figure january european commission approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma fda have approve drug indication july zack consensus estimate drug sale fourth quarter be november bristol myer announce fda have approve line extension orencia pediatric patient ph chronic myeloid leukemia chronic phase label expansion include psoriatic arthritis july new administration option approve june be expect fuel growth drug register growth previous quarter zack consensus estimate orencia sale be other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter actual figure company be develop key drug opdivo monotherapy well combination therapy several tumor type multiple study label expansion application review unite state expect investor focus update related opdivo conference call likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price consensus bristol myer squibb company price consensus bristol myer squibb company quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter alexion pharmaceutical inc alxn free report be schedule release result feb company have earning esp zack rank see complete list today zack rank stock here anthera pharmaceutical inc anth free report be expect release result feb company have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
164,BMY,seattle genetic inc sgen free report be company focuse development therapy target treatment cancer company have only market product adcetris approve several indication past year seattle genetic share price have be trading industry stock have lose increase broader industry adcetris have be perform well begin prompt company raise guidance drug sale year moreover prospect drug receive boost line extension primary cutaneous anaplastic large cell lymphoma pcalcl cd express mycosis fungoide mf november moreover collaboration takeda pharmaceutical global development adcetris be also encourage seattle genetic earn royalty payment be entitle milestone payment june company announce encourage datum phase iii study echelon evaluate adcetris front line classical hodgkin lymphoma datum study show adcetris achieve statistically significant improvement modify progression free survival versus standard care supplemental biologic license application be submit fda base datum november phase iii study echelon be evaluate drug front line cd express mature cell lymphoma datum be expect study year apart adcetris company have adc candidate novel immuno oncology candidate be be evaluate early mid stage study phase ib study be evaluate pipeline candidate enfortumab vedotin combination bristol myer bmy free report opdivo roche hold ag rhhby free report tecentriq however dependence single product be concern company decline sale unfavorable response label expansion study affect stock moreover label expansion merck co inc mrk free report keytruda lymphoma indication march have increase competition adcetris wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
165,BMY,qiagen qgen free report ipsogen jak rgq pcr kit ipsogen jak assay receive fda approval additional use diagnosis neoplasms mpns cancer group blood cell bone marrow do not mature become healthy cell fda clearance now cover additional type mpn essential thrombocythemia primary myelofibrosis notably ipsogen jak assay be available europe other market management assay make simple hematologist oncologist follow recommend diagnostic testing algorithms international guideline patient suspect have mpns company be consistently try enhance molecular diagnostic segment be highest revenue grosser last report quarter notably segment contribute total revenue regard qiagen recently announce signing collaboration agreement diasorin post collaboration qiagen quantiferon tb diagnostic test be available diasorin liaison portfolio fully automate analyzer cancer diagnosis market too company have make several development recent time last august qiagen partner clinical genomic implement paxgene blood ccfdna tube sample collection clinical genomic colvera colorectal cancer recurrence assay june company have receive worldwide license biomarker be used identify patient have benefit immune oncology therapy cancer treatment also company collaborate global company bristol myer squibb company bmy free report utilization next generation sequence technology develop gene expression profile same month accord report market market cancer tumor profile market be estimate reach value cagr investor keen investing molecular diagnostic space major player look forward be myriad genetic mygn free report genomic health ghdx free report wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
166,BMY,be eventful year pharma biotech stock industry face challenge drug pricing scrutiny pricing pressure increase competition concern regard amazon interest enter healthcare arena fewer expect acquisition deal major pipeline setback be positive development well be significant surge fda approval investor appear more comfortable drug pricing controversy innovation win day fda grant approval gene therapy cancer well rare form blindness tax reform be also expect work sector favor merger acquisition expect pick come quarters keep mind here be look key takeaway presentation make major pharma biotech stock annual morgan healthcare conference largest most informative healthcare investment symposium industry pfizer inc pfe free report pharmaceutical giant pfizer expect be rich datum delivery year company focus be therapeutic area include oncology inflammation immunology vaccine rare disease internal medicine immuno oncology portfolio focus remain mainly drug combination bavencio variety pfizer target agent first half year company present late stage datum bavencio second line small cell lung cancer vyndaqel cardiomyopathy regulatory submission be expect xtandi metastatic castration resistant prostate cancer parp inhibitor talazoparib breast cancer second half year see company present phase iii datum rivipansel sickle cell tanezumab pain company also have couple pdufa date xeljanz ulcerative colitis first indication outside rheumatology lorlatinib second line small cell lung cancer pfizer be zack rank hold stock company share be last year compare gain record industry belong celgene corporation celg free report biotech company celgene announce preliminary result well outlook healthcare conference celgene also be present significant amount datum year include revlimid rituxan relapse refractory follicular lymphoma otezla scalp psoriasis several study initiation be also expect year moreover company expect submit supplemental new drug application snda fda revlimid combination bortezomib dexamethasone rvd patient newly diagnosed multiple myeloma ndmm new drug application nda fedratinib myelofibrosis snda otezla behçet disease meanwhile fda decision be expect year ozanimod relapse multiple sclerosis rm once daily formulation otezla company say continue invest business development celgene be zack rank stock company share be last year compare gain record industry belong bristol myer squibb company bmy free report bristol myer pipeline represent several opportunity long term growth company provide update blockbuster drug opdivo be expect drive mid term growth small cell lung cancer renal cell carcinoma rcc hepatocellular carcinoma gastric cancer be area represent commercial potential excess be disease area high prevalence high unmet medical need low survival rate bristol myer have several datum readout opdivo plan company immuno oncology portfolio have several early stage candidate late stage asset relatlimab lag bms bms ido company say business development remain important priority focus be deal make sense financial perspective asset technology be strategically align priority be potentially bristol myer be zack rank hold stock company share be last year merck mrk free report merck too business development remain key priority company say be look opportunity licensing deal bolt acquisition add drug technology address unmet medical need merck provide outlook february company say headwind remain form competitive pressure drug zostavax zepatier zetia vytorin still feel impact generic competition however keytruda represent significant growth opportunity drug be several study label expansion combination use moreover company pipeline oncology asset novel vaccine select hospital specialty product also provide scope long term growth merck be also zack rank stock see complete list today zack rank strong buy stock here company share be last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
167,BMY,exelixis inc exel free report announce amendment protocol phase ib trial cabozantinib combine roche holding rhhby free report tecentriq patient locally advanced metastatic solid tumor amendment be new expansion cohort trial cohort include include patient nsclc crpc addition previously include patient renal cell carcinoma rcc urothelial carcinoma uc primary objective expansion stage trial be determine objective response rate cohort cohort now include follow patient advanced squamous nsclc defined tumor genetic alteration egfr alk ro braf have not receive prior therapy immune checkpoint inhibitor patient nsclc defined tumor genetic alteration have progressed follow treatment immune checkpoint inhibitor patient uc have progressed follow treatment immune checkpoint inhibitor patient crpc have previously receive enzalutamide abiraterone acetate experience radiographic disease progression soft tissue multicentre phase ib open label study be divide part dose escalation phase expansion cohort phase main objective be calculate optimal dose schedule daily oral administration cabozantinib trial begin enrolment expansion cohort once recommend dose schedule be determine anticipate occur first half exelixis stock have rally massive last year compare industry gain april tablet formulation cabozantinib cabometyx be approve unite state treatment patient advanced renal cell carcinoma rcc have receive prior angiogenic therapy cabometyx deliver strong sale first month underlie increase demand drug new patient market share second line set increase recent fda approval cabometyx treatment previously untreated advanced rcc further boost demand drug demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus current standard care pfizer inc pfe free report sutent apart roche exelixis also inked agreement bristol myer squibb bmy free report jointly develop cabozantinib collaboration immunotherapy agent exelixis collaborate bristol myer evaluate cabozantinib combination opdivo alone yervoy phase iii trial first line rcc potentially other tumor type include hcc bladder cancer company have initiate phase iii trial checkmate july evaluate opdivo combination cabometyx opdivo yervoy combination cabometyx versus sutent patient previously untreated advanced metastatic rcc competition stiffen bit fda accept bristol myer supplemental biologic license application application include priority review opdivo yervoy treat intermediate poor risk patient advanced rcc action date apr expect exelixis ride high performance cabometyx zack rankexelixis flaunt zack rank strong buy see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
168,BMY,seattle genetic inc sgen free report announce today fda have accept filing supplemental biologic license application sbla label expansion lymphoma drugadcetris brentuximab vedotin grant priority review sbla be file adcetris combination chemotherapy frontline treatment patient advanced classical hodgkin lymphoma fda also set action date generally priority review designation fda be grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease adcetris be only market product seattle genetic drug be approve relapse hodgkin lymphoma relapse systemic anaplastic large cell lymphoma salcl suffering classical hodgkin lymphoma be high risk relapse progression post autologous hematopoietic stem cell transplantation auto hsct consolidation share seattle genetic have increase compare industry gain submission sbla be base positive result phase ii study call echelon june company have announce positive top line datum echelon study demonstrated adcetris achieve improvement modify progression free survival statistical significance compare standard care chemotherapy fact echelon study evaluate adcetris addition adriamycin vinblastine dacarbazine patient advanced classical hodgkin lymphoma prior treatment november fda approve expand indication lymphoma drug seattle fda have approve adcetris treatment primary cutaneous anaplastic large cell lymphoma pcalcl cd express mycosis fungoide mf have receive prior systemic therapy notably approval be receive month action date set fda dec furthermore seattle genetic be develop adcetris more clinical study key study include evaluation cell lymphomas hodgkin lymphoma phase iii study be also evaluate adcetris frontline mature cell lymphomas drug be be study combination bristol myer squibb company bmy free report opdivo relapse refractory hodgkin lymphoma well however adcetris face competition other drug include merck co inc mrk free report keytruda be approve lymphoma indication march seattle genetic inc price seattle genetic inc price seattle genetic inc quotezack rank stock considerseattle genetic carry zack rank hold better rank health care stock be sucampo pharmaceutical carry zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise last quarters average beat share price company have surge investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
169,BMY,hampton nj base celldex therapeutic inc cldx free report be company develop immunotherapy technology other cancer target biologic company be still development stage do not have market product portfolio company be develop most advanced candidate glembatumumab vedotin triple negative breast cancer metastatic melanoma stock carry zack rank buy look good investment now see complete list today zack rank strong buy stock here let see reason stock prove be valuable addition portfolio favorable share price movement share celldex have rise past month industry register loss moreover company be trading cheaper price book ratio compare industry company be also better position pay obligation current ratio be rise estimate fact celldex earning performance have be pretty impressive company exceed expectation past quarters meeting same once average positive earning surprise last quarters be moreover loss estimate have narrow past day revenue be expect grow pipeline progress celldex most advanced pipeline candidate glembatumumab vedotin be be investigate phase iib study triple negative breast cancer separate phase ii study metastatic melanoma datum breast cancer study be expect second quarter moreover celldex be also evaluate glembatumumab combination varlilumab checkpoint inhibitor arm include bristol myer squibb company bmy free report opdivo merck co inc mrk free report keytruda melanoma study glembatumumab perform well single agent set apart glembatumumab vedotin celldex have several promising candidate pipeline include varlilumab be evaluate phase ii combination opdivo various cancer cdx cdx phase ii multiple solid tumor collaboration citn cdx phase advanced renal cell carcinoma other acquisition collaboration celldex have collaboration agreement bristol myer provide company strong partner expertise field immuno oncology strong financial also acquisition privately hold development stage company kolltan pharmaceutical strengthen immuno oncology pipeline add unique platform antibody target receptor tyrosine kinase celldex be develop candidate several cancer indication oncology market be highly competitive immuno oncology attract lot interest company juno therapeutic inc bluebird other be involved development immuno oncology treatment zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
170,BMY,share clovis oncology inc clvs free report have be roll small biotech company be so far year outperform increase register industry period let analyze factor have drive stock rally so far company only market drug rubraca have receive accelerate approval december drug be parp inhibitor be approve monotherapy treatment advanced ovarian cancer third later line setting drug see slower adoption third quarter competition tesaro tsro free report zejula astrazeneca azn free report lynparza sale grow sequentially company have also make effort increase patient awareness accessibility drug company have new patient therapy period drug register sale first month patient be select therapy base fda approve companion diagnostic rubraca datum confirmatory study ariel be conduct convert accelerate approval continue approval rubraca show promising progression free survival patient company file supplemental new drug application snda fda october base ariel datum expand rubraca label include second line later maintenance indication advanced ovarian cancer company believe label expansion increase patient population least time fda have accept snda priority review dec decision be expect april next year meanwhile other phase iii confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy rubraca be also review eu comparable ovarian cancer indication approval be expect eu first quarter clovis be establish commercial infrastructure same clovis be also develop rubraca other cancer indication monotherapy combination other agent separate study be evaluate rubraca combination roche tecentriq gynecologic cancer bristol myer squibb company bmy free report opdivo ovarian breast prostate cancer clovis oncology inc price clovis oncology inc price clovis oncology inc quoteclovis have zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
171,BMY,portola pharmaceutical inc ptla free report recently announce fda have accept resubmit biologic license application bla reversal agent factor xa inhibitor andexxa andexanet alfa decision regulatory body be expect feb andexxa have be develop patient treat direct indirect factor xa inhibitor reversal anticoagulation be need due life threaten uncontrolled bleed notably andexxa be also review eu marketing application file third quarter portola share have significantly outperformed industry so far year stock have soar compare broader industry decrease resubmission include additional information request fda complete response letter crl issue portola august last year letter fda have request information related product manufacturing have also ask more datum support inclusion direct factor xa inhibitor lixiana edoxaban indirect factor xa inhibitor lovenox enoxaparin product label remind investor bla be base positive datum phase iii annexa study evaluate safety efficacy andexxa reverse anticoagulant activity factor xa inhibitor xarelto rivaroxaban johnson johnson inc jnj free report eliquis apixaban bristol myer squibb company bmy free report older healthy volunteer significantly andexxa enjoy orphan drug status unite state company press release more patient treat oral factor xa inhibitor be admit hospital due excessive bleed have also be estimate more patient take injectable factor xa inhibitor lovenox unite state benefit antidote year currently approve antidote factor xa inhibitor yet be high unmet need same market go ahead expect investor focus remain further detail andexxa regulatory aspect portola pharmaceutical inc priceportola pharmaceutical inc price portola pharmaceutical inc quotezack rank stock considerportola currently carry zack rank hold better rank stock pharma sector be acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here acadium loss estimate narrow last day company come positive earning surprise trail quarters average beat simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
172,BMY,gilead science inc gild free report announce fda have grant priority review company new drug application nda investigational fix dose combination bictegravir mg bic novel investigational integrase strand transfer inhibitor insti emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv infection nda be file jun fda have set target action date prescription drug user fee act pdufa feb marketing application bic ftc taf be also review european union be validate european medicine agency ema july potential approval be expect toboost gilead hiv gilead be dominant player hiv market impressive portfolio same newly launch taf base product genvoya odefsey descovy be perform well strong adoption eu genvoya have already become most prescribe regimen treatment naïve switch patient launch nov taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy genvoya be now company bestselling hiv product surpass truvada atripla fourth quarter genvoya be now company bestselling hiv product treatment naïve patient share gilead expect use truvada pre exposure prophylaxis prep continue boost sale hiv franchise go forward particularly strong uptake truvada use pre exposure prophylaxis set also boost sale company see significant uptick prep usage estimate patient used truvada end second quarter meanwhile gilead stock have gain only year so far industry gain uptake hiv franchise help company combat persistent decline hcv franchise due competitive pressure hcv business see improvement second quarter hcv franchise be boost fda approval vosevi hcv patient start first half be better expectation see gradual decline second half due increase competition harvoni sovaldi epclusa have be face competition abbvie abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza competition well pricing pressure intensified further launch merck mrk free report zepatier zack rank gilead currently carry zack rank buy see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
173,BMY,second quarter earning season be draw close most major company have report result week company endo mylan myl free report nordisk perrigo prgo free report present second quarter result recap week most important storiesa look earning result mylan second quarter result be disappointing company miss earning revenue cut outlook also read mylan miss earning sale lower view mylan have push back major product launch reflect ongoing challenge uncertain regulatory environment product launch include generic version advair copaxone escalate price erosion generic market remain major challenge meanwhile mylan get subpoena department justice doj late jul seek information relate opioid manufacture market sell company jan dec mylan have lose value year date versus decline industry perrigo second quarter result be better expect company raise outlook also read perrigo earning sale top view raise nordisk also top earning estimate raise outlook meanwhile endo top earning revenue estimate lower outlook also read endo beat earning sale guidance lower endo stock have lose value year date versus decline industry perrigo be zack rank hold stock see complete list today zack rank strong buy stock here esperion positive mid stage datum esperion espr free report share be positive top line datum study evaluate company bempedoic acid zetia ezetimibe combination lipitor versus placebo patient mid stage triplet oral therapy study meet primary endpoint greater ldl lower compare placebo company intend conduct additional study next year expect file fda approval combination first quarter zynerba plunge star fail shine zynerba see share plunge disappointing mid stage datum company experimental cannabinoid treatment zyn result double blind placebo controlled star study adult epilepsy patient focal seizure show dose zyn fail meet endpoint compare placebo focus have now shift couple more study be conduct zyn osteoarthritis top line datum expect aug fragile syndrome top line datum expect sep valeant get crl eye drop valeant vrx free report report second quarter result week also read valeant beat earning sale line trim view get complete response letter crl fda new drug application nda vyzulta latanoprostene bunod ophthalmic solution company be look gain approval use intraocular pressure lower single agent eye drop patient open angle glaucoma ocular hypertension safety efficacy concern be raise fda crl refer current good manufacturing practice cgmp inspection bausch lomb manufacturing facility tampa fl valeant be work resolve manufacturing quality issue tampa plant be work agency determine path forward cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock bristol myer bmy free report be glaxo lose last month be merck mrk free report decline see last pharma stock roundup here mixed result pfizer bristol myer announce io deal next pharma world watch usual pipeline regulatory update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
174,BMY,seattle genetic inc sgen free report report loss cent share second quarter narrower zack consensus estimate loss cent wider year loss cent share revenue come year year primarily back strong sale adcetris revenue also beat zack consensus estimate seattle genetic share price have gain year date compare industry rise same period quarter detailseattle genetic top line comprise product revenue collaboration license agreement revenue royalty company only market product adcetris generate revenue year year collaboration license agreement revenue increase almost collaboration revenue include fee earn company agreement takeda pharmaceutical company ltd adcetris other adc collaboration royalty revenue increase year year attributable international sale adcetris takeda pharmaceutical co research development expense be year year also selling general administrative sg expense increase cost be high primarily due investment vadastuximab talirine enfortumab vedotin adcetris other pipeline development outlook company raise outlook net sale adectris canada range previously pipeline updateseattle genetic continue work expand adcetris label further phase iii trial note company report positive datum alcanza phase iii study recently submit supplemental biologic license application bla june include cutaneous cell lymphoma label company announce top line datum jun phase iii echelon study frontline classical hodgkin lymphoma adcetris show statistically significant improvement modify progression free survival pfs seattle generic takeda be plan submit application regulatory approval territory moreover top line datum echelon study frontline cd express mature cell lymphoma be company be also evaluate adcetris combination bristol myer squibb bmy free report opdivo relapse hodgkin lymphoma adcetris receive conditional approval canada hodgkin lymphoma high risk relapse addition company expect initiate pivotal phase ii study enfortumab vedotin patient metastatic urothelial cancer patient late also quarter diffuse large cell lymphoma candidate polatuzumab vedotin receive prime designation europe be be evaluate combination roche hold ag rhhby free report rituxan however company discontinue phase iii cascade study vadastuximab talirinein frontline older patient acute myeloid leukemia jun base higher rate death observed study company second quarter loss be narrower estimate sale also beat expectation positive news announce adcetris study investor focus update adcetris label expansion increase net sale guidance adcetris be also encourage seattle genetic inc price consensus ep surprise seattle genetic inc price consensus ep surprise seattle genetic inc quoteseattle genetic currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
175,BMY,roche hold ag rhhby free report report sale chf first half year period core earning come chf share first half share roche have perform better zack classify industry year so far fact stock gain time frame compare gain industry company report result division pharmaceutical diagnostic growth rate mentioned be year year basis constant exchange rate sale pharmaceutical division increase drive strong growth tecentriq ocrevus perjeta be partially offset lower sale tarceva tamiflu pegasys diagnostic division sale climb primarily back strong business first half detailherceptin sale improve due increase demand brazil additional reimbursement approval broader use china perjeta sale grow follow increase demand neoadjuvant metastatic setting europe international market sale kadcyla be drive increase demand international market meanwhile sale avastin be strong international region especially china sale grow due broader market penetration lung colorectal cancer set however sale drop due increase use new immunotherapy agent lung cancer set overall sale decline sale rituxan mabthera contribute top line growth oncology well immunology segment growth gazyva gazyvaro be witness europe increase competition chronic lymphocytic leukemia recently launch drug tecentriq bladder cancer alecensa lung cancer be encourage start initial uptake have be strong tecentriq ocrevus alecensa contribute chf new sale contribute half division growth performance immunology franchise be drive increase sale actemra roactemra strong uptake esbriet xolair increase use actemra roactemra single agent subcutaneous formulation be key growth driver globally however sale tarceva decline due grow use other therapeutic option sale xeloda continue be hit generic competition sale tamiflu also decline revenue diagnostic division climb back solid performance centralised point care solution unit be turn propel tissue diagnostic molecular diagnostic also perform impressively however diabetes care sale decline sale continue be impact challenge market condition particularly north america outlook raisedroche now expect sale grow mid single digit prior guidance low mid single digit company expect core earning grow tandem sale company intend further increase dividend local currency roche hold ag revenue ttm roche hold ag revenue ttm roche hold ag quotepipeline progressroche continue expand cancer immunotherapy drug tecentriq bladder lung cancer label tecentriq receive accelerate approval fda treatment person locally advanced metastatic urothelial carcinoma be not eligible cisplatin chemotherapy apr lucentis be approve fda monthly treatment form diabetic retinopathy actemra roactemra subcutaneous injection be approve fda treatment giant cell arteritis fda further approve rituxan hycela rituximab hyaluronidase human subcutaneous injection treatment adult specific form blood cancer other hand new tablet formulation esbriet be approve european commission treatment mild moderate idiopathic pulmonary fibrosis ipf fda have already approve same early roche also present positive result emicizumab patient suffering haemophilium phase iii study haven meanwhile study show roche ocrevus significantly reduce risk relapse primary progressive multiple sclerosis rm ppms patient require mobility aids versus comparator however phase iii study imvigor evaluate tecentriq patient locally advanced metastatic urothelial cancer disease progressed treatment platinum base chemotherapy previously treat do not meet primary endpoint overall survival compare chemotherapy takeroche result first half be impressive sale be boost new product launch tecentriq ocrevus sale tecentriq be mainly drive strong uptake metastatic bladder cancer metastatic small cell lung cancer nsclc label expansion drug be expect boost sale further successful launch ocrevus treatment form multiple sclerosis have also boost topline base strong performance first half company also raise sale guidance however sale avastin tarceva continue decline generic competition xeloda also continue hurt sale note competition biosimilar loom large roche key drug herceptin avastin rituxan first biosimilar mabthera be already market company expect biosimilar herceptin end early note novartis ag nvs free report have already launch bisomilar version rituxan mabthera europe moreover roche be face stiff competition like merck co inc mrk free report keytruda bristol myer squibb company bmy free report opdivo immuno oncology space zack rankroche currently carry zack rank hold see complete list today zack strong buy rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
176,BMY,share procter gamble co pg free report increase post net sale surpass zack consensus estimate mastercard inc free report post revenue exceed zack consensus estimate increase year year bristol myer squibb co bmy free report report second quarter earning share surpass zack consensus estimate increase year period share anheuser busch inbev bud free report decline earning share decrease earn year quarter also lag zack consensus estimate
177,BMY,bristol myer squibb company bmy free report second quarter earning cent share beat zack consensus estimate cent increase year period bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotetotal revenue increase year year surpass zack consensus estimate strong sale opdivo eliquis drive top line report quarter note bristol myer share have decline so far year compare unfavorably industry increase quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase increase outside ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year melanoma drug yervoy contribute top line report quarter opdivo be approve multiple cancer indication generate revenue year period however performance key drug virology unit be disappointing sale baraclude decline reyataz sustiva franchise deteriorate year year respectively nevertheless sale eliquis be report quarter year year bristol myer have partnership pfizer inc pfe free report eliquis bristol myer hcv franchise contribute top line orencia revenue be multiple myeloma drug empliciti record sale year year research development expense quarter increase due charge related license asset acquisition marketing selling administrative expense fall gross margin be quarter compare year quarter due change product mix recognition impairment charge related expect sale manufacturing operation sword ireland feb company repurchase common stock worth accelerate share repurchase asr agreement asr funding be do combination debt cash part company exist share repurchase authorization pipeline updatebristol myer key drug opdivo receive approval label expansion locally advanced unresectable metastatic urothelial carcinoma adult failure prior platinum contain therapy squamous cell cancer head neck adult progress platinum base therapy eu quarter supplemental biologic license application sbla label extension opdivo include hepatocellular carcinoma hcc prior sorafenib therapy update dose currently approve monotherapy indication be review earning guidance revisedbristol myer have raise lower end earning expectation company now project earning range share old guidance zack consensus estimate earning be peg takebristol myer deliver yet strong quarter top bottom line beating expectation robust sale drug opdivo eliquis yervoy quarter drive top line revise guidance be also encourage meanwhile be positive bristol myer effort develop pipeline bristol myer carry zack rank hold couple better rank stock health care sector be enzo inc sanofi sny free report enzo sport zack rank strong buy sanofi carry zack rank buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day earning estimate sanofi have decrease cent share second quarter increase full year last day more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
178,BMY,gilead science inc gild free report report result second quarter earning revenue surpass expectation second quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue report quarter be top zack consensus estimate however revenue decline year year share be market hour trading follow release second quarter result however share gilead have underperform zack classify industry year so far stock gain period compare industry gain hiv impress yet againproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi recently launch epclusa be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch various location sale harvoni decline year year report quarter decline be mainly due lower sale europe further sovaldi sale record steep year year decline epclusa garner sale report quarter lower prior quarter figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due purchase nimbus apollo inc food drug administration fda priority review voucher other hand selling general administrative sg expense be roughly flat adjust product gross margin be year period guidance updatedbased better expect performance first half specifically gilead raise guidance gilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project cent earlier projection cent dividend share gilead declare cash dividend cent share common stock third quarter dividend be payable sep stockholder record close business sep second quarter company paid cash dividend repurchase share gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteour better expect performance second quarter be drive positive trend hcv business better expect result hcv business market share particularly due rapid uptake epclusa hcv franchise be boost fda approval vosevi hcv patient start first month be better company expectation company however expect gradual decline second half year market start due increase competition note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza other meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set be alsoexpect toboost sale company see significant uptick prep usage estimate patient used truvada end second quarter however gilead lose exclusivity viread country outside impact sale zack rank key pickgilead currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report currently sport zack rank strong buy see complete list today zack rank stock here exelixis have deliver positive earning surprise trail quarters average beat exelixis share have soar so far year more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
179,BMY,aveo pharmaceutical inc aveo free report report second quarter adjust loss cent share exclude change fair value warrant liability narrower zack consensus estimate cent well year loss cent however report loss quarter be cent share share company rise more wednesday fact aveo share price movement show stock have significantly outperformed industry year date aveo have surge period compare industry gain period aveo do not have approve product portfolio company top line mainly comprise collaboration revenue milestone other payment total collaboration revenue second quarter be approximately compare year quarter quarterly development expense be however general administrative expense increase year year pipeline updatesaveo have make significant progress lead pipeline candidate tivozanib be currently review eu first line treatment advanced rcc jun committee medicinal product human use chmp recommend approval candidate final response approval status candidate be expect third quarter company also announce achievement enrollment target phase iii study tivo evaluate tivozanib june ahead prior deadline aug top line datum be expect first quarter study compare tivozanib bayer bayry free report nexavar patient refractory advanced renal cell carcinoma rcc datum study previously complete tivo study support regulatory application approval tivozanib first third line treatment rcc aveo pharmaceutical announce june phase ii study tinivo evaluate tivozanib combination bristol myer squibb bmy free report opdivo patient advanced rcc have be advanced phase ii study successful completion phase ii study establish tivozanib regimen mg daily day follow rest period week guidanceaveo expect present cash resource allow company fund plan operation second quarter positive chmp recommendation tivozanib be encourage expect investor focus remain tivo trial third line treatment patient refractory rcc trial be be conduct address overall survival concern tivo trial identify fda however aveo be heavily dependent partnership pipeline development ophthotech corporation opht free report terminate agreement develop tivozanib apr hiccup partnership development regulatory process lead candidate tivozanib pull stock significantly aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc quotezack rankaveo pharma carry zack rank buy see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
180,BMY,infinity pharmaceutical inc infi free report report loss cent share second quarter wider zack consensus estimate loss cent company have report loss cent year quarter infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc quotesince infinity do not have approve product portfolio company earn revenue form royalty license milestone payment well research development support fee paid partner infinity do not record revenue second quarter however record collaboration revenue year quarter related infinity previous collaboration agreement abbvie inc abbv free report infinity share price have increase year date compare industry gain quarter detailin report quarter expense plummet decline be mainly related decrease clinical development expense duvelisib addition company restructure activity general administrative expense be report quarter year quarter decrease be mainly due company restructure activity outlook expect net loss be range company anticipate end year end cash cash equivalent available sale security balance band moreover infinity expect exist cash cash equivalent jun be adequate fund company capital need first quarter pipeline updatecurrently infinity be evaluate ipi monotherapy combination bristol myer squibb company bmy free report opdivo nivolumab phase study patient advanced solid tumor company complete evaluation escalate monotherapy dose ipi range mg qd once daily have determine mg dose evaluation expansion component study selection mentioned dose be base pharmacokinetic pharmacokinetic analysis show ipi maintain full suppression pi gamma dose level further datum study also show ipi dose mg qd be well tolerate dose limit toxicity be observed subsequently monotherapy expansion component study be now available enrolment study evaluate safety activity ipi dose qd approximately patient meanwhile dose escalation evaluate ipi combination opdivo be currently ongoing company plan initiate combination expansion component study second half other hand company amend license agreement takeda oncology jul ipi amend agreement company longer have obligation pay takeda future royalty worldwide net sale selective inhibitor pi gamma include ipi lieu infinity issue unsecured convertible note takeda mature accrue interest annual rate wider expect loss second quarter be disappointing infinity receive huge setback abbvie terminate collaboration agreement development duvelisib hence expect investor focus pipeline progress upcoming quarters zack rank key pickinfinity currently hold zack rank hold better rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
181,BMY,week company pfizer pfe free report allergan agn free report teva teva free report report second quarter result pfizer report mixed quarter allergan top expectation teva however have tough quarter meanwhile bristol myer bmy free report announce immune oncology io focuse deal include acquisition recap week most important storiesa look earning result big company pfizer allergan teva report second quarter result week pfizer surpass earning estimate miss revenue raise concern company top line growth prospect prevnar enbrel sale decline quarter pfizer be face key loss exclusivity loe viagra later year lyrica end read more pfizer surpass earning estimate miss sale meanwhile allergan top earning sale estimate raise outlook well read more allergan earning sale top restasis sale teva share fall dismal quarter company miss earning sale reflect performance generic business continue deterioration venezuela generic business be hit accelerate price erosion lower volume mainly due customer consolidation higher competition delay new product launch teva lower outlook year slash dividend well company also expect exit market globe year end be cut headcount close actavis generic business deal teva have lose value year date versus decline industry abbvie drug get fda nod cgvhd johnson johnson jnj free report abbvie btk inhibitor imbruvica gain fda approval first cancer indication chronic graft versus host disease cgvhd adult failure more systemic line therapy make imbruvica first only approve treatment patient population mark sixth indication imbruvica stock have gain year date outperform rally industry belong bristol myer acquisition deal worth bristol myer announce be acquire ifm therapeutic venture backed biotech company work treatment modulate novel target innate immune system treat cancer autoimmunity inflammatory disorder acquisition bristol myer gain full right ifm preclinical sting stimulator interferon gene nlrp agonist program be focuse cancer sting agonist program include lead asset nlrp agonist program include potential first class pipeline candidate acquisition schedule close third quarter strengthen bristol myer immune oncology io pipeline deal see bristol myer shell upfront additional payment be make first product program achievement certain milestone additional milestone payment be make further product result program bristol myer sign io focuse deal week company sign clinical collaboration agreement clovis oncology immunotherapy opdivo be evaluate combination clovis parp inhibitor rubraca mid late stage study different type tumor meanwhile opdivo label be expand week treatment adult pediatric year older patient microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan accelerate approval be grant basis overall response rate orr duration response however note merck keytruda gain approval earlier year patient msi dmmr wider patient population merck label include patient solid tumor have progressed follow prior treatment have satisfactory alternative treatment option well colorectal cancer patient disease have progressed follow treatment certain chemotherapy drug ra drug fail get fda advisory panel support investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor fail get support fda arthritis advisory committee safety concern company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person fda be not require do so usually follow advice advisory panel consider safety concern raise panel agency well ask additional information grant approval pfizer drug get advisory panel support pfizer supplemental new drug application snda jak inhibitor xeljanz mg twice daily xeljanz xr mg once daily treatment adult patient active psoriatic arthritis psa get support fda arthritis advisory committee advisory panel vote favor approve propose dose xeljanz psa indication decision fda be dec xeljanz currently approve ra bring sale first half priority review astrazeneca btk inhibitor astrazeneca azn free report investigational btk inhibitor acalabrutinib be grant priority review fda company be look get drug approve use patient relapse refractory mantle cell lymphoma mcl have receive least prior therapy response agency be expect first quarter acalabrutinib be also give breakthrough therapy designation btd indication astrazeneca imfinzi also get btd week treatment patient locally advanced unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemoradiation therapy positive datum lilly migraine drug lilly lly free report present late stage datum investigational migraine drug lasmiditan say meet primary endpoint well key secondary endpoint result be consistent result present earlier late stage study lilly expect file fda approval second half lilly be zack rank buy stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock pfizer be lilly lose last month be astrazeneca gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch usual pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
182,BMY,exelixis inc exel free report report impressive result second quarter back increase cabometyx sale company post second quarter earning cent beating zack consensus estimate cent notably company have report loss cent share year quarter exelixis inc price ep surprise exelixis inc price ep surprise exelixis inc quotenet revenue come significantly year quarter revenue also surpass zack consensus estimate revenue be boost fda approval tablet formulation cabozantinib distinct capsule form brand name cabometyx apr treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy exelixis share price have increase year date compare industry gain quarter detailtotal product revenue be year quarter cabometyx generate net product revenue sequentially drive growth demand be attributable new patient start refill patient already therapy continue expansion prescriber base cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare year quarter report quarter research development expense decline primarily result increase clinical trial cost cost related cabosun start cost associate checkmate phase ib trial cabozantinib tecentriq locally advanced metastatic solid tumor be partially offset decrease cost related meteor personnel expense selling general administrative expense be drive increase headcount connect build support commercial organization increase legal cost increase consult outside service support marketing activity pipeline company continue focus cabometyx exelixis plan file supplemental new drug application snda cabozantinib treatment previously untreated patient advanced rcc third quarter base positive datum randomize phase ii trial cabosun independent radiology review committee have confirm primary efficacy endpoint result investigator assessed progression free survival pfs cabosun trial analysis committee cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death measure pfs first quarter exelixis inked agreement bristol myer squibb company bmy free report roche hold ag rhhby free report collaborate development cabozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate jul exelixis have also initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma uc rcc mar fda grant cabozantinib orphan drug designation treatment hcc phase iii trial celestial be currently ongoing patient advanced hcc company now expect complete second intermin analysis event second half meanwhile exelixis roche have agree revise revenue cost sharing arrangement other drug former portfolio cotellic roche also announce imspire trilogy evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma enrolled first patient jan imspire trial evaluate combination cotellic tecentriq versus merck co inc mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma be likely enroll first patient third quarter year expect total cost operate expense range guidance include cash cost expense related primarily stock base compensation expense expense be project increase second half due initiation combination study takeexelixis second quarter result be impressive earning sale beat estimate sequential increase cabometyx sale be positive company thereby underlie increase demand drug go forward expect investor further label expansion cabozantinib cotellic potential label expansion first line rcc significantly boost growth prospect zack rank key pickexelixis currently carry zack rank buy see complete list today zack strong buy rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
183,BMY,fda approve treatment last year have give approval drug so far include july key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month august new indication bristol myer opdivo bristol myer squibb bmy free report be look get label pd inhibitor expand use patient mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer crc prior oxaliplatin irinotecan base chemotherapy regulatory application be currently priority review response expect aug opidivo be currently approve wide range indication bring sale first half bristol myer have lose value year date ytd versus growth industry ra drug support fda panel fda arthritis advisory committee be meeting tomorrow discuss bla johnson johnson jnj free report investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person new treatment option have enter market last couple decade ra patient be still not adequately manage many left fewer therapeutic option due loss response available agent poor compliance due inconvenient dose earlier week fda have release briefing document meeting indicate lot emphasis be place safety profile drug especially imbalance cause death plivensia placebo approve plivensia enter pretty crowd market give presence drug humira actemra kevzara other once monthly dose schedule give advantage share have gain ytd outperform industry rally fda follow eu path give green signal abbvie maviret abbvie abbv free report also have important regulatory event come fda expect respond approval status company latest hepatitis virus hcv offer month maviret investigational pan genotypic regimen glecaprevir pibrentasvir be once daily ribavirin free treatment have potential provide faster path virologic cure major hcv genotype gt maviret represent blockbuster potential help abbvie gain major market share once approve launch note maviret gain eu approval just last week share abbvie have gain ytd outperform industry rally third time lucky dynavax heplisav be great week clinical stage immunology company dynavax technology corp dvax free report get favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote be third time lucky company have previously receive complete response letter heplisav nov other feb fda decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share shot positive panel vote be whopping ytd significantly outperform industry rally pfizer xeljanz be review fda advisory panelpfizer pfe free report have regulatory event month first be fda advisory panel meeting other pdufa date fda arthritis advisory committee be meeting aug discuss supplemental new drug application snda submit company jak inhibitor xeljanz xeljanz xr treatment adult patient active psoriatic arthritis efficacy safety datum benefit risk consideration be discuss panel xeljanz currently approve ra bring sale meanwhile fda be expect give response regard approval status pfizer besponsa recently gain approval eu approve besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less pfizer stock have gain ytd lag industry belong pfizer be zack rank hold stock see complete list today zack rank strong buy stock here other fda decision schedule month include response regard agio pharmaceutical inc agio free report partner celgene celg free report idhifa priority review relapse refractory acute myeloid leukemia aml idh mutation aug meanwhile fda be expect decide approval status valeant eye drug vesneo latanoprostene bunod ad treatment levodopa induced dyskinesia person parkinson disease aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
184,BMY,bristol myer squibb company bmy free report be new york base major producer distributor pharmaceutical other healthcare related product company key oncology product include opdivo sprycel yervoy recently launch empliciti other oncology company be focuse immunology cardiovascular drug orencia eliquis also market drug hbv hcv baraclude daklinza company virology portfolio comprise product reyataz sustiva franchise bristol myer be also active partnership front pursue strategic acquisition therapeutic area include immunoscience oncology fibrosis genetically defined disease however many peer bristol myer be face generic competition several key product moreover hiv hcv business be competitive pressure scenario investor focus remain company high profile immuno oncology drug opdivo apart usual top bottom line number bristol myer have mixed record earning surprise recent quarters company earning surpass expectation last quarters average positive surprise bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotecurrently bristol myer have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning bristol myer beat second quarter earning company report ep cent consensus call ep cent revenue revenue be also expectation bristol myer post revenue compare consensus estimate guidance bristol myer update earning outlook company expect earning range share zack consensus estimate earning stand share pre market trading share be more pre market trading check back later full bmy earning report later more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
185,BMY,total earning total healthcare market capitalization be revenue growth earning growth appear solid compare many other sector earning revenue beat ratio respectively look disappointing most notable player johnson johnson jnj free report be first major drug company report earning oct follow eli lilly company lly free report bristol myer squibb company bmy free report oct oct respectively other major drug company merck mrk free report pfizer pfe free report report oct oct respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance read healthcare etfs focus johnson johnson earning pfizer earning drug giant come earning beat line revenue earning share cent come couple cent zack consensus estimate revenue be line estimate year year basis earning share revenue rise respectively pfizer narrow revenue guidance range raise earning share guidance range merck earning focusmerck beat earning estimate miss revenue earning share come surpass zack consensus estimate improve year quarter revenue decline year year be zack consensus estimate merck raise revenue guidance earning share guidance year bristol myer earning focusbristol myer miss earning beat revenue report earning share cent couple cent estimate revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lilly earning focuseli lilly top zack consensus estimate front earning outpaced zack consensus estimate couple cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously etf string earning beat fail boost pharma etfs see rough trading past month have highlighted detail fund have zack etf rank hold high risk outlook powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month read lie store pharma etfs spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take nearly share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket johnson johnson pfizer bristol myer eli lilly account least share merck make asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose month want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
186,BMY,nektar therapeutic nktr free report share increase more nov report better expect third quarter result earning sale surpass estimate quarterly earning cent beat zack consensus estimate cent notably company report loss cent year quarter nektar share have significantly outperformed industry so far year stock have sky-rocket industry have register increase quarterly revenue substantially rise year quarter upside mainly be attribute massive increase license collaboration revenue top line also beat zack consensus estimate quarter top line comprise product sale royalty revenue cash royalty revenue license collaboration other revenue third quarter product sale tumble year however cash royalty revenue increase company report royalty revenue thereby register huge improvement third quarter compare year quarter uptrend be mainly back royalty revenue receive license agreement astrazeneca movantik shire plc adynovate license collaboration other revenue come compare year quarter nektar receive upfront payment eli lilly company development nktr amount have be recognize time research development expense climb primarily due investment pipeline include key candidate nktr nktr nktr general administrative expense be quarter review pipeline most advanced candidate company portfolio be onzeald currently accelerate assessment eu treatment adult advanced breast cancer have brain metastase nektar also initiate randomize phase iii confirmatory study attain onzeald compare single agent chemotherapy physician choice patient advanced breast cancer have brain metastase shortly positive result study support regulatory filing unite state apart onzeald candidate company immuno oncology portfolio be nktr september nektar announce initiation phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab phase ii study evaluate nktr potential combination treatment regimen bristol myer squibb bmy free report opdivo be also underway candidate be be examine tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication candidate nktr be be evaluate phase iii study treatment chronic pain july company report positive top line result oral human abuse potential hap study evaluate nktr assess opioid abuse potential compare oxycodone company be plan submit new drug application nda candidate april outlook updatednektar raise revenue outlook account upfront payment receive eli lilly company report quarter company now estimate revenue range compare project previously cash investment marketable security sep be comparison dec nektar continue expect cash year end approximately nektar therapeutic price consensus ep surprise nektar therapeutic price consensus ep surprise nektar therapeutic quotezack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
187,BMY,infinity pharmaceutical inc infi free report report loss cent share third quarter narrower zack consensus estimate loss cent company have report loss cent year quarter infinity do not have approve product portfolio company earn revenue form royalty license milestone payment well research development support fee paid partner infinity record revenue third quarter amount be paid verastem inc vstm free report milestone payment related phase iii duo study evaluate duvelisib however do not record revenue year quarter infinity share price have increase year date compare industry gain quarter detailin report quarter expense plummet year quarter decline be mainly due company restructure activity general administrative expense be report quarter year quarter decrease be mainly due company restructure activity partially offset issuance convertible note eliminate infinity royalty obligation takeda outlook expect net loss be range company anticipate year end cash cash equivalent available sale security balance band moreover infinity expect exist cash cash equivalent sep be adequate fund company capital need first quarter other updatesinfinity be evaluate ipi monotherapy combination bristol myer squibb company bmy free report opdivo phase study patient advanced solid tumor company have expand collaboration bristol myer include triple negative breast cancer patient study earlier agreement allow study patient small cell lung cancer melanoma head neck squamous cell carcinoma second quarter company have complete evaluation escalate monotherapy dose ipi range mg qd once daily set mg dose evaluation expansion component study meanwhile dose escalation evaluate ipi mg qd combination opdivo be currently ongoing company plan initiate combination expansion component study restructure initiative take company have lower operate expense expect initiative have significant positive cumulative effect company margin go forward infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc quotezack rank stock have zack rank hold better rank stock health care sector be exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate increase cent cent cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
188,BMY,celldex therapeutic inc cldx free report incur third quarter loss adjust time item cent share be narrower zack consensus estimate loss cent well year loss cent share lower cost higher revenue lead narrower loss quarter total revenue quarter rise year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative lead higher revenue quarter share biotech company rise hour trading tuesday however stock have not do too well year so far have decline year date increase register industry research development expense decline year period due lower varlilumab contract manufacturing clinical study expense general administrative spend decline due lower commercial plan cost stock base compensation expense sep celldex have cash cash equivalent marketable security compare jun celldex expect cash net proceed raise sale common stock month agreement cantor be enough fund work capital requirement plan operation pipeline updatecelldex most advanced pipeline candidate be antibody drug conjugate glembatumumab vedotin currently be evaluate treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment key metric study close august datum expect second quarter melanoma study celldex add new cohort glembatumumab varlilumab arm glembatumumab checkpoint inhibitor arm include bristol myer bmy free report opdivo merck mrk free report keytruda apart glembatumumab vedotin other promising candidate pipeline include varlilumab cdx phase advanced renal cell carcinoma other varlilumab be be evaluate combination opdivo phase ii study include cohort indication colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex plan complete enrolment cohort phase ii portion study first quarter earning release celldex announce datum phase ii study evaluate combination glembatumumab vedotin varlilumab melanoma patient have progressed checkpoint inhibitor eligible patient only have confirm partial response patient have partial response single timepoint median progression free survival be month patient have stable disease week more full datum set be present society immunotherapy cancer sitc annual meeting week kolltan acquisition nov celldex gain right kolltan cancer pipeline candidate cdx cdx cdx be be evaluate phase study refractory stromal tumor gist other kit positive tumor phase ii study cdx patient recurrent metastatic head neck squamous cell cancer be refractory eli lilly lly free report bristol myer erbitux be expect be initiate year end celldex carry zack rank hold see complete list today zack rank strong buy stock here celldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
189,BMY,aveo pharmaceutical inc aveo free report be expect report second quarter result next week last report quarter aveo deliver positive surprise let see thing be shape quarter aveo share price movement show stock have significantly outperformed industry so far year fact aveo have surge period compare rise industry factor playaveo development stage company be focuse development treatment cancer other area unmet medical need company have show impressive progress most advanced candidate fotivda tivozanib eusa pharma european licensee tivozanib submit written response european medicine agency ema day list outstanding issue loi apr complete oral presentation related marketing authorization application maa tivozanib first line treatment renal cell carcinoma rcc committee medicinal product human use chmp recommend approval fotivda treat rcc june boost potential marketing authorization candidate eu moreover jun company announce phase ii tinivo study have progressed phase ii base successful completion phase dose escalation study phase ii study evaluate mg dose tivozanib combination bristol myer squibb company bmy free report opdivo daily patient advanced rcc follow positive safety review safety monitoring committee replace early dropout feb company complete enrolment phase iii tivo study jun ahead set timeline aug study compare fotivda bayer ag bayry free report nexavar patient refractory advanced rcc apart tivozanib aveo have several early mid stage candidate pipeline include ficlatuzumab june company announce positive result phase study evaluate candidate metastatic head neck squamous cell carcinoma relapse refractory acute myeloid leukemia company depend entirely collaboration revenue milestone other payment top line apr receive milestone payment canbridge life science ltd related technology transfer milestone inhibitory antibody candidate av also quarter company secure credit facility hercule market issuance common stock part agreement fbr co investor focus likely remain tivozanib progress other pipeline related update surprise historyaveo pharma performance last quarters have be mixed company surpass expectation thrice miss same once average positive surprise last quarters be aveo pharmaceutical inc price ep surprise aveo pharmaceutical inc price ep surprise aveo pharmaceutical inc quoteearning whispersour proven model do not conclusively show aveo pharma be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank aveo pharma zack rank increase predictive power esp esp make surprise prediction difficult quarter note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report have earning esp zack rank company be schedule release result aug see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
190,BMY,second quarter earning season be strong start july approximately company index total membership have report result deep look result show earning company report so far be year year higher revenue have top earning estimate have beat revenue estimate however pace growth be first quarter line quarter average have improve quarter average go forward estimate third quarter be go estimate growth be start quarter pharma sector have more less combat overall decline financial market maintain momentum last week industry bellwether johnson johnson jnj free report report mixed second quarter result beating earning miss sale swiss major novartis ag nvs free report report encourage second quarter result meanwhile biotech giant biogen inc biib free report surpass expectation earning sale second quarter raise annual guidance let take look biotech company be set report second quarter result jul bristol myer squibb company bmy free report be schedule report open bell last quarter company beat earning estimate bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise currently company have zack rank hold earning esp current rank increase predictive power esp esp make unlikely stock beat quarter uncover best stock buy sell re report earning esp filter bristol myer high profile immuno oncology drug opdivo be expect continue drive company top line be report quarter first quarter see stability second line lung cancer recent fda approval merck co inc mrk free report keytruda first line treatment metastatic nonsquamous nsclc impact sale read more offing bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report open bell last quarter company beat expectation celgene key product revlimid be expect continue be main growth driver first quarter drive share gain important market longer treatment duration newly diagnosed multiple myeloma mm other key product pomalyst imnovid abraxane otezla continue perform well second quarter call investor be expect remain focuse company performance label expansion effort update pipeline front celgene have submit new drug application fda idhifa relapse refractory aml nda idhifa be grant priority review prescription drug user fee act pdufa action date aug celgene track record have be pretty decent company toppingearning estimate thrice trail quarters overall company have deliver average positive surprise currently company carry zack rank earning esp indicate likely earning beat quarter read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last report quarter company earning surpass zack consensus estimate alexion blockbuster drug soliris continue perform well label expansion drug additional indication be expect boost revenue new product strensiq be do well kanuma lag expectation management be reassess strategy drug go forward alexion track record be excellent company have consistently top expectation last quarters average positive earning surprise currently company carry zack rank earning esp indicate be likely beat estimate quarter read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
191,BMY,exelixis inc exel free report be schedule report second quarter result aug market close exelixis track record be outstanding company have surpass expectation trail quarters average positive earning surprise exelixis share price have increase year date compare zack classify industry gain factor likely impact resultsexelixis receive major boost fda approval cabometyx tablet apr treatment patient advanced renal cell carcinoma rcc initial uptake drug be encourage be expect propel top line forthcoming quarters sequential increase cabometyx sale be also positive moreover cabometyx be also approve eu meanwhile exelixis be develop cabozantinib broad development program oct company announce positive result phase ii cabosun study cabozantinib versus sunitinib formerly untreated advanced rcc be present esmo base cabosun result company have plan submit supplemental new drug application snda cabozantinib treat first line advanced rcc third quarter company present further positive analysis trial jun potential label expansion drug further boost result early exelixis collaborate bristol myer squibb bmy free report evaluate cabozantinib combination opdivo alone combination yervoy phase iii trial first line rcc potentially other tumor type include hcc bladder cancer exelixis also evaluate cabometyx combination tecentriq pd antibody patient advanced rcc bladder cancer jun exelixis initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma uc rcc collaboration allow exelixis earn milestone payment royalty boost top line however expense continue increase exelixis expect total cost operate expense range exelixis inc price ep surprise exelixis inc price ep surprise exelixis inc quoteearning whispersour proven model do not conclusively show exelixis be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat earning be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be most accurate be cent zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank exelixis sport zack rank be favorable however combine negative esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
192,BMY,hurdle trump plan repeal replace obamacare healthcare be second best perform sector year lag technology optimism come especially encourage industry trend hope favorable policy environment trump administration plan focus ease regulatory hurdle rather lower drug price expedite new drug approval additionally shift investor sentiment defensive sector healthcare generally outperform period low moderate growth rise geopolitical uncertainty have lead rally healthcare stock read top rank healthcare etfs long term investor such popular fund health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far year trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock see earning estimate revision yet be report quarter deliver negative earning surprise past quarters additionally have impressive growth momentum style score respectively value style score be favorable pfizer be schedule report earning august open bell read build winning etf portfolio second half pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result july market open have zack rank earning esp make surprise prediction difficult stock witness positive earning estimate revision penny past day be report quarter deliver positive earning surprise last quarters average beat merck have strong value momentum style score unfavorable growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen have zack rank earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision couple cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning july market close amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see positive earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report july open bell read brighten outlook healthcare etfs focus abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning july market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter have solid value momentum style score respectively growth style score look ugly gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning july open bell have zack rank earning esp make surprise prediction difficult stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision cent be report quarter have unfavorable value growth momentum style score respectively see healthcare etfs here bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum healthcare sector be expect post earning decline second quarter have dismal zack rank bottom surprise well be card suggest upside healthcare etfs particular xlv vht iyh have zack etf rank fhlc have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
193,BMY,aveo pharmaceutical inc aveo free report report third quarter adjust loss cent share exclude loss due change fair value warrant liability narrower zack consensus estimate cent well year loss cent however include loss related change fair value warrant liability net loss share quarter be cent share company rise more tuesday fact aveo share price movement show stock have significantly outperformed industry year date basis aveo have surge period compare industry gain aveo first drug fotivda tivozanib receive eu approval august first line treatment advanced renal cell carcinoma rcc company receive double digit royalty payment eusa pharma net sale drug europe however fotivda do not record sale quarter aveo top line mainly comprise collaboration revenue milestone other payment total collaboration revenue third quarter be approximately compare year quarter revenue miss zack consensus estimate quarterly development expense be however general administrative expense decrease year year pipeline updatesin june company announce completion enrollment phase iii study tivo evaluate fotivda top line datum be expect first quarter subsequent quarter october base pre plan futility analysis aveo announce study compare tivozanib bayer bayry free report nexavar patient refractory advanced rcc continue unmodified datum study previously complete tivo study first line set support regulatory application approval tivozanib unite state first third line treatment rcc potential approval unite state indication provide further boost company september aveo announce eusa pharma have opted phase ii tinino study evaluate fotivda combination bristol myer squibb company bmy free report opdivo rcc eusa pharma use study datum regulatory commercial purpose exchange payment guidanceaveo expect present cash resource allow company fund plan operation fourth quarter approval fotivda eu wass huge boost company first line rcc be lucrative market europe moreover also remove aveo dependence collaboration revenue milestone payment aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc quotezack rank stock consideraveo pharma carry zack rank hold better rank stock health care sector be exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate increase cent cent cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
194,BMY,horizon pharma plc hznp free report report better expect result third quarter company also raise annual sale guidance follow news company share go however horizon pharma stock have decline year date industry gain company report third quarter earning cent share beat zack consensus estimate cent be cent year quarter sale third quarter be year year beat zack consensus estimate horizon pharma plc price consensus horizon pharma plc price consensus horizon pharma plc quote quarter orphan unit record revenue year period strong performance be backed solid net sale ravicti generate sale quarter year year drive continue conversion older generation nitrogen scavenger therapy well addition treatment naïve patient due recent label expansion remind investor fda approve supplemental new drug application ravicti expand age range chronic management urea cycle disorder patient month older year older additionally procysbi contribute performance net sale actimmune sale report quarter be year year drive continue effort establish role actimmune broader range chronic granulomatous disease patient rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive continue strong year year vial demand primary care garner revenue year year decline net sale be due implementation new contract model order secure broader inclusion company primary care medicine formulary sale also decline sequentially result lower average net realize price net sale pennsaid duexix vimovo be respectively report quarter company raise outlook now expect sale range compare earlier estimate company continue invest expansion krystexxa nephrology indication expect sale growth more guidance include assumption lower net average net realize price begin second half primarily result government health resource service administration final rule drug ceiling price implementation schedule july horizon pharma be significantly increase investment key growth driver krystexxa expect net sale krystexxa more drive higher demand company expect continue double digi net sale growth ravicti room additional uptake due recent label expansion sale procysbi decline divestiture european right sale actimmune be project grow other company announce first patient be enroled infuse phase iii confirmatory clinical trial evaluate teprotumumab treatment thyroid eye disease ted remind investor company acquire river vision earlier add biologic candidate teprotumumab pipeline june horizon pharma sell marketing right procysbi quinsair europe middle east africa region chiesi farmaceutici company focus higher return business meanwhile company be work expand actimmune label investigator initiate study moffitt cancer center be underway enrolling patient study be evaluate actimmune combination roche holding rhhby free report herceptin perjeta taxol aim determine optimal dose treatment combination certain advanced breast cancer patient company have collaborate fox chase cancer center evaluate actimmune combination bristol myer squibb company bmy free report opdivo phase dose study treatment kidney bladder cancer study continue enroll fourth cohort patient expect have dose level result end year national cancer institute have plan evaluate actimmune combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study remain track begin company remain track submit supplemental new drug application first quarter expand age range chronic management urea cycle disorder ucds birth older takehorizon pharma third quarter result be impressive company beating top bottom line estimate moreover increase sale guidance be encourage well expect krystexxa ravicti actimmune drive further growth acquisition teprotumumab have further diversify company portfolio zack rankhorizon pharma currently have zack rank sell see complete list today zack rank strong buy stock here zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
195,BMY,major pharma company pfizer pfe free report teva pharmaceutical industry limit teva free report sanofi read more sanofi earning line sale lag diabetes weak allergan read more allergan top earning estimate tweak view nordisk read more nordisk top earning estimate lag sale report third quarter result last week recap week most important storieswhy do teva share plunge earning teva share plunge follow release third quarter result company miss earning revenue be line expectation however key reason stock poor performance be lower outlook company face huge revenue erosion key brand drug copaxone face generic competition mg formulation well development alone be expect hit earning cent share meanwhile generic business continue face headwind price erosion remain major challenge read more teva stock plunge earning miss view cut key takeaway pfizer conference call pfizer third quarter earning surpass expectation result company raise earning outlook year read more pfizer beat earning raise ep view company say key brand include ibrance eliquis globally xtandi lyrica xeljanz chantix unite state continue perform well however company be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue time acquire hospira complete september pfizer have expect take couple year integrate manufacturing plant resolve majority supply chain issue third quarter call company say expect make substantial progress cut sterile injectable shortage regard inflectra pfizer biosimilar version remicade company say penetration unite state continue be slower expect due exclusionary contract remicade remind investor pfizer have file lawsuit district court related provide patient physician access lower cost biosimilar read more pfizer sue accuse prevent inflectra uptake pfizer also provide insight expect impact loss exclusivity loe next few year loe be expect affect revenue next year go approximately not be more far term pipeline regulatory update be concern pfizer expect decision fda type ii diabetes drug ertugliflozin december meanwhile top line result parp inhibitor talazoparib phase iii embraca study read year end study be evaluate talazoparib versus standard care chemotherapy patient germline brca positive metastatic breast cancer datum pd inhibitor bavencio pfizer bb agent patient have not be previously treat immune checkpoint inhibitor be also due later year pfizer be also look submit application fda lorlatinib next generation alk inhibitor treatment alk positive metastatic small cell lung cancer year end pfizer have gain year date compare rally industry belong novartis seek label expansion kymriah novartis nvs free report be look expand label kymriah first car therapy gain fda approval company be seek fda approval use kymriah treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible autologous stem cell transplant asct novartis have breakthrough therapy designation dlbcl dlbcl be most common form hodgkin lymphoma nhl dlbcl be highly aggressive difficult treat hodgkin lymphoma be fatal almost patient due relapse refractory disease kymriah be currently approve patient year age cell precursor acute lymphoblastic leukemia be refractory have relapse least twice approval dlbcl indication expand patient population kymriah gilead already have presence area car therapy yescarta be approve treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment novartis also announce intention acquire advanced accelerator application strengthen presence oncology read more novartis buy french company fda approve astrazeneca blood cancer drug astrazeneca azn free report gain accelerate fda approval btk inhibitor calquence acalabrutinib adult patient previously treat mantle cell lymphoma aggressive type blood cancer be usually diagnosed advanced stage associate high relapse rate note abbvie imbruvica be also approve patient population astrazeneca also expand clinical trial collaboration incyte company evaluate efficacy safety incyte investigational selective ido enzyme inhibitor epacadostat combination astrazeneca pd inhibitor imfinzi compare imfinzi alone early lung cancer meanwhile astrazeneca say il human monoclonal antibody tralokinumab fail achieve primary endpoint late stage study severe uncontrolled asthma top line result late stage study show tralokinumab fail achieve statistically significant reduction oral corticosteroid ocs use primary endpoint add standard care patient dependent ocs fda nod drug label expansion fda also grant approval new dosage mg once daily johnson johnson xarelto mg formulation be approve use reduce continue risk recurrent venous thromboembolism vte completion least month initial anticoagulation therapy johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here valeant get fda nod vyzulta pdufa date idp valeant pharmaceutical international inc vrx free report vyzulta latanoprostene bunod ophthalmic solution also gain fda approval reduction intraocular pressure iop patient open angle glaucoma ocular hypertension company also announce fda have accept regulatory application idp halobetasol propionate tazarotene lotion investigational topical treatment plaque psoriasis response fda regard approval status treatment be expect jun cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline marginally week major stock bristol myer squibb bmy free report be merck mrk free report be last month be merck decline see last pharma stock roundup here lilly top front mixed result bristol myer next pharma world quite few small mid cap pharma company be yet report result moreover bristol myer get response fda regard label expansion blockbuster drug sprycel use treatment child ph chronic phase cp chronic myeloid leukemia cml company be also seek approval powder oral suspension pfos formulation sprycel response agency be expect november wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
196,BMY,clovis oncology inc clvs free report incur third quarter loss share be narrower year loss share however report figure be wider zack consensus estimate loss clovis only market drug rubraca be grant accelerate approval fda december treatment advanced ovarian cancer patient have receive prior chemotherapy net product revenue entirely rubraca be approximately quarter sequentially however miss zack consensus estimate markedly company register new patient report quarter however adoption rubraca be slower due limit brca mutant label increase competition recently approve maintenance therapy include tesaro inc tsro free report zejula astrazeneca plc azn free report lynparza year quarter clovis do not generate revenue share company decline market trading wednesday lower expect rubraca sale nonetheless clovis significantly outperformed industry year date stock have be industry gain quarter detaildure third quarter research development expense decrease year year primarily due decrease development activity related rubraca rociletinib program however selling general administrative sg expense climb year year reflect increase activity support rubraca cash used operate activity quarter be less year quarter clovis end quarter cash equivalent available sale security support proceed raise share offering january june update rubracalast month clovis submit supplemental new drug application snda rubraca seek label expansion maintenance treatment patient platinum sensitive recurrent ovarian cancer snda be submit base positive datum ariel confirmatory study rubraca be also review eu comparable ovarian cancer indication clovis expect opinion committee medicinal product human use later year additionally have plan submit supplemental application second line later maintenance treatment indication eu potential approval ovarian cancer july clovis collaborate bristol myer squibb company bmy free report evaluate rubraca combination latter opdivo multiple tumor type ariel confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy be open enrolment go forward clovis plan expand rubraca label additional indication prostrate breast pancreatic cancer other monotherapy combination other agent clovis oncology inc price consensus ep surprise clovis oncology inc price consensus ep surprise clovis oncology inc quotezack rankclovis hold zack rank buy see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
197,BMY,exelixis inc exel free report report impressive result third quarter back increase cabometyx sale company post third quarter earning cent beating zack consensus estimate cent notably company report loss cent share year quarter exelixis inc price ep surprise exelixis inc price ep surprise exelixis inc quotenet revenue come significantly year quarter revenue also surpass zack consensus estimate millionrevenue be boost increase cabometyx sale fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy exelixis share price have increase year date compare industry gain quarter detailtotal product revenue be year quarter cabometyx generate net product revenue sequentially drive growth demand be attributable new patient start refill patient already therapy continue expansion prescriber base cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare year quarter report quarter research development expense increase primarily result increase personnel expense clinical trial cost consult outside service selling general administrative expense be drive increase consult outside service support company marketing activity result primarily increase general administrative headcount support company commercial research development organization pipeline company continue focus cabometyx unite state exelixis file supplemental new drug application snda cabozantinib treatment previously untreated patient advanced rcc august fda have accept snda grant priority review assign prescription drug user fee act pdufa action date feb march fda grant cabozantinib orphan drug designation treatment advanced hepatocellular carcinoma hcc october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter first quarter exelixis inked agreement bristol myer squibb company bmy free report roche hold ag rhhby free report develope cabozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate july meanwhile exelixis roche have agree revise revenue cost sharing arrangement other drug former portfolio cotellic unite sate imspire trilogy trial evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma be underway imspire trial evaluate combination cotellic tecentriq versus merck co inc mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma be open enrolment expect total cost operate expense range takeexelixis third quarter result be strong earning sale beat estimate drive solid cabometyx sale sequential increase cabometyx sale be positive company thereby underlie increase demand drug new patient market share second line set increase go forward expect investor focus remain further label expansion cabozantinib cotellic potential label expansion first line rcc advanced hcc significantly boost growth prospect company zack rank key pickexelixis currently carry zack rank buy see complete list today zack strong buy rank stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
198,BMY,third quarter earning season continue full swing investor be keep eye financial performance company bet stock just base quarterly performance be not correct long term investment strategy several technical fundamental aspect need be take consideration choose stock steady performance therefore expert advice come handy select such stock easily pick attractive stock follow broker upgrade have deeper understand happen particular company also comprehensively analyze strength weakness company consider present economic backdrop figure stock fare investment also broker directly communicate top management attend conference call go company publicly available financial document even talk customer understand like dislike product service offer company so broker upgrade stock definitely rely merely depend be not wise take consideration several other factor ensure strong return select winning strategywe have screening strategy help search potential winner broker rating upgrade week more screen select stock have witness broker rating upgrade more last week current price greater stock be trading average day volume greater large trading volume guarantee stock be easily tradable zack rank equal matter market condition be good bad stock zack rank strong buy buy have proven record success see complete list today zack rank stock here vgm score equal research show stock vgm score combine zack rank offer best upside potential here be stock make screen headquarter new york bristol myer squibb company bmy free report discover develop license manufacture market distribute product company earning be expect grow current year stock have witness upward revision broker rating past week quintile im holding inc headquarter durham nc provide integrate information technology enabled healthcare service company current year earning be expect grow stock have witness upward revision broker rating past week santa clara base intel corporation intc free report design manufacture sell computer networking communication platform company earning be expect grow year stock have witness upward revision broker rating past week coresite realty corporation cor free report base co be engage ownership acquisition construction management datum center company current year earning be expect grow rate stock have witness upward revision broker rating past week headquarter charlotte nc curtiss corporation cw free report design manufacture overhaul precision component engineer product service company earning be expect grow current year stock have witness upward revision broker rating past week get remain stock list start putt other idea test be do research wizard stock pick back testing software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
199,BMY,fda approve novel drug last year have give approval drug so far include key approval october gilead science gild free report yescarta cell base gene therapy treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment make yescarta second gene therapy gain fda approval first be novartis ag nvs free report kymriah kymriah be approve late august certain pediatric young adult patient form acute lymphoblastic leukemia other key approval year include lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month november keryx auryxia review label expansion keryx inc kerx free report be focuse develop medicine renal disease be seek fda approval label expansion auryxia company be look get auryxia approve treatment patient iron deficiency anemia dialysis dependent chronic kidney disease ckd decision be november approval indication expand patient population auryxia bring sale first half keryx share be year date compare industry rally label expansion bristol myer sprycel bristol myer squibb company bmy free report be look expand label blockbuster drug sprycel so be used treatment child ph chronic phase cp chronic myeloid leukemia cml company be also seek approval powder oral suspension pfos formulation sprycel response fda regulatory application be priority review be expect november label expansion boost sprycel sale further drug bring sale first month bristol myer share be year date compare industry rally bristol myer be zack rank hold stock see complete list today zack strong buy rank stock here be third time lucky dynavax heplisav dynavax technology corporation dvax free report be await response fda hepatitis vaccine heplisav month earlier year vaccine have get favorable recommendation fda vaccine related biological product advisory committee vrbpac positive vote expectation be high company finally gain approval vaccine have previously receive complete response letter november other february however fda action date august be push month agency ask more detailed information company propose post marketing study vaccine additional information be consider major amendment biologic license application bla fda be expect give response regard approval status vaccine november approval allow dynavax go ahead plan launch vaccine early next year dynavax share be year date compare industry rally heron cinvanti review cinv commercial stage biotech company heron therapeutic inc hrtx free report be await decision fda cinvanti be review prevention chemotherapy induced nausea vomit cinv approval strengthen heron cinv franchise add second complementary therapeutic agent fda be expect give decision november heron share be year date industry record decline ultragenyx gain fda approval first product clinical stage company ultragenyx pharmaceutical inc rare free report have fda action date come month vestronidase alpha rhgus be review mps also know sly syndrome patient world be afflict disease be rarest form mps currently be approve treatment mps approval rhgus november transform ultragenyx commercial stage company ultragenyx share be year date compare industry rally zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
200,BMY,aduro biotech inc adro free report report third quarter loss cent share line zack consensus estimate narrower year loss cent share quarterly revenue fall year year top line also miss zack consensus estimate july company recognize milestone payment merck co mrk free report related development aduro cd antibody aduro share have underperform industry so far year stock have decline industry register increase research development expense show substantial increase quarter mainly due increase cost related manufacturing select antibody higher facility related cost general administrative expense be year year due lower consult professional fee pipeline updateaduro have broad pipeline novel immunotherapy development treatment variety cancer company initiate phase study september evaluate personalize live attenuate double delete pladd base immunotherapy immunotherapy used patient specific antigen be study patient microsatellite stable metastatic colorectal cancer aduro most advanced ladd candidate crs be be evaluate combination bristol myer squibb company bmy free report opdivo separate phase ii study gastric cancer mesothelioma datum mesothelioma study be expect end year meanwhile company initiate phase ib study evaluate sting pathway activator adu combination novartis ag nvs free report pd checkpoint inhibitor pdr treat solid tumor lymphomas quarter aduro announce fda have clear investigational new drug application ind april antibody bion company expect initiate phase study aduro biotech inc price consensus ep surprise aduro biotech inc price consensus ep surprise aduro biotech inc quotezack rankaduro currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
201,BMY,celldex therapeutic inc cldx free report be expect report third quarter result next week performance have be encourage beat estimate trail quarters meet estimate deliver average positive surprise last report quarter company deliver positive earning surprise celldex therapeutic share be so far year increase register industry period let see thing be shape announcement factor playcelldex earn revenue entirely product development licensing agreement contract grant company recognize revenue clinical trial collaboration bristol myer squibb company bmy free report varlilumab company continue record revenue source third quarter approve product portfolio investor focus remain pipeline development celldex most advanced pipeline candidate be glembatumumab vedotin be currently be evaluate treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment metric study close september datum expect second quarter melanoma study celldex add new cohort glembatumumab varlilumab arm datum expect fall glembatumumab checkpoint inhibitor arm include bristol myer opdivo merck keytruda melanoma study glemba perform well single agent set apart glembatumumab vedotin celldex have several promising candidate pipeline include varlilumab cdx cdx phase ii multiple solid tumor cdx phase advanced renal cell carcinoma other varlilumab be be evaluate combination opdivo phase ii study include cohort indication colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex plan complete enrolment cohort phase ii portion study first quarter meanwhile datum phase study varlilumab opdivo combination study be present june study meet primary endpoint combination be well tolerate test dose level sg cost decline second quarter operate expense vary quarterly basis earning whispersour proven model do not conclusively show celldex be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank celldex zack rank increase predictive power esp esp make surprise prediction difficult note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision celldex therapeutic inc price ep surprise celldex therapeutic inc price ep surprise celldex therapeutic inc quotestock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report be schedule release result nov market close company have earning esp zack rank see complete list today zack rank stock here syndax pharmaceutical inc sndx free report have earning esp zack rank company be schedule release result nov more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
202,BMY,share clovis oncology inc clvs free report have witness continuous upside year share small biotech company be so far year outperform increase register industry period let analyze factor have drive rally so far company only approve drug rubraca have show impressive growth trend drug receive accelerate approval dec company effort have help ovarian cancer drug register almost growth sale sequentially second quarter rubraca sale be first half company have new patient therapy period rubraca be parp inhibitor be approve monotherapy treatment advanced ovarian cancer patient have be treat more chemotherapy patient be select therapy base fda approve companion diagnostic rubraca drug be license pfizer inc pfe free report confirmatory study ariel ariel be be conduct clovis convert accelerate approval continue approval rubraca company share get boost announce positive top line result ariel june promising progression free survival pfs safety result pivotal maintenance confirmatory study demonstrated rubraca have meaningful impact delay disease recurrence advanced ovarian cancer patient clovis be plan file supplemental new drug application snda fda october year base ariel datum include second line later maintenance indication advanced ovarian cancer label rubraca company expect label expansion increase patient population least time meanwhile other phase iii confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy rubraca be also review eu comparable ovarian cancer indication approval be expect eu first quarter clovis be establish commercial infrastructure same be immense commercial potential rubraca target market due increase demand parp inhibitor american cancer society ovarian cancer rank fifth death cancer woman case ovarian cancer be estimate be diagnosed be huge unmet need new treatment option give woman ovarian cancer have germline somatic brca mutation rubraca be also be develop additional cancer indication monotherapy combination other agent include tecentriq rubraca combination gynecologic cancer combination study be sponsored roche moreover jul company collaborate bristol myer squibb company bmy free report evaluate rubraca combination latter opdivo ovarian breast prostate cancer be important note ovarian cancer market be already crowd presence major player launch tesaro inc tsro free report zejula apr competition have intensified further clovis oncology inc price consensus clovis oncology inc price consensus clovis oncology inc quoteclovis currently have zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
203,BMY,bristol myer squibb company bmy free report be schedule report first quarter result jul open bell last quarter company beat earning estimate bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotebristol myer stock have lose past year underperform industry remain flat period bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise bristol myer surpass expectation time well let see thing be shape quarter factor impact quarterbristol myer high profile immuno oncology drug opdivo continue drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication boost drug sale however lung cancer market become more competitive due entry tecentriq bristol myer expect second line lung cancer business be competitive pressure result sale drug market be project be flat first quarter see stability second line lung cancer recent fda approval merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc further impact sale other hand virology business be expect decline significantly due competition epclusa hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise bristol myer be also look diversify portfolio development bms nash positive note bristol myer raise earning expectation concurrent first quarter result company now project earning range share old guidance revenue be expect grow mid single digit range due strong trend business particularly key product opdivo eliquis yervoy gross margin be project decline year progress be estimate range expense be expect increase low double digit range second quarter earning call investor be expect focus company performance label expansion effort opdivo update business development activity earning whispersour proven model do not conclusively show bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen unfortunately be not case here elaborate zack esp earning esp bristol myer be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank bristol myer currently carry zack rank increase predictive power esp however esp make unlikely stock beat earning quarter be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp carry zack rank company be schedule release result jul see complete list today zack rank stock here gilead science inc gild free report have earning esp carry zack rank company be schedule release result jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
204,BMY,gilead science inc gild free report announce health canada have grant notice compliance single tablet regimen vosevi sofosbuvir mg velpatasvir mg voxilaprevir mg treatment chronic hepatitis virus hcv infection vosevi have be approve treatment hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sofosbuvir contain regimen ns inhibitor drug be already approve gilead be know presence hcv market blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost epclusa gain approval jun eu jul become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection approval voseviwill further boost gilead strong hcv portfolio however hcv franchise be pressure result competition pricing issue note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report daklinza other competition well pricing pressure intensified further launch merck mrk free report zepatier gilead stock have moved year so far compare industry gain meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen eu now represent total prescription volume genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set be expect further boost sale however gilead lose exclusivity viread country outside impact sale zack rank gilead currently carry zack rank buy see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
205,BMY,pharmaceutical stock be limelight week merck mrk free report ceo ken frazier resign president donald trump manufacturing council sector be also news investigation be launch rise price multiple sclerosis ms drug recap week most important storiesbayer novartis teva other face ms drug price probe drug pricing be back news investigation skyrocket price ms drug be launch rep elijah cumming rep peter welch letter have be send company include biogen teva roche novartis nvs free report merck kgaa bayer sanofi request information pricing strategy ms drug letter have also raise issue shadow pricing expensive new drug be launch price exist drug be raise other company follow suit increase price match higher price accord american academy neurology study annual sale ms drug double almost meanwhile information provide national multiple sclerosis society show average wholesale price ms disease modify therapy be shot mylan pay doj settlement mylan myl free report announce agreement have be sign department justice doj relator regard medicaid drug rebate settlement move claim relate classification mylan epipen auto injector epipen jr auto injector purpose medicaid drug rebate program have be resolve epipen be list innovator drug be reclassify mylan say also enter corporate integrity agreement office inspector general department health human service also read do mylan stock surge today broader label astrazeneca merck parp inhibitor fda expand label astrazeneca azn free report merck parp inhibitor lynparza ovarian cancer new tablet formulation be also approve maintenance treatment woman platinum sensitive recurrent ovarian cancer regardless brca mutation status well use third line set brca mutate ovarian cancer approval tablet formulation provide patient convenient dose option take tablet twice daily instead capsule twice daily astrazeneca merck be zack rank hold stock see complete list today zack rank strong buy stock here pfizer get fda nod target cancer drug pfizer pfe free report gain fda approval besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less besponsa approval path include breakthrough therapy designation priority review label come black box warning hepatotoxicity not impact uptake give poor survival rate patient population eu approval besponsa come earlier year june bristol myer opdivo combination disappoint kidney cancer study bristol myer squibb bmy free report opdivo fail meet co primary endpoint late stage study evaluate pd immune checkpoint inhibitor yervoy versus sutent sunitinib intermediate poor risk patient previously untreated advanced metastatic renal cell cancer opdivo yervoy combination meet objective response rate co primary endpoint versus fail show statistical significance progression free survival third co primary endpoint overall survival be yet mature opdivo be approve second line renal cell carcinoma positive datum study have help support label expansion first line set study ongoing overall survival datum hit co primary endpoint support label expansion also read bristol myer opdivo fail kidney cancer trial checkmate bristol myer stock have lose value year date versus gain industry cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock glaxo gsk free report be lilly lose last month be merck decline see last pharma stock roundup here mylan miss perrigo top zynerba plunge study failure next pharmaceutical world watch usual pipeline regulatory update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
206,BMY,exelixis inc exel free report announce have complete submission supplemental new drug application snda fda cabometyx tablet patient previously untreated advanced renal cell carcinoma rcc snda submission be base positive result phase ii trial cabosun patient previously untreated advanced rcc intermediate poor risk disease international metastatic renal cell carcinoma database consortium imdc independent radiology review committee have confirm primary efficacy endpoint result investigator assessed progression free survival pfs cabosun trial study compare cabometyx pfizer pfe free report sutent first line treatment intermediate poor risk advanced rcc patient analysis committee cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death measure pfs exelixis announce cabosun meet primary endpoint cabometyx demonstrated statistically significant clinically meaningful improvement pfs compare sutent patient advanced intermediate poor risk rcc determine investigator assessment remind investor cabometyx be approve fda apr treatment patient advanced rcc receive prior angiogenic therapy potential label expansion drug further boost result new patient start refill patient already therapy continue expansion prescriber base cabometyx be drive drug sale sequential increase cabometyx sale be drive growth prescription exelixis have collaborate bristol myer squibb co bmy free report roche holding rhhby free report development drug combination immunotherapy agent exelixis share price have increase year date compare industry gain earlier week bristol myer announce disappointing top line result checkmate trial investigate immuno oncology drug opdivo combination yervoy versus sutent intermediate poor risk patient previously untreated advanced metastatic rcc trial do not meet primary endpoint note renal cell carcinoma rcc be most common type kidney cancer adult account more death worldwide year clear cell rcc be most prevalent type rcc constitute case thereby underlie demand same hence potential approval cabometyx previously untreated advanced metastatic rcc boost sale zack rankexelixis currently carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
207,BMY,bristol myer squibb company bmy free report announce disappointing top line result checkmate trial study investigate immuno oncology drug opdivo nivolumab combination yervoy ipilimumab versus pfizer inc pfe sutent intermediate poor risk patient previously untreated advanced metastatic renal cell carcinoma combination show improvement progression free survival pfs do not reach statistical significance median pfs be month opdivo yervoy combination versus month sutent hence trial do not meet primary endpoint nevertheless combination meet co primary endpoint objective response rate orr achieve orr versus sutent however company have decide continue study plan allow third co primary endpoint overall survival mature tolerability profile observed checkmate be consistent observed previously report study dose schedule note renal cell carcinoma rcc be most common type kidney cancer adult account more death worldwide year clear cell rcc be most prevalent type rcc constitute case thereby underlie demand same bristol myer receive huge boost high profile immuno oncology drug opdivo become first pd immune checkpoint inhibitor gain regulatory approval anywhere world jul be currently approve several country include eu japan several cancer indication however company have have share pipeline regulatory setback oct bristol myer announce final primary analysis checkmate phase iii study evaluate use opdivo monotherapy first line treatment patient advanced small cell lung cancer nsclc tumor expressed pd greater equal jan company announce not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum bristol myer fail effort expand opdivo label include first line treatment lung cancer adversely impact share bristol myer stock have decline year so far industry gain opdivo face stiff competition merck co mrk free report keytruda roche hold rhhby free report tecentriq recent fda approval merck keytruda first line treatment metastatic nonsquamous nsclc further impact sale moreover failure astrazeneca azn free report mystic study imfinzi nsclc investor be worry outcome checkmate study opdivo first line nsclc give similarity trial management have play uncertainty regard trial concern remain zack rank bristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
208,BMY,issue update research report boulder co base clovis oncology inc clvs free report aug rubraca have show impressive growth trend back company effort rubraca sale double sequentially second quarter rubraca sale be quarter however general administrative expense increase year year due effort rubraca be only approve drug company portfolio be first only oral parp inhibitor receive approval monotherapy drug be approve patient have be treat more chemotherapy select therapy base fda approve companion diagnostic rubraca clovis be conduct confirmatory study ariel ariel convert accelerate approval continue approval rubraca rubraca be license pfizer inc pfe free report jun company announce promising progression free survival pfs safety result pivotal maintenance confirmatory study ariel study demonstrated rubraca have meaningful impact delay disease recurrence advanced ovarian cancer patient clovis intend submit supplemental new drug application snda label expansion rubraca second line later maintenance indication advanced ovarian cancer october year company believe label increase patient population least time meanwhile second phase iii confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy meanwhile rubraca be also review eu comparable ovarian cancer indication approval be expect eu first quarter clovis be establish commercial infrastructure same rubraca have immense commercial potential target market be tremendous demand parp inhibitor american cancer society ovarian cancer rank fifth death cancer woman case ovarian cancer be estimate be diagnosed be huge unmet need new treatment option give woman ovarian cancer have germline somatic brca mutation clovis be also develop rubraca additional cancer indication monotherapy combination other agent include tecentriq rubraca combination gynecologic cancer combination study be sponsored roche moreover company collaborate bristol myer squibb company bmy free report jul evaluate rubraca combination latter opdivo ovarian breast prostate cancer ovarian cancer market be already crowd presence major player launch tesaro inc tsro free report zejula apr competition have intensified further zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
209,BMY,nektar therapeutic nktr free report share have decline almost aug company report second quarter result biotech report wider expect loss sale miss estimate nektar second quarter loss cent share be wider zack consensus estimate loss cent report loss be also wider year loss cent share nektar share have significantly outperformed industry so far year company share have surge industry have register decrease quarterly revenue rise year quarter increase revenue mainly be attribute rise product sale royalty revenue however top line miss zack consensus estimate quarter top line comprise product sale royalty revenue cash royalty revenue license collaboration other revenue second quarter product sale increase year however cash royalty revenue decrease company report royalty revenue register huge improvement second quarter compare year quarter be mainly thank royalty revenue movantik sale license collaboration other revenue come compare year fall revenue mainly be attribute recognition receive daiichi sankyo sublicense onzeald formerly know nktr europe second quarter research development expense climb primarily due investment pipeline include key candidate nktr nktr general administrative expense be massive jump mainly be attribute payment settlement litigation regard cross license agreement enzon inc florida base pharma company pipeline most advanced candidate company portfolio be onzeald currently accelerate assessment eu treatment adult advanced breast cancer have brain metastase however company be inform last month committee medicinal product human use chmp have adopt negative opinion conditional marketing application candidate eu subsequently same month company file request examine opinion adopt chmp apart onzeald candidate company immuno oncology portfolio be nktr phase ii study evaluate nktr potential combination treatment regimen bristol myer squibb bmy free report opdivo be underway second quarter nektar announce have start dose patient trial plan enroll patient target cancer indication company expect report initial datum dose escalation part study soon notably nektar announce research collaboration agreement japanese pharma company takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio last month nektar announce have enter strategic collaboration contract eli lilly company lly free report co develop nktr phase study ongoing treatment number autoimmune other chronic inflammatory condition outlook updatednektar raise revenue outlook account upfront payment expect receive lilly company now estimate revenue range compare project previously drive same reason nektar also raise expect cash position year end approximately compare estimate previously nektar therapeutic price consensus ep surprisenektar therapeutic price consensus ep surprise nektar therapeutic quotezack rank key picksnektar currently carry zack rank hold better rank stock health care sector be enzo inc carry zack rank buy see complete list today zack rank strong buy stock here enzo loss share estimate narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat stock surge so far year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
210,BMY,celldex therapeutic inc cldx free report incur second quarter loss cent share be narrower zack consensus estimate loss cent well year loss cent share lower cost higher revenue lead narrower loss quarter total revenue quarter rise year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative lead higher revenue quarter share biotech company rise hour trading tuesday however stock have not do too well year so far have decline year date increase register industry research development expense decline year period general administrative spend decline jun celldex have cash cash equivalent marketable security compare mar celldex expect cash anticipate proceed future sale common stock agreement cantor be enough fund work capital requirement plan operation however guidance assume celldex pay future kolltan contingent milestone stock not cash pipeline updatecelldex most advanced pipeline candidate be glembatumumab vedotin currently be evaluate treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment metric study be expect be complete september year top line datum expect second quarter datum phase ii metastatic melanoma study glemba single agent be present june annual meeting american society clinical oncology asco glemba perform well single agent set response rate disease control rate median duration response month patient have fail prior line therapy study also include new cohort glembatumumab varlilumab arm datum expect year end glembatumumab checkpoint inhibitor arm include bristol myer squibb company bmy free report opdivo merck co inc mrk free report keytruda apart glembatumumab vedotin celldex have several promising candidate pipeline include varlilumab cdx phase advanced renal cell carcinoma other varlilumab be be evaluate combination bristol myer opdivo phase ii study include cohort indication colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex plan complete enrolment cohort phase ii portion study first quarter meanwhile company present datum phase potion varlilumab opdivo combination study asco june datum show combination be well tolerate test dose level increase autoimmunity inappropriate immune activation kolltan acquisition nov celldex gain right kolltan cancer pipeline candidate cdx cdx cdx be be evaluate phase study refractory stromal tumor gist other kit positive tumor datum expect year end phase ii study cdx patient recurrent metastatic head neck squamous cell cancer be refractory eli lilly company lly free report bristol myer erbitux be expect be initiate fourth quartercelldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quotecelldex carry zack rank sell see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
211,BMY,total earning total healthcare market capitalization be revenue growth earning growth be weak compare many other sector earning revenue beat ratio respectively be particularly encourage fact healthcare be fourth sector surprised investor most earning trail aerospace technology material most notable player johnson johnson jnj free report be first major drug company report earning july follow eli lilly company lly free report bristol myer squibb company bmy free report july july respectively other major drug company merck mrk free report pfizer pfe free report report july august respectively industry prime post solid result earning beat few lag revenue front johnson johnson earning world biggest maker healthcare product continue long streak earning beat narrowly miss top line estimate earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance zack consensus estimate be peg earning share revenue time earning release jnj have gain date earning announcement read brighten outlook healthcare etfs focus pfizer earning drug giant beat earning miss revenue earning share cent come couple cent zack consensus estimate revenue fall shy estimate annual basis earning share rise revenue decline pfizer expect revenue range raise lower end earning share guidance zack consensus estimate be correctly peg revenue earning share share pfe be earning announcement merck earning focusearning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck raise revenue guidance reiterate earning share projection year zack consensus estimate be currently peg revenue earning share stock have lose follow earning announcement bristol myer earning focusbristol myer report earning share cent penny ahead estimate increase year quarter revenue grow edge past zack consensus estimate company raise low end earning share guidance year zack consensus estimate time earning announcement be peg share bmy be date earning announcement see healthcare etfs here eli lilly earning focusearning eli lilly outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously zack consensus estimate time earning release be peg revenue earning share share lly have lose earning release etf string earning beat fail boost pharma etfs see rough trading past day have highlighted detail powershare dynamic pharmaceutical fund pjp be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see moderate volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose past day have zack etf rank hold rating high risk outlook read lie ahead pharma etfs second half ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top hold basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed past day have zack etf rank buy rating high risk outlook spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period have zack etf rank high risk outlook vaneck vector pharmaceutical etf etf follow mvis list pharmaceutical index hold stock basket johnson johnson take top spot basket asset pfizer bristol myer merck eli lilly collectively account asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose past day have zack etf rank medium risk outlook read etfs buy avoid healthcare bill failure want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
212,BMY,second quarter earning season pharma sector kick week industry bellwether johnson johnson jnj free report swiss pharma giant novartis nvs free report report result meanwhile merck mrk free report gain tentative approval fda follow biologic basal insulin company launch immediately due ongoing patent infringement case recap week most important storiesa look novartis result industry bellwether swiss pharma giant novartis report second quarter result earlier week surpass earning expectation revenue fall short company raise outlook year operational sale growth expect accelerate second half factor help include earlier launch tremfya more moderate erosion remicade business compare previous expectation well continue strong performance key drug contribution new product medical device segment be also expect pick back half year strong growth vision care segment expect continue consumer segment however continue be impact weaker macroeconomic dynamic read more beat earning lag sale up view novartis second quarter result be better expect company beating earning revenue entresto cosentyx continue perform well sandoz sale decline reflect pricing pressure meanwhile alcon performance improve encourage company raise alcon sale outlook low single digit growth read more novartis top earning sandoz face pricing pressure novartis stock have gain year date outperform rally industry belong tentative approval merck follow basal insulin merck get tentative approval fda biosimilar version sanofi sny free report blockbuster diabetes drug lantus lusduna nexvue insulin glargine injection technically follow biologic basal insulin have be develop merck funding samsung bioepis however merck have launch product due automatic month stay result patent infringement lawsuit initiate sanofi sep merck launch product expiry stay period favorable court ruling occur first note biosimilar version lantus be already market form lilly lly free report boehringer ingelheim basaglar enter market mid dec lantus sale decline first quarter include decline reflect lower average net price patient switch toujeo impact formulary exclusion pricing pressure increase once merck product enter market sanofi merck be zack rank buy stock see complete list today zack rank strong buy stock here sanofi nanobody deal ablynx sanofi have enter research collaboration global exclusive licensing agreement belgian company ablynx focuse development nanobody base therapeutic treatment various immune mediate inflammatory disease deal sanofi gain access certain nanobody ablynx exist portfolio well ablynx scientist proprietary nanobody platform sanofi make upfront payment other financial detail include milestone payment well tiered royalty collaboration sanofi be look expand drug discovery pipeline immunology eu nod astrazeneca kyntheum astrazeneca azn free report psoriasis treatment kyntheum gain approval eu iceland liechtenstein norway company say partner leo pharma gain approval use biologic medicine treatment moderate severe plaque psoriasis adult be candidate systemic therapy kyntheum be approve trade name siliq feb black box warning regard risk patient suicidal thought behavior cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock astrazeneca be gain last month astrazeneca be gain see last pharma stock roundup here fda panel vote novartis car drug sny buy vaccine co next pharma world watch second quarter earning result company lilly bristol myer bmy free report astrazeneca other make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
213,BMY,aveo pharmaceutical inc aveo free report be expect report third quarter result nov last report quarter aveo deliver positive surprise aveo share price movement show stock have significantly outperformed industry so far year fact aveo have surge period compare rise industry let see thing be shape quarter factor playaveo development stage company be focuse development treatment cancer other area unmet medical need august european commission approve fotivda tivozanib treat first line treatment renal cell carcinoma rcc adult drug have demonstrated superiority bayer ag bayry free report nexavar treat rcc fotivda become first approve drug company however expect minimal impact top line launch process be currently underway company depend entirely collaboration revenue milestone other payment revenue aveo have receive payment research development payment eusa pharma follow approval fotivda meanwhile also receive canbridge achieve milestone related manufacturing development activity av moreover june company announce phase ii tinivo study have progressed phase ii base successful completion phase dose escalation study september aveo announce eusa pharma have opted phase ii tinino study evaluate fotivda combination bristol myer squibb company bmy free report opdivo rcc eusa pharma use study datum regulatory commercial purpose exchange payment apart tivozanib aveo have several early mid stage candidate pipeline include ficlatuzumab june company announce positive result phase study evaluate candidate metastatic head neck squamous cell carcinoma relapse refractory acute myeloid leukemia investor focus likely remain update related tivozanib launch progress other pipeline candidate surprise historyaveo pharma performance last quarters have be mixed company surpass expectation thrice miss same once average positive surprise last quarters be earning whispersour proven model do not conclusively show aveo pharma be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank aveo pharma zack rank increase predictive power esp esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision aveo pharmaceutical inc price ep surprise aveo pharmaceutical inc price ep surprise aveo pharmaceutical inc quotea stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report have earning esp zack rank company be schedule release result nov see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
214,BMY,third quarter report cycle be witness revenue acceleration positive revision trend result half member be already oct total earning member be same period last year higher revenue surpass earning revenue estimate respectively accord earning preview company account index total market capitalization report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning biotech pharma bigwig merck co inc mrk free report celgene corporation celg free report abbvie inc bristol myer squibb company bmy free report gilead science inc gild free report report third quarter result last week merck celgene abbvie outpaced zack consensus estimate earning lag same revenue however bristol myer gilead surpass expectation earning revenue notably bristol myer gilead raise earning outlook well merck raise previously issue adjust earning guidance up sale guidance marginally abbvie celgene also tighten earning guidance here have biotech pharma company be set report third quarter result oct let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning market open deliver positive earning surprise last quarter company earning performance have be mixed bottom line miss last quarters beating same other bring average surprise negative quarter pfizer have earning esp zack rank hold zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully meanwhile sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue well sale viagra be expect be affected lower demand read more be beat likely pfizer earning season previous article show pfizer be likely beat earning quarter however estimate change thereafter be not certain beat earning season pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteincyte corporation incy free report incyte be schedule release earning market open witness negative earning surprise last quarter company earning performance have be mixed so far have deliver positive surprise last quarters miss estimate unavailable average earning surprise last quarters be negative company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here company key growth driver jakafi have be perform well expect trend continue be report quarter well incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quoteacorda therapeutic inc acor free report acorda be schedule release earning market open witness negative earning surprise last quarter company earning performance have be disappointing so far company have incur negative surprise last quarters average earning surprise last quarters be negative company have earning esp zack rank strong sell make surprise prediction difficult zack consensus estimate be peg cent share be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision expect investor focus refusal file rtf relief late stage pipeline candidate inbrija be develop treatment patient be suffering parkinson disease acorda therapeutic inc price ep surprise acorda therapeutic inc price ep surprise acorda therapeutic inc quotezack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor
215,BMY,exelixis inc exel free report be schedule report third quarter result nov market close exelixis track record be outstanding company have surpass expectation trail quarters average exelixis share price have increase last month compare industry loss factor likely impact resultsexelixis receive major boost fda approval cabometyx tablet april treatment advanced renal cell carcinoma rcc drug uptake be encourage be expect propel top line forthcoming quarters moreover cabometyx be also approve eu new patient start refill patient already therapy continue expansion prescriber base cabometyx be drive drug sale meanwhile exelixis be develop cabozantinib broad development program have submit supplemental new drug application snda advanced rcc fda assign pdufa action date feb potential label expansion cabometyx significantly boost growth prospect first quarter exelixis inked agreement bristol myer squibb company bmy free report roche hold ag rhhby free report develop abozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate july exelixis also initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma uc rcc collaboration allow exelixis earn milestone payment royalty boost top line however expense continue increase exelixis expect total cost operate expense range earning whispersour proven model do not conclusively show exelixis be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat earning be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be most accurate be cent zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank exelixis carry zack rank be favorable however combine negative esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat quarter incyte corporation incy free report have earning esp zack rank company be expect release result oct see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
216,BMY,seattle genetic inc sgen free report report loss cent share third quarter significantly narrower zack consensus estimate cent year quarter loss cent share however include gain exercise warrant grant termination license transaction immunomedic company report earning cent share revenue come year year primarily back strong sale adcetris revenue also beat zack consensus estimate seattle genetic share be market trading thursday fact company share price have gain year date compare industry rise same period quarter detailseattle genetic top line comprise product revenue collaboration license agreement revenue royalty company only market product adcetris generate product sale year year collaboration license agreement revenue increase almost mainly drive strong demand adcetris international market collaboration revenue include fee earn company agreement takeda pharmaceutical company ltd adcetris other adc collaboration royalty revenue increase year year attributable international sale adcetris takeda pharmaceutical co research development expense be year year also selling general administrative sg expense increase cost be high primarily due investment vadastuximab talirine enfortumab vedotin adcetris other pipeline development outlook company raise outlook collaboration license agreement revenue range previously royalty be expect range previously net sale adcetris be expect range company lower upper limit expect expense projection be currently expect be compare previous expectation pipeline updateseattle genetic continue work expand adcetris label further phase iii study note fda have grant priority review supplemental biologic license application august include cutaneous cell lymphoma label decision be expect december meanwhile fda have grant breakthrough therapy designation adcetris base datum phase iii echelon study frontline classical hodgkin lymphoma adcetris show statistically significant improvement modify progression free survival seattle generic takeda be plan submit application regulatory approval year end moreover top line datum echelon study frontline cd express mature cell lymphoma be company be also evaluate adcetris combination bristol myer squibb bmy free report opdivo relapse hodgkin lymphoma addition company initiate pivotal phase ii study enfortumab vedotin patient metastatic urothelial cancer patient late moreover seattle genetic astella pharma be plan initiate phase ib study evaluate candidate combination cpi therapy include pembrolizumab patient locally advanced metastatic urothelial cancer july seattle genetic collaborate genentech member roche hold ag rhhby free report evaluate combination roche immunotherapy tecentriq seattle genetic antibody drug conjugate sgn liv patient metastatic triple negative breast cancer company third quarter loss be narrower estimate sale also beat expectation give positive development adcetris investor focus update label expansion approval cell lymphoma indication boost sale further seattle genetic currently carry zack rank hold better rank stock health care sector include adaptimmune therapeutic plc adap free report carry zack rank buy see complete list today zack rank strong buy stock here adaptimmune loss estimate narrow cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
217,BMY,gilead science inc gild free report announce fda have approve vosevi sovaldi velpatasvir mg voxilaprevir mg tablet drug be single tablet regimen str re treatment chronic hepatitis virus hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor approval come back positive datum phase iii study polaris polaris study study evaluate week vosevi direct act antiviral experience chronic hcv infected patient cirrhosis compensate cirrhosis however vosevi have be warn product label regard risk hepatitis virus hbv reactivation hcv hbv co infected patient nevertheless approval make vosevi first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor approval be expect boost gilead strong hcv portfolio gilead have strong presence hcv market due blockbuster hcv drug sovaldi harvoni sovaldi continue be very important product company harvoni label have be expand twice approval be now approve use broader range patient population hcv portfolio get huge boost epclusa gain approval jun eu jul become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection initial uptake epclusa have be encourage formulary reviews be track gilead expect launch epclusa other large eu market once pricing reimbursement be place second half boost sale further last month committee medicinal product human use chmp adopt positive opinion company marketing authorization application maa vosevi follow accelerate assessment procedure gilead hcv franchise be pressure due intense competition pricing issue hcv product sale be weaker expect mainly due fewer new patient start harvoni lower revenue patient harvoni sovaldi epclusa have be face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report daklinza johnson johnson jnj free report olysio company expect persistent decline hcv patient start be primary factor year year decrease revenue increase competition impact patient share pricing share gilead have underperform zack classify medical biomedical genetic industry year so far stock lose period industry gain nevertheless hiv franchise gilead be perform well be expect help company combat persistent decline hcv franchise zack rank gilead currently carry zack rank hold see complete list today zack rank stock here look stock skyrocket upsizack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
218,BMY,share exelixis inc exel free report have gain almost aug company share have rally whopping year so far outperform increase register zack categorize medical biomedical genetic industry period here analyze factor lead rally exelixis be company focuse develop commercialize small molecule therapy treatment cancer exelixis lead product cometriq capsule form cabozantinib be approve treatment progressive metastatic medullary thyroid cancer mtc exelixis be develop cabozantinib broad development program comprise clinical study multiple indication company receive major impetus apr fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx treatment rcc patient have receive prior angiogenic therapy cabometyx be also approve eu treatment advanced rcc adult have receive prior vascular endothelial growth factor vegf target therapy result phase ii cabosun study cabozantinib versus pfizer pfe free report sutentin formerly untreated advanced rcc be positive base cabosun result company have plan submit supplemental new drug application snda cabozantinib treat first line advanced rcc third quarter company present further positive analysis trial jun potential label expansion drug further boost result datum american cancer society kidney cancer be most commonly diagnosed form cancer man woman hence believe exelixis be poise capture major chunk market approve first line kidney cancer meanwhile early exelixis inkedagreement bristol myer squibb bmy free report roche holding ag rhhby free report develop cabozantinib combination immunotherapy exelixis collaborate bristol myer evaluate cabozantinib combination opdivo alone combination yervoy phase iii trial first line rcc potentially other tumor type include hcc bladder cancer company have initiate phase iii trial checkmate jul evaluate opdivo combination cabometyx opdivo yervoy combination cabometyx versus sutent patient previously untreated advanced metastatic rcc exelixis have also collaborate roche evaluate cabozantinib combination tecentriq pd antibody patient advanced rcc bladder cancer jun exelixis initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma uc rcc label expansion additional indication give product access higher patient population increase commercial potential drug zack rankexelixis currently sport zack rank strong buy see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
219,BMY,share twitter inc twtr free report gain post third quarter earning share surpass zack consensus estimate loss share ford motor company free report rally post third quarter earning share surpass zack consensus estimate bristol myer squibb company bmy free report share plummet post third quarter earning share lower zack consensus estimate abiom inc abmd free report share rally post second quarter earning share surpass zack consensus estimate
220,BMY,aduro biotech inc adro free report report second quarter loss cent share narrower zack consensus estimate loss cent however company report earning cent share year quarterly revenue plunge year year top line deterioration be mainly due recognition milestone payment second quarter pursuant agreement novartis nvs free report development adu combination pd checkpoint inhibitor however decrease be partially offset recognition milestone payment collaboration merck co mrk free report view investigate crs combine merck pd therapy keytruda treat gastric cancer revenue surpass zack consensus estimate aduro share have outperformed industry so far year share company have rally industry have register increase research development expense show substantial decline quarter mainly due decrease expense related manufacturing gvax pancreas pancreatic cancer clinical study expense incur second quarter general administrative expense be year year due lower consult professional fee pipeline updateaduro have broad pipeline novel immunotherapy development treatment variety cancer most advanced program ladd platform be combination crs aduro ladd live attenuate double delete base immunotherapy gvax pancreas bristol myer squibb company bmy free report opdivo pd checkpoint inhibitor be currently evaluation phase ii stellar study patient metastatic pancreatic cancer aduro have also complete enrollment initial cohort phase ib study evaluate combination crs standard care chemotherapy patient unresectable malignant pleural mesothelioma jun aduro biotech announce initiation phase ii study evaluate combination therapy crs merck keytruda treat patient previously nurse malignant pleural mesothelioma mpm same month aduro announce fda have clear investigational new drug application ind adu miw combine novartis investigational pd checkpoint inhibitor pdr candidate be develop treat advanced metastatic solid tumor lymphomas aduro biotech inc price consensus ep surpriseaduro biotech inc price consensus ep surprise aduro biotech inc quotezack rankaduro currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
221,BMY,clovis oncology inc clvs free report report second quarter loss share be narrower year loss share report loss be however wider zack consensus estimate loss clovis parp inhibitor rubraca rucaparib receive accelerate approval fda dec treatment advanced ovarian cancer patient have be treat more chemotherapy drug be only market product portfolio net product revenue entirely rubraca be approximately quarter sequentially also beat zack consensus estimate company register new patient quarter year quarter clovis do not generate revenue company share rise market trading wednesday stock have significantly outperformed industry have surge year so far industry rise quarter detaildure report quarter research development expense decrease year year primarily due decrease development activity related rubraca rociletinib program general administrative expense increase year year reflect increase activity support rubraca cash used operate activity quarter be slightly more year quarter company end quarter cash equivalent available sale security support proceed raise share offering january june update rubracain order convert accelerate approval continue approval clovis be run confirmatory study jun company announce promising progression free survival pfs safety result pivotal maintenance confirmatory study ariel demonstrated parp inhibitor rubraca have meaningful impact delay disease recurrence advanced ovarian cancer patient clovis intend submit supplemental new drug application snda label expansion rubraca second line later maintenance indication advanced ovarian cancer october year company believe label expansion be expect increase patient population least time meanwhile rubraca be also review eu comparable ovarian cancer indication clovis expect eu approval first quarter be establish commercial infrastructure same company also have plan submit supplemental application second line later maintenance treatment indication eu drug be approve ovarian cancer phase iii confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy be open enrolment meanwhile clovis be look expand rubraca label additional indication prostrate breast pancreatic cancer other monotherapy combination other agent earlier week company collaborate bristol myer squibb bmy free report evaluate rubraca opdivo combination study ovarian breast prostate cancer several clinical study be initiate early include triton triton prostate cancer tecentriq rubraca combination study gynecologic cancer be sponsored roche hold ag rhhby free report clovis oncology inc price consensus ep surprise clovis oncology inc price consensus ep surprise clovis oncology inc quotezack rank key picksclovis carry zack rank hold stock better rank stock health care sector be arena pharmaceutical inc arna free report carry zack rank buy see complete list today zack strong buy rank stock here arena pharma loss share estimate narrow last day company deliver positive earning surprise trail quarters average beat company share be so far year company be schedule report aug more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
222,BMY,share incyte corporation incy free report be company report loss second quarter incyte report loss cent penny wider zack consensus estimate loss cent incyte have report earning cent share year quarter quarterly revenue be year year beat zack consensus estimate top line be drive higher sale jakafi iclusig europe well royalty ex sale jakavi olumiant incyte share have moved year so far compare industry gain quarter detailjakafi sale grow year year net product revenue iclusig amount product royalty revenue novartis ag nvs free report jakafi ex market grow research development expense be year quarter increase be primarily due expansion portfolio well upfront milestone expense related collaboration license agreement selling general administration sg expense amount year year outlook company now expect jakafi revenue range iclusig revenue be expect range expense be now expect range earlier forecast due acceleration phase iii plan epacadostat sg expense be still expect range incyte corporation price consensus ep surprise incyte corporation price consensus ep surprise incyte corporation quotepipeline updatea phase iii trial reach evaluate jakafi treatment patient steroid refractory chronic graft versus host disease gvhd be expect be initiate jun pivotal program reset evaluate jakafi versus anagrelide patient essential thrombocythemia be now open enrolment first patient be dose come week phase iii trial gravita itacitinib patient treatment naïve acute gvhd be initiate july earlier incyte extend collaboration merck co inc mrk free report pivotal program study epacadostat combination keytruda total tumor type incyte merck advance additional tumor type melanoma small cell lung cancer bladder renal head neck cancer phase iii trial trial be expect begin additionally incyte extend collaboration bristol myer squibb company bmy free report evaluate epacadostat combination opdivo pivotal study tumor type plan initiation end european commission approve olumiant feb treatment moderate severe active rheumatoid arthritis adult patient have respond inadequately be intolerant more disease modify rheumatic drug drug be approve japan too however company suffer setback fda issue complete response letter olumiant fda indicated additional clinical datum be need determine most appropriate dose fda further state additional datum be necessary further characterize safety concern treatment arm jul lilly incyte announce resubmission new drug application nda olumiant be delay period anticipate be minimum month company be further evaluate future plan agency analyse option resubmission include potential additional clinical study request fda takeincyte report wider expect loss second quarter nevertheless revenue beat be impressive jakafi sale be drive patient demand be expect boost revenue increase sale guidance be also encourage most demand be due larger establish patient base myelofibrosis be also expect be major long term driver jakafi growth be owing larger potential patient population possibility longer duration treatment jakafi be include recommend treatment patient myelofibrosis patient latest national comprehensive cancer network nccn clinical practice guideline oncology neoplasms mpns jul be likely boost demand further however delay nda submission olumiant be disappointing zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
223,BMY,celldex therapeutic inc cldx free report be schedule report second quarter result aug market close celldex performance have be encourage deliver positive surprise trail quarters meet estimate deliver average positive surprise celldex therapeutic inc price ep surprise celldex therapeutic inc price ep surprise celldex therapeutic inc quotein last report quarter company earning come line expectation celldex therapeutic share be so far year increase register industry period let see thing be shape announcement factor playcelldex earn revenue entirely product development licensing agreement contract grant company recognize revenue clinical trial collaboration bristol myer squibb company bmy free report varlilumab believe company continue record revenue source second quarter approve product portfolio investor focus remain pipeline development celldex effort build immuno oncology pipeline be impressive lead pipeline candidate glembatumumab vedotin be currently be evaluate treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii be also be evaluate treatment other cancer squamous cell lung cancer uveal melanoma pediatric osteosarcoma glycoprotein nmb be expressed company announce jun glembatumumab vedotin demonstrated median overall survival month patient month patient stage iii iv checkpoint refractory metastatic melanoma improve previous result moreover phase portion phase dose escalation cohort expansion studyshow varlilumab combination bristol myer opdivo advanced cancer patient be well toleratedat test dose level apart glembatumumab vedotin celldex have several promising candidate pipeline include cdx cdx phase ii multiple solid tumor collaboration citn cdx phase advanced renal cell carcinoma other operate expense vary quarterly basis earning whispersour proven model do not conclusively show celldexis likely beat earning be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank celldex have zack rank sell note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter arena pharmaceutical inc arna free report be schedule release result aug close bell company have earning esp zack rank see complete list today zack rank stock here puma biotechnology inc pbyi free report have earning esp zack rank company be expect release result aug more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
224,BMY,last week several pharma major report second quarter result meanwhile important study datum be release merck mrk free report astrazeneca azn free report recap week most important storiesa look earning result big pharma company merck lilly lly free report glaxo roche bristol myer bmy free report astrazeneca report second quarter result last week bristol myer lilly merck beat expectation merck maintain outlook year read more merck beat earning sale keep view bristol myer update same read more bristol myer beat earning tweak view lilly be hit baricitinib update report beat raise quarter read more key takeaway lilly call baricitinib cancer pipeline meanwhile astrazeneca result be shadow disappointing mystic datum imfinzi treatment naïve small cell lung cancer nsclc patient company share fall read more astrazeneca beat earning fall fail study british drugmaker glaxo set new priority company company decide allocate capital priority asset current respiratory hiv infectious disease potential oncology immuno inflammation therapy area glaxo also say more pre clinical clinical program be stop read more glaxosmithkline beat earning lower guidance lilly merck be zack rank buy stock see complete list today zack rank strong buy stock here merck keytruda miss endpoint hnscc study be lot update merck last week addition earning result company be hit disappointing result late stage study evaluate pd therapy keytruda monotherapy patient previously treat recurrent metastatic head neck squamous cell carcinoma hnscc study fail meet pre specify primary endpoint overall survival os be latest keytruda related setback merck earlier month company have announce fda have place clinical hold combination study keynote keynote keynote be conduct keytruda multiple myeloma mm meanwhile look merck second quarter result show keytruda remain strong lung cancer set keytruda be currently more study include more combination study merck astrazeneca sign oncology collaboration merck astrazeneca be collaborate global development merck keytruda astrazeneca parp inhibitor lynparza different type cancer lynparza currently approve brca mutate ovarian cancer multiple line treatment be different study range tumor type include breast prostate pancreatic cancer deal cover evaluation parp mek inhibitor pd pd inhibitor astrazeneca stand receive include upfront payment certain license option additional achievement regulatory sale milestone merck stock have gain year date ytd lag rally industry belong astrazeneca have gain ytd janssen inks deal bavarian nordic johnson johnson janssen pharmaceutical company denmark base biotech company bavarian nordic enter additional worldwide exclusive license collaboration agreement janssen get exclusive right bavarian nordic mva bn technology additional program target vaccine hepatitis virus hbv hiv make upfront payment equity investment worth bavarian nordic also be eligible receive milestone payment worth tiered royalty future sale deal company be now collaborate program combine bavarian nordic mva bn technology janssen advac technology platform pfizer astella xtandi breast cancer program drop astella report result last week provide update pipeline show company partner pfizer pfe free report have decide drop development xtandi breast cancer development program include phase iii study triple negative breast cancer phase ii study pr positive positive breast cancer astella say decision be base discussion pfizer change competitive landscape need further diagnostic development new phase ii datum ongoing program xtandi include metastatic castration resistant prostate cancer phase iii prostate cancer patient metastatic biochemical recurrence phase iii metastatic hormone sensitive prostate cancer phase iii hepatocellular cancer phase ii cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock merck be astrazeneca lose last month be bristol myer gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch second quarter earning result company pfizer shire shpg free report allergan agn free report other moreover fda arthritis advisory committee be meeting aug discuss regulatory application investigational rheumatoid arthritis treatment plivensia sirukumab more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
225,BMY,gilead science inc gild free report report third quarter result earning revenue surpass expectation however stock be expect open red give decline hepatitis virus hcv franchise nevertheless gilead stock have gain year date industry decline company third quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue top zack consensus estimate however revenue decline year year hiv impress yet again harvoni sovaldi plungesproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch sale vosevi approve unite state europe july sale harvoni decline year year report quarter further sovaldi sale record steep year year decline epclusa garner sale report quarter year figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline other hand selling general administrative sg expense increase adjust product gross margin be compare year period guidance updatedgilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project earlier projection cent kite company recently acquire kite pharma last week company receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy dividend share gilead declare cash dividend cent share common stock fourth quarter dividend be payable dec stockholder record close business dec quarter company paid cash dividend repurchase share company top earning revenue estimate third quarter witness decline hcv sale hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza other competition well pricing pressure have intensified further launch merck co inc mrk free report zepatier only patient begin treatment gilead regimen quarter prior quarter meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set further boost sale company see significant uptick prep usage estimate patient used truvada end third quarter approval yescarta also bode well gilead however gilead have lose exclusivity viread truva further impact performance expect decline hcv franchise offset positive momentum hiv franchise zack rank gilead currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
226,BMY,major pharma company eli lilly lly free report bristol myer squibb bmy free report glaxosmithkline plc gsk free report novartis read more novartis earning sale top new drug strength report third quarter result week be beat raise quarter lilly bristol myer result be mixed recap week most important storieslilly top expectation mull option animal health segment lilly third quarter result be better expect company beating top bottom line raise outlook year reflect uptake trend new pharmaceutical product company also announce be explore strategic alternative animal health business elanco animal health update expect mid company be weigh option initial public offer merger sale retention business segment bring revenue so far read more lilly beat earning explore sale elanco lilly be zack rank buy stock see complete list today zack rank strong buy stock here mixed quarter bmy be mixed quarter bristol myer company miss earning surpass revenue expectation opdivo performance remain strong presence increase competition sale grow eliquis also perform well company say business development remain top priority expect buy back share worth additional year end read more bristol myer miss earning opdivo focus company have gain year date compare rally industry belong sanofi file patent infringement lawsuit mylan lantus french drugmaker sanofi sny free report have file patent infringement suit mylan myl free report lantus lantus solostar lawsuit file unite state district court district new jersey allege infringement patent sanofi diabetes product sale be immense pressure lantus franchise remain major contributor top line earlier year august sanofi have file patent infringement suit merck allege infringement patent related lantus product interest increase pfizer consumer healthcare business ever pfizer pfe free report announce be explore strategic option consumer healthcare business include full partial separation spin sale quite few company have be rumore be interested striking deal week british pharma major glaxo be ask third quarter call interest acquire pfizer consumer healthcare business glaxo own consumer segment have be witness material slowdown global growth key category factor pricing pressure increase competition tougher emerge market weigh performance read more glaxo earning beat revenue line share meanwhile accord reuter article pfizer expect start auction process consumer healthcare business november accord source possible bidder apart glaxo reckitt benckiser include name procter gamble sanofi johnson johnson nestle nyse arca pharmaceutical index decline week major stock glaxo decline mainly reflect concern company dividend payout especially strike deal pfizer consumer healthcare business last month be see last pharma stock roundup here beat raise quarter allergan hit restasis ruling next pharma world watch earning result company merck mrk free report pfizer wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
227,BMY,bristol myer squibb company bmy free report third quarter earning cent share fall short zack consensus estimate well year quarter earning cent however total revenue come ahead zack consensus estimate well record year period strong sale opdivo eliquis contribute top line report quarter share company be pre market trading presumably due lower expect earning bristol myer share have increase so far year compare unfavorably industry increase quarterly detailsrevenue be year year adjust foreign exchange impact revenue unite state increase increase outside unite state ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year melanoma drug yervoy contribute top line report quarter opdivo be approve multiple cancer indication generate revenue year period drug receive approval label expansion more indication include hepatocellular carcinoma metastatic colorectal cancer recurrent gastric cancer however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively nevertheless sale eliquis be report quarter year year multiple myeloma drug empliciti record sale year year research development expense quarter increase mainly due charge related acquisition ifm therapeutic marketing selling administrative expense remain flat gross margin be quarter compare year quarter due change product mix recognition inventory charge september bristol myer complete acquisition outstanding capital stock ifm gain full right ifm preclinical sting nlrp agonist program enhance body immune response treat cancer moreover company sign global collaboration license agreement halozyme therapeutic develop subcutaneous administration immuno oncology medicine used halozyme enhanze drug delivery technology quarter bristol myer enter multiple collaboration develop opdivo combination antibody drug conjugate parp inhibitor tyrosine kinase inhibitor several tumor type include daiichi sankyo investigational candidate ds abbvie inc abbv free report abbv exelixis inc exel free report cabometyx clovis oncology inc clvs free report rubraca pipeline updatein september bristol myer announce datum phase iii study checkmate show significant improvement recurrence free survival stage iiib stage iv melanoma treat opdivo yervoy combination compare yervoy alone meanwhile phase iii study checkmate be stop early opdivo yervoy achieve superior overall survival compare current standard care sunitinib study be conduct previously untreated patient advanced metastatic renal cell carcinoma however study be place partial clinical hold evaluate opdivo base combination patient relapse refractory multiple myeloma hold be place base risk observed study evaluate pd agent pembrolizumab multiple myeloma patient earning guidance revisedbristol myer have raise adjust earning expectation company now project earning range share old guidance zack consensus estimate earning be peg takebristol myer miss earning expectation primarily due increase expense however robust sale drug opdivo eliquis yervoy quarter drive top line revise guidance be also encourage meanwhile be positive bristol myer effort develop pipeline especially opdivo bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotebristol myer carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
228,BMY,bristol myer squibb company bmy free report be new york base major producer distributor pharmaceutical other healthcare related product company key oncology product include opdivo sprycel yervoy recently launch empliciti other oncology company be focuse immunology cardiovascular drug orencia eliquis also market drug hbv hcv baraclude daklinza company virology portfolio comprise product reyataz sustiva franchise bristol myer be also active partnership front pursue strategic acquisition therapeutic area include immunoscience oncology fibrosis genetically defined disease however many peer bristol myer be face generic competition several key product moreover hiv hcv business be competitive pressure scenario investor focus remain company high profile immuno oncology drug opdivo apart usual top bottom line number bristol myer have mixed record earning surprise recent quarters company earning surpass expectation last quarters average positive surprise currently bristol myer have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning bristol myer miss third quarter earning company report ep cent consensus call ep cent revenue however revenue be expectation bristol myer post revenue compare consensus estimate guidance bristol myer update earning outlook company expect earning range share zack consensus estimate earning stand share pre market trading share be pre market trading check back later full bmy earning report later bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
229,BMY,third quarter earning season be strong start result company have report number show earning revenue growth pace be accelerate first quarters particular revenue growth have show significant momentum evident proportion positive revenue surprise total earning index third quarter be expect be higher revenue oct company account index total market capitalization have report result result reveal earning company be year quarter increase revenue beat earning estimate beat revenue estimate medical sector medical sector have perform relatively well date quarter be not go be different estimate company have report so far beat revenue company surpass earning expectation go forward sector be expect record year year growth revenue earning bellwether sector johnson johnson jnj free report report better expect third quarter result raise outlook swiss giant novartis ag nvs free report too beat earning sale back new drug cosentyx entresto eli lilly company lly free report also report better expect result third quarter here have major biotech giant be set report third quarter result oct let see thing be shape gilead science inc gild free report be expect beat expectation report market close zack model stock need have positive earning esp zack rank strong buy buy hold beat zack consensus estimate gilead track record be pretty mixed company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead currently carry zack rank earning esp combination zack rank positive esp make confident earning beat uncover best stock buy sell re report earning esp filter strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue third quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy specifically genvoya be now company bestselling hiv product treatment naïve patient share zack consensus estimate genvoya stand strong uptake truvada use pre exposure prophylaxis set be also expect boost sale read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotebristol myer squibb company bmy free report be likely beat expectation report result market open bristol myer track record have be positive so far company deliver positive earning surprise last quarters miss expectation company average positive earning surprise last quarters be company currently carry zack rank earning esp see complete list today zack rank stock here bristol myer high profile immuno oncology drug opdivo be expect be primary sale driver third quarter meanwhile rheumatoid arthritis drug orencia receive approval treat psoriatic arthritis unite state well europe july moreover june bristol myer announce availability subcutaneous administration option orencia patient moderately severely active polyarticular juvenile idiopathic arthritis label expansion new administration option be expect fuel growth drug read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report result open bell celgene have excellent track record company beating earning estimate last quarters last quarter company beat expectation overall company have deliver average positive surprise celgene currently carry zack rank esp combination zack rank positive esp make confident earning beat expect company beat estimate once again back strong performance key drug revlimid drug perform well first half combat challenge uneven buy pattern coverage gap continue momentum core indication label expansion global launch help product keep contribute top line zack consensus estimate drug currently stand read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently beaten expectation last quarters average positive earning surprise company currently carry zack rank esp make surprise prediction difficult alexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be also work expand soliris label additional indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quotezack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
230,BMY,expect pfizer inc pfe free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise pfizer share have rise year so far compare unfavorably increase zack classify industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue sale viagra be also likely be affected lower demand zack consensus estimate prevnar enbrel be respectively call management say penetration inflectra pfizer biosimilar version jnj free report blockbuster rheumatoid arthritis drug remicade unite state have be slower expect be experience access challenge national commercial payer fact september pfizer file lawsuit district court allege wasresorting unfair practice prevent sale inflectra do not discuss much inflectra impact brand drug sale lawsuit call expect update pfizer upcoming investor call meanwhile bottom line be likely be drive cost saving share buyback however new product launch expense investment be expect hurt profit pfizer acute lymphoblastic leukemia candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be also approve eu japan september leukemia treatment besponsa inotuzumab ozogamicin relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be also approve fda third quarter besponsa be also approve eu june expect management record sale new cancer drug quarter earlier month pfizer say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction update matter be expect investor call model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteother stock considera couple stock pharmaceutical sector also have positive earning esp favorable zack rank be merck co inc mrk free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here bristol myer squibb company bmy free report schedule release result oct have earning esp zack rank zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
231,BMY,thank encourage industry trend hope favorable policy environment healthcare be top perform sector year notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far read healthcare etf hit new week high bullish trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive value style score growth momentum style score respectively look disappointing pfizer be schedule report earning oct open bell pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result oct market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision cent past day be report quarter merck have strong momentum style score value growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning oct market close read keep portfolio healthy biotech etfs amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see negative earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report oct open bell abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning oct market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision nickel past month be report quarter have solid value style score growth momentum style score respectively look ugly see healthcare etfs here gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning oct open bell have zack rank earning esp stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision couple cent be report quarter have solid growth style score unfavorable value momentum style score respectively bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum earning surprise well card healthcare sector be expect witness earning growth third quarter have strong zack rank top suggest further upside healthcare etfs particular etfs have zack etf rank read top rank healthcare etfs long term investor want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
232,BMY,expect merck co inc mrk free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be merck share have rise year so far compare unfavorably increase industry factor considermerck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe key recent approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer new approval have expand patient population be expect drive sale third quarter however call management warn zepatier uptake be impact ongoing decline overall patient volume many market increase competition previously strong underlie demand trend unite state europe japan have support zepatier sale company also face headwind form genericization well increase competition negative impact currency exchange sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection unite state june zetia lose market exclusivity unite state december vytorin lose exclusivity april be likely decline quarter sluggish growth integrase class continue competitor dynamic unite state europe continue affect isentress sale zack consensus estimate isentress sale be third quarter investor also be focuse performance merck dpp inhibitor januvia pricing pressure hurt sale januvia janumet franchise first half vaccine animal health franchise be expect boost sale quarter zack consensus estimate vaccine total animal health segment be respectively call merck mentioned network cyber attack june disrupt global operation include manufacturing research sale time merck have say full recovery cyber attack take time result temporary delay fulfill order product not keytruda zepatier januvia certain market expect update upcoming conference call remediation expense related cyber attack increase investment ongoing launch additional cost associate new oncology collaboration astrazeneca be expect result higher operate cost quarter earning whispersour proven model show merck be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank merck have zack rank combination merck zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision merck company inc price ep surprise merck company inc price ep surprise merck company inc quoteother stock considerother large cap pharma stock have positive esp favorable zack rank include bristol myer squibb company bmy free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result oct today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
233,BMY,expect bristol myer squibb company bmy free report beat expectation report third quarter result oct market open year date bristol myer share have increase industry have record increase bristol myer track record have be positive so far company deliver positive earning surprise last quarters miss expectation average positive earning surprise last quarters be last report quarter bristol myer come positive surprise let see thing be shape quarter factor playbristol myer high profile immuno oncology drug opdivo be expect be primary sale driver third quarter drug be already approve multiple cancer indication quarter fda approve drug additional indication hepatocellular carcinoma metastatic colorectal cancer patient have receive prior treatment label expansion be not expect have much impact top line combine label expansion second quarter certainly boost sale second quarter see stability second line lung cancer set fda approval merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc increase competition impact sale unfavorably zack consensus estimate indicate drug sale increase year quarter july fda also approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma zack consensus estimate drug quarter be meanwhile rheumatoid arthritis drug orencia receive approval treat psoriatic arthritis unite state well europe july moreover june bristol myer announce availability subcutaneous administration option orencia patient moderately severely active polyarticular juvenile idiopathic arthritis label expansion new administration option be expect fuel growth drug drug register growth previous quarter be expect generate sale quarter zack consensus estimate other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter company be develop key drug opdivo monotherapy well combination therapy several tumor type multiple study label expansion application review unite state expect investor focus update related opdivo conference call likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer currently have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quoteother stock warrant lookhere be biotech stock also want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report be expect release result nov company have earning esp zack rank see complete list today zack rank stock here celgene corp celg free report be schedule release result oct company have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
234,BMY,roche hold ag rhhby free report report sale chf first month year period roche stock have gain year date compare industry gain company report result division pharmaceutical diagnostic growth rate mentioned be year year basis constant exchange rate sale pharmaceutical division increase drive strong growth tecentriq ocrevus alecensa perjeta be partially offset lower sale tarceva tamiflu avastin diagnostic division sale climb primarily back strong business result detailherceptin sale improve due increase demand unite state brazil additional reimbursement approval broader use china perjeta sale grow follow increase demand neoadjuvant metastatic setting europe unite state brazil sale kadcyla be drive increase demand international market meanwhile sale avastin decrease due increase use cancer immunotherapy medicine lung cancer sale rituxan mabthera be drive growth oncology well immunology segment growth gazyva gazyvaro be strong increase competition chronic lymphocytic leukemia recently launch drug tecentriq bladder cancer alecensa lung cancer be strong start tecentriq ocrevus alecensa contribute chf new sale performance immunology franchise be drive increase sale actemra roactemra strong uptake esbriet xolair increase use actemra roactemra single agent subcutaneous formulation be key growth driver however sale tarceva decline due grow use other therapeutic option sale xeloda continue be hit generic competition sale tamiflu also decline revenue diagnostic division climb back solid performance centralised point care solution unit be turn propel tissue diagnostic molecular diagnostic also perform impressively however diabetes care sale decline sale continue be impact challenge market condition particularly north america outlook reiteratedroche now expect sale grow mid single digit company expect core earning grow tandem sale company intend further increase dividend local currency pipeline progressroche continue expand cancer immunotherapy drug tecentriq label tecentriq be approve unite state monotherapy treatment patient suffering locally advanced metastatic bladder cancer have be previously treat platinum contain chemotherapy be consider ineligible cisplatin chemotherapy regardless pd status arthritis drug roactemra be approve treatment giant cell arteritis gazyvaro combination chemotherapy be approve previously untreated advanced follicular lymphoma fda also approve actemra intravenous injection treatment chimeric antigen receptor car cell induced severe life threaten cytokine release syndrome patient year age older takeroche performance first month be strong drive contribution newly launch drug label expansion key drug further drive growth however sale avastin tarceva continue decline generic competition xeloda also continue hurt sale note competition biosimilar loom large roche key drug herceptin avastin rituxan first biosimilar mabthera be already market company expect biosimilar herceptin end early note novartis ag nvs free report have already launch bisomilar version rituxan mabthera europe moreover roche be face stiff competition like merck co inc mrk free report keytruda bristol myer squibb company bmy free report opdivo immuno oncology space zack rankroche currently carry zack rank hold see complete list today zack strong buy rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
235,BMY,approval gilead science inc gild free report yescarta week see approval second car therapy treat cancer be regard most advanced immune oncology treatment option moreover fda have grant priority review label expansion application major cancer drug include astrazeneca plc azn free report lynparza advanced breast cancer imfinzi earlier stage lung cancer bristol myer squibb company bmy free report opdivo melanoma patient high risk recurrence exelixis inc exel free report cabometyx advanced renal cell carcinoma rcc meanwhile ipsen partner exelixis announce positive result phase iii study hepatocellular carcinoma candidate moreover abbvie abbv free report enter immuno oncology research collaboration harpoon therapeutic focuse novel cell recruit biologic therapy abbvie use harpoon tri specific cell activate construct platform develop immuno oncology pipeline let see news detail key newsgilead acquisition kite pharma nearly have finally paid approval yescarta axicabtagene ciloleucel latter chimeric antigen receptor cell car therapy candidate fda approve therapy treat relapse refractory large cell lymphoma rlbcl adult have receive more line systemic therapy various form rlbcl yescarta be approve include diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl high grade cell lymphoma be second gene therapy be approve unite state novartis ag nvs free report kymriah receive approval august acute lymphoblastic leukemia car therapy be most advanced form treat cancer be do modify patient cell part body immune system fight cancerous cell therapy be manufacture specifically single patient gilead science inc price consensus gilead science inc price consensus gilead science inc partner merck mrk free report market advanced ovarian cancer drug lynparza receive priority review supplemental new drug application snda seek approval previously treat chemotherapy patient negative metastatic breast cancer fda be expect give decision first quarter lynparza be different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer meanwhile fda have also grant priority review astrazeneca snda key cancer drug imfinzi unresectable small cell lung cancer read more astrazeneca snda cancer drug get priority review astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quotebristol myer announce fda have grant priority review supplemental biologic license application sbla label expansion opdivo company be look get drug approve treat patient melanoma be high risk disease recurrence follow complete surgical resection drug be already approve treatment patient braf mutation positive unresectable metastatic melanoma moreover company announce opdivo alone combination yervoy achieve encourage result previously treat small cell lung cancer patient phase ii checkmate study opdivo monotherapy combo therapy achieve objective response rate respectively read more bristol myer get priority review opdivo label expansion bristol myer squibb company price consensus bristol myer squibb company price consensus bristol myer squibb company quoteother newsexelixis renal carcinoma drug cabometyx be also grant priority review fda snda snda seek approval cabometyx patient treatment naive advanced rcc fda deem snda be sufficiently complete decision expect feb moreover company advanced hepatocellular carcinoma candidate cabozantinib achieve statistically significant clinically meaningful improvement median overall survival rate placebo phase iii celestial study exelixis be develop candidate partnership ipsen meanwhile inovio pharmaceutical inc ino free report initiate phase ib ii study evaluate combination ino cell activate immunotherapy ino immune activator roche pdl inhibitor tecentriq advanced bladder cancer immune design also initiate pivotal phase iii study support regulatory application cmb treat patient synovial sarcoma wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
236,BMY,expect glaxosmithkline plc gsk free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise glaxo share be year so far underperform increase witness industry glaxo performance have be pretty good so far company earning beat expectation thrice trail quarters meeting estimate remain quarter overall company have deliver average positive earning surprise let see thing be shape quarter factor considerglaxo continue see strong performance pharmaceutical vaccine business segment glaxo pharmaceutical segment be expect be drive strong sale new hiv product tivicay triumeq sale newly launch respiratory drug ellipta product nucala be expect offset decline seretide advair avodart many glaxo key drug lovaza avodart be face decline sale due generic competition importantly pricing dynamic competitive pressure be hurt sale top selling drug advair unite state generic competition be hurt advair sale europe generic version advair unite state be unlikely be approve year vaccine segment continue benefit continue uptake meningitis vaccine bexsero menveo acquire novartis ag nvs free report importantly sale growth be slow consumer healthcare segment due slowdown market condition impact divesture consumer healthcare segment be expect remain pressure third fourth quarters be not expect contribute much sale growth year meanwhile cost saving restructure continue efficiency boost operate profit september glaxo partner innoviva gain fda approval once daily single inhaler triple therapy trelegy ellipta copd combination inhaled corticosteroid ics long act muscarinic antagonist lama long act beta adrenergic agonist laba trelegy ellipta provide patient convenient dose option be expect bring blockbuster sale expect management comment plan newly approve product conference call earning whispersour proven model show glaxo be likely beat estimate have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise glaxo have right mix zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be uncover best stock buy sell re report earning esp filter zack rank glaxo have zack rank combination glaxo zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quoteother stock considerother large cap pharma stock have positive esp favorable zack rank includebristol myer squibb company bmy free report schedule release result oct earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result oct wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
237,BMY,johnson johnson jnj free report kick third quarter earning season pharmaceutical sector strong note company beating earning revenue focus remain strong earning result company allergan agn free report be also news regard patent litigation recap week most important storiesj result impress raise outlook earning result be strong company beating earning revenue segment consumer medical device pharmaceutical do well oncology record robust growth result include contribution pulmonary hypertension product become part company portfolio follow acquisition actelion base solid third quarter result raise outlook year well read more beat earning actelion buyout drife sale company have gain year date compare rally industry belong sanofi dupixent top allergic inflammatory disease study sanofi partner regeneron pharmaceutical announce positive phase ii result dupixent dupilumab adult active moderate severe eosinophilic esophagitis chronic allergic inflammatory disease patient receive dupixent weekly report significant improvement ability swallow versus placebo read more sanofi regeneron dupixent succeed phase ii study market be huge dupixent gain timely approval give lack fda approve treatment dupixent have orphan drug status unite state indication dupixent have blockbuster potential be currently approve eczema be be evaluate additional indication apart eosinophilic esophagitis fact last month company have announce positive top line datum late stage study dupixent uncontrolled persistent asthma regeneron sanofi be also collaborate aimmune therapeutic clinical stage company focuse development treatment potentially life threaten food allergy clinical collaboration aimmune ar be evaluate adjunctive dupixent peanut allergic patient mid stage study be schedule commence next year study be sponsored regeneron aimmune provide clinical supply ar food challenge material datum merck keytruda priority review lynparza snda merck mrk free report present update overall survival os datum pd therapy keytruda first line treatment patient suffering metastatic small cell lung cancer high level pd company say additional month available datum continue show reduction risk death keytruda compare chemotherapy keytruda more double median os compare chemotherapy year follow keytruda be key product merck portfolio drug bring sale first half merck partner astrazeneca also announce have be grant priority review fda supplemental new drug application snda use parp inhibitor lynparza tablet patient gbrca negative metastatic breast cancer mbc have be previously treat chemotherapy neoadjuvant adjuvant metastatic setting response agency be expect first quarter nordisk diabetes drug get fda panel support nordisk nvo free report get boost fda advisory panel endocrinologic metabolic drug advisory committee voting unanimously favor approve once weekly semaglutide use type ii diabetes patient give favorable vote chance gain fda approval look pretty high second quarter call nordisk have say expect decision fda year end semaglutide approval be major positive company drug expect be key growth driver nordisk be zack rank buy stock see complete list today zack rank strong buy stock here priority review bmy drug label expansion bristol myer squibb company bmy free report immuno oncology therapy opdivo have be grant priority review fda label expansion treatment melanoma patient be high risk disease recurrence follow complete surgical resection opdivo prioritize brand bristol myer portfolio bring sale first half read more bristol myer get priority review opdivo label expansion adverse ruling allergan restasis patent litigation allergan continue make headline related blockbuster eye drug restasis time round company announce have receive adverse ruling district court eastern district texas regard patent cover drug court find patent be invalid allergan intend appeal ruling say fda be yet approve generic version drug however ophthalmology focuse company imprimis pharmaceutical announce be work make lower cost alternative restasis available company say initial prescription be cent month supply refill start month include shipping accord allergan restasis patent be schedule expire aug allergan enter settlement agreement generic challenger recently innopharma have be adopt different way protect restasis generic competition company come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent deal have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug impax combine amneal specialty pharma company impax laboratory be merge privately hold generic company amneal pharmaceutical stock transaction merger combine company have high value generic product pipeline grow specialty business deal be expect boost impax stand alone earning share first month generate double digit revenue earning share growth year follow close transaction annual cost synergy be expect be achieve year merger be expect go first half read more impax laboratory amneal pharmaceutical agree merge cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be week sector react positively result major stock be bristol myer decline last month bristol myer be see last pharma stock roundup here pfizer mull option consumer healthcare lly pipeline setback next pharma world watch earning result company novartis eli lilly lly free report bristol myer other come week wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
238,BMY,johnson johnson jnj free report be first large cap pharma stock report earning result season oct beat zack consensus estimate earning revenue third quarter also raise sale profit outlook share be more tuesday sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter acquire swiss biotech actelion june year overall pharma sector have witness great turnaround year drug pricing issue cripple performance last year decline last year large cap pharma industry have rise year so far outpace gain same time frame new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval new drug approve alone continue strong performance legacy product have play pivotal role bring sector track year factor be likely drive sector rest year probably next challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug better expect result especially strong performance pharmaceutical segment have raise optimism strong quarterly performance pharma sector mainly large cap company let have closer look expect big pharma stock report month early next month company be expect deliver earning beat quarter pfizer inc pfe free report pfizer be schedule announce third quarter result oct market open zack rank hold earning esp chance stock beating zack consensus estimate third quarter be high uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be expect contribute pfizer top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth blockbuster drug enbrel sale continue be soft quarter due biosimilar competition pfizer surpass zack consensus estimate trail quarters show chart pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotebristol myer squibb company bmy free report bristol myer be schedule release result oct market open similar pfizer quantitative model indicate earning beat bristol myer zack rank stock have earning esp see complete list today zack rank strong buy stock here bristol myer high profile immuno oncology drug opdivo be likely drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication also boost drug sale bristol myer outpaced zack consensus estimate trail quarters reflect chart bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotemerck company inc mrk free report merck be schedule release result oct market open zack rank earning esp chance stock beating zack consensus estimate third quarter be high merck new product keytruda cancer zepatier hcv bridion sugammadex injection likely drive revenue quarter well keytruda sale unite state be gain particularly strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe new approval expand patient population be expect drive sale further however genericization increase competition likely remain overhang merck outpaced zack consensus estimate trail quarters reflect chart merck company inc price ep surprise merck company inc price ep surprise merck company inc plc gsk free report brentford uk base glaxosmithkline be expect report result oct glaxosmithkline be also expect outperform third quarter due zack rank buy earning esp glaxo pharmaceutical vaccine business segment be expect perform well glaxo pharmaceutical segment be expect continue be drive strong sale new hiv product tivicay triumeq however many glaxo key drug lovaza avodart be face decline sale due generic competition moreover sluggish sale growth consumer healthcare segment due slowdown market condition impact divesture negatively impact top line third quarter notably company surpass zack consensus estimate trail quarters show chart glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quoteeli lilly company lly free report eli lillyis slate announce third quarter result oct market open zack rank earning esp chance earning beat be report quarter be high continue trend past few quarters new product trulicity cyramza taltz jardiance be likely support top line report quarter however sluggish performance alimta cymbalta zyprexa be expect continue third quarter due loss exclusivity notably eli lilly surpass zack consensus estimate trail quarters show chart eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotenovartis ag nvs free report swiss company novartis be schedule report result oct market open novartis be not expect beat estimate third quarter due zack rank earning esp recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space moreover new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie humira amgen enbrel cosentyx achieve blockbuster status however weak alcon business generic competition several key drug be expect hurt revenue quarter notably novartis outpaced zack consensus estimate trail quarters reflect chart novartis ag price ep surprise novartis ag price ep surprise novartis ag hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
239,BMY,expect biogen inc biib free report well know name multiple sclerosis ms market beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise biogen share have rise year better industry growth same time frame biogen earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be let see thing be shape announcement factor considerglobal patient growth be drive prescription trend sale biogen ms drug expect trend continue third quarter however rise competition roche rhhby free report newly launch ms drug ocrevus hurt sale tysabri modestly second quarter zack consensus estimate key ms drug tysabri tecfidera be respectively meanwhile combine number patient used avonex plegridy continue decline patient transition other oral ms therapy well due higher discount allowance spinraza approve spinal muscular atrophy december witness faster anticipate adoption unite state first half backed robust underlie demand june july spinraza be approve eu canada japan boost sale however call management have mentioned spinraza sale slow second half more difficult treat patient be come patient transition intensive spinraza treatment induction less intensive maintenance schedule biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate higher revenue trend continue quarter well headcount reduction restructure initiative be expect continue lower operate expense meanwhile expense be expect increase due increase business development payment investor focus remain tecfidera scrip trend sale rampup spinraza pipeline progress acquisition plan earning whispersour proven model show biogen be likely beat estimate have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise biogen have right mix zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank biogen have zack rank combination biogen zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision biogen inc price ep surprise biogen inc price ep surprise biogen inc quoteother stock considersome other stock biotech pharmaceutical sector have positive esp favorable zack rank includebristol myer squibb company bmy free report schedule release result oct earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result oct hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
240,BMY,eli lilly company lly free report report third quarter result oct market open last quarter company deliver positive earning surprise lilly share have rise year so far industry record increase lilly performance have be mixed earning miss expectation last quarters beating same other bring average negative surprise let see thing be shape quarter factor considernew product trulicity taltz jardiance have support top line past few quarters expect trend continue third quarter well trulicity sale be expect be drive growth glp market market share gain jardiance sale be likely be drive increase market share grow sglt class newer product basaglar lartruvo taltz continue witness better sequential sale backed strong launch uptake however sale alimta cymbalta zyprexa be expect decline due loss exclusivity cymbalta have lose exclusivity europe canada zyprexa japan alimta several country outside unite state meanwhile lower demand unite state due competitive pressure mainly immuno oncology agent be hurt alimta sale country consensus estimate alimta third quarter be new drug olumiant baricitinib have be launch select european country july drug be approve japan be likely add top line third quarter however unite state drug be review august lilly partner incyte corporation incy free report announce re submit nda baricitinib much faster previously expect nda be expect be re submit january next year meanwhile older product humulin trajenta forteo continue do well animal health segment sale past quarters have be hurt global competitive pressure conference call management have say global competitive pressure continue hurt revenue segment rest year lesser extent consensus estimate animal health segment third quarter be earning whispersour proven model do not conclusively show lilly be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank lilly zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotestock considerstock pharmaceutical sector have positive esp favorable zack rank includebristol myer squibb company bmy free report schedule release result oct earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result oct hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
241,BMY,bristol myer squibb company bmy free report extend strategic partnership target pharmasolution inc partnership have be extend target nash multus year deal note company announce new collaboration nov treatment alcoholic steatohepatitis nash hepatocellular carcinoma hcc target model be design provide pharmaceutical biotechnology partner access robust disease state registry be also link biorepository patient report outcome provide unique datum insight compare typical patient registry target nash longitudinal observational study be evaluate patient suffering alcoholic steatohepatitis have enroled patient site study be collect retrospective prospective datum enroled patient be develop biorepository stakeholder access translational study include genomic biomarker bristol myer stock have rally last month compare industry rally gain bristol myer already have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo april company be entitle right research develop commercialize bms ambrx inc chronic liver disease nash be cause excessive fat accumulation liver turn be know steatosis nash be know affect person unite state lead inflammation hepatocellular injury progressive fibrosis cirrhosis be expect be lead cause liver transplantation notably be currently lead cause liver transplant person unite state other major company promising candidate nash include intercept pharmaceutical inc icpt free report gilead science inc gild free report novartis ag nvs free report zack rank bristol myer squibb be zack rank hold stock see complete list today zack rank strong buy stock here stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
242,BMY,company pfizer pfe free report merck mrk free report eli lilly lly free report be news week pfizer be mull strategic option consumer healthcare business merck say not file cetp inhibitor recap week most important storiespfizer divest consumer healthcare segment pfizer be currently review different strategic option consumer healthcare business include full partial separation spin sale company also ultimately decide retain business be not first time pfizer have decide spin sell core business segment strategic step take pfizer include sale hospira infusion system business icu medical february spin animal health business lead creation zoetis well divestment nutrition business nestle pfizer have sell capsugel business affiliate kohlberg kravis robert co divestment consumer healthcare business help pfizer focus innovative health segment also bring fund company use return value shareholder form share buyback dividend read more pfizer consider sale spin consumer healthcare unit pfizer be zack rank hold stock see complete list today zack rank strong buy stock here company have gain year date compare rally industry belong merck collaborate kalvista clinical stage pharma company kalvista pharmaceutical see share shoot collaboration agreement merck kvd future oral diabetic macular edema dme compound base plasma kallikrein inhibition kvd investigational intravitreal ivt injection be schedule move phase ii proof concept study later year merck have option acquire right candidate follow completion study merck have similar option certain other dme candidate kalvista receive refundable upfront payment well payment associate exercise option merck achievement milestone program add company also stand receive tiered royalty net sale candidate commercialize deal merck also acquire ownership stake kalvista worth pipeline setback lilly lilly suffer setback recently approve breast cancer drug verzenio fail meet primary endpoint late stage study kra mutate advanced small cell lung cancer cdk inhibitor fail meet primary endpoint overall survival os analysis secondary endpoint progression free survival pfs overall response rate orr show evidence monotherapy activity read more lilly verzenio fail phase iii lung cancer study meanwhile verzenio have be grant priority review fda use initial treatment advanced breast cancer mean response agency be month receive regulatory application instead usual timeframe month seek fda nod new prostate cancer treatment johnson johnson janssen biotech be seek fda approval apalutamide investigational next generation oral androgen receptor ar inhibitor man metastatic castration resistant prostate cancer crpc be significant unmet need patient population give absence fda approve treatment patient prostate cancer most common cancer american man be expect be diagnosed more man american cancer society apalutamide become part pipeline follow acquisition privately hold aragon pharmaceutical apalutamide approval strengthen expand presence prostate cancer market company currently sell zytiga be approve use combination prednisone treatment patient metastatic castration resistant prostate cancer mcrpc be look expand zytiga label earlier stage metastatic prostate cancer allergan settle restasis litigation innopharma allergan agn free report enter settlement agreement innopharma related litigation regard restasis patent challenged patent be list orange book be schedule expire aug settlement agreement innopharma start selling generic version eye drug unite state feb earlier certain circumstance moreover certain circumstance innopharma be allow launch authorize generic version restasis aug allergan be adopt different way protect restasis generic competition company recently come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect blockbuster eye drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent fact tribe be filing dismiss ongoing parte review ipr restasis patent base sovereign immunity ipr challenge deal tribe have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug allergan have be ask committee oversight government reform provide certain document information deal oct merck not file anacetrapib merck have decide not seek regulatory approval investigational cetp inhibitor anacetrapib company decision be base thorough review clinical profile drug note merck be not first company drop cetp inhibitor plan company lilly roche pfizer have have high profile setback cetp inhibitor class be more less written read more merck not seek approval cetp inhibitor anacetrapib crl acelrx acelrx pharmaceutical acrx free report share plunge company get complete response letter crl fda sufentanil sublingual tablet fda say approve regulatory application current form have ask additional safety datum agency have also ask company make certain change direction use ensure proper administration tablet acelrx have be ask validate same human factor study acelrx be look get approve reduction moderate severe acute pain dose error associate iv administration invasive single dose applicator sda medically supervised setting cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain week major stock be lilly decline last month bristol myer squibb bmy free report be see last pharma stock roundup here mylan teva copaxone news lawmaker question allergan deal next pharma world aerie pharmaceutical aeri free report rhopressa be evaluate fda advisory panel treatment patient open angle glaucoma ocular hypertension october company share be favorable briefing document be report earning october read more kickstart pharma earning store stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
243,BMY,infinity pharmaceutical inc infi free report announce have expand exist clinical collaboration bristol myer squibb bmy free report evaluate ipi combination latter checkpoint inhibitor opdivo collaboration include patient triple negative breast cancer tnbc have not be previously expose pd pd therapy very few patient triple negative breast cancer respond checkpoint inhibitor alone so be left very limit therapeutic option thus expand collaboration include patient triple negative breast cancer tnbc have not be previously expose pd pd therapy turn enable infinity test ipi combination opdivo increase number patient respond checkpoint inhibition markedly ipi be lead pipeline candidate infinity pharmaceutical be be evaluate phase ib study treatment patient solid tumor be orally administer treatment selectively inhibit kinase pi gamma november infinity enter clinical trial collaboration bristol myer evaluate ipi combination opdivo patient advanced solid tumor meanwhile opdivo be approve varied indication eu unite state also have receive approval several indication include melanoma head neck lung kidney blood cancer however infinity share have underperform industry year date stock have be industry gain same time frame be note phase ib study evaluate ipi monotherapy combination opdivo patient advanced solid tumor patient enrollment be complete monotherapy dose escalation monotherapy expansion be ongoing combination dose escalation be also ongoing expansion be expect begin second half markedly combination expansion component comprise multiple cohort design evaluate ipi patient specific type cancer include patient small cell lung cancer nsclc melanoma head neck squamous cell carcinoma hnscc tumor show initial resistance subsequently develop resistance immune checkpoint blockade therapy additionally also have cohort patient tnbc have not be previously expose immune checkpoint blockade therapy infinity pharmaceutical inc price infinity pharmaceutical inc price infinity pharmaceutical inc quotezack rank stock currently carry zack rank sell better rank stock health care sector include regeneron pharmaceutical inc regn free report alexion pharmaceutical inc alxn free report regeneron sport zack rank strong buy alexion hold zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
244,BMY,key highlight pharma sector include complete response letter crl fda johnson johnson jnj free report investigational rheumatoid arthritis ra treatment fda approval merck mrk free report bristol myer squibb bmy free report cancer drug recap week most important storiescrl ra drug janssen biotech get crl fda sirukumab treatment moderately severely active ra agency have ask additional datum safety sirukumab do not come surprise consider investigational treatment fail get support fda advisory panel last month give safety concern raise panel request additional datum be more less expect intend meet agency determine requirement gain approval il inhibitor meanwhile company have submit new drug application nda first darunavir base single tablet regimen treatment hiv approval make combination only complete regimen potential deliver advantage single table regimen high genetic barrier resistance darunavir demonstrated safety profile taf fda nod merck keytruda merck pd therapy keytruda have gain fda approval yet indication cancer therapy be already available wide range indication now be used previously treat patient recurrent locally advanced metastatic gastric junction gej adenocarcinoma tumor express pd mark tenth new indication keytruda year period keytruda be key product merck portfolio drug bring sale first half company be work expand label drug be currently more study cover wide range cancer treatment setting read more merck keytruda get fda nod advanced gastric cancer merck be zack rank hold stock see complete list today zack rank strong buy stock here allergan announce share buy back cfo departure allergan agn free report continue work return capital shareholder company announce intention buy back share worth come shortly company complete share buyback program allergan also reaffirm commitment increase cash dividend year reiterate commitment maintain investment grade credit rating pay debt company also announce departure tessa hilado executive vice president chief financial officer cfo be retire company once successor be appoint bristol myer opdivo get approval bristol myer also gain approval indication immune oncology therapy opdivo latest approval opdivo now be used treatment hepatocellular carcinoma patient previously treat nexavar sorafenib make opdivo first only immuno oncology agent be approve patient population read more bristol myer opdivo get approval liver cancer company also gain approval japan use opdivo treatment unresectable advanced recurrent gastric cancer have progressed chemotherapy gastric cancer be highly prevalent asian country be second most commonly diagnosed cancer japan bristol myer also enter clinical trial collaboration abbvie combination opdivo abbvie investigational antibody drug conjugate abbv be evaluate meet overexpressing small cell lung cancer nsclc bristol myer stock have gain year date compare rally industry belong priority review aradigm drug aradigm get priority review linhaliq treatment cystic fibrosis bronchiectasis ncfbe patient chronic infection pseudomona aeruginosa aeruginosa response agency regard approval status drug be jan ncfbe severe chronic rare disease affect more person unite state person europe drug currently approve treatment condition be significant unmet need aradigm share be news cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be so far week major stock lilly lly free report be pfizer pfe free report be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here pfizer file suit supernus hit study update next pharma world watch usual pipeline regulatory update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
245,BMY,abbvie abbv free report bristol myer squibb company bmy free report enter deal evaluate combination abbvie investigational antibody drug conjugate abbv bristol myer squibb immune oncology drug opdivo nivolumab meet overexpressing small cell lung cancer nsclc currently combination be phase study evaluate patient second line treatment have fail prior line chemotherapy specific term deal be not disclose notably abbvie be sponsor conduct trial abbvie share have outperformed industry year date stock have be compare industry gain same time frame remind investor opdivo be approve varied indication eu unite state drug have also receive approval several indication include melanoma head neck lung kidney blood cancer abbv be meet antibody drug conjugate target meet amplify meet overexpressing tumor be currently be develop treat advanced solid tumor fact opdivo continue be launch globally approval label expansion label expansion additional indication give product access higher patient population increase commercial potential drug significantly markedly opdivo be be study combination bristol myer other drug yevroy melanoma indication opdivo yervoy regimen be contribute growth opdivo yervoy also drug become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november second quarter opdivo generate revenue year period abbvie inc price abbvie inc price abbvie inc quotezack rank stock considerabbvie currently carry zack rank hold better rank stock health care sector include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report sporting zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
246,BMY,bristol myer squibb company bmy free report announce fda have approve immuno oncology drug opdivo intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar approval indication be grant accelerate approval base tumor response rate durability response however continue approval indication be contingent verification description clinical benefit confirmatory trial estimate hcc be most common type liver cancer fastest grow cause cancer death note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy bristol myer stock have rally year date compare industry gain label expansion additional indication give product access more patient increase commercial potential drug additionally company enter collaboration agreement seattle genetic inc sgen free report june deal bristol myer evaluate combination opdivo seattle genetic antibody drug conjugate adc adcetris phase iii trial potential treatment option patient relapse refractory transplant ineligible advanced classical hodgkin lymphoma hl however bristol myer suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share meanwhile fda put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma addition concern astrazeneca azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo zack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
247,BMY,key highlight week include lawsuit file pfizer pfe free report accuse johnson johnson jnj free report adopt exclusionary contract other anticompetitive practice prevent biosimilar uptake meanwhile company glaxosmithkline gsk free report supernus pharmaceutical supn free report be news regulatory pipeline update recap week most important storiessupernus study update supernus provide update first phase iii study spn be be evaluate treatment impulsive aggression ia patient age year have attention deficit hyperactivity disorder adhd base plan interim analysis company have decide drop lower dose mg study patient be randomize receive mg dose placebo investor be disappoint update share be read more supernus drop spn lower dose test phase iii trial chmp positive psoriasis drug tremfya guselkumab get positive opinion eu committee medicinal product human use chmp recommend marketing authorization treatment adult moderate severe plaque psoriasis be candidate systemic therapy timely approval make tremfya first biologic selectively block interleukin il cytokine play key role plaque psoriasis accord information press release person europe be estimate suffer psoriasis tremfya gain fda approval earlier year july pfizer file suit biosimilar pfizer have file lawsuit district court eastern district pennsylvania related provide patient physician access lower cost biosimilar accord lawsuit have adopt exclusionary contract other anticompetitive practice deny access undermine benefit price competition biologic market order maintain monopoly connection remicade infliximab be accuse lawsuit inappropriately exclude biosimilar competitor pfizer have launch inflectra biosimilar version remicade late biosimilar available eu many year be relatively recent entrant unite state be yet have significant impact reference product sale read more pfizer sue accuse prevent inflectra uptake glaxo innoviva copd treatment get fda nod glaxo partner innoviva get boost fda approval once daily single inhaler triple therapy trelegy ellipta treatment appropriate patient chronic obstructive pulmonary disease copd combination inhaled corticosteroid ics long act muscarinic antagonist lama long act beta adrenergic agonist laba trelegy ellipta provide patient convenient dose option be expect bring blockbuster sale read more glaxo innoviva triple combo therapy get fda nod copd glaxo stock have gain year date compare rally industry belong teva divest woman health business teva teva free report recently get new chief executive officer ceo be take step get performance back track company announce sale remain asset specialty global woman health portfolio plan divestiture segment bring total proceed be used teva pay debt decision sell woman health business be part teva effort divest core segment focus key strategic area company also announce amendment usd jpy term loan revolve credit facility teva be currently go tough time company be hit generic pricing erosion company need work pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track roche abbvie cancer drug positive late stage study roche rhhby free report partner abbvie be look expand label cancer therapy venclexta venclyxto result late stage study murano show venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll independent datum monitoring committee have recommend unblind study base positive result label expansion indication expand patient population venclexta significantly boost commercial potential read more roche announce positive datum leukemia drug roche be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index slip last trading session major stock bristol myer squibb bmy free report gain slip last month bristol myer be glaxo decline see last pharma stock roundup here achillion slump end hcv deal teva get new ceo next pharma world watch usual pipeline regulatory update bristol myer pd inhibitor opdivo be priority review use patient hepatocellular carcinoma hcc prior treatment nexavar sorafenib fda be expect give response sep meanwhile be expect response fda investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor however plivensia fail get support fda arthritis advisory committee safety concern quite likely agency ask additional information grant approval trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
248,BMY,roche holding ag rhhby free report announce fda have put partial clinical hold phase ib phase ii trial evaluate tecentriq due safety issue partial hold be put due emerge safety datum clinical trial evaluate merck co mrk free report keytruda combination celgene corporation celg free report revlimid pomalyst note fda have put hold several trial fusion program celgene fda be currently evaluate ongoing blood cancer trial investigate pd pdl drug combination drug order determine be class wide pd pdl concern multiple myeloma blood cancer specific concern certain combination drug study include cohort evaluate tecentriq combination medicine imid relapse refractory multiple myeloma relapse refractory follicular lymphoma result partial clinical hold patient be currently enroled trial be derive clinical benefit continue receive treatment additional patient be enroled note fda grant accelerate approval immuno oncology drug tecentriq treatment patient suffering locally advanced metastatic urothelial carcinoma initial uptake drug have be encourage october tecentriq become first only pdl cancer immunotherapy be approve fda treatment metastatic nsclc fda recently grant accelerate approval tecentriq treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug be previously approve patient suffering locally advanced muc have disease progression follow platinum contain chemotherapy month receive chemotherapy surgery neoadjuvant surgery adjuvant news come disappointment label expansion drug boost sale roche stock have gain industry gain year so far earlier fda also put partial clinical hold bristol myer squibb company bmy free report clinical trial checkmate checkmate same reason trial be investigate opdivo base combination patient relapse refractory multiple myeloma zack rankroche currently carry zack rank hold see complete list today zack rank stock here new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
249,BMY,bristol myer squibb company bmy free report recently enter collaboration license agreement halozyme therapeutic inc halo free report agreement bristol myer use halozyme enhanze drug delivery technology facilitate subcutaneous administration bristol myer immuno oncology drug enhanze technology be base proprietary recombinant human hyaluronidase enzyme rhuph temporarily degrade hyaluronan chain natural sugar body enable dispersion absorption other inject therapeutic drug term agreement bristol myer pay initial use enhanze technology company have also designate multiple immuno oncology target include programme death pd have option select additional target year effective date collaboration extend maximum target halozyme be entitle milestone payment nominated collaboration target additional milestone payment combination product moreover bristol myer be also require pay halozyme royalty drug used enhanze technology develop collaboration bristol myer transaction be expect have dilutive impact bottom line approximately cent cent addition halozyme license enhanze technology roche holding ag rhhby free report exclusive development undisclosed therapeutic target term deal halozyme receive initially potential earn milestone payment subject achievement specify development regulatory sale base milestone halozyme also receive tiered mid single digit royalty sale commercialize product concurrent deal company raise sale guidance share halozyme be follow news meanwhile news bode well bristol myer too note bristol myer opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november label expansion additional indication give product access higher patient population increase commercial potential drug company have earlier suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share hence access larger population improve sale share price movement bristol myer stock have gain year date compare industry gain zack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
250,BMY,bristol myer squibb company bmy free report announce encourage result phase iii study checkmate opdivo checkmate be ongoing phase iii randomize double blind study opdivo versus yervoy patient have undergo complete resection stage iiib stage iv melanoma result study show opdivo mg kg lead significant improvement recurrence free survival rfs compare yervoy ipilimumab mg kg patient stage iiib stage iv melanoma follow complete surgical resection result plan interim analysis show opdivo meet primary endpoint statistically significant improvement rfs compare yervoy july company report positive result same study last week company report positive result phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc meet co primary endpoint study show superior overall survival compare current standard care pfizer inc pfe free report sutent intermediate poor risk patient base plan interim analysis independent datum monitoring committee recommend study be stop early note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy label expansion additional indication give product access higher patient population increase commercial potential drug however bristol myer suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share meanwhile fda put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma bristol myer stock have gain year date industry gain fda put study hold due risk identify keytruda pd agent patient multiple myeloma addition concern astrazeneca plc azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo zack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
251,BMY,share teva pharmaceutical industry ltd teva free report surge company announce kare schultz new chief executive officerbristol myer squibb co bmy free report share increase company report positive result study conduct immunotherapy drug name opdivoshare equifax inc efx free report tank monday suffer datum breach weekendfacebook inc fb free report share increase company announce invest generate original content next year end
252,BMY,share bristol myer squibb company bmy free report gain company end phase iii combination study checkmate earlier expect meet co primary endpoint phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc meet co primary endpoint study show superior overall survival os compare current standard care sunitinib market sutent pfizer pfe free report intermediate poor risk patient fact combination opdivo yervoy also meet secondary endpoint improve overall survival randomize patient base plan interim analysis independent datum monitoring committee dmc recommend study be stop early safety tolerability combination treatment observed study be consistent previous report dose schedule similar subgroup august bristol myer announce top line result checkmate study study meet co primary endpoint objective response rate orr markedly co primary endpoint progression free survival favore combination opdivo yervoy versus sunitinib do not reach statistical significance bristol myer share have underperform industry year date stock have be compare industry gain same time frame note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy fact renal cell carcinoma be most common type kidney cancer adult have huge unmet medical need thus label expansion additional indication give product access higher patient population increase commercial potential drug additionally company enter collaboration agreement seattle genetic inc sgen free report june deal bristol myer evaluate combination opdivo seattle genetic antibody drug conjugate adc adcetris phase iii trial potential treatment option patient relapse refractory transplant ineligible advanced classical hodgkin lymphoma hl however bristol myer suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
253,BMY,abbvie inc abbv free report partner neurocrine bioscience announce new drug application nda pipeline candidate elagolix have be submit fda abbvie be look get elagolix approve oral medicine management pain associate endometriosis nda filing be support positive result replicate pivotal phase iii trial evaluate elagolix gonadotropin release hormone gnrh antagonist indication detailed datum study present october last year show treatment elagolix result statistically significant reduction menstrual menstrual pelvic pain associate endometriosis compare placebo datum study also demonstrated superiority compare placebo reduce painful intercourse associate endometriosis endometriosis affect estimate woman reproductive age be associate pain symptom present be cure endometriosis pain associate endometriosis be currently manage oral contraceptive progestin danazol nsaid opioid gnrh agonist many medicine be not specifically indicated treatment endometriosis so far year abbvie share price have increase compare favorably gain record industry elagolix be also be evaluate phase iii study reduce heavy menstrual bleed premenopausal woman uterine fibroid datum pivotal study be expect end apart elagolix abbvie have several candidate different stage development wide range therapeutic area have partnership company roche rhhby free report bristol myer bmy free report biogen biib free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
